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SUMMARY
Disregarding the widely used division of skull base into anterior and lateral, since the skull base should be conceived as a single anatomic 
structure, it was to our convenience to group all those approaches that run from the antero-lateral, pure lateral and postero-lateral side of the 
skull base as “Surgery of the lateral skull base”. “50 years of endeavour” points to the great effort which has been made over the last dec-
ades, when more and more difficult surgeries were performed by reducing morbidity. The principle of lateral skull base surgery, “remove 
skull base bone to approach the base itself and the adjacent sites of the endo-esocranium”, was then combined with function preservation 
and with tailoring surgery to the pathology. The concept that histology dictates the extent of resection, balancing the intrinsic morbidity of 
each approach was the object of the first section of the present report. The main surgical approaches were described in the second section 
and were conceived not as a step-by-step description of technique, but as the highlighthening of the surgical principles. The third section 
was centered on open issues related to the tumor and its treatment. The topic of vestibular schwannoma was investigated with the current 
debate on observation, hearing preservation surgery, hearing rehabilitation, radiotherapy and the recent efforts to detect biological markers 
able to predict tumor growth. Jugular foramen paragangliomas were treated in the frame of radical or partial surgery, radiotherapy, partial 
“tailored” surgery and observation. Surgery on meningioma was debated from the point of view of the neurosurgeon and of the otologist. 
Endolymphatic sac tumors and malignant tumors of the external auditory canal were also treated, as well as chordomas, chondrosarcomas 
and petrous bone cholesteatomas. Finally, the fourth section focused on free-choice topics which were assigned to aknowledged experts. 
The aim of this work was attempting to report the state of the art of the lateral skull base surgery after 50 years of hard work and, above all, 
to raise questions on those issues which still need an answer, as to allow progress in knowledge through sharing of various experiences. At 
the end of the reading, if more doubts remain rather than certainties, the aim of this work will probably be achieved. 
KEY WORDS: Lateral skull base surgery • Lateral approaches to the skull base • Skull base surgery • Benign tumors of the skull base • 
Malignant tumors of the skull base
RIASSUNTO
La base del cranio non è anatomicamente divisa in anteriore e laterale, ma è per semplicità che comunemente si intendono i corridoi 
chirurgici con direzione antero-laterale, laterale pura e postero laterale come “Approcci chirurgici della base del cranio laterale”. Una 
relazione con titolo “Cinquant’anni di impegno”, di sforzo o di dedizione, vuole essere il riconoscimento a questa chirurgia che nel corso 
degli anni ha sviluppato interventi sempre più complessi con una morbidità sempre minore. Il principio della chirurgia della base del cra-
nio laterale si fonda sulla possibilità di “fare spazio”, esporre adeguatamente, rimuovere osso per salvaguardare il cervello, insieme alla 
possibilità di preservare la funzione e adattare l’approccio chirurgico all’istologia della lesione. Il concetto che l’istologia detta l’entità 
della resezione chirurgica, bilanciando la morbidità intrinseca di ciascun approccio, è oggetto di trattazione nella prima sezione di questa 
relazione. Nella seconda sezione sono descritti i principali approcci chirurgici, intesi non come descrizione tecnica di ciascun tempo chi-
rurgico, ma dei principi che sono alla base di ciascun approccio. La terza sezione è dedicata alle questioni aperte, quelle ancora irrisolte, 
inerenti alcuni tumori ed il loro trattamento. L’argomento del neurinoma sporadico dell’ottavo nervo cranico è trattato riportando l'attuale 
dibattito sulla osservazione, la chirurgia di preservazione dell’udito, la riabilitazione con l’impianto cocleare, la radioterapia e le ricerche 
recenti su marcatori tumorali predittivi di crescita. Il paraganglioma del forame giugulare è trattato nel contesto della chirurgia radica-
le, chirurgia parziale, osservazione e radioterapia. La terapia dei meningiomi della base del cranio analizza il punto di vista specifico 
dell’otochirurgo e del neurochirurgo. Cordomi e condrosarcomi, tumori del sacco endolinfatico, carcinomi dell’orecchio e colesteatoma 
della rocca sono le altre lesioni affrontate. Infine, nella quarta sezione è proposto un contributo a libera scelta ad autori di riconosciuta 
esperienza. Lo scopo di questa relazione è stato quello di fornire un aggiornamento della chirurgia della base del cranio laterale dopo 
50 anni di duro lavoro e, o forse soprattutto, di permettere alle tante questioni irrisolte, alle domande che ancora non hanno risposta, di 
trovare espressione, affinchè il dibattito ed il progresso possano continuare con la condivisione di esperienze. Se al termine della lettura vi 
saranno più domande che risposte, potremo dirci che l’obiettivo di questa relazione è stato raggiunto.
PAROLE CHIAVE: Chirurgia della base cranio laterale • Approcci laterali alla base del cranio • Chirurgia della base del cranio • Tumori 
benigni della base del cranio • Tumori maligni della base del cranio
1. Introduction
A. Martini 
It is my pleasure to thank the Italian Society of 
Otorhinolaryngology Head and Neck Surgery for the task I 
was entrusted. The previous report on the topic was assigned 
42 years ago… to one of the present three authors and this 
makes me particularly happy. 
It has been a hard work, since the subject of the lateral skull 
base surgery is so fascinating and so demanding that only a 
humble, caparbious  attitude to improve knowledge and expe-
rience may lead to progress. This was the case of these 50 years 
where the role of the surgeon of the skull base has been wit-
nessing a more and more comprehensive surgery, where exper-
tise in microsurgery, otology, oncology, head and neck surgery 
combines to approach the various diseases of the skull base.
My special thanks are to both the foreign and Italian authors 
who contributed to the present work. To Antonio Mazzoni, 
who some years ago decided to share his knowledge and 
experience in the lateral skull base surgery to train younger 
colleagues in our group in Padova, for the progress of such 
demanding field.
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Surgeon sits up straight on a seat with back support, so as to be 
comfortable with the arms, the chair is easily adjusted up and 
down, both feet on the floor. There are no foot pedals. Support 
is needed for the surgeons’ forearm, the ulnar side of the hand, 
the fingers, and sometimes the instrument shaft. The patient’s 
body and head provide support, and the bony margins of the 
entry gate can be used. 
Principles of skull base surgery
The lateral skull base is conceived as a connection between 
different compartments – the neck and face on its exocranial 
side, brain on its endocranial side  –  and it is crossed by 
vessels and nerves running through bony orifices or canals.
These three levels of tissues – brain, skull base, and face and 
neck  –  interact differently with the various histologies and 
present different clinical and radiological features, as well as 
suggesting several different therapeutic approaches. The choice 
of surgical approach depends on the histology of the lesion.
It is important to preliminarily focus on the multiple 
problems to be considered in planning and performing skull 
base surgery.
• The correlation between pathology and resection concerns 
different tissues, each featuring its own interface with the 
skull base. Tumors have own ways of interacting with 
tissues and influencing the resection. In short, skull base 
surgery carries to a higher degree the problems common 
to any form of oncological surgery as regards the variable 
effects of tumor histology, site and size, the extent of the 
lesion and the tissues invaded.
• The spaces in the skull base and adjacent sites where 
tumors can grow are narrow, limited by bone, major 
vessels and nerves. In this setting, surgery has to gain its 
own space to complete tumor resection safely.
• The skills required for the various surgical approaches 
can make it difficult to choose the most appropriate one, 
and the choice is often erroneously related more to the 
size of the tumor than to its nature.
• Surgical resections must be planned so as to achieve 
oncologically safe margins, depending on the type of 
neoplasm involved. The same approach cannot be equally 
suitable for schwannoma, meningioma, chordoma, 
chondrosarcoma, carcinoma, etc. Even within the same 
pathological diagnoses, different aspects of a given histotype 
of tumor can make a lesion more or less aggressive.
• Despite the nature of a tumor is fundamentally important, 
biopsies of skull base tumors are unfortunately rarely 
obtained, as the diagnosis is commonly established from 
radiological and clinical findings. The reliability of such a 
diagnosis is questionable, but it is often the only feasible 
option. Preoperative biopsy is recommended when it 
might change aim of surgery and choice of approach and 
when clinical-radiological diagnosis is missing.
The concept of a team is of tremendous importance in the skull 
base surgery and this report shows how every topic may be 
treated from different points of view, how many problems and 
different perspectives are encountered in a therapeutic choice. 
Many thanks to the readers who will comprehend the effort 
we made and will excuse us if some of their expectations will 
not be satisfied. We tried all to do our best.
2. Generalities on skull base surgery
2.1. Surgery of the skull base  
as it relates to pathology
E. Zanoletti
Introduction
The skull base is a bony diaphragm separating the brain 
from the face and neck. Skull base surgery runs across the 
bone and adjacent areas of neck and face to reach the lesions 
lying in bone, and/or in the exo- and endocranial regions or 
both. A lesion may be endocranial or exocranial, or both and 
be accessed through the skull base. The route taken for the 
surgical procedure runs from an opening to a target, thus 
delineating an “approach”. 
The deep target is exposed by creating a gateway for entering 
the skull and a corridor by removing, retracting, or bypassing 
tissues and organs. The gate is wider than both the corridor 
and the target in order to enable structures to be visualized, 
and to allow for precise surgical maneuvers. The surgical 
cavity is cone-shaped and wide enough to accommodate 
instruments, allow for their handling, and afford multiple 
angles of view with different magnification systems 
(microscope, endoscope). 
The boundaries of the access are often organs that are 
not expendable, whereas the width of the access can be 
significantly enhanced if a structure can be sacrificed. The 
extent and boundaries of the approach are defined by the 
nature of the lesion.
Ergonomics
Understanding the principles behind the surgical procedures, 
and the basic skills needed to perform them are prerequisite 
for the skull base surgeon. Given that surgery is a mechanical 
action performed on tissues by hand, or using hand-held 
instruments, and that microsurgery relies on the use of 
stereoscopic optical enlargement and dedicated instruments, 
surgeon’s training should preferably begin at a young age, 
enabling him/her to gain sufficient experience to ensure a 
smooth and natural communication between mind and target. 
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as it enables appropriate, case-specific treatment planning 
(based on the tumor’s histology and aggressiveness, the 
compartments involved, potential for spread hidden diffusion) 
and can suggest the oncological safe resection. Biopsy should 
be performed before any treatment as surgery hardly relies on 
the often erroneous results of intraoperative frozen section. 
When imaging is the only tool available, it should be planned 
under the best possible conditions in terms of technique and 
expertise. The clinical onset of signs and symptoms and 
the course of the disease also contribute to establishing the 
diagnosis.
Treatment
Treatment is planned and adjusted throughout the course of 
the disease. When surgery is chosen (as a single treatment 
or combined with other neo- or post-operative adjuvant 
radiotherapy/chemotherapy), the oncological margins 
required must be considered during the planning of the 
resection, as single or multiple approaches may be needed. If 
a combination of approaches is indicated, the postoperative 
complications (CFS leaks, infections, other) should be 
taken into account: in some cases, they can be prevented by 
planning staged surgery. When neck and brain compartments 
are broadly communicating due to an extensive resection of 
the skull base, staged procedures are preferable in order to 
limit infections and CSF leakage into the soft tissues. 
In principle, the choice of surgical approach should ensure: 
1. the lowest morbidity on the cranial nerves (the factors 
with the greatest influence on postoperative course and 
quality of life); 
2. the highest chance of achieving a complete resection (the 
oncological margins are dictated by tumor histology and 
established preoperatively);
3. the goal of surgery (to cure the disease, for symptom relief, 
or as a preliminary step before other, more effective ther-
apies), striking for the best balance between tumor factors 
and patient factors;
4. functional rehabilitation. The predictable morbidity of each 
surgical approach cannot disregard the options available for 
the rehabilitation after surgery of functions such as hearing, 
facial mimicking, and swallowing. This makes extensive 
surgery more feasible than in the past and allows a better 
chance of achieving oncologically safe resections;
5. the availability of alternative/complementary therapies, 
considering the patient’s treatment as a whole. The role 
and timing of adjuvant therapies such as traditional 
radiotherapy, stereotactic or multi-fractionated therapy, 
or protons, may suggest a planned subtotal surgery if the 
pathological prognosis is not affected;
6. the surgeons’experience of using the different approaches: 
is the choice of surgical approach tailored to the tumor, 
the patient or the surgeon? 
Tumors of the lateral skull base
Tumors of the lateral skull base may originate from the 
bone, endocranial nervous tissues, or various tissues of the 
face and neck, and then cross the skull base to spread into 
surrounding areas.
The natural history of a tumor varies, depending on several 
factors:
1. Histopathology, which not only differentiates between 
benign and malignant lesions, but also identifies a lesion’s 
risk of loco-regional aggressiveness, recurrence, and 
distant metastasis, and often dictates whether multiple 
treatment strategies are needed.
2. Site of origin, as a tumor may be a primary lesion of the 
skull base, or a secondary lesion from adjacent sites.
3. Behavior: tumors have different growth patterns at different 
locations. The same neoplasm can have an expansive growth 
in the soft tissues, but be erosive or infiltrative in bone or 
nerve tissues. It can behave differently with the dura mater, 
displacing it at some interfaces, infiltrating it at others. It 
may infiltrate the brain or grow undisturbed until it prompts 
late signs of compression (in the cerebellopontine angle, for 
instance, it finds some free space to occupy before causing 
any symptoms). It can encase vessels with or without 
infiltration of their walls or erode their bony channels. 
Shortly, most types of neoplasm show different growth 
patterns as they spread through the three compartments of 
the skull base region, and resections must adapt accordingly. 
4. Degree of aggressiveness, i.e. whether it is well or poorly 
differentiated. All tumors have their own potential for 
hidden, undetectable diffusion, so completeness of 
resection and oncological radicality can mean different 
things. The degree of differentiation also influences the 
foreseeable response to adjuvant/neo-adjuvant therapies, 
and consequently affects how surgery is planned.
5. Sporadic or syndromic disease: skull base tumors are 
treated differently if the lesions are sporadic or part 
of a syndrome. Syndromic cases are generally more 
aggressive, develop more quickly and at an earlier age. 
They may occur in association with other multiple 
concomitant tumors, involve a greater risk of malignant 
transformation after radiotherapy and functional issues 
relating to the not infrequent presence of bilateral disease. 
Diagnosis
Skull base tumors are diagnosed by high-resolution, contrast-
enhanced MRI, and high-resolution bone CT scan, occasionally 
replaced by cone-beam CT. Further imaging (angioMRI or the 
less-reliable angioCT) helps to clarify venous drainage, sinus 
involvement or infiltration of the walls of arteries and veins. 
Angiography enables the diagnosis of vascular tumors as well 
as pre-surgical embolization. Contrast-enhanced CT scanning 
has a very limited role, if any.
Biopsy should be performed whenever feasible, although rarely, 
Surgery of the lateral skull base: a 50-year endeavour
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auditory canal (IAC), around 270° of its circumference, the 
vestibule and the superior vestibular nerve; superiorly, the 
superior petrosal sinus and temporal dura; and posteriorly, 
the retrosigmoid dura and occipital squama for an extent 
depending on tumor size and anatomy of the temporal 
bone. In small tumor, the Tlab approach involves only a 
mastoidectomy and labyrinthectomy. In large tumours 
bone removal is more extensive both in temporal and 
retrosigmoid squamous bone.
Tumor removal: this is done via a centrifugal resection 
from the brainstem to the IAC and, for medium-to-large 
tumors, it involves repeated steps of intracapsular debulking, 
dissection and removal of the fragments detached. The goal 
of this piecemeal procedure is to create the best conditions 
for freeing nerves, vessels and brainstem. The facial nerve, 
and the cochlear nerve in some cases, are the pivot of the 
procedure, the aim of which is to visualize and dissect the 
nerve from the brainstem to the meatal porus. The facial 
nerve is first exposed at its brainstem root, then followed up 
to where it crosses the cerebellopontine angle from the tumor 
to the meatus. This is the most vulnerable portion of the nerve 
and should dictate the course of the procedure. Direct or 
indirect stretching is limited as the procedure is progressing 
from angle to periphery, freeing the facial nerve along with 
piecemeal removal up to the porus, then dissecting towards 
the center from the fundus. Salient steps are: 
• The opening in the dura is wide, especially for large 
tumors, and extends to one millimeter away from the 
sigmoid, superior petrosal sinus and jugular bulb.
• The cisternal arachnoid involves most of the tumor, and 
provides a free surgical plane along the tumor’s surface.
• The first part of the tumor to be exposed is the posterior 
surface, which has to be inspected to check for any 
exceptional course of the facial nerve, before the tumor 
is extensively coagulated, then incised and debulked.
• The first landmarks are the roots of the VIII and 
VII  nerves, which are found after debulking, on 
retracting the inferior pole of the tumor.
• Repeated steps of coagulation, debulking and removal 
reduce the volume of the tumor and allow for the 
dissection of nerves, vessels and brainstem.
• Tumor removal proceeds in a proximal-to-peripheral 
direction toward the superior pole and meatus, and ends 
with a strip of tumor extending from the brain to the 
meatus and carrying the facial nerve.
• The facial nerve gradually comes into view on one of 
the tumor meridians, usually on its anterior aspect, and 
running more or less directly to the meatus, or to the 
superior pole and from there to the meatus. Beware of 
any sudden change of course with a sharp angle.
• Dissection of the facial and cochlear nerves proceeds in 
a proximal-to-distal direction up to the vicinity of the 
meatus, then goes from there to the meatal fundus. Here 
2.2. Evidence-based therapy  
in diseases of the skull base 
A. Mazzoni
The treatment of lesions of the skull base has two striking 
features in clinical practice: one is the high level of the 
diagnostic process thanks to the use of advanced technologies, 
such as imaging; the other concerns the lack of a consensual 
approach to the treatment of the growing number of cases 
diagnosed early on. The options range from surgery to 
radiotherapy, to observation, but none of them have been the 
object of rigorous, randomized clinical trials to compare them, 
often because patients have the inalienable right to choose 
how they wish to be treated. Even the most accurate non-
randomized studies have produced only level three evidence. 
This situation is a real obstacle to advances in surgery, which 
can improve in terms of technique, but not in its indications. 
One way to escape this impasse of unpredictable duration may 
be to opt for a given therapy once several different studies 
concur in favor of it, albeit with a low level of evidence. This 
would demand a preliminary effort to define a common method 
for the therapy in question, and to use validated instruments 
to assess the methodological quality of the studies 1 2. As for 
the contribution from surgeons, it is worth noting that most 
papers on surgical procedures fail to explain the crucial steps 
in sufficient detail, and the authors seem to forget that any 
surgical technique needs to be clear in every respect before it 
can be discussed and shared.
3. The lateral approaches:  
principles and highlights
3.1. The translabyrinthine approach
E. Zanoletti
The principle of the translabyrinthine approach (Tlab) 1-4 
is removing the bone from the lateral surface to the 
internal auditory canal and petrous dura. No cerebellar and 
temporal retraction is required and the cerebellopontine 
angle (CPA) is straightfordly reached. 
This access route through the skull base involves the 
drilling out of the temporal bone to the sigmoid sinus, and 
a portion of retrosigmoid occipital squama and temporal 
squama. After completion, the osseous boundaries are: 
anteriorly, the posterior wall of the external auditory 
canal and the mastoid Fallopius canal; inferiorly, the 
jugular bulb and IX  cranial nerve; medially, the internal 
E. Zanoletti et al.
S6
3.2. The transcochlear approach 
G. Restivo, G. Danesi
Described for the first time in 1976 by House and 
Hitselberger, the transcochlear approach was designed 
for large intradural median lesion, petroclival lesions and 
cerebellopontine angle (CPA) tumors with an anterior and 
medial extension in respect to the internal auditory canal. 
These lesions are difficult to handle with other approaches 
and until 1976 were considered inoperable because of the 
obstacles represented by the brainstem and the cerebellum. 
The original transcochlear approach was idealized as an 
anterior extension of the classic translabyrinthine approach, 
performed through various steps: the posterior transposition 
of the facial nerve, the removal of the cochlea and of the 
petrous apex’s bone through a corridor created by removing 
the latter structure. This approach was then modified by 
Brackman in 1987, who proposed a removal of the external 
auditory canal, the skin of the canal, the tympanic membrane 
together with the ossicles and a blind sac closure of the 
auditory external canal. These steps granted a greater control 
of very anterior and medial lesions and of those lesions 
involving the intrapetrous tract of the carotid artery. 
Surgical technique
A C-shaped retroauricolar incision of skin and 
subcutaneous tissues is performed to elevate the anterior 
flap. T-incision of the muscle-periosteum flap is to 
expose the mastoid and then used as a second layer in 
the closure of the obtained surgical cavity. Subsequently 
the skin of the external auditory canal is incised at the 
level of the bony-cartilagineous junction. The skin of the 
cartilaginous external auditory canal is dissected for at 
least one centimeter towards the concha. Once everted, 
the skin will be closed with non-absorbable stitches. The 
residual skin of the bony external auditory canal and the 
tympanic membrane with the ossicles are then removed. 
An enlarged mastoidectomy with skeletonization of the 
dura of the middle and posterior fossa for about 2-3 cm 
posteriorly to the sigmoid sinus, is then performed. 
The facial nerve is identified and skeletonized along 
its course, from the stylo-mastoid foramen until to the 
geniculate ganglion and to the great petrosal nerve. Only 
a thin layer of bone covers the nerve at the end of the 
latter step. An open mastoidectomy is performed by 
removing the posterior and superior walls of the external 
auditory canal. The jugular bulb is now skeletonized and 
the labyrinthectomy starts from the lateral and posterior 
semicircular canals. Opening of the vestibule is performed 
on its floor, at the level of the fundus, where it is possible to 
identify the superior and inferior vestibular nerves divided 
by the horizontal crest. More laterally and anteriorly to 
the dissection becomes centripetal. The facial nerve is 
exposed by lifting the superior vestibular nerve from 
its canal (Sanna method), or by adding the pink line of 
the Fallopius. The vulnerable portion of nerve from the 
porus to the tumor can be freed by converging from both 
directions. 
• Monitoring the facial nerve makes it easier to identify 
and helps to control dissection-related trauma, up to 
the final excitability measure, which is of prognostic 
relevance. Loss of excitability coincides with loss of 
the ability to monitor the nerve proximal to the site of 
injury.
Translabyrinthine-transapical approach 
A correct Tlab approach to 270° of the circumference 
of the canal affords adequate access to the CPA, but can 
be improved by adding a transapical extension. This is 
convenient in the case of large tumors or an unfavorable 
anatomy, such as a contracted mastoid, low-lying 
temporal dura, anterior sigmoid sinus, or high jugular 
bulb. It may be recommended when, on axial and coronal 
MRI, large tumors extend beyond the projection in the 
CPA of the anterior and superior walls of the canal. The 
transapical approach involves removing the petrous bone 
anteromedial to, and including, the anterior wall of the 
canal, up to the vicinity of the horizontal carotid artery. 
It provides a wider route and exposes the anterior CPA at 
the beginning of the procedure. This early visual control 
enables the facial nerve to be assessed better than with the 
Tlab approach. Having three facial nerve landmarks – the 
canal fundus, the tumor’s supero-anterior aspect, and the 
root on the brainstem  –  makes this approach especially 
useful for cystic and medial tumor.
Limitations of the translabyrinthine approach 
It is extremely unusual for the jugular bulb and sigmoid 
sinus complex to be an insurmountable obstacle and 
necessitate switching to the retrosigmoid approach. On 
the other hand, it is not uncommon for the Tlab approach 
to be so narrow that it demands additional expertise. 
An unfavorable anatomy is not easily appreciated on 
current imaging, in terms of suggesting the change of 
the approach to the retrosigmoid. While the sigmoid 
sinus can be displaced, the jugular bulb is too fragile 
to withstand instrumental retraction. Thrombosis of the 
sinus can be caused by aggressive maneuvers, coagulation 
of the sinus wall to induce retraction, or the placement of 
fragments of surgical wax on the wall. There are usually 
no clinical signs of thrombosis of the sinus, and the rate 
of its occurrence is not known. The absence of clinical 
symptoms may relate to the fact that this approach entails 
little or no retraction on the cerebellum. 
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cave and the medial boundary is the clivus. The anterior 
wall of the bony meatus is then removed, exposing the 
temporomandibular joint. The mandibular condyle is 
dislocated forward by using a Fish’s infratemporal fossa 
retractor, in order to allow exposure of the carotid artery for 
270°, or even up to 360° when its complete mobilization 
is required. By further drilling of the bone of the petrous 
apex, the lateral portion of the clivus is reached. When 
the bone-dura interface straightens, the posterior aspect of 
the clivus on the midline has been reached. Thus a dural 
“triangular window” is obtained. Anatomical boundaries 
of this triangular window are the internal carotid 
anteriorly, the superior petrous sinus superiorly and the 
inferior petrous sinus infero-medially. The apex of the 
triangle lies under the Meckel’s cave. Usually the drilling 
of the apex bone causes an important venous bleeding that 
requires use of Surgicel and bone wax. The incision of 
the dura is then carried out anteriorly to the porus of the 
internal auditory canal, from the superior petrosal sinus 
to the inferior petrosal sinus. The facial nerve is usually 
found on the posterior surface of the tumor. After the 
nerve is dissected from the tumor’s surface, the rerouting 
is completed by protecting the nerve with cottonoids 
soaked in saline solution. The incision of the dura can be 
dangerous as cranial nerves VII and VI could be damaged 
in correspondence of the internal acoustic porus. The 
approach allows a wide exposure of the anterior CPA 
together with the lateral and anterior surfaces of the pons. 
Other exposed structures are the V, VII, VIII, IX and 
XI cranial nerves and both the VI cranial nerves, the clivus, 
the basilar and vertebral arteries, and even the contralateral 
cranial nerves. This large exposure allows removal of the 
wide tumor implantation base and control of the arterial 
vascularization coming from the internal carotid, which is 
particularly important for the treatment of meningiomas. 
The large cavity obtained needs to be filled by placing 
a single large piece of autologous abdominal fat, after 
obliteration of the tuba with autologous temporal muscle 
or fat, with possible further reinforcement with bone wax. 
Finally, the periosteal and muscular flaps and the skin are 
sutured. A compressive dressing is carried out and must 
be maintained for 5  days. The abdominal surgical field 
will require a suction drainage. 
Indications for the transcochlear approach are represented 
by extensive lesions of the CPA extended to the prepontine 
cistern whose epicenter is anterior and medial to the 
internal auditory canal such as: petroclival meningiomas, 
meningiomas anterior to the brainstem, intradural clival 
lesions, congenital cholesteatomas of the apex, epidermoid 
tumors anterior to the internal auditory canal, chordomas 
of the clivus and chondrosarcomas. 
The advantages of the transcochlear approach are the 
following: the approach does not require retraction 
the latter structures lies the facial nerve, protected by the 
vertical crest (Bill’s bar). Skeletonization of the internal 
auditory canal (IAC) with a diamond burr reaching up 
to the internal acoustic meatus is now performed. The 
tympanic bone must be removed, and the anterior auditory 
bony canal is then drilled at the level of the tubal ostium. 
The vertical tract of the internal carotid artery, which lies 
on the medial wall of the Eustachian tube in front of the 
cochlea, is now identified and skeletonized. Following 
steps include removal of the cochlea together with the 
cochleariform process and skeletonization of the genu 
of the carotid by removing the bone, including bone that 
lies between the cochlea and the geniculate ganglion; 
dissection then continues with the aggressive removal of 
the tympanic bone until the dura of the middle fossa is 
reached. The thin layer of bone previously left on the facial 
nerve is now removed using a dissector. Skeletonization 
of the labyrinthine portion of the facial nerve represents 
the point with the highest risk of iatrogenic injury, as an 
acute angle with the ganglion is created. Skeletonization 
of the facial nerve continues until the emergence of the 
VII cn from the fundus is reached. Facial rerouting begins 
at the level of the geniculate ganglion, after bipolar 
coagulation and section of the greater superficial petrosal 
nerve. The geniculate ganglion and the labyrinthine 
portion of the facial nerve are released for about 180° 
from the underlying bone and are then detached from it by 
using angled instruments. At this point usually the nerve 
becomes electrically non-stimulable, as a consequence of 
vascular compromise. Subsequently, detachment of the 
tympanic and the mastoid portion of the facial nerve is 
performed. In order to be able to completely mobilize the 
facial nerve and to maintain the protection offered by the 
dura of the internal auditory canal, the superior vestibular 
nerve and inferior vestibular nerve and cochlear nerve are 
interrupted at their emergence from the fundus by using an 
angled hook, completely freeing the facial nerve from the 
bone below. It is now possible to carry out the posterior 
transposition of the facial nerve, included in the dura of 
the IAC, which will be housed in the corner between the 
sigmoid sinus and the jugular bulb on the dura of the 
middle cranial fossa. Is very important to remove all the 
bone at the stylomastoid foramen, because incomplete 
removal would not allow a complete mobilization of this 
portion of the facial nerve. The bone from the residual 
fallopian canal is removed with a rongeur. Now that the 
facial nerve is no longer present in the operative field, it 
is possible to complete the skeletonization of the internal 
carotid artery, of the cochlea and of the petrous apex 
which lies medially to the carotid artery. The lower limits 
of the skeletonization are represented by the inferior 
petrosal sinus and the jugular bulb, the upper boundaries 
go from the superior petrosal sinus up to the Meckel 
E. Zanoletti et al.
S8
abyrinthine, apical and (less commonly) supralab-
yrinthine types;
 – recurrent acoustic neuroma with petrous bone 
invasion;
 – extensive facial nerve tumors;
 – cholesterol granuloma (only with preoperative 
facial and hearing impairment).
• Intradural lesions:
 – large clival and petroclival lesions lying ventral to 
the brainstem, e.g. petroclival meningiomas;
 – previously irradiated petroclival meningiomas;
 – residual or recurrent non-acoustic lesions of 
the posterior fossa with anterior extension into 
the prepontine cistern, particularly those with 
encasement of the vertebrobasilar artery and/
or perforating arteries, e.g huge posterior fossa 
epidermoids;
 – recurrent acoustic neuromas with facial nerve 
paralysis.
• Transdural lesions: 
 – lesions invading the petrous apex as en plaque 
meningiomas or primary clival or temporal bone 
lesions with secondary posterior fossa extension as 
chordomas, chondrosaromas and extensive glomus 
jugulare tumors.
Surgical technique
1. A wide C-shaped post-auricular incision is made. 
The incision starts 3  cm above the auricle, curves 
posteriorly to about 4-5  cm posteriorly to the retro-
auricular sulcus and ends inferiorly at the level of the 
mastoid tip.
2. The skin and subcutaneous tissues are elevated, 
of the cerebellum or of the temporal lobe, it allows a 
wide exposure of the anterior, medial and median CPA, 
together with the control of the intrapetrous tract of the 
internal carotid, the basilar and both vertebral arteries. 
The transcochlear approach can also be associated with a 
transtentorial approach for lesions that originate from the 
tentorium or that extend to the peri-mesencephalic cistern. 
Disadvantages of this technique are represented by 
associated comorbidities: the posterior rerouting of the 
facial nerve determines a post-operative paresis up to a 
House-Brackman grade III. 
3.3. The modified transcochlear approaches 
L. Lauda, A. Taibah, V. Mastronardi, R. Albertini, M. Sanna
The transcochlear approaches
The original transcochlear approach described by House 
and Hitselberger (1976) includes internal auditory canal 
identification, posterior rerouting of the facial nerve and 
removal of the cochlea and petrous apex with preservation 
of the middle ear and external auditory canal 1.
Fisch (1978) described the transotic approach in which 
the external auditory canal and middle ear are removed 
but the facial nerve is left in situ 2.
The modified transcochlear approach, on the other hand, 
combines the removal of the external auditory canal 
and middle ear together with the posterior rerouting of 
the facial nerve, thus eliminating the major obstacle 
to the anterior extension of the approach. This wider 
surgical corridor allows better control of the vertical and 
horizontal intrapetrous portions of the internal carotid 
artery and eases a complete removal of the petrous apex 3. 
The extensive anterior bone removal provides an excellent 
control of the ventral surface of the brainstem without the 
need of cerebellar and brainstem retraction.
The modified transcochlear approaches
Classification
We have further classified this approach into four types 
according to its extension. Type  A approach is the 
basic approach (Fig.  3.3.1), whereas types B, C and D 
indicate the anterior, superior and inferior extensions, 
respectively 4.
Type A modified transcochlear approach (the basic type)
Indications
• Extradural lesions: extensive petrous apex lesions with 
preoperative facial nerve and inner ear impairment, 
e.g.:
 – massive petrous bone cholesteatoma of the infral-
Fig. 3.3.1. Schematic drawing showing the outlines of the modified transco-
chlear approach type A. About 3/4 of the vertical portion of the internal carotid 
artery (ICA-V) are exposed in contrast to only 1/4 of the horizontal portion of the 
internal carotid artery (ICA-H) by using this approach.
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13. At the end of the procedure, the eustachian tube is closed 
with a muscle plug and the cavity is obliterated with a 
single piece of abdominal fat. The musculoperiosteal 
flap is repositioned and sutured with Vicryl 1/0 and the 
wound is closed in 2 layers. A tight dressing is applied 
and no drainages are inserted.
Advantages
1. Wide exposure of the cerebellopontine angle and 
prepontine cistern without need for cerebellar and 
brainstem retraction.
2. Removal of invaded dura and bone is allowed. 
3. Excellent control of the intrapetrous internal carotid 
artery.
4. The approach can be extended according to the extent 
of the disease.
5. In cases of meningioma, the blood supply of the tumor 
is controlled before dural opening.
Disadvantages
1. Sacrifice of ipsilateral hearing.
2. Facial nerve rerouting leads to postoperative paralysis 
which usually recovers up to House-Brackmann 
grade III (rarely to grade II).
3. Lengthy procedure. However, wide exposure greatly 
shortens the time needed for tumor removal.
Type B modified transcochlear approach
This type of transcochlear approach incorporates Fisch’s 
infratemporal fossa approaches of type B or C into the 
modified transcochlear approach type A. In addition to the 
wide exposure of the infratemporal fossa, this type also 
allows an additional access to anteromedial tumors lying 
ventrally to the brainstem (Fig. 3.3.2) 5.
Indications
• Extradural lesions with circumferential involvement 
of the internal carotid artery (e.g. clival chordomas 
and some cases of infralabyrinthine apical and massive 
petrous bone cholesteatomas).
• Intradural lesions: petroclival lesions passing the 
midline with limited contralateral extension (e.g. 
meningiomas, epidermoid cysts, etc.).
• Transdural lesions involving the parapharyngeal 
spaces (e.g. extensive clival chordomas or en-plaque 
meningiomas with extracranial extension). In these 
cases, the procedure is usually staged to avoid the 
risk of post operative cerebrospinal fluid leakage. The 
extradural portion of the lesion is first removed, while 
the removal of the intradural component of the lesion is 
performed in a second-stage procedure.
Surgical steps
1. A wide post-auricular incision is performed as in the 
type A approach. However, the incision extends more 
anteriorly up to the lateral margin of the orbit. 
2. The modified transcochlear approach type  A is 
the musculoperiosteal layer is incised in a T-shaped 
fashion. A small Palva flap based anteriorly is outlined. 
3. The external auditory canal is transected and closed as 
a cul de sac. The anterior skin flap is retracted using 
skin hooks, whereas the musculoperiosteal layer is 
raised and kept retracted by using 1/0 silk sutures.
4. An extended mastoidectomy is performed, with 
removal of bone 2-3 cm posteriorly to the sigmoid sinus 
and over the dura of the middle fossa. The external 
auditory canal (posterior and superior walls) is drilled 
and the facial nerve is skeletonized. The inferior 
tympanic bone is also drilled. Labyrinthectomy is 
therefore performed and the internal auditory canal is 
identifed as previously described. 
5. The facial nerve is skeletonized from the stylomastoid 
foramen until the geniculate ganglion. Using a diamond 
burr, the greater superficial petrosal nerve is idenfied 
by drilling anteriorly to the geniculate ganglion. Next, 
the middle fossa dura is gently retracted with suction-
irrigation and the labyrinthine segment of the nerve 
is identified. A small diamond burr is used at this 
crucial step. Drilling proceeds carefully parallel to the 
direction of the nerve with the direction of rotation 
being away from the nerve. 
6. The last thin layer of bone over the facial nerve is 
removed using a rasp. The facial nerve is released for 
about 270  degrees in its mastoid and tympanic parts 
and for about 180 degrees in the area of the geniculate 
ganglion and the labyrinthine segment.
7. The greater superficial petrosal nerve and its 
accompanying vessels are identified and cut after 
bipolar coagulation. 
8. Using an angled pick, the geniculate ganglion and the 
labyrinthine portion of the facial nerve are carefully 
separated from the underlying bone. The tympanic 
segment is carefully freed. The mastoid segment is 
then freed using sharp dissectors to cut the through 
adhesions at this level.
9. The nerve is rerouted posteriorly together with all the 
contents of the internal auditory canal. The superior 
vestibular, inferior vestibular and cochlear nerves are 
torn away at the fundus of the canal and all the contents 
of the canal are rerouted posteriorly together with the 
facial nerve. The nerve is then fixed to the posterior fossa 
dura just anteriorly to the sigmoid sinus using fibrin glue.
10. The fallopian canal is now removed with a rongeur.
11. The cochlea is drilled and the vertical segment of the 
internal carotid artery is identified. The petrous apex 
is drilled until the level of the midclivus exposing the 
dura on the posterior surface of the temporal bone.
12. For extradural lesions, tumor removal proceeds. In 
case of intradural lesions, the posterior fossa dura is 
incised and the pathology is managed.
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performed as previously described. In addition, the 
mandibular condyle is displaced inferiorly using a 
Fisch infratemporal fossa retractor, after removal 
of the articular capsule. The glenoid and the base 
of the middle fossa are drilled. The bony part of the 
eustachian tube is drilled until the isthmus is reached. 
This provides complete control of the vertical segement 
of the internal carotid artery. The middle meningeal 
artery is then identified.
3. After bipolar coagulation, the middle meningeal artery 
is sectioned; the mandibular nerve is also transected 
after bipolar coagulation.
4. Meckel’s cave can be opened if it is involved by the 
tumor. 
5. If more exposure is required, the internal carotid artery 
can be mobilized anteriorly in order to create more 
space for tumor exposure.
The type C modified transcochlear approach
Certain posterior fossa tumors (particularly petroclival 
meningiomas) can extend to the middle fossa either by 
direct tentorial invasion or through Meckel’s cave or the 
tentorial notch. The type C approach allows control of both 
the infratentorial and the supratentorial parts of the tumor 
lying ventral to the pons and midbrain, as well as removal 
of the infiltrated tentorium with only minimal temporal 
lobe retraction (Fig. 3.3.3).
Indications
Petroclival lesions with supratentorial extension (e.g. 
petroclival meningiomas).
Surgical steps
1. The skin incision is performed as in the type B approach. 
The approach is performed as previously described in 
the type A approach. However, the middle fossa dura is 
widely uncovered. Bone removal at this level is much 
wider than in the type A approach.
2. The dura of the middle fossa is incised 3-4 mm above and 
parallel to the superior petrosal sinus. 
3. The superior petrosal sinus is opened and coagulated 
or packed with Surgicel. The tentorium is cut with 
microscissors anteromedially starting just in front of 
the junction between the superior petrosal sinus and the 
sigmoid sinus.
4. Cutting of the tentorium is continued until the tentorial 
notch is reached. If the tentorium is involved by tumor 
as in cases of meningiomas, it is completely excised and 
removed.
The type D modified transocochlear approach
The major limitation of the type A approach is the limited 
access to tumors extending into the lower clivus and 
jugular foramen region. The type D approach is designed 
to overcome this limitation by combining the type A 
approach with the petro-occipital trans-sigmoid (POTS) 
approach, thereby obtaining excellent control of these areas 
(Fig. 3.3.4). 
Indications
Lesions of the middle and lower clivus, e.g., chordomas 
with involvement of the lower clivus, some cases of pet-
roclival meningiomas, and extensive lower cranial nerve 
schwannomas.
Surgical steps
1. The incision is performed as in the type A approach. The 
lower limb of the incision extends inferiorly to about 2 cm 
below the mastoid tip.
2. An inferiorly based U-shaped musculoperiosteal flap is 
raised as described in the POTS approach. Anteriorly, a 
small Palva flap is created to form the second layer after a 
cul-de-sac closure of the external auditory canal.
3. The approach is performed as described in the type A. In 
Fig. 3.3.2. Schematic drawing showing the limits of the transcoch-
lear approach type B. Note the complete circumferential exposure of the 
vertical (ICA-V) and horizontal (ICA-H) segments of the internal carotid 
artery. 
Fig. 3.3.3. Schematic drawing showing the extent of the modified transc-
ochlear type C approach. Note the superior extent of the craniotomy and the 
cut of the tentorium.
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the internal auditory canal (IAC) in neurofibromatosis 2 
(NF2) patients.
Hearing and facial nerve preservation
The middle fossa procedure is a hearing-preservation 
approach. It has been shown that hearing preservation 
is possible for the vast majority of patients, with 
about two thirds of the patients keeping their good 
hearing (class A+B according to AAO-HNS  7) function 
postoperatively  8-10. Besides preservation of good 
functional hearing, the preservation of facial nerve 
function is also very important. In small tumours using 
hearing preservation procedures, about 90-95% of the 
patients retain good facial nerve function (class HB1+2 
according to the House-Brackmann scale  11)  12 13. Due to 
necessary microsurgical manipulations during separation 
of tumour tissue from the facial nerve, early postoperative 
facial nerve weakness is common (in about 30% of the 
cases directly postoperatively 10 12-16), but this resolves in 
most cases within the first three months. 
These excellent results in function preservation were enabled 
by appropriate intraoperative monitoring techniques. We 
use continuous facial nerve monitoring with fine wire 
needle electrodes placed into the m. orbicularis oris and m. 
orbicularis oculi (e.g. Neurosign 100, Magstim Company 
Ltd., Whitland, UK). Auditory Brainstem Response (ABR) 
monitoring is also continuously recorded via self-adhesive 
electrodes during surgery (e.g. Nicolet Viking, Viasys 
Healthcare, Madison, WI, USA/Höchberg, Germany). In-ear 
speakers that are fixed in the outer ear canal with a silicone 
compound are used to perform acoustic stimulation. If ABR 
are getting worse during surgery, or if preoperative waves are 
too small, we extend the monitoring and use a ball electrode 
(Fig. 3.4.2) for cochlear nerve action potentials (CNAP) after 
removal of the tumour (e.g. Tyrek® Roll; Johnson & Johnson 
addition, a wider removal of the occipital bone posteriorly 
and inferiorly to the sigmoid sinus is performed.
4. The sigmoid sinus is closed extraluminally at the junction 
with the transverse sinus. The sinus is then opened and 
intraluminally packed with large pieces of Surgicel®. The 
internal jugular vein is identified in the neck and ligated 
twice. The dura is opened as previously described with 
the additional opening of the jugular bulb as described in 
the POTS approach.
3.4. The middle cranial fossa approach
M. Scheich, R. Hagen
Introduction
Microsurgery for vestibular schwannomas can be 
performed via several different approaches. The middle 
cranial fossa (MCF) corridor is an extradural approach 
that was first described as early as 1904, but the beginning 
of its widespread use dates back to the description made 
by William House in 1961  1 2. The clinical application of 
this approach was facilitated after the introduction of 
the operating microscope from middle ear surgery into 
modern otoneurosurgery. Various modifications have been 
carried out over the past several years (e.g. Fisch 1969  3, 
Brackmann 1994  4), but the basic principles remain the 
same. The technique can also be enlarged as proposed by 
Wigand et al. 5 or even extended as described by Kanzaki et 
al. 6 for larger tumours. 
The major indication for the middle fossa approach is 
the resection of small intra-/ extracanalicular vestibular 
schwannomas without contact to the brainstem (Fig. 3.4.1) 
in patients with good hearing. Another less frequent 
indication is vestibular neurectomy or decompression of 
Fig. 3.3.4. Schematic drawing showing the modified transcochlear ap-
proach type D. The red outline shows the additional bone to be removed.
Fig. 3.4.1. Coronal MRI (T1 sequence with contrast enhancement). Dpt. 
of Neuroradiology, University Hospital of Würzburg, Germany; Chair: Prof. Dr. 
M. Pham. 
*: intrameatal acoustic neuroma of the left side
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Company, Division of Ethicon Inc.; Bridgewater, NJ, USA). 
This can provide additional important information about the 
success of hearing preservation 17.
Surgical procedure
The patient is placed in a supine position with the head 
turned; fixation in a Mayfield head holder is not necessary 
for a safe MCF procedure. Preoperatively we inject 
about 15  ml of articain (1%) mixed with epinephrin 
(1:200,000) for local anaesthesia and reduction of bleeding. 
Perioperative antibiotic prophylaxis is applied according to 
current guidelines (usually 2  gr of cefazolin and 500  mg 
of metronidazole), which can be repeated after 3 hours of 
surgery. After sterile disinfection, the middle cranial fossa 
approach begins with a (reverse) question mark-shaped, 
curved skin incision (also called “lazy S”) starting anterior 
to the tragus. After incising the fascia, a temporal muscle 
flap is elevated off the calvarium and rotated laterally using 
a raspatory. Sometimes the temporal artery needs to be 
ligated. The flaps can be easily retracted with stay sutures. 
It can also be useful to wrap the skin and muscle flaps in 
moist gauze to prevent desiccation. At this time, one can 
already harvest a piece of muscle and store it for closure 
of the inner ear canal later. At this point in the surgery, 
250  ml of mannitol (20%) are applied intravenously by 
the anaesthesiologist to reduce intra-cranial pressure. 
After exposure of the squamous part of the temporal 
bone, a craniotomy of 4 × 3 cm is performed superior to 
the zygomatic root. The craniotomy is placed two thirds 
anteriorly and one third posteriorly to the outer ear canal. 
Various instruments can be used to perform the craniotomy. 
We prefer a large cutting burr to thin out the bony cortex, 
and then a diamond burr is used until the dura is exposed. 
Alternatively, also a piezo surgical instrument or a classical 
saw can be used. The extracted bone flap is set aside and 
stored in a bowl covered with moist gauze together with 
the extracted muscle graft. The graft should not be stored it 
in saline solution, as this would elute the tissue. The sharp 
edges of the craniotomy should be smoothened using a 
diamond burr or luer-rongeur forceps to keep the retractors 
from rocking. After extraction of the bone, the dura of the 
middle fossa has to be detached from the temporal bone 
from in a postero-anterior fashion with a sharp raspatory or 
the tip of sharp scissors. Bipolar cautery can also be used 
to shrink and contract the dura. Usually this step can be 
performed very easily without applying too much force. In 
some cases, the dura is very adherent and extreme attention 
must be paid in order not to stretch it too much to avoid 
cerebrospinal fluid (CSF) leakage. Undesirable lateral 
venous bleeding can be stopped by temporarily applying 
neurosurgical swabs soaked with articain/epinephrin, or by 
packing the bleeding vessels with oxidized cellulose (e.g. 
Tabotamp®). Afterwards, the self-retaining retractor can 
be placed. We use the House retractor modified by Ugo 
Fisch to lift the temporal lobe. The blade of the retractor 
is placed at the margo superior of the petrous bone sparing 
the superior petrosal sinus and then fixed to the retractor.
At this stage, the most important two landmarks have to 
be identified: the canal of the major petrosal nerve and 
the superior semicircular canal, which is often outlined 
by the so-called arcuate eminence. The bone of the 
superior semicircular canal is carefully removed using a 
diamond burr until the perilymphatic space (“blue line”) 
is identified. Sometimes the exposition of the blue line is 
impeded by a missing acuate eminence due to compact 
surrounding bone or pneumatized cells 18 19. Opened cells 
have to be carefully sealed before completing the surgery 
in order to avoid CSF leakage. Anterior to the blue line, 
the geniculate ganglion can be exposed, if necessary. 
The roof of the internal auditory canal is completely 
removed from the fundus to the porus and the intrameatal 
dura is exposed. Particular care must be taken when 
dissecting the lateral end of the IAC since the basal turn 
of the cochlea is very close. An additional bony landmark 
should be identified at the fundus of the IAC, the crista 
verticalis (“Bill’s Bar”), which separates the beginning 
of the facial canal and the area of the superior vestibular 
nerve. Subsequently, the intrameatal dura is incised and 
dissected up to the cerebellopontine angle. Now the 
facial nerve can be visually and electrically identified 
using the stimulation probe. Depending on the origin 
of the tumour, which can arise either from the superior 
or – much more often – the inferior vestibular nerve, the 
surface of the tumour comes into vision. In very small 
Fig. 3.4.2. Intraoperative CNAP measurements after tumour removal.
*: n. facialis; #: n. cochlearis; §: ball electrode
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opened temporal bone cells have to be sealed meticulously 
using either bone wax or fibrin patches to avoid CSF 
leakage. Furthermore, the bony flap has to be replanted. 
Fixation of the flap can be performed with titanium 
microplates, resorbable sutures or plates, or simply by 
sticking it back into position with the help of fibrin glue 
and fibrin sealant patches (e.g. Tachosil®). When extensive 
drilling was necessary to enlarge the craniotomy, the flap 
sometimes does not cover the defect completely. Some 
authors recommend using porous polyethylene implants 
(e.g. Medpor®) in this situation, but we avoid to use any 
synthetic material. In fact, we observed that even larger 
gaps close spontaneously by osteogenesis over the course 
of time. 
To allow an adequate postoperative wound drainage, a small 
suction drain is placed between the dura and the bone. Wound 
closure is performed by continuous sutures of the temporal 
muscle in two layers, followed by interrupted sutures of the 
subcutaneous tissue and a continuous skin closure. Finally, 
a soft pressure dressing is applied. The patient is monitored 
at the intensive care unit for one night. The suction drain is 
removed on the second or third postoperative day. 
Complications
Although complications are rare, it is very important to 
know how to deal with them routinely, especially since 
hearing preservation surgery is increasingly recommended 
for small tumours. The most common complication of 
the MCF approach is cerebrospinal fluid leakage, which 
can occur in more than 10% of patients  27-30. In most 
cases, it starts within the first few postoperative days, but 
sometimes there is a delay of even several weeks after 
discharge of the patient. CSF leakage is observed as a 
leakage into the wound or suction-drainage, or more often 
as posterior rhinorrhoea. It is typically the result of spinal 
fluid escaping through aerated petrous bone cells. The 
existence and opening of well-pneumatised temporal bone 
cells above the IAC and the superior semicircular canal 
is a reliable predictor for postoperative liquorrhoea  31. 
In contrast to others  32  33, we could demonstrate that 
stepwise conservative treatment is successful in most 
cases  31. This includes bedrest, pressure dressings and 
i.v. antibiotics, and leads to spontaneous suspension of 
liquorrhea in up to 70% of cases  31. If not, the next step 
would be to place a spinal lumbar drainage. Only if these 
nonsurgical steps are unsuccessful, surgical re-exploration 
is indicated. Fortunately, more severe complications such 
as haemorrhage, meningitis or pulmonary embolisms that 
can be lethal are very rare. Overall, mortality following 
MCF surgery for acoustic neuroma removal decreased 
within the last 5 decades below 1%, which was confirmed 
in different large series 27 34-36. 
tumours, the superior vestibular nerve can be separated 
and preserved. In larger tumours the facial nerve already 
might be flattened or thinned out by the growing tumour. 
The cochlear nerve is always inferior to the facial nerve, 
but cannot be visualized at this point of the surgery as 
the tumour mass blocks the direct view to the nerve in 
most cases. A representative portion of the tumour should 
always be assessed for histopathological examination. 
Next, the tumour mass is debulked. This procedure can be 
done using classical bipolar ring forceps. Alternatively we 
prefer to use a flexible CO2 laser fibre (Omniguide® Inc., 
Lexington, MA, USA), as this allows for a contactless 
tumour resection (Fig. 3.4.3) without damaging the facial 
or the cochlear nerve, which run alongside the surface of 
the tumour  20. Parts of the tumour can be luxated using 
a small 45° hook. Residual tumour parts contacting the 
facial and the cochlear nerve have to be sharply dissected 
with neurectomy scissors or a sickle knife.
If intraoperative monitoring of hearing is not possible due 
to poor ABR preoperatively, or if a relevant reduction in the 
morphology of the elicited waves during tumour removal 
occurs, direct cochlear nerve action potentials (CNAP) can be 
registered using a small ball electrode.
Finally, intracranial haemostasis has to be ensured before 
closure of the site. The inner ear canal is sealed with a piece 
of temporal muscle or abdominal fat in combination with 
fibrin glue. It is still very controversial whether fat 21-23 or 
muscle 24-26 is better in this task. The selection of materials 
depends on both surgeon’s preference and experience. In 
our opinion, muscle is safe enough and efficacious in MCF 
cases in which only small defects have to be plugged. All 
Fig. 3.4.3. Intraoperative contactless laser resection.
*: tumour; #: laser probe
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Positioning and preparation
The patient is placed supine with the shoulders at the edge 
of the surgical table. A three-pin fixation device is used to 
affix the head to the table. The single pin of the head fixator 
may be placed in the contralateral frontal area (forehead) or, 
alternatively, above the ipsilateral mastoid process with the 
two pins in the frontal area (at a similar height). In general, 
the pin(s) should not be placed near the skin incision or into 
the temporalis muscle (TM). Then there are three movements 
to position the head: lifting, rotation and extension. First, the 
head is lifted above the level of the heart to facilitate venous 
drainage. Rotation and extension movements depend to the 
location and type of lesion: 30 degrees of rotation are needed 
for posterior exposure (e.g. posterior communicating artery, 
carotid bifurcation, and basilar tip aneurysms), 45 degrees of 
rotation allow a middle exposure (e.g. middle cerebral artery 
aneurysms whereas 60 degrees of rotation are required for 
an anterior exposure (e.g. anterior communicating artery 
aneurysms, suprasellar tumors). The extent of rotation also 
determines the need for ipsilateral shoulder lift to reduce 
neck torsion and therefore jugular vein occlusion. The final 
maneuver places the zygoma as the highest point in the 
surgical field, tilting the vertex backward toward the floor.
Skin flap
The skin incision extends from the root of the zygoma, 
approximately 1-1.5 cm anterior to the tragus to the midline 
in a curvilinear fashion, just behind the hairline (Fig. 3.5.1). 
Conclusions
Middle cranial fossa approach offers a safe access for 
removal of small acoustic neuromas without contact to 
the brainstem. By consequent use of important technical 
refinements (e.g. monitoring, laser) it became possible to 
achieve excellent functional results in hearing and facial 
nerve preservation over the last decades.
3.5. The pterional approach
V. Baro, A. Landi, L. Sartori, L. Denaro, D. d'Avella
Introduction
Pterional craniotomy is one of the most long-lived 
approaches in neurosurgical practice, thus representing 
an cornerstone of the anterior and medial cranial fossa 
surgical corridor. Its history started in the early ’900 when 
Heuer  1 developed the first frontotemporal craniotomy. 
Furthermore, across many decades, this elegant cranial 
approach incurred several modifications and finally has 
been popularized by Yasargil 2 in the second half of the last 
century 3. 
This approach is one of the most versatile and useful in 
neurosurgery because it limits brain manipulation and 
retraction, reducing complications 4 5. In fact, this approach 
cleverly exploits cerebrospinal fluid (CSF) pathways 
to reach the surgical target located in the skull base: the 
Sylvian fissure and the adjoining basal cisterns.
Indications
This approach enables the exposure of lesions affecting 
the frontal and temporal lobes, the insula, the uncus and 
the Sylvian fissure; the circle of Willis and the cavernous 
sinus area; the anterior and middle cranial fossa (orbit, 
sphenoidal and ethmoidal regions); sellar and suprasellar 
lesions and the mesencephalus 6.
• Aneurysms and vascular malformations arising mostly 
from the anterior part of the Willis polygon and, less 
commonly, from the posterior circulation (e.g. basilar 
apex aneurysm).
• Anterior skull base meningiomas (e.g. olfactory 
groove meningioma, tuberculum sellae meningioma, 
sphenoid wing or plenum sphenoidalis meningioma, 
cavernous sinus meningioma) or deep Sylvian fissure 
meningioma.
• Diffuse gliomas or metastases located in the frontal 
lobe, temporal lobe and insula.
• Selective amigdalohyppocampectomy for refractory 
epilepsy.
• Congenital pathologies of the frontotemporal region 
(e.g. arachnoid cysts).
Fig. 3.5.1. This drawing shows the skin incision with the relevant neuro-
vascular anatomy. 
FB: frontal branch of the superficial temporal artery;  
FTB: frontotemporal branch of the facial nerve; PB: parietal branch of the superficial 
temporal artery; TA: superficial temporal artery
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TM could limit the inferior exposure but the retraction with 
fishhooks usually reduces this drawback 16 17. Preservation of 
a superior cuff of fascia, together with a blunt dissection, are 
considered necessary measures to achieve a proper muscular 
healing 15.
Osteoplastic craniotomy (OC)
This technique has been developed to answer the crescent 
need for excellent cosmetic results, especially in elective 
surgery and in young patients. The TM is retained over the 
bone but dissected and elevated only from its frontozygomatic 
attachment. The craniotomy is then performed form a burr 
hole placed anteriorly and superiorly to the STL, encircling 
the TM and ending at the posterior zygomatic root. The final 
osteotomy is carried under the subperiostal tunnel and finally 
the osteoplastic flap is reflected anteroinferiorly, hinged on 
the frontozygomatic attachment of the TM 18-20.
Craniotomy
The purpose of the craniotomy is to widely expose the Silvian 
fissure and the surrounding frontal and temporal lobes. The 
burr holes required for the craniotomy vary between various 
authors, ranging from one 16 21 to three 22. The number of holes 
also depend from the underlying pathology: 1) between the 
STL and the frontozygomatic suture, behind the orbital rim 
(key hole); 2) at the inferior temporal fossa, just above the 
root of the zygoma; 3) at the posterior part of the STL (if 
a greater exposure of the fissure is needed, e.g. for middle 
cerebral artery aneurysms). 
The dura mater is dissected at the level of the burr holes 
with a Penfield dissector n. 3 and the craniotome is used 
to cut the bone flap, joining the burr holes (Fig.  3.5.2). 
Usually the sphenoid ridge is too prominent, stopping the 
craniotome from advancing. In the latter case, superficial 
drilling of the lateral surface of the greater sphenoid wing 
allows fracturing of the bone with a periosteal elevator. The 
free bone flap is carefully separated from the underlying 
dura and removed. The next step involves drilling, which 
completes the extent of bony removal. The dura mater is 
dissected off the sphenoid wing and the sphenoid ridge and 
thus removed with a high-speed drill towards the superior 
orbital fissure. The extent of drilling is different depending 
on the pathology. Extradural drilling may include an 
anterior clinoidectomy and the removal of the remaining 
part of the squama temporalis.
Dural opening
The dura mater is incised in a curvilinear, anteriorly based 
fashion. Peripheral dural sutures are placed to lift up dural 
edges in order to prevent ooze bleeding from the epidural 
space. It is important to limit dural coagulation and to keep 
the dura wet with irrigation during the surgery, to minimize 
its retraction.
We usually shave only a corridor of hair 2  cm along the 
planned incision line, combing the hair with chlorhexidine.
The skin incision is made with a scalpel as deep as the 
superficial layer of the temporalis fascia (STF), carefully 
at the level of the zygoma, to preserve the common trunk 
of the superficial temporal artery (STA)  7. It is crucial to 
preserve some blood supply (at least one of the major trunks 
of the STA) to the TM to reduce the risk of muscle atrophy, 
masticatory dysfunction and temporomandibular joint pain 8. 
When the STA is needed for a bypass, the artery and its main 
branches are mapped with Doppler ultrasonography (or 
with neuronavigation system) before the incision. Another 
insidious structure is the frontotemporal branch (FTB) 
of the facial nerve, which is exposed to damage both by 
direct injury during the approach, and by traction due to the 
retraction of the skin flap. Its damage could be disfiguring 
because the FTB innervates the orbicularis oculi, frontalis, 
and corrugator supercilii muscles, resulting in a paralysis 
of the eyebrow  9-11. Indeed, one of the goal of modern 
neurosurgical approaches is to ensure the best functional and 
cosmetic results for the patients. 
Temporalis muscle dissection
This step hides some neurovascular pitfalls, as previously 
highlighted. Currently, there are three main techniques 
used to dissect safely the temporal muscles: the interfascial 
dissection, the myofascial (one-layer) technique and the 
osteoplastic craniotomy.
Interfascial dissection
This technique is used especially when a wide anterior 
exposure, toward the zygomatic arch, is needed. The 
dissection starts approximately 4 cm above the lateral orbital 
rim, at the upper edge of the interfascial fat pad. The incision 
extends in depth all the way to the deep layer of the TM 
fascia, parallel to the ascending part of the skin incision. 
The fat pad, which contains the FTB, is carefully dissected 
and reflected anteriorly over the skin flap. The deep layer of 
the fascia is incised at the same level, from the root of the 
zygoma to the superior temporal line (STL) 12-14. Generally, 
a superior cuff of fascia is preserved over the STL on the 
bone. In fact, this will enable re-approximation of the TM 
during closure. The incision is carried inferiorly and finally 
the TM, its adherent fascia and periosteum are dissected, 
using a periosteal elevator or a Penfield dissector. Monopolar 
cautery should not be used to preserve the vascularization of 
the subperiosteum, preventing TM atrophy 15.
Myofascial (one-layer) technique
The TM is incised from the ascending limb of the skin 
incision down to the bone, the incision is then carried 
along the STL and finally downwards. The TM is dissected 
from the bone, as previously mentioned, and reflected 
anteroinferiorly together with the skin flap. The bulk of the 
E. Zanoletti et al.
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Closure
Dura mater is closed with running 4-0 not absorbable 
suture in a watertight fashion, after abundant irrigation of 
the surgical field in order to check final hemostasis and to 
reduce pneumocephalus. The closure should be strengthened 
with dural substitutes or with galea capitis grafting and fibrin 
glue when a complete closure is not possible (mostly due 
to dura retraction during surgery or for extensive bipolar 
coagulation). Circumferential tack-up sutures are placed 
through small holes at the bony edges and a central tack-
up suture is placed in the bone flap, to prevent epidural 
bleeding. The bone flap is reaffixed with a titanium plate (at 
least three) and screws. The bony defect created from the 
removal of the inferior temporal bone can be filled with bony 
substitutes (hydroxyapatite, methyl methacrylate) or with 
a titanium mesh. The TM and fascia are reapproximated in 
separated layers. 
3.6. The infratemporal A  
(and B, C, D) approach
R. Pareschi
This approach allows a wide access to the jugular foramen, 
the infralabyrinthine area, the vertical intrapetrous carotid 
artery (C1 and C2 segments) and the upper retrostyloid 
spaces. It can be enlarged anteriorly to the petrous apex and 
to the middle-lower clivus by drilling out the choclea and 
the bone located medially to the internal carotid artery, or 
posteriorly into the cerebello-pontine angle by transecting 
the dura of the posterior cranial fossa.
The approach proceeds under microscopy, with the opening 
of the Sylvian fissure and the basal cisterns to relax the brain 
by removing CSF. This step is fundamental to minimize 
the use of retractors and to ease the splitting of the fissure. 
The quantitative dissection of the Sylvian fissure depends 
from the underlying pathology. Figure 3.5.3 (cadaveric) and 
Figure  3.5.4 (intraoperative) show a view of the anterior 
cranial fossa, reached after the complete opening of the 
fissure.
Fig. 3.5.2. Exposure of the pterional region afforded by inferior retraction 
of the musculocutaneous flap with the three burr holes, immediately before 
the realization of the bone flap. 1: the key hole burr hole, 2: the temporobasal 
burr hole, 3: the burr hole placed at the posterior part of the superior tem-
poral line. A superior cuff of temporalis fascia is preserved over the bone to 
ease muscular suture during closure.
Fig. 3.5.3. Cadaveric picture showing the neurovascular anatomy after the 
opening of the Silvian fissure, anterior exposure.
Fig. 3.5.4. Intraoperative view showing the neurovascular anatomy after 
the opening of the Silvian fissure, anterior exposure. 
III: third cranial nerve; ICA: internal carotid artery; LT: lamina terminalis;  
OC: optic chiasma; ON: optic nerve; TL: temporal lobe
A1: anterior cerebral artery; A-ComA: anterior communicating artery;  
ICA: internal carotid artery; LT: lamina terminalis; OC: optic chiasma
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cervical root is raised. The flap is formed by the nuchal 
and mastoid insertions of the posterolateral muscles of 
the neck and by the periosteum and galea of the petro-
occipital region. The temporal muscle is left in place.
• The facial nerve is found at its exit from the stylo-mastoid 
foramen and dissected from the parotid tissue until the 
main branches of the nerve are identified.
• The posterior belly of the digastric muscle is elevated 
from the digastric groove. The internal jugular vein and 
internal and external carotid arteries, the IX, X, XI and 
XII cranial nerves are identified in the neck and followed 
upwards until their exit from the skull-base after the 
removal of the styloid process and the anterior dislocation 
of the muscles inserted on it.
• The skin of the external auditory canal, the tympanic 
membrane, the malleus and incus are removed.
• A wide radical mastoidectomy is performed and the 
This approach is indicated for extensive extra-intradural 
tumors involving the aforementioned anatomical regions.
The cornerstone of the approach is the anterior rerouting of 
the facial nerve, from the geniculate ganglion to its main 
intraparotid branches.
Neurovascular surgical anatomy
• The vertical tract of the facial nerve runs straight down 
from its second turn to the stylo-mastoid foramen and 
is centred on the jugular bulb, which lies medially and 
anteriorly to the nerve.
• The periostium of the skull-base forms a thick ring 
around the internal jugular vein as the latter structure 
exits the jugular foramen.
• The medial aspect of the jugular bulb is a wall of 
periostium presenting multiple entrances of the inferior 
petrosal sinuses.
• The condylar emissary vein drains into jugular bulb in 
2/3 of the cases. It is exposed together with with the 
hypoglossal nerve when drilling out the condylar process 
of the occipital bone.
• The lower cranial nerves (IX, X, XI), run together through 
the medial thick wall of the jugular bulb (pars nervosa) 
when exiting from the skull-base into the upper neck.
• The IX cranial nerve is the most lateral and anterior while 
the XI cranial nerve is the most medial and posterior.
• The ascending pharyngeal artery passes through the 
jugular foramen to supply the dura of the posterior fossa.
• The IX cranial nerve crosses anteriorly the internal 
carotid artery.
• The XII cranial nerve turns inferiorly to run together with 
with the X cranial nerve for a short tract in the upper 
neck. More inferiorly the XII cranial nerve crosses the 
external carotid artery to then move anteriorly towards 
the tongue. The X cranial nerve runs between the internal 
jugular vein and the internal carotid artery.
• The XI cranial nerve crosses the lateral wall of the internal 
jugular vein in 50% of the cases, anterolaterally to C1.
• The styloid process and the muscles inserted on it are 
lateral to the internal carotid artery at its entrance at the 
foramen caroticum. 
Surgical technique
• A retroauricolar “C” shaped incision in made from 3 cm 
above the helix to 2  cm below the tip of the mastoid 
(Fig. 3-6.1).
• The external auditory canal is transected at the bony-
cartilagineous junction. The skin of the canal is raised 
from the cartilage and the edges are reverted and sutured 
as a cul de sac. In addition, a pedicled tragal flap is 
created as a second layer for the closure of the external 
auditory canal (Fig. 3.6.2)
• A wide reversed “U” shaped mioperiosteal flap with a 
Fig. 3.6.1. The retroauricolar “C” shape incision. The extension to the neck 
is interrupted at 2 cm below the mastoid tip.
Fig. 3.6.2. Closure of the external auditory canal with a pedicled tragal 
flap.
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injuring the lower cranial nerves under the XI cranial 
nerve.
• The lateral wall of the jugular bulb is opened and bleeding 
occurring from the opening of the inferior petrosal sinus 
is controlled with surgicel.
• Particular attention must be taken in not injuring the 
medial wall of the jugular bulb where the lower cranial 
nerves are located at their exit from the skull base.
• At this point tumour removal begins. The infiltrated bone 
of the fallopian canal and of the tympanic bone is drilled 
out and the tumour is removed from the posterior dura. 
The tumour is removed from the jugular bulb area and the 
infiltrated infralabyrinthine cells are drilled. The sigmoid 
sinus and the internal jugular vein are now opened and 
the tumour, if present, is removed. The tumour, when 
possible, is separated from the lower cranial nerves. This 
can be accomplished for small C1 tumours. For C2-C3 
tumours, the sacrifice of the lower cranial nerves is 
necessary if total removal is the goal of surgery.
• The internal carotid artery must be identified after 
extensive drilling of the infiltrated tympanic bone 
and bipolar cauterization of the tumour around the 
artery is necessary. Further drilling of the infiltrated 
infralabyrinthine apical cells, and of the clivus allows a 
complete exposure of the tumour that is bluntly dissected 
from the artery following a subperiosteal plane (between 
the periostium of the carotid canal and the adventitia of 
the artery). Sub-adventitial dissection must be strongly 
discouraged to avoid dangerous pseudoaneurisms of the 
vessel which may lead to subsequent thrombosis.
• The posterior dura is now opened and even a huge 
(> 2 cm) intradural portion of the lesion can be removed 
in a single-stage fashion together with the extradural 
tumour. 
• A translabyrinthine extension, which would allow 
further medial and superior exposure is unnecessary. 
A petro-occipital trans-sigmoid approach (POTS, the 
combination of a retrolabyrinthine petrosectomy and a 
suboccipital craniectomy) is adequate.
• The posterior dura is then transected and the tumour 
is rather easily dissected from the anterior inferior 
cerebellary artery (AICA), posterior inferior cerebellary 
artery (PICA), vertebral artery and from the facial-
acoustic bundle (Fig.  3.6.4). Dissection of the lower 
cranial nerves from the tumour, even if their anatomical 
preservation is achieved, will result in a pharyngo-
laryngeal palsy.
• The major risk of opening the intracranial compartments 
and putting them in continuity with the petro-occipital 
area and the spaces of the upper neck is to have a sub-
cutaneous collection of cerebro-spinal fluid (CSF) and/
or a cutaneous CSF leak at this level. The latter fact 
could lead to life-threatening infectious complications. 
bone that lies anteriorly, superiorly and posteriorly to the 
sigmoid sinus is completely drilled out from to expose 
the transverse sinus until the jugular bulb.
• The facial nerve is skeletonised from the stylo-mastoid 
foramen to the geniculate ganglion by removing all the 
overlying bone.
• The tympanic bone, the mastoid tip and the bone between 
the posterior semicircular canal and the jugular bulb is 
widely drilled out.
• The sigmoid sinus, the jugular bulb and the internal 
jugular vein are put in continuity by removing the bone 
located inferiorly to the jugular bulb (condylar process of 
the occipital bone).
• A new bony canal is drilled in the root of the zygoma.
• The facial nerve is freed at the stylomastoid foramen 
leaving the surrounding soft tissue around it.
• The mastoid and tympanic segments of the nerve are 
now elevated from the fallopian canal until the geniculate 
ganglion is reached.
• The anterior rerouting of the facial nerve is completed 
in continuity with the intraparotid tract (Fig. 3.6.3). This 
delicate manoeuvre is the key point of the infratemporal 
approach type  A. It allows access to the medial 
compartments of the petrous bone (the infralabyrinthine 
and inframeatal area, the vertical and horizontal canal 
of the carotid artery, the petrous apex and the lower and 
middle clivus).
• The mandibular condyle is anteriorly displaced and 
separated from the anterior wall of the external auditory 
canal that is completely drilled out to expose the vertical 
portion of the internal carotid artery.
• The internal jugular vein in the neck is ligated and 
transected whilst the sigmoid sinus is packed with 
intraluminal surgicel.
• The internal jugular vein is elevated upwards without 
Fig. 3.6.3. Surgical field after the rerouting of the facial nerve.
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3.7. The petro-occipital transigmoid 
approach (POTS)
A. Mazzoni, D. Cazzador, E. Zanoletti
Generalities on the jugular foramen  
in skull base surgery 
The jugular foramen (j.f.) is the largest transition channel 
from the intradural endocranium to esocranial skull 
base face and neck. It is composed by different tissues, 
each one having different interaction with the histotypes 
of the different lesions. Meningioma, paraganglioma, 
schwannoma interact differently with bone, nerves, dura 
and vessels. This involves a specific modality of surgery 
both as approach and resection. Bone, that is the petro-
occipital bone, is the place where the variable relation 
between histology and site of lesion is most obvious. 
The infratemporal approach type A is the traditional corri-
dor to the jugular foramen (Fig. 3.7.1). It allows resection 
of tumors located in the jugular foramen, a wide connec-
tion with the neck, a good control of the vertical carotid 
artery up to its first genu and the beginning of its horizon-
tal tract. The anterior trasposition of the facial nerve, the 
exenteratio of the middle ear and drilling of the labyrinth 
are the planned surgical steps which allow, as well as the 
visualization of structures, the adequate working space so 
as to drill as much of bone as required by the pathology. 
The lateral corridor of the infratemporal A may be replaced 
This risk can be avoided by taking care to: 1) minimize 
the exposure of the upper neck. The incision must stop 
1-2 cm below the mastoid tip. The internal jugular vein is 
ligated just anteriorly to C1 and the internal carotid artery 
must be exposed at the level of the styloid process; 2) 
watertight closure of the “U” shaped muscular-periosteal 
flap raised at the beginning of the procedure.
Infratemporal B, C, D approaches (ITb, ITc, ITd)
While the ITa approach extends dorsally from the carotid 
artery up to the petrous bone, the cerebello-pontine angle 
and the parapharyngeal space, the ITb and ITc extend 
ventrally from the carotid artery to the petroclival bone, the 
rhinopharynx and the infrasphenotemporal space. These are 
extradural approaches and do not allow intradural work. 
Their gate of entry excludes the external auditory canal 
and the tympanum together with the Eustachian tube in 
order to reach the vertical and horizontal segments of the 
carotid artery, and thus the petrous apex, the clivus (b) or the 
rhinopharynx (c). A temporal craniotomy opens the surgical 
corridor superiorly. The facial nerve is left in situ. Chordomas 
of the clivus, which require large bony removal, or residual-
recurrent carcinomas of the rhinopharynx are the common 
indications to infratemporal B and C approaches, respectively. 
The preauricular subtemporal-infratemporal approach was 
described by Sekhar, and it is also called infratemporal type 
D approach. It runs anteriorly to the external auditory canal 
and preserves the Eustachian tube. It is directed to the lateral 
infratemporal fossa, the pterygopalatine fossa and the orbital 
apex.
Fig. 3.6.4. Surgical field after the transection of the posterior fossa dura. 
Fig. 3.7.1. The left infratemporal A approach involves the removal of the 
external auditory canal, the middle ear, the anterior transposition of the facial 
nerve from the fallopian canal. The labyrinth may be left in place or removed, 
if required. This allows a complete visualization of the jugular foramen, the 
vertical carotid artery and space is left for surgical manoeuvers in the jugu-
lar foramen area. The sigmoid sinus is transected ant the presigmoid dura 
may be opened to enter the posterior fossa. The connection with the petrous 
cavity and the neck is wide and allows control of the tumor in the soft tissues 
and in the bone.
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POTS too, visualized (Fig.  3.7.3), but drilling up to its 
genu is endangered by the posterior wall of the external 
auditory canal, the labyrinth and the facial nerve in situ. 
This is why a C1 paraganglioma might be approached by 
a POTS, but C2 paraganglioma (which involves erosion of 
the bone of the vertical tract of the internal carotid artery) 
cannot be removed around the carotid artery without the 
risk of residual disease. When the diagnosis is schwanno-
ma of the jugular foramen, or low-aggressive chondrosar-
coma, or meningioma, the amount of bone which should be 
drilled is less than in paraganglioma and POTS approach 
may be the choice. Being the jugular foramen paragan-
glioma the most frequent lesion to be treated at this site, 
the choice between infratemporal A and POTS depends on 
the C1-C2 classification of the tumor. The N (neck) and 
intracranial (D) extra (De) or intradural (Di) extensions 
of the tumor are not conditioning factors in favour of one 
approach or to the other one, since both approaches allow 
intradural resection of tumor in the posterior fossa, also 
at its lower aspect. In principle, the intradural resection 
of tumor may be performed in a single stage procedure in 
POTS, while a staged approach is advised in infratempo-
ral A, since a wide connection between the neck and the 
by a more posterior corridor, wihich does not involve the 
sacrifice of the middle ear, and labyrinth, the cul-de-sac 
closure of the external auditory canal and the anterior 
transposition of the facial nerve (Fig. 3.7.2). This reduces 
enormously the morbidity of the approach to the jugular 
foramen, since the facial nerve is left in situ and hearing 
is completely preserved as well as the natural aestethic 
contour of the ear and head. The drawbacks of this less 
extensive and more conservative approach is not the vi-
sualization of the jugular foramen, neither the connection 
with the neck, but the working space in the bone around 
the jugular foramen, which is reduced and prevented by 
the facial nerve, the external and middle ear and labyrinth 
in situ. The amount of bone which is to be removed is dic-
tated by the pathology. In paraganglioma is more than the 
involvement of the neurovascular structures of the jugular 
foramen and extensive drilling requires a wider exposure 
than as allowed by petro-occipital trans-sigmoid (POTS) 
approach. The internal carotid artery may be reached by 
Fig. 3.7.2. The left POTS approach involves the preservation of the ex-
ternal auditory canal, the middle ear, the facial nerve in its Fallopian canal. 
The labyrinth is left in place. This allows a visualization of the jugular fo-
ramen, the vertical carotid artery is hidden and the space left for surgical 
manoeuvers in the jugular foramen area is reduced, by the presence of the 
posterior wall of the external ear and the facial nerve in situ. The sigmoid 
sinus is transected  and the presigmoid dura may be opened to enter the 
posterior fossa. The connection with the petrous cavity and the neck is 
wide and allows control of the tumor in the soft tissues and in the bone. 
This more posterior and conservative approach needs the adition, as de-
scribed in the text, of a retrosigmoid craniotomy to widen the corridor and 
allow exposure of the posterior fossa.
Fig. 3.7.3. Jugular foramen paraganglioma, C2 . The CT bone scan shows 
erosion of the vertical tract of the carotid artery: this should orient the sur-
geon to consider infratemporal A approach to allow an adequate resection of 
tumor with the least risk of microscopic residual disease. A POTS approach 
is feasible, when a planned deliberate incomplete removal is considered or 
the risk of microscopic disease is accepted.
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• dura is closed with interrupted suture, the fat is placed 
on the residual dural window corresponding to the 
jugular foramen, the muscular flap is sutured back.
This single stage transcervical transpetrous approach is a 
prioritarian choice for schwannoma, meningioma, chon-
drosarcoma. It involves however a limitation, this is the 
scarce control of the carotid artery in paraganglioma, 
which requires a large drilling of the osseous bed of the 
tumor and a safe control of the latter connection with the 
carotid wall.
The POTS approach in extradural lesions can enlarge the 
transit to the neck by drilling the process of C1. Several 
approaches (transcondylar = drilling the occipital condyle 
and transjugular = drilling the jugular tubercle) were de-
scribed in the nineties, all being already contained within 
the POTS approach, as part of the enlargement of the sur-
gical field.
The advantage of this single stage cranio-cervical 
transpetrous approach involves a limitation. This is the 
scarce control of the carotid artery, which is sufficient for 
schwannoma, meningioma and other lesions  1 2, but it is 
not adequate for paraganglioma, which requires a large 
drilling of the osseous bed of the tumor and a safe control 
of the latter connection with the carotid wall. 
The POTS approach in extradural lesions assure the transit 
to the neck by drilling the process of C1. Other approaches 
(trancondylar, transjugular) were described, all being a 
part of and contained within the POTS approach.
3.8. Presigmoid retrolabyrinthine approach 
and variation
I.N. Kanaan
Introduction
The retrosigmoid (RS) approach is the most popular 
and versatile corridor used for management of a wide 
spectrum of neoplastic and vascular lesions confined to 
the cerebellopontine angle (CPA) and its surrounding 
structures. Most common indications are schwannomas, 
meningiomas, epidermoids and vascular compressions. 
This technique represents an evolution of the unilater-
al suboccipital approach that was credited first to Bal-
ance in 1894 and Thomas Annandale for the removal of 
a vestibular schwannoma in 1895  1. It was successfully 
performed by Krause using an osteoplastic flap in 1903 2 
and popularized by Dandy in 1934 with a reduction in 
its related mortality  3  4. The approach was refined by 
McKenzie and Alexander  5 using a seated position and 
eventually perfected by Kunze and Rand in 1965 using 
the microscope.The technique was then complemented 
with a transmeatal approach in 1965 6 7. Middle fossa and 
intradural compartment exposes the latter more to the risk 
of CFS leak. 
When the disease is benign and slow growing and the 
morbidity of surgery on the lower cranial nerves has 
been balanced, the use of POTS today finds its role in 
the planned subtotal resections, in partial targeted sur-
gery, even in radical surgery where we accept a higher 
risk of microscopic residual. The conventional and new 
percutaneous techniques of embolization of tumors, like 
in jugular foramen paraganglioma, allow safe and almost 
bloodless resections of hypervascularized tumors thus 
increasing the application of this more conservative ap-
proach.
Petro-occipital transigmoid approach (POTS a) 1 2
The POTS a presents a postero-lateral entry, while the ITa 
has a lateral entry. This oblique antero-medial direction 
allows to leave the external auditory canal, tympanum 
and facial nerve at their natural place. The approach is 
centered on the jugular foramen and the endocranial and 
cervical spaces where the lesion grows from the foramen. 
It is essentially made of a retrosigmoid craniotomy, a 
retrolabyrinthine petrosectomy and a jugulo-carotid 
cervicotomy, all combined in a single surgical field. 
The watertight closure to CSF is obtained by placing a 
single piece of fat in the petrous cavity. The fat does not 
migrate to the neck as it is held by the isthmus between 
the transverse process of C1 and the tympanic bone. The 
approach exposes the jugular foramen, cerebello-pontine 
angle, petrous bone, occipital condyle and low clivus, 
the jugulo-carotid space in the neck. The petrous bone 
boundary of the surgical space is the posterior wall of 
the external auditory canal, mastoid Fallopius, posterior 
aspect of labyrinth and vertical internal carotid artery. 
Salient steps are as follows: 
• wide C shaped retroauricular skin flap, and U shaped 
fibro-muscular flap rooted at level of C1; 
• mastoidectomy with exposure of jugular bulb and 
sigmoid sinus; the posterior side of the labyrinth and 
the dura medial to sigmoid are exposed; the condyle 
can be removed up to its posterior half if required by 
the lesion; 
• lower aspect of mastoid is opened to the neck and the 
jugulo-carotid space is dissected in continuity with 
the foramen; this communication is the canon of a 
cervico-temporal approach;
• the cerebellopontine angle is entered by horizontal 
sectioning of the dura from the jugular foramen to 
close the acoustic porus;
• resection of the lesion depends on the histology; from 
neck to petrous area or viceversa; in transdural lesions, 
the extradural is mostly removed first, the intradural 
follows; 
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provides a clear surgical field because of better venous 
drainage. It is also more comfortable for the surgeon.
Exposure
The exposure entails a combination of retrolabyrinthine-
presigmoid, retrosigmoid and sub-temporal avenues. An 
inverted J-shape skin incision is fashioned from the zygo-
matic arch at the pre-tragal region curving up 2 cm above 
the pinna and descending posteriorly and inferiorly be-
hind the mastoid process as in thepresigmoid approach. 
The temporalis muscle fascia is incised and reflected infe-
riorly in continuity with the sternocleidomastoid muscle 
and fascia. The temporalis muscle is released and reflect-
ed inferiorly. Localization of the lateral and sigmoid si-
nuses are defined by using the aforementioned landmarks 
and supported by the use of the neuronavigation. The bo-
ny exposure includes three steps:
• Step 1. A temporal-suboccipital bone flap is elevated 
in one or two pieces using 2  burr holes spanned on 
both sides of the transverse sinus just lateral to the 
asterion with special attention not to injure the lateral 
sinus (or vein of Labbé).
• Step 2. A simple mastoidectomy is performed by 
elevating a triangular mastoid cortical flap which is 
extended from the supramastoid ridge to the mastoid 
tip using a pediatric oscillating saw or B1 Midas Rex 
cutter. This procedure is followed by drilling out the 
mastoid air cells and the antrum using a  mm burr to 
expose the presigmoid dura (Trautman triangle) and 
skeletonize the sigmoid sinus down to the jugular bulb. 
The latter maneuver is crucial in allowing maximal 
mobilization of the sigmoid sinus after opening the 
tentorium. 
• Step 3. The presigmoid dura and the temporal-basal 
dura are opened toward the superior petrosal sinus.
While performing the latter steps, special attention 
must be taken to preserve the vein of Labbé. The 
superior petrosal sinus is then coagulated, double 
ligated and cut.The tentorium is now incised parallel 
to the petrous ridge dorsal to the tentorial incisura, 
where the entry of the IV nerve is seen. 
translabyrintnine approaches were promoted by William 
House in 1961 8. 
The presigmoid-retrolabyrinthine approach was first de-
scribed by H. Silverstein in 1980 9 and eventually refined 
and adopted by other pioneer skull base surgeons for di-
rect access to CPA tumors, treatment of Meniere’s disease 
and placement of auditory brainstem implants 10. 
The retrosigmoid (RS) and retrolabyrinthine (RL) ap-
proaches can be used independently or combinedtogether 
with other established approaches such as in the combined 
presigmoid petrosal approach described by Hakuba 11 (lat-
er refined and popularized by Fukushima and Almefty 
among others) to provide a panoramic exposure of Meck-
el’s cave, of the tentorial notch, the petroclival region, 
the anterolateral aspect of the brainstem and the basilar 
artery 12-18. The neuronavigation and the hybrid use of en-
doscopy jointly with microscope surgery have reduced the 
need for complex skull base exposures.
Approach selection 
The main factors that influence the choice of the surgical 
approach to CPA lesions are: nature, location, size and 
extent of the lesion, presence of intra-canalicular growth, 
baseline hearing function as well as patient’s and sur-
geon’s preference and experience. Variation of temporal 
bone anatomy, its aeration, the measure of Trautmann’s 
triangle, the petrous slope, and position of the sigmoid 
sinus may impact the choice for apresigmoid retrolaby-
rinthine (RL) approach in favor toa combined presigmoid 
approach 19 20. 
Indication
CPA region may be affected directly or indirectly by 
various neoplastic or vascular lesions. The name of the 
anatomical site was coined by Hellenberger and Kock in 
1800 and was later namedthe “bloody angle” by Harvey 
Cushing, referring to its surgical complications 21. The de-
tailed cisternal and 3D-anatomy of the CPA were elegant-
ly described by Yasargil and later by the masterpiece work 
of Rhoton 22 23. Retrosigmoid approach (RS) with hybrid 
use of endoscopy or the combined presigmoid retrolaby-
rinthine petrosal approach are the most commonly used 
neurosurgical approaches for successful treatment of the 
following conditions.
Surgical steps
Presigmoidretrolabyrinthine combined petrosal approach 
(Modified Hakuba Approach).
Position
The author favors the park bench position (Fig. 3.8.1), the 
same as for the retrosigmoid approach but with no head 
flexion. This position facilitates gravitational CSF leak-
age, minimizes blood pooling in the surgical field and 
Fig. 3.8.1. A), B): modified park bench position adopted by the author.
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but may be challenging at the presigmoid level. When 
primary closure was not achievable, we have successfully 
used a small patch of autologous tissue taken from the 
temporal muscle fascia or, alternatively, artificial dura. 
Dural repair is supported. This procedure can be per-
formed with a fat graft or rotating a flap of the posterior 
third of the temporal muscle down to fill the bony defect 
in the mastoid and pack any potential patent air cells. The 
mastoid cortical flap is fixed to the craniotomy flap using 
low profile mini titanium plates. The intervention is com-
pleted with multilayer closure of the surgical site and a 
gentle compressive dressing. 
Special considerations
All patients should have comprehensive preoperartive 
MRI studies including magnetic resonance angiography 
and venography (MRA & MRV) to guide the selection 
of the best approach and anticipate potential pitfalls. In-
traoperative neurophysiology monitoring is a vital part of 
these approaches in order to guarantee a safe surgical in-
tervention, minimize potential complications and achieve 
better clinical outcomes. 
Patients with large tumors and risk of associated hydro-
cephalus may be considered for simple preoperative CSF 
diversion procedure.
Dural sinus thrombosis and venous injury are of concern 
during these interventions. Meticulous review of the preop-
Intervention
This approach provides a direct anterior and superior multi-
channel access to large tumors of the CPA region, of Meck-
el’s cave with supratentorial extension or of lesions deeply 
located in the petroclival region and of the anterior brain-
stem. It entails minimal cerebellar retraction and short work-
ing channels free of cranial nerves to work through, as they 
are posteriorly located. The steps of tumor resection follow 
the same aforementioned principles including: maintenance 
of the subarachnoid plane for dissection, mass devasculariza-
tion, internal decompression, segmental resection using fine 
microsurgical techniques, cavitron ultrasonic surgical aspi-
rator (CUSA), copious irrigation, minimal vascular compro-
mise and special attention to venous drainage. The author 
has used the stimulation probe as a dissection tool during 
the final stage of tumor capsule removal. This tool is also 
of great value during resection of large epidermoid lesions 
growing along multiple cisterns and around intervening cra-
nial nerves. In recent years, we decided not to treat residual 
tumors invading the posterior cavernous sinus as treatment 
of these lesions is associated with a relatively high incidence 
of ocular paresis. In these cases we follow the “wait and see” 
principle and advise for adjuvant therapy if any sign of pro-
gression is reported (Fig 3.8.2).
Closure
Primary closure of the temporal dura is usually feasible 
Fig. 3.8.2. Pre and post-operative MRI (T1 + Gadolinium) showing petroclival meningioma with superior extension and subtotal resectiom leaving small re-
sidual severely adherent to 3 and 6 cranial nerves. The surgical approach selected was the modified “Hakuba” presigmoid retrolabyrinthine combined approach.
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craniotomy and a corridor which is retro-infracerebellar, 
or supracerebellar. The lateral occipital approach involves 
a craniotomy on the lateral aspect of the occipital bone 
and currently includes the suboccipital approach with a 
craniotomy close to the foramen magnum and the patient 
preferably in semisitting position (or else the supine 
position); and the retrosigmoid approach. The direction of 
the surgical corridor varies according to the entry window 
and the position of the head, that is supero-medial direction 
for the suboccipital and medial direction for the retrosigmoid 
approach. 
The cerebellum retracts following the cerebrospinal fluid 
(CSF) drainage, it also can be displaced with an autostatic 
retractor or with the dissecting instruments. 
The resection of the tumor occurs in a single or few pieces 
with the small tumor, it usually involves a succession of 
inner debulking and outer piecemeal removal. In acoustic 
neuroma, the sequential steps include the dissection on the 
cerebellum-tumor interface, inferior pole of the tumor, roots 
of the VII-VIII nerves, brainstem, the tumor superior pole, 
having the inner-outer piecemeal removal as the method 
and the VII-VIII  nerves as the phulcrum of advancing the 
procedure, in much the same way as the translabyrinthine 
approach. 
The internal auditory canal lies in a different plane than 
the cerebellopontine angle and requires a  >  30° change 
of the direction of view, which is obtained by angling the 
michroscope and/or changing the head orientation by 
rotating the table. 
erative MRI and MRV images is a prerequisite forselection 
of the proper approach and safest intervention. An attempt 
is made to protect the dural sinuses and their patency during 
their exposure. A constructive repair of iatrogenic tearing is 
mandatory, as should be avoidance of their compression or 
ablation. It is important to maintain the integrity of the vein 
of Labbé during the combined approach and to limit the 
number of sacrificed cerebellar bridging veins including 
the petrosal vein to prevent resultant hemorrhagic edema of 
the cerebellum and the brain stem. 
Measures taken to prevent CSF leakage include: sealing of 
the exposed air cells of the mastoid using bone wax, muscle 
or fat graft; watertight closure of the dura, supported with 
biological or artificial dural graft and Tisseel tissue glue 
and meticulous soft tissue closure when needed. CSF con-
version procedure may be unavoidable in some preexisting 
hydrocephalus cases, as a transient or long term measure.
Conclusions
The presigmoid retrolabyrinthine approach offers an an-
terolateral extension of the retrosigmoid approach with 
shorter working channels and lesser cerebellar retraction. 
This approach often entails significant bone drilling and 
increases operative time together with associated com-
plications. The integration of this approach into the mod-
ified presigmoid combined petrosal approach (Fig.  3.8.2) 
provides wide panoramic exposure of large lesions in the 
CPA and petroclival region with transtentorial extension 
yet maintains the preexisting integrity of hearing and fa-
cial nerve function. We select this approach in patients with 
giant petroclival meningiomas and chordomas in order to 
achieve a more radical resection and a better long term out-
come. Recently, the hybrid use of endoscopy coupled with 
an inferior incision of the tentorium and potential negoti-
ation along the suprameatal route have fostered the solo 
use of the retrosigmoid approach for microsurgical man-
agement of such lesions and limited the need for complex 
skull base bony exposure (Fig. 3.8.3). The value of emerg-
ing adjuvant treatment in interventional neuroradiology, 
stereotactic radiation and medical oncology should not be 
underestimated but rather considered as new useful tools 
in the decision making process of complex comprehensive 
care management.
3.9. Occipital approaches,  
retrosigmoid approach
A. Mazzoni, D. d’Avella, E. Zanoletti
There are two basic approaches across the occipital 
squama, the posterior and the lateral occipital approach. 
The posterior occipital approach involves a posterior, median 
Fig. 3.8.3. A), B): intraoperative photograph of left CPA epidermoid; 
C), D): endoscopic view depicting residual deposits followed by complete 
removal.
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the landmark leading to the dura of the fundus roof where 
the facial nerve enters the Fallopius canal (Fig.  3.9.1). 
The orifice of the cochlear nerve is lying below the crista 
trasversalis. The drilling of the remaining bone ring 
overhanging the fundus affords the control of the area 
of the Fallopius orifice and the vestibular orifice. This 
crucial step deserves a detailed description. The drilling 
is targeted to the portion of fundal roof overhanging like 
a ring the bony plate of fundus with its orifices. A probe 
is to asssess the width of remaining bone to be drilled 
with a 2 mm diamond burr. Successive “probe and drill” 
steps will expose the area of the vestibular channell and 
the Fallopius orifice (Fig. 3.9.2). 
The drilling is to be strictly limited to the roof as only 
there it does not risk to hit the labyrinth. The labyrinth 
does not overlap the fundus as it is separated from it by 
bone thick enough to accomodate a 2 mm burr. The bone 
becomes thinner while passing from roof to posterior 
wall. Note that the vestibular orifice is seen by a sideview 
and the Fallopius orifice with a more favorable view, 
and both orifices are masked by their nerves. The orifice 
of the vestibular nerve can be masked by the common 
crus and superior semicircular canal, but its exposure is 
exceptionally necessary as the distal portion of tumor is 
already under view and can be lifted off. The orifice can 
be exposed if the angle of view is increased by enlarging 
5 mm medially the craniotomy on a small spot close to its 
superior limit. 
Meatotomies 
Approaching the internal auditory canal meets some 
critical conditions:
1. the lumen of the canal is completely occupied by 
tumor and nerves with no room left for vision and 
instruments;
2. the cochlear nerve more than the facial is overvulnerable 
to surgical maneuvers such as pressure and stretching 
either direct or transmitted;
3. the bulge of the labyrinth is an obstacle to viewing the 
lateral half of the canal; 
4. the fundus of the canal is occupied in half of the cases 
by tumor which is adherent to it in one quarter. 
Solution of this problems involved two different 
techniques:
• Drilling of the petrous bone to remove the posterior 
wall of the canal limited to the proximal seven 
millimeters in order to preserve the labyrinth. Control 
of the lateral half of the canal is precarious especially 
on the fundus. An angled endoscope allows visual 
control and elementary maneuvers with dissectors and 
forceps. 
• Maximal bone removal around the canal with the 
retrolabyrinthine meatotomy as follows.
Retrolabyrinthine meatotomy (RLM )
The RLM is performed as a part of the retrosigmoid 
approach and requires the lateral or prone position. The 
rationale of the RLM is twofold, the control of the full 
internal auditory canal and a wide, multiangled exposure 
for handling of tissues and instruments. This is obtained 
with two steps. First, the occipital craniotomy of the 
retrosigmoid approach is to be extended enough posteriorly 
to afford the oblique view bypassing the bulge of the 
labyrinth up to the fundus. Second, drilling the petrous 
bone up to the blue line of the labyrinth allows the maximal 
removal of bone around the canal with a multiangled view 
and room for instruments. The RLM essentially involves 
a threedimensional microsurgical corridor from a postero-
medial gate on the occipital squama running adjacent to 
the tentorium to the retrolabyrinthine petrous bone, and 
thereon following the labyrinthine landmarks to the roof of 
the canal like an interdural route between the middle cranial 
fossa and the internal auditory canal. It exposes the fundus 
at the orifices of the superior vestibular and facial nerves. 
The RLM  1 involves successive steps from the first 
landmark of the vestibular aqueduct to the last one of the 
dural transition to the Fallopius canal at the fundus. The 
entry of the aqueduct on the posterior side of the petrous 
bone marks the area to be drilled. The architecture of the 
bone is here illustrated by the axial bone window CT and 
itself leads to the ivory bone of the labyrinth. The blue line 
of the posterior canal leads to the superior canal which is 
Fig. 3.9.1. Axial bone window CT scan, the surgical corridor from crani-
otomy to Fallopius in retrosigmoid RLM, left.
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Historically, Samii introduced the RISA in 1983 and 
reported the surgical technique and outcomes for 
petroclival meningiomas 1. Seoane and Rhoton described 
the anatomical aspects of the approach 2.
Technical description
We position the patient for the RISA either supine with the 
head turned to the contralateral side or semisitting. This 
depends mainly on the characteristics of the addressed 
pathology: in case of large, well-vascularized tumors 
(e.g. petroclival meningiomas) we take advantage of the 
reduced intracranial pressure, the clean operative field 
and the optimized caudo-cranial perspective provided by 
the semisitting position. However, if the lesion is small 
(petrous apex meningioma) or avascular (epidermoid 
cyst) the supine position is usually sufficient to resect 
the pathology avoiding the drawbacks of the semisitting 
position. In our opinion intraoperative electrophysiological 
monitoring is mandatory. It routinely comprises bilateral 
somatosensory evoked potentials (SEP) and motor evoked 
potentials (MEP) of the extremities, auditory evoked 
potentials (AEP), free running EMG, motor evoked 
potentials of the facial nerve (FMEP), and direct facial 
nerve stimulation. Depending on the growth pattern of 
the tumor free running EMG, direct nerve stimulation and 
MEPs are extended to the lower cranial nerves, and/or 
cranial nerves III, IV and VI. 
For both the semisitting and the supine position we rotate 
the patient’s head only after obtaining/recording a SEP 
baseline. A decrease of the SEPs  >  50% requires an 
immediate repositioning in order to avoid complications 
related to the head’s rotation or flexion with compression 
of the spinal cord due to degenerative spinal changes or 
concomitant intraspinal tumors (as in neurofibromatosis 
type II). 
Remarks for the semisitting position: gravity is the key 
concept of the semisitting patient position. It reduces the 
pressure inside the posterior fossa, continuously drains 
CSF, and allows for coupious irrigation of the operative 
field, thus gravity greatly facilitates the microsurgical 
dissection of cleavage planes and neurovascular structures. 
The main concerns regarding the semisitting position 
are venous air embolism and paradoxical air embolism 
(in case of a patent foramen ovale) and their respective 
cardiopulmonary and neurological sequelae.
However, operating on large and vascularized tumors the 
advantages of the semisitting position optimize surgical 
results, reduce operating times, and outweight their 
disadvantages. As a matter of course, an interdisciplinary 
and experienced team is mandatory to guarantee patient 
safety. 
First of all, we do not position the patient sitting, but 
The meatotomy is completed by removing the bone which 
extends from the labyrinth to the canal porus and all 
around the canal close to 180° of its section. At the end of 
tumor resection, the opened air cells are easily appreciated 
and sealed with bone wax.
3.10. The suprameatal approach  
and the transpetrous-transapex approach
M. Tatagiba, S. Lieber, F.H. Ebner
Introduction
The retrosigmoid approach provides straightforward 
access to the cerebellopontine angle (CPA) and to the 
petroclival region. The approach can be extended in 
different ways:
• inframeatally for tumors originating from within or 
growing into the jugular foramen;
• transmeatally for tumors involving the inner auditory 
canal;
• suprameatally for tumors located in the ventral 
posterior fossa or those extending from the CPA into 
the middle fossa.
In this chapter we provide a technical description of the 
retrosigmoid intradural suprameatal approach (RISA) 
with a focus on its practical aspects.
Fig. 3.9.2. Operative picture showing transverse crista (*), facial nerve 
running up to Fallopius on the righr of crista, cochlear nerve on left up to 
cochlear quadrant.
Surgery of the lateral skull base: a 50-year endeavour
S27
cerebellomedullary cistern to release cerebrospinal fluid 
(CSF). This maneuver relaxes the intracranial structures. 
Gentle elevation of the collapsed cerebellum in a cranio-
medial direction exposes the CPA with the respective 
pathology. The cranio-medial elevation of the cerebellum 
avoids tension and possible rupture of the superior petrosal 
vein complex.
As a general concept, the neurovascular structures inside 
the CPA are displaced depending on the lesion’s origin. 
This means, that the corridors between CN IX/X/XI 
and CN VII/VIII, between CN VII/VIII and CN V, and 
between CN V and the tentorium respectively can be 
widened, narrowed, or obliterated, and the CN displaced 
posteriorly, anteriorly, caudally or cranially. As skilled 
neurosurgeons trained in microsurgical techniques, 
it is feasible to cross these nerves using the respective 
corridors and follow the tumor from the posterior to the 
middle fossa. The expansile growth of the tumor itself 
might enlarge the working space. We progressively 
debulk the tumor to create space between the respective 
structures. This allows for dissection of the capsule 
from the neurovascular structures in the classical three-
hand plus technique in semisitting position: the main 
surgeon dissects the arachnoid cleavage plane using 
tumor grasping and dissecting forceps, the assistant 
intermittently irrigates and gravity cleans the field.
Once the tumor in the posterior fossa has been removed 
there are four options to address the supratentorial tumor 
component depending of the patient’s anatomy: 
1. the tumor created a corridor sufficient in size to access 
the supratentorial compartment;
2. a prominent suprameatal tubercle hinders access to the 
ventrally located structures and thus has to be drilled;
3. the tentorium has to be incised parallelly to the superior 
petrosal sinus to gain access to the supratentorial 
space;
4. the techniques 2) and 3) have to be combined.
The suprameatal bone is located superiorly to the 
internal auditory canal (IAC) and exhibits significant 
individual variation 3. Whenever its removal is necessary, 
we advise drilling with diamond burrs under continuous 
irrigation. A small piece of rubber may be placed on the 
CN VII/III for protection of the neurovascular complex 
during this maneuver. The extent of drilling is indeed 
an individual matter depending on the anatomical 
situation and the surgical access required  4. Once the 
approach is accomplished, Meckel’s cave is opened, 
the trigeminal nerve mobilized and the tumor further 
debulked. Stepwise resection of the tumor leads through 
the ambient and crural cisterns up to the middle fossa. 
Opening of the tentorium posteromedially to the entrance 
of CN IV into the posterior petroclinoidal fold further 
widens the access to the supratentorial compartment. In 
semisitting. That means, that the legs are raised to the level 
of the head (Fig.  3.10.1). This elevates central venous 
pressure and thereby reduces the risk of air embolism.
The diagnostic preparation of the patients includes:
• Thin-slice bone window CT scan. Position and 
diameter of the emissary veins?
• Clinical and radiological evaluation of the cervical 
spine. Instability?
• Transthoracic echocardiography. Patent foramen 
ovale?
In the OR the anesthesiological monitoring comprises:
• Transesophageal echocardiography. Air bubbles?
• Continuous measurement of end-tidal CO
2
. Entrance 
of air in the veins causing drop of CO
2
?
• Continuous arterial pressure monitoring. 
Cardiovascular instability?
The Tübingen classification of venous air embolism is 
based on these criteria.
A slightly curvilinear incision is placed two fingers 
behind the ear, extending from the upper end of the 
ear lobe to the level of the mastoid tip. Bony exposure 
comprises the landmarks: the asterion, the mastoid tip and 
the horizontal part of the occipital squama. Depending on 
the age of patient we either perform a lateral suboccipital 
craniotomy (<  50  years) or a craniectomy (>  50  years). 
It is crucial to expose the lower border of the transverse 
sinus and the posterior border of the sigmoid sinus. 
This facilitates entering the posterior fossa tangentially 
to the posterior surface of the petrous bone and thereby 
minimizes cerebellar retraction.
We open the dura with a straight incision parallel to the 
sigmoid sinus with the option of extending it medially 
parallel to the transverse sinus to provide access also to 
the so-called supracerebellar route.
The first intradural step consists in opening the lateral 
Fig. 3.10.1. See text.
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nerve inside the posterior petroclinoidal fold (F, G). (H) 
Microscopic view to the supratentorial compartment after 
resection of the meningioma. (G) Postoperative overview 
from the posterior to the middle fossa.
The MRI with contrast two years after surgery documents 
the good removal of the tumor (Fig. 3.10.4). The patient 
cases lacking significant displacement of the brainstem 
and neurovascular structures, an endoscope-assisted 
technique facilitates access to and visualization of the 
middle fossa 5. In case of adequate tumor consistency (in 
terms of avascular and soft consistency), this technique 
allows for the removal of supratentorial tumor parts with 
angled instruments despite the overall limited access.
At the end of surgery two aspects are crucial:
• meticulous sealing of intradural – at the level of the 
drilled suprameatal tubercle  –  and extradural  –  at 
the level of the mastoid  –  potentially opened airs 
cells with bone wax and a free muscle transplant 
with fibrin glue in order to avoid a postoperative 
rhinoliquorrhea;
• repeated jugular vein compression before closing 
the dura in case of the semisitting position to check 
for venous oozing and therefore avoid postoperative 
venous bleeding.
Optimal results can be achieved with this approach in 
demanding tumors like petroclival meningiomas 6.
Illustrative case
Figure  3.10.2 shows the axial T1wi MRI after contrast 
of a 45-year-old woman complaining about facial 
hypoesthesia on the left side. The meningioma involves 
the inner auditory canal, petroclival region and extends to 
the supratentorial compartment and posterior cavernous 
sinus. Histologically it was a meningotheliomatous 
meningioma WHO I. 
Figure 3.10.3 provides the intraoperative microscopic view 
into the left cerebellopontine angle (A). The patient is in 
semisitting position. We performed retrosigmoid craniotomy 
on the left. The meningioma can be seen ventrally to 
the prominent suprameatal tubercle. (B) Drilling of the 
suprameatal tubercle with the high speed diamond burr. 
Microsurgical dissection and resection of the meningioma 
superiorly to the trigeminal nerve (C, D, E). Opening of the 
tentorium posteromedially to the entrance of the trochlear 
Fig. 3.10.2. See text.
Fig. 3.10.3. A), B), C), D), E), F), G), H) from left to right.
Fig. 3.10.4. See text.
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tubercle, the most lateral bony wall of the foramen magnum 
and the inferior wall of the hypoglossal canal 9. 
Hypoglossal canal
The hypoglossal canal is divided into an intracranial and 
extracranial part. The intracranial part is located at the 
junction of posterior and middle third of the OC below the 
jugular tubercle; the extracranial part is above the junction 
of the anterior and middle third of the occipital condyle 
medially to the jugular foramen 10.
C1 vertebra
C1 is a ring-shaped vertebra consisting of two arches 
and two thick lateral masses located at its anterolateral 
aspect. The posterior arch in its upper-outer surface 
presents the groove on which the V3 segment of VA lies. 
Between the lateral mass and the transverse process of 
C1 lies the transverse foramen inside of which the VA 
courses.
Key steps of the extreme lateral approach (ELA)
The ELA allows direct access to extradural bony lesions 
anteriorly to the lower brainstem and located into lower 
clivus, occipital condyle, C1 lateral mass, odontoid 
process, lateral mass and body of C2, and prevertebral 
space. It requires the control and mobilization of V3, 
control of the lower cranial nerves, jugular vein (IJV), 
and ICA  4  7  8. ELA can be confused with the far lateral 
approach (FLA). The main difference between ELA and 
FLA lies in the direction of the approaches. In the FLA, 
exposure is done medially at first, then extending toward 
a more lateral corridor, making the condyle resection and 
the VA transposition supplements of the approach. FLA 
is dedicated to intradural lesions located anteriorly or 
antero-laterally to the lower brainstem. In case of tumours, 
the drilling of the condyle is most often unnecessary, as 
the surgical corridor is created by the tumour volume 
itself. On the other hand, the ELA allows a more direct 
lateral corridor to the extradural anterior bony structures, 
being centred on the occipital condyle, C1 and C2 lateral 
masses. 
Position and skin incision
The patient lies supine, the head is rotated as needed to the 
contralateral side with some degree of extension. Lateral 
or park bench positioning have also been described for 
this approach. Monitoring of the facial nerve and lower 
cranial nerves are systematically used. An incision is 
made along the anterior border of the SCM and over 
the mastoid process, and then turned posteriorly along 
the superior nuchal line (Fig.  3.11.1). The incision can 
be tailored depending if a retrosigmoid craniotomy or 
mastoid drilling are contemplated. Other types of skin 
incision such as a retroauricular curvilinear C-shaped skin 
has no neurological deficits. The remnant inside the 
cavernous sinus is stable. We recommend radiosurgery in 
case of documented tumor growth. 
3.11. The extreme lateral approach:  
highlights on the key steps  
of surgical technique 
R.V. Abbritti, P.-O. Champagne, S. Hanakita, E. Roca, S. Froelich
Introduction
Access to lesions located at the anterolateral aspect of 
the cranio-vertebral junction (CVJ) remains challenging 
because of their deep location and relationship with 
critical neurovascular structures  1. Lesions at these 
regions can be treated through anterior, posterior 
or lateral approaches. The anterior routes, such as 
trans-nasal or trans-oral, have been mainly used for 
extradural lesions of the anterior CVJ, since they bear 
a potentially higher risk of cerebrospinal fluid (CSF) 
leak and infection with opening of the dura. From the 
anterior corridor, the surgical view can also be limited 
laterally by the atlanto-occipital joint, internal carotid 
artery (ICA), hypoglossal canal, and lower cranial 
nerves  2. The posterior approaches, mostly based on a 
lateral sub-occipital trajectory, are generally selected 
for intradural lesions, particularly those located laterally 
and posteriorly to the foramen magnum and CVJ 3. The 
conventional posterolateral access to these sites is the 
far-lateral approach, which provides a direction behind 
the sternocleidomastoid muscle (SCM) and medial to the 
vertebral artery (VA) and occipital condyle (OC) 1. The 
concept of an extreme lateral route was introduced and 
refined by several authors  4-6 who reported a variety of 
definitions and variations, including other names such 
as the anterolateral. The aim of this chapter is to present 
the key steps of the extreme lateral approach (ELA), 
highlighting its indications and limitations. 
Surgical landmarks
V3 segment of vertebral artery (VA)
The V3 segment of the VA begins at the transverse 
foramen of C2 and runs until the dura mater of the 
foramen magnum 7. It is located at the centre of the sub-
occipital triangle which is delineated medially by the 
rectus capitis posterior major, cranially and laterally by 
the superior oblique, and caudally and laterally by the 
inferior oblique 8. 
Occipital condyle
The occipital condyle forms, together with the jugular 
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digastric muscle (DM) has to be detached from its groove 
and retracted inferiorly. The facial nerve lies anteriorly to the 
insertion of the DM; care must be taken to remain behind the 
anterior aponeurosis of the muscle.
The occipital artery can be identified, running on the surface 
of the sub-occipital triangle. The latter structure can be 
dissected, released and mobilized inferiorly if needed for 
further revascularization procedures. 
Exposure of the sub-occipital triangle
Deeply to the fat pad, the sub-occipital triangle is identified. 
The insertions of the muscles to the C1 transverse process, 
including the superior and inferior oblique, the levator 
scapulae and the cervicalis are progressively coagulated and 
cut to free the transverse process. Care must be taken not to 
open the venous plexuses around the VA. Once the muscles 
are detached, the posterior aspect of the transverse process 
and C1 lamina are subperiosteally exposed.
Exposure and transposition of the VA
One of the crucial steps in the ELA is the transposition of 
the VA. The VA is identified in the C1 groove. The proximal 
control of V3 between C2 and C1 is also achieved. This is 
mandatory to take into consideration because of the rotation 
of the head. The C2-C1 segment of the VA is identified 
immediately below and almost parallel to C1 lamina. Once 
the transverse foramen of C1 is identified, the tip of the 
transverse process and the transverse foramen of C1 are 
removed and opened with a Kerrison rongeur, respectively. 
The VA is then freed subperiosteally from the foramen and 
transposed posteriorly (Fig. 3.11.2). Particular care must be 
taken not to leave pieces of bone on the posterior margin of 
the foramen that could injure the VA during the transposition. 
Transposition of the VA exposes the atlanto-occipital joint 
and the lateral mass of C1, creating a wide corridor towards 
these structures and the odontoid process. Additionally, the 
exposure of the VA can be extended inferiorly toward the 
incision, starting approximately 2 to 3 cm posteriorly to 
the upper border of the ear, can be also considered 11 12.
Muscular dissection
The SCM is detached from the mastoid process and reflected 
infero-medially. The longissimus capitis is also detached from 
the nuchal line and mastoid process and reflected posteriorly. 
The digastric muscle is identified in the retromastoid groove 
and followed anteriorly. The tip of the transverse process of 
C1, which is a major landmark to locate the XI cranial nerve 
(c.n.) is palpated about 1 cm below the mastoid tip. 
Control of the lower cranial nerves, IVJ and carotid artery
The IJV is then exposed inferiorly. The internal and external 
carotid artery (ICA, ECA), vagus and hypoglossal nerve 
with its descending branch are also identified.
Identification of the XI cranial nerve
The XI c.n. courses over the transverse process of C1 or, more 
often, immediately below it. It runs obliquely in a posterior 
and inferior direction toward the inferior surface of the SCM 
and is embedded into a fat pad located under the muscle. 
Once the XI c.n. is identified, the fat pad located above the 
nerve is dissected and elevated from the deep muscles and 
used to gently retract the XI inferiorly.
Exposure of the prevertebral space 
The IJV, ICA, hypoglossal nerve and X c.n. are retracted 
all together medially and elevated in order to expose the 
prevertebral space and the lower aspect of the lesion. The 
sympathetic chain is identified along the anterior surface of 
the longus colli and is also retracted medially and elevated 
with the previously mentioned neurovascular structures. The 
connections between the sympathetic chain and the cervical 
nerve roots are sectioned. The longus colli is identified 
together with the anterior aspect of the anterior arch of C1, 
and the C2 and C3 vertebral bodies. 
In order to access the exit zone of the jugular foramen, the 
Fig. 3.11.1. Skin incision marked 6 cm below the mastoid tip, along the 
anterior border of the SCM, and curving superiorly toward the superior nu-
cal line.
Fig. 3.11.2. VA transposition from its groove after unroofing and removal 
of the transverse process.
OC: occipital condyle; OA: occipital artery; X: 10th cranial nerve; IJV: internal jugular vein
Surgery of the lateral skull base: a 50-year endeavour
S31
fusion is mandatory when unilateral occipital condyle, C1 
lateral mass or C0-C1 facets are removed entirely, and the 
contralateral bony complex is involved by the lesion. Cement 
can be used to transiently ensure a sufficient CVJ stability 
waiting for a posterior fixation. 
In conclusion, the ELA provides an excellent surgical 
route to access extradural lesions located to the anterior 
brainstem, lower clivus, upper portion of the CVJ, the lateral 
complex of C0-C1 and C1-C2 vertebrae, and intradural-
extradural lesions invading the more medial aspect of the 
aforementioned regions. The classical concept of a higher 
morbidity compared to the posterolateral approaches has 
actually changed due to both technical refinements, and 
tailored surgical steps related to the tumour extension.
3.12. En bloc resections of the temporal bone 
A. Mazzoni, E. Zanoletti
There are two en-bloc resections of the temporal bone, the 
lateral block resection and the subtotal block resection; and 
the “piecemeal” resection. 
The SCC of the external auditory canal arises from the 
skin of the canal and spreads to the temporal bone and 
the surrounding sites, mastoid, periauricular soft tissues, 
parotid gland and temporo-mandibular joint. The carotid 
canal, jugular foramen, dura, middle and posterior 
cranial fossae are invaded in advanced stages. Planning 
of surgery involves identifying the sites and subsites of 
tumor growth as well as the the safe margins for resection. 
En-bloc lateral temporal bone resection (LTBR) and en-
bloc subtotal temporal bone resection (STBR) combine 
the widest safe margins with a clear and reproducible 
approach. The “piecemeal” resection, as performed by the 
majority of authors, includes a block LTBR and a drilling 
out of the remaining petrous bone to follow the tumor 
diffusion. 
In the LTBR 1, the block of the outer ear canal is contoured 
with an extended mastoidectomy and freed through a 
temporal craniotomy. The same craniotomy enables the 
carotid artery to be exposed by drilling off its vertical 
canal and displacing it from canal down to the neck. The 
ostheotomy from the carotid canal to the glenoid fossa 
makes it possible to free the tympanic block and preserve 
continuity with the soft tissues of the parotid and neck 
dissection. 
The STBR  1 2 requires freeing the bone from dura, carotid 
artery and jugular foramen, and involves temporal and 
occipital craniotomies, the first one to free the carotid as 
mentioned under LTBR, and four ostheotomies to deliver 
the block, as follows. One ostheotomy from the carotid 
canal to the glenoid fossa (Figs. 3.12.1, 3.12.2 ) through the 
transverse process of C2. The C2 nerve root runs over the 
C2-C1 segment of the VA and is therefore identified. The 
transverse process of C2 can be removed and its transverse 
foramen opened, in order to expose and further mobilize the 
VA if needed.
Bony resection and ELA variants
The bony resection of the ELA usually involves drilling of 
the lateral structures of CVJ such as the occipital condyle and 
the lateral masses of C1 and C2, giving a direct lateral access 
to the odontoid process and body of C2, and contralateral 
condyle. The limit of the bony resection is the contralateral 
VA on the other side of it. Anterior access can be gained via 
further drilling of the occipital condyle and C1 lateral mass, 
keeping in mind that the hypoglossal nerve and canal lie at 
the junction of the middle and anterior third of the condyle at 
that point. Depending on the lesion’s location, bony resection 
can be tailored. To access lesions infiltrating the inferior 
clivus, drilling of the mastoid process, identification of the 
fallopian canal, infralabyrinthine drilling and removal of the 
mastoid tip might be needed. The sub-occipital craniectomy 
is completed by exposing the sigmoid sinus and jugular bulb. 
Opening of the jugular foramen can also be added depending 
on the pathology and tumour extension (Fig. 3.11.3).
Although the ELA offers a great lateral window on the CVJ 
and on the upper cervical spine, with the advantage to tailor the 
bony resection to the targeted region, a higher risk of VA injury 
is reported  6, compared to the FLA. Conversely, the rate of 
lower cranial nerve injury, especially of the hypoglossal nerve, 
is slightly inferior due to the early exposure of the latter at the 
beginning of the procedure, compared to other posterolateral 
approaches. Another neurosurgical issue regarding the ELA 
is CVJ instability. Several authors recommend an occipito-
cervical fixation after unilateral occipital condyle drilling 
of  >  50%  13, while others reported that the stability can be 
preserved even after complete unilateral condyle resection 14, 
stressing on the importance of ligamentous elements. However, 
Fig. 3.11.3. Tumor exposure through the ELA approach: after completing 
the mastoidectomy, the sigmoid sinus (SS) is unroofed and exposed to allow 
the drilling of the occipital condyle.
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Retrograde parotidectomy is indicated in both LTBR and 
STBR, total parotidectomy in cases of anterior growth beyond 
the anterior wall of the external auditory canal, superficial 
parotidectomy as a prophylactic measure on the intraparotid 
nodes in tumors limited to the external auditory canal (T1, T2). 
The neck is treated in both LTBR and STBR with elective 
selective dissection for clinically negative neck, and a 
modified type III radical neck dissection in clinically positive 
lymphnodes. Condyle of mandible, temporo-mandibular joint, 
and dura are resected if indicated. With tumor confined to the 
lateral canal with no bone erosion, the LTBR lies lateral to the 
ear drum. General principles regulate handling of the facial 
temporal craniotomy. A second ostheotomy on the antero-
superior (Fig. 3.12.2) and the posterior (Fig. 3.12.3) side of 
the petrous bone with transection of the internal auditory 
canal. A third ostheotomy (Fig. 3.12.3) through the occipital 
craniotomy from the previous cut on the petrous bone to the 
jugular foramen and preserving its medial wall with the low 
cranial nerves. A fourth and final ostheotomy goes from the 
jugular fossa to the carotid canal (Fig.  3.12.4). The block 
remains continous with the neck dissection and the parotid 
without violating the safe margins. 
Fig. 3.12.1. The vertical carotid canal represents the axis of the en bloc 
subtotal temporal bone resection, as it carries both the start and the end of 
the bone cuts. Right temporal bone, lateral side. Temporal and retrosigmoid 
craniotomies allow to free the bone block from dura of the temporal and 
petrous sides, to close the sigmoid-jugular complex and to free the vertical 
carotid artery by drilling off its bone canal up to the neck.
Fig. 3.12.2. First cut from vertical carotid canal to glenoid fossa (broken 
line) as seen from the temporal craniotomy. First part of the second cut (see 
at Fig. 3.12.3).
Fig. 3.12.3. Posterior side of petrous bone as seen from the retrosig-
moid craniotomy. Second cut from carotid canal all across the anterosuperior 
(Fig. 3.12.2) and posterior side of the petrous bone, and cutting through the 
internal auditory canal. The cut from the petrous ridge (arrow) down to the 
jugular fossa (JF).
Fig. 3.12.4. Low side of the temporal bone. Final cut from the jugular 
fossa to vertical carotid canal.
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of the open approaches. The deep and complex nature of 
CPA anatomy makes this region an attractive candidate 
for endoscope-assisted surgery and, in selected cases, for 
exclusive endoscopic surgery.
Thanks to endoscopic visualization of anatomical structures 
lying in the tympanic cavity, anatomical knowledge is steadily 
improving, pushing surgical indications from the middle to 
the inner ear and to the lateral skull base, using the external 
auditory canal (EAC) as a natural corridor to reach lesions.
Regarding endoscopic techniques for inner ear surgery, 
and in particular for acoustic neuroma removal, there has 
been the development of transcanal transpromontorial 
approaches, and, in particular, the exclusive endoscopic 
transcanal transpromontorial approach (EndoTTA) and the 
expanded endo/microscopic transcanal transpromontorial 
approach (ExpTTA). 
Other transpromontorial approaches to the lateral skull 
base are represented by the infracochlear route and the 
suprageniculate route.
Transcanal approaches are illustrated specifically as follows: 
Transcanal transpromontorial corridor (Fig. 3.13.1)
Following this corridor, the fundus of the IAC is reached by 
passing through the promontory for diseases located in the 
vestibule, cochlea, and/or IAC. With this surgical approach, 
hearing loss is expected, because of the extirpation of the 
promontory area to create a corridor through the cochlea to 
finally reach the IAC. 
The indications for this approach are:
• tympanic cavity cholesteatoma with medial extension 
toward inner ear structures (cochlea, vestibule, IAC);
• small symptomatic or growing acoustic neuromas with 
exclusive extension to IAC fundus;
nerve, which is to be included in the resection when clinical 
data or imaging indicate involvement by tumor, or when the 
safe resection margin includes the Fallopius.
Our experience can be conveyed with few points. The surgical 
failures were only due to local recurrence. The amount of 
bone involvement by tumor correlated with local recurrence. 
For example, T1-2 tumors which present little growth in the 
tympanic bone had a fairly good prognosis. Larger tumors 
had a different outcome depending on the amount of bone 
involvement. T 3-4  tumor growing full thickness on the 
anterior wall of the tympanic bone and thereon into the parotid 
demonstrated a significant less dismal prognosis than a similar 
sized tumor growing in the larger bone bed of the mastoid. The 
incontrollable diffusion seemed to take the numerous channels 
of the bone. Radiotherapy at full dosage follows surgery in 
T3-T4 tumors.
Recurrence after en-bloc resection most often occurred in the 
soft tissues corresponding to the low aspect of the temporal 
bone, thus suggesting that the bony channels, which become 
larger and numerous towards the low side of the bone, were 
the way of diffusion of the tumor to the periostheum and soft 
tissues 3. 
In our experience, enlarging the block resection to include 
jugular foramen, carotid artery and their adjacent soft tissues 
on the exocranial base were to imply such a burden of acute 
losses that it did not support its hypothetical benefit.
3.13. Totally endoscopic and combined  
endo-microscopic approaches in lateral  
skull base surgery
D. Marchioni, M. Bonali, D. Soloperto, F. Maccarrone, G. Ferri, 
L. Presutti
The lateral skull base and the internal auditory canal (IAC) 
can be considered as one of the most inaccessible spaces to 
visualize and to operate in otoneurosurgery. Limited access to 
these regions has prompted investigators to innovate methods 
for the creation of an adequate surgical corridor while limiting 
the damage and sacrifice of surrounding structures. 
As for any surgical procedure, an adequate window of 
visualization is the key to provide operative success. 
Microscopic surgical approaches have been developed to 
remove pathologies located in the IAC and cerebellopontine 
angle (CPA) (retrosigmoid, translabyrinthine and middle 
cranial fossa approaches).
However, these techniques require brain, meningeal and 
vascular manipulation to obtain an adequate surgical corridor, 
increasing the possibility of complications. 
This associated morbidity has led the surgeons to try to use 
the endoscope during lateral skull base accesses. Endoscopic 
surgery to the skull base may obviate many of the drawbacks 
Fig. 3.13.1. Left side: schematic drawing showing anatomical details of 
the transcanal endoscopic transpromontorial approach of the left ear. The 
orange area indicates the bony area which may be removed to reach the 
internal auditory canal (IAC) passing through the cochlea and the vestibule. 
Right side: computed tomography scan (coronal view), showing the work-
ing area and the bony removal (yellow area), to reach the fundus of the IAC.
MCF: middle cranial fossa dura; GPN: great petrous nerve; GG: geniculate ganglion; 
FN: facial nerve (second tract); LSC: lateral semicircular canal; SPH: spherical recess; 
FN*: facial nerve (first tract); PSC: posterior semicircular canal; RW: round window 
area; PR: promontory; CA: carotid artery
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present and well pneumatized, showing the route to reach 
the petrous apex cells. The jugular bulb is thus identified 
below the finiculus bone in the floor of the hypotympanum, 
and identification of the vertical tract of the carotid artery 
is performed by drilling the protympanic cells just below 
the Eustachian tube orifice. Drilling of the medial aspect 
of the tympanic cavity into the round window fossa, of the 
hypotympanic and protympanic cells between the jugular 
bulb, carotid artery and basal turn of the cochlea, is performed 
with a diamond burr. The removal of the aforementioned 
bony anatomical triangle allows to reach the disease in the 
petrous apex, which lays below the IAC and medial to the 
vertical portion of the internal carotid artery. 
Transcanal suprageniculate corridor (Fig. 3.13.3)
This approach allows removal of diseases located between the 
geniculate ganglion and the second portion of the facial nerve 
inferiorly, the middle cranial fossa (MCF) superiorly, and the 
labyrinthine block posteriorly. Working above the cochlea and 
labyrinth allows sensorineural hearing function preservation, 
although an ossiculoplasty is required after disease removal. 
This approach is indicated for diseases with limited extension 
into the suprageniculate area, like cholesteatomas or 
hemangiomas. This area can be endoscopically reached by a 
transcanal route avoiding a middle cranial fossa approach. After 
obtaining a good exposure of the medial wall of the tympanic 
cavity, removal of the incus and of the head of the malleus is 
required to expose the entire second portion of the facial nerve, 
which goes from the second genu to the geniculate ganglion 
and involves the greater petrosal nerve area. The cog and the 
cochleariform process are identified endoscopically and used 
as an anatomical landmark for the geniculate ganglion area 
because of the close anatomical relationship between the 
• cochlear schwannomas with or without IAC involvement.
The surgical steps are the following: first, a wide canalplasty 
is created, the incus and the malleus then are removed, before 
the section of the tensor tendon. Using a hook, the stapes is 
removed to expose the vestibule. An inferior enlargement of 
the oval window opening is performed with a micro-curette. 
This procedure leads to the complete exposition of the 
spherical recess in the saccular fossa. This area appears like 
a thin cribriform plate and is the site of medial termination of 
the inferior vestibular nerve. It is also the anatomical barrier 
between the vestibule and the fundus of the IAC representing 
a crucial anatomical landmark for the fundus of the IAC. 
The cochlea is then endoscopically identified removing the 
promontory. The tegmen of the round window is removed 
and the basal, middle, and apical turns of the cochlea are 
exposed by drilling over the promontory region. 
After identification of the anatomical landmarks, as the 
tympanic segment of facial nerve together with the geniculate 
ganglion and the cochlea, the position of the labyrinthine tract 
of the VII cranial nerve can be identified through an imaginary 
line that arises from the geniculate ganglion, passing just above 
the apical turn of the cochlea and entering into the fundus of the 
IAC in the same plane of the spherical recess. When the disease 
is located in the cochlea, a gentle dissection of the tumor is 
performed, trying to avoid CSF leakage. When the tumor is 
located in the IAC, the fundus of the IAC is carefully opened 
through the cochlea just below the vestibule and the spherical 
recess, thus exposing the lesion in the IAC. During this surgical 
maneuver, an outflow of cerebrospinal fluid occurs. By gently 
maneuvering the tumor mass, the facial nerve is detected 
endoscopically, and the tumor mass is dissected from the 
IAC and from the facial nerve, paying careful attention not to 
damage the nerve. Afterwards, a final inspection of the surgical 
cavity and the IAC is made to confirm complete removal of 
the mass. Closure of the IAC is performed with abdominal fat, 
packing the promontorial defect and closing the communication 
between the inner and middle ear. Fibrin glue is used to secure 
the sealing of the promontorial defect, and a cul-de-sac closure 
of the skin of the EAC is performed.
Transcanal infracochlear approach (Fig. 3.13.2)
This approach allows removal of diseases located in the 
petrous apex below the IAC with limited extent, preserving 
hearing function. The corridor to the inferior portion of the 
petrous apex is created by drilling the bone between the 
cochlea superiorly, the carotid artery anteriorly, and the 
jugular bulb inferiorly. The ossicular chain is preserved and 
the hearing function is left intact. 
The inferior limit of the promontory with the anatomical 
structures forming the round window niche (the posterior 
pillar, the tegmen and the anterior pillar with the finiculus 
bone) is detected endoscopically. Furthermore, under the 
finiculus bone, a subcochlear canaliculi is identified when 
Fig. 3.13.2. Left side: schematic drawing showing anatomical details 
of the transcanal endoscopic infracochlear approach of the left ear. The 
orange area indicates the bony area which may be removed to reach the 
petrous apex under the cochlea. Main landmarks of this area are the 
cochlea superiorly, the carotid artery anteriorly, and the jugular bulb in-
feriorly. Right side: computed tomography scan (coronal view), showing 
the working area and the bony removal (yellow area) needed to reach the 
petrous apex cells.
CHO: cochlea; FN: facial nerve; CA: carotid artery; F: finiculus; STY: styloid 
prominence; JB: jugular bulb; AP: anterior pillar; PP: posterior pillar; S: stapes
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Surgical procedure
The patient lies in the supine position, with the head slightly 
rotated contralaterally. A retro auricular incision similar to 
that of traditional microscopic techniques is made and the 
dissection of the soft tissues is performed to reach the EAC. 
A circular incision of the external auditory canal is performed 
about 1.5 cm from the tympanic anulus, and the distal part 
of the skin is removed with the tympanic membrane. Under 
microscopic view, the bone is drilled to gain better access to 
the tympanic cavity. Removal of the incus and the malleus 
is then performed. The tympanic tract of the facial nerve, 
the geniculate ganglion, and the cochleariform process are 
exposed. The following landmarks are clearly detectable at 
the end of this step: the carotid artery anteriorly below the 
tympanic tube orifice, the jugular bulb inferiorly, and the 
third tract of the facial nerve posteriorly. 
The vestibule and the spherical recess are identified in the 
saccular fossa after removal of the stapes. The oval window 
is enlarged and the promontorial bone is removed with a 
progressive exposure of the basal, medial, and apical turns of 
the cochlea, preserving the modiolar structure of the cochlea 
and the cochlear nerve. The IAC is exposed by drilling the 
bone between the vestibule and the basal turn of the cochlea 
while maintaining the integrity of the middle and apical turns. 
The IAC is skeletonized as far as the porus by removing the 
bone circumferentially and exposing the dura of the IAC 
posteriorly and inferiorly. The dura along the IAC is then 
opened to reach the tumor, which is removed in a piecemeal 
fashion with traditional microscissors. The endoscope is used 
during this step as a complementary instrument for better 
identification of surgical landmarks and to safely dissect the 
facial nerve from the VS. The CPA portion of the tumor is 
visualized and removed after enlarging of the approach at 
the level of the fundus of the IAC with a burr following the 
acoustic-facial bundle toward their entry zone.
The microscopic view of the CPA is limited; consequently, 
complete removal of the tumor is performed and checked 
with the endoscope (Fig. 3.13.4). Facial function is evaluated 
geniculate ganglion and the mentioned structures. The dura of 
the MCF is exposed by removing bone from the tegmen of the 
anterior epitympanum, and represents the upper surgical limit. 
The lateral semicircular canal is also endoscopically detected 
in its posterior and superior aspects, with respect to the second 
genu of the facial nerve, representing the posterior limit of the 
surgical field. The cog is gently removed using a microcurette, 
increasing the exposure of the geniculate ganglion area, and, 
when required, the greater petrosal nerve is also exposed just 
anteriorly to the geniculate ganglion. Based on the extent of 
the disease, a diamond burr or a Piezoelectric device (Mectron, 
Carasco/Genova, Italy) is used to remove the bone between the 
MCF superiorly, the labyrinthine block posteriorly, and the facial 
nerve inferiorly, reaching the pathological tissue in this area. 
After disease removal, a fragment of temporal muscle is used to 
obliterate the cavity created, an ossicular chain reconstruction is 
performed, and the tympanomeatal flap is replaced. 
Expanded transcanal transpromontorial approach 
In 2013, the exclusive endoscopic transcanal 
transpromontorial technique has been introduced to treat 
Koos stage I and II vestibular schwannoma (VS) thanks 
to a higher magnification and a direct visualization of all 
the structures in the IAC and CPA. Recently, an expanded 
transcanal transpromontorial approach has been developed. 
This approach is a combined endoscopic and microscopic 
technique, used for the treatment of tumors that occupy the 
IAC involving the CPA (Koos stages II-III). This technique 
allows bimanual dissection with direct control of the tumor 
and neurovascular structures, as well as a reduction in 
surgery time. 
Fig. 3.13.3. Left side: schematic drawing showing anatomical details of 
the transcanal endoscopic suprageniculate approach of the left ear. The or-
ange area indicates the bony area, which may be removed to reach the pe-
trous apex in the suprageniculate region. Main landmarks of this area are 
the middle cranial fossa superiorly, the facial nerve and geniculate ganglion 
inferiorly and the labyrinthine block posteriorly. Right side: computed tomog-
raphy scan (coronal view), showing the working area and the bony removal 
(yellow area) needed to reach the suprageniculate area.
Fig. 3.13.4. Left ear: A) microscopic view during ExpTTA approach, show-
ing drilling of the cochlear turns; B) endoscopic view after tumor removal, 
with final check of the anatomical structures. 
MCF-D: middle cranial fossa dura; COG: transverse crest; LSC: lateral 
semicircular canal; FN: facial nerve; S: stapes; PE: piramidal eminence; CA: 
carotid artery; CHO: cochlea; RWN: round window niche; CP: cochleariform 
process
BASIL M: basilar membrane; OW: oval window; S: stapes; FN: facial nerve; RW: 
round window; TYMP S: tympanic scale; VEST S: vestibular scale; V CN: fifth 
cranial nerve; VII CN: seventh cranial nerve
E. Zanoletti et al.
S36
advocate that as long as the speech discrimination (SD) 
score is better than 50%, hearing is considered serviceable. 
This is because hearing aids can be used with some benefit. 
However, most authors use the AAO-HNS class A hearing 
(PTA < 30 dB and SD > 70%) as definition of good hearing 
and class A-B (PTA < 50 dB and SD > 50%) 5 as definition of 
serviceable hearing, thus worthy of preservation. The AAO-
HNS classification system is used in this review, as it is the 
most widely reported in literature.
The surgical approach or the radio-therapeutic strategy may 
include hearing preservation as a goal. In addition, preserved 
hearing may itself be an indication to perform surgery, even in 
smaller or non-growing tumours or in case the only hearing 
ear is on the tumour side  6. However, in order to justify an 
active treatment based on hearing acuity, the outcome of the 
strategy should be superior to that of the natural course of the 
disease, as hearing is one of the most important aspects for the 
patient, as compared to dizziness, tinnitus or facial weakness 7.
The treatment strategy for VS has gradually changed during 
recent decades, as several studies (including larger series of 
patients), report a significant proportion of VS that remained 
stable in size after diagnosis, which justifies the increasing 
numbers of diagnosed and subsequently observed-only 
patients with VS 3 4 8-10. Importantly, hearing at diagnosis is 
reported as increasingly better, with an increasing number 
of patients presenting with close-to-normal hearing at 
diagnosis 11. 
Only a detailed knowledge of the spontaneous course of VS 
will allow a comparison with, and a proper evaluation of, the 
outcome of any active treatment. Accordingly, this systematic 
review addresses the natural history of tumour growth and 
hearing through repeated MRI scans and audiometries in 
patients observed with a unilateral, sporadic VS.
Materials and methods
A research on PubMed, Embase, Medline, Cochrane library 
and CINAHL using the keywords “vestibular schwannoma”, 
“acoustic neuroma”, “growth”, “hearing”, “natural history”, 
alone and in combination was performed. The research 
yielded 121 papers with no early date limit and included 
publications up to September 2018. All papers were read 
and their references minutely checked for additional papers 
not occurring in the original search, yielding 103 additional 
papers. From their references further 21 papers were added.
Pubmed search syntax
((“neuroma, acoustic”[MeSH Terms] OR (“neuroma”[All 
Fields] AND “acoustic”[All Fields]) OR “acoustic 
neuroma”[All Fields] OR (“vestibular”[All Fields] 
AND “schwannoma”[All Fields]) OR “vestibular 
schwannoma”[All Fields]) OR (“neuroma, acoustic”[MeSH 
Terms] OR (“neuroma”[All Fields] AND “acoustic”[All 
Fields]) OR “acoustic neuroma”[All Fields] OR 
with the intraoperative monitoring system. The defect in the 
inner and middle ear is closed using abdominal fat and fibrin 
glue. The Eustachian tube is closed with muscle fragments 
and bone dust. A blind sac closure of the residual skin of the 
external auditory canal concludes the surgery.
In our opinion the transcanal endoscopic approaches to the 
lateral skull base have proven to be successful for removal 
of lesions involving the fundus, IAC, cochlea, petrous 
apex, and geniculate ganglion region, providing a low risk 
of complications and allowing a good quality of life for 
the patients. With the development of future technologies, 
and the progressive improvement in surgical skills, this 
endoscopic corridor will likely represent one of the main 
approaches to treat lateral skull base diseases, together with 
the traditional techniques.
4. Advancements and open issues
4.1. Acoustic neuroma
4.1.1. Observation in vestibular schwannomas  
- a systematic review
M. Reznitsky, P. Cayé-Thomasen
Introduction
Evidence-based management of vestibular schwannomas 
(VS) depends on knowledge of the natural history of the 
disease. VS is a benign tumour of the VIII cranial nerve and 
comprises 90% of cerebellopontine angle (CPA) tumours 
and 8% of all intracranial tumours  1. The incidence is 
increasing and ranges from 11 to 19 VS/million/year and 
a number of studies report that the tumours are being 
diagnosed earlier, i.e. the tumour size is decreasing  2  3. 
Tumour growth percentages vary from 30 to 90%, partly 
due to varying lengths of observation 4. Available treatment 
modalities are observation, radiotherapy or microsurgery, 
and although other factors may be present, the choice of 
treatment is most often based on the size of the tumour, on 
occurring tumour growth, and/or the hearing level of the 
patient.
Surgery is usually the first choice in patients with a large 
VS, as a large intracranial tumour may be associated with 
serious – at times life threatening – complications. Success 
of treatment is usually considered as control of tumour 
growth and preservation of a serviceable hearing level in 
patients presenting with a hearing worthy of preservation, 
with no or minimal treatment side effects. The definition of 
hearing worthy of preservation is debatable. Some authors 
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For what concerns data on hearing, weighted calculation 
showed a mean follow-up of 4.9  years, ranging from 2.6 
to 9.5  years. Only three papers, representing a total of 
390  patients, have a follow-up that exceeds 5  years (6.8, 
8.3 and 9.5  years)  17  19  20. Weighted calculation of hearing 
preservation showed that 50.3% of patients presenting with 
good hearing at diagnosis will preserve this within 4.9 years 
of observation, whereas 55.1% of patients with serviceable 
hearing at diagnosis preserve this within the same period of 
observation (Table 4.1.1.II).
All papers are subject to some degree of selection bias 
concerning tumour size, as most larger tumours were excluded 
(typically operated). All but six papers  4  11  17  21-23 involved 
potential referral bias (patients may not be representative for 
the general VS population) and the majority of studies have 
patient selection bias related to age and co-morbidities. A 
number of studies have an additional selection bias related to 
symptoms (usually vertigo/dizziness and hearing loss).
Some of the reporting centres have published more than one 
paper on their patient cohort/series, mostly as updates on 
the same patients, or with addition of new patients. Thus, 
an unspecified number of patients have been included more 
than once in Table 4.1.1.I.
In Table 4.1.1.II, nearly half the patients are presented in the 
2010 paper by Stangerup et al. 11. Some of these patients are 
also included in the 2008 paper by Stangerup et al.  23 and 
this paper was therefore disregarded in the analysis. The 
2007 paper by Cayé-Thomasen et al. 22 is likewise excluded 
from the analysis, as the patients in this paper are part of the 
prospective cohort included in the most recent publication 
from 2017 by Kirchmann et al. 17.
Most studies do not distinguish between purely intrameatal 
(IM) tumours and tumours with an extrameatal (EM) 
extension, whereas some do (often influencing the definition 
of growth). In addition, most studies define a small- to 
medium-sized tumour to have a largest EM diameter of 
less than 20 mm (not including the IM part of the tumour). 
Definition of growth is specified directly or indirectly in all 
papers, according to the paper inclusion criteria of the review. 
The definition varies, which introduces additional bias, either 
under- or overestimating the occurrence of growth. Most of 
the early studies are not considering error of measurements, 
as they use  >  0  mm tumour enlargement as a growth 
definition. Knowledge regarding the error of measurement 
was later introduced to the research community and the 
literature, so that more recent studies have used  >  1  mm, 
> 2 mm or even > 3 mm enlargement as a growth definition. 
Linear measurement of the largest EM tumour diameter has 
been used by most authors, although some have used linear 
measurement of the total tumour diameter, including the 
portion within the internal acoustic canal (IAC). Yet others 
have used volume rendering or Bayesian methods for the 
evaluation of growth. The partial use of CT in some of the 
(“acoustic”[All Fields] AND “neuroma”[All Fields]))) AND 
((“growth and development”[Subheading] OR (“growth”[All 
Fields] AND “development”[All Fields]) OR “growth and 
development”[All Fields] OR “growth”[All Fields] OR 
“growth”[MeSH Terms]) OR (“hearing”[MeSH Terms] 
OR “hearing”[All Fields])) AND (“natural history”[MeSH 
Terms] OR (“natural”[All Fields] AND “history”[All Fields]) 
OR “natural history”[All Fields]) AND (hasabstract[text] 
AND (“0001/01/01”[PDAT] : “2018/09/30”[PDAT])).
Paper inclusion criteria
The 245 identified papers were screened using the following 
criteria:
• Clinical articles reporting original data. Reviews, meta-
analyses and conference abstracts were thus excluded.
• Observational studies based on case series/cohorts and 
repeated MRIs and/or audiometries.
• Sporadic/unilateral vestibular schwannomas, excluding 
NF2-associated tumours.
• More than 30 patients included.
• Reported mean/median follow-up.
• Reported definition of tumour growth (directly or 
indirectly).
• Use of MRI only or predominantly (excluding studies 
based on CT).
• Use of AAO-HNS guidelines for classification of 
hearing 5and reported class A and/or class A-B hearing. 
175 papers did not fulfill one or more of these inclusion criteria 
and were therefore discarded. This selection left 64 papers 
for inclusion concerning natural history of tumour growth 
and 18 papers (of which 12 also included tumour growth) 
for inclusion regarding hearing. Two of the papers regarding 
hearing were discarded, as they included patients from 
previously published papers. An overview of included papers 
regarding tumour growth and hearing are listed by number 
of included patients and presented in Tables 4.1.1.I, 4.1.1.II, 
respectively. The quality of all studies was evaluated using 
the Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) system 12.
Results
Data on the natural history of VS growth was collected from 
almost 7,800 patients, as reported in 64 papers (Table 4.1.1.I). 
Data on hearing in patients with VS was collected from more 
than 2,200  patients, reported in 18 papers (Table  4.1.1.II). 
Regarding growth, weighted calculation based on the number 
of included patients in each paper shows a mean follow-up 
of 3.4 years, ranging from 0.5 to 10 years. Only 6 papers, 
representing 539  patients, have  ≥  5-years follow-up (5.0, 
5.5, 5.7, 6.7, 9.5 and 10 years, respectively) 13-18. Weighted 
calculation on the occurrence of growth show that 36.7% of 
tumours grow within a mean observation period of 3.4 years 
(Table 4.1.1.I).
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Table 4.1.1.I. Selected papers on natural history.
Author Year Study design Patients 
(number)
Mean 
follow-up
(years)
Growth
(%)
Growth
definition
Grade
quality of 
evidence
Grade
strength of 
recommendation
Hunter 34 2016 Retro cohort 564 1.9 41% ≥ 2 mm Moderate Strong
Stangerup 4 2006 Pro cohort 552
322 EM
230 IM
3.6 29
17 > 2 mm
Growth to CPA
Moderate
Strong
Moffat 35 2012 Pro cohort 381 4.2 33 > 2 mm Moderate Strong
Lees 36 2018 Retro cohort 361
129 EM
232 IM
4.1 48 ≥ 2 mm Moderate Strong
Bakkouri 37 2009 Retro cohort 325 1.0 12 ≥ 3 mm Low Weak
Martin 38 2009 Pro cohort 276 3.6 22 > 2 mm Moderate Strong
Artz 39 2009 Pro cohort 243 2.3 58 ≥ 1 mm Moderate Strong
Suryanarayanan 40 2010 Pro cohort 240 3.6 32 ≥ 1 mm Low Weak
Al Sanosi 41 2006 Retro cohort 197 3.4 28 > 0 mm Very low Weak
Caye-Thomasen 21 2006 Pro cohort 196 IM 4.4 19 Growth to CPA Moderate Strong
Breivik 10 2012 Pro cohort 186 3.6 40 > 2 mm Moderate Strong
Agrawal 42 2010 Retro cohort 180 2.7 37 ≥ 1 mm/year Low Weak
Varughese 43 2012 Pro cohort 178 (88% IM) 3.6 29 ≥ 1 mm/year Moderate Strong
Ferri 44 2013 Cohort 161 0.5 36 ≥ 2 mm Very low Weak
Kirchmann 17 2017 Pro cohort 156 9.5 37 ≥ 2 mm Moderate Strong
Patnaik 13 2014 Retro cohort 154 5 45.5 ≥ 1 mm Very low Weak
Ferri 45 2008 Pro cohort 123 4.8 35 ≥ 2 mm Moderate Strong
Quaranta 46 2003 Retro cohort 122 3.5 40 > 2 mm Low Weak
Fucci 47 1999 Retro cohort 119 2.5 30 > 2 mm Very low Weak
Roehm 48 2007 Retro cohort 114 (> 65y) 3.0 50 > 0mm Very low Weak
Fayad 33 2014 Retro cohort 114 4.8 38 ≥ 2 mm Very low Weak
Battaglia 49 2006 Retro cohort 111 3.2 50 > 0 mm Very low Weak
Grayeli 8 2005 Retro cohort 111 2.8 47 > 0 mm Very low Weak
Solares 9 2008 Retro cohort 110 2.6 21 > 2 mm Very low Weak
Hoistad 50 2001 Retro cohort 102 2.4 44 > 1 mm Very low Weak
Kishore 51 2003 Retro cohort 100 3.2 29 > 1 mm Very low Weak
Flint 52 2005 Retro cohort 100 2.2 36 > 0 mm Very low Weak
Remenyi 32 2009 Retro cohort 95 3.7 23 > 2 mm Low Weak
Jethanamest 53 2015 Retro cohort 94 2.9 38 ≥ 1 mm Very low Weak
Whitehouse 54 2010 Retro cohort 88 3.7 51 > 1 mm Very low Weak
Shin 55 2000 Retro cohort 87 2.6 53 > 0 mm Very low Weak
Kandathil 56 2016 Retro cohort 86 4.4 51 > 20% change Very low Weak
Moller 57 2003 Pro cohort 82 3.0 43 > 0 mm Low Weak
Rosenberg 58 2000 Retro cohort 80 4.4 58 > 0 mm Very low Weak
Nutik 59 2001 Retro cohort 75 4.1 41 > 0 mm Very low Weak
Tschudi 60 2000 Retro cohort 74 2.9 31 > 0 mm Very low Weak
Alvarez-Morujo 61 2014 Retro cohort 73 3.0 12 ≥ 2 mm Low Weak
Hajioff 18 2008 Pro cohort 72 10.0 35 > 1 mm Low Weak
Walsh 62 2000 Retro cohort 72 3.2 36 > 0 mm Low Weak
Bederson 63 1991 Retro cohort 70 2.2 53 > 0 mm Low Weak
Quaranta 64 2007 Retro cohort 70 2.8 40 > 2 mm Very low Weak
u
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including larger patient series were not accounted for. 
Especially, the otherwise excellent studies by Malhotra 
et al.  25 and Timmer et al.  26, which included 202 and 
240  patients, respectively, had to be excluded, as they 
did not define growth or report follow-up period. Other 
studies were primarily excluded due to the lack of a growth 
definition. All together, the excluded papers included 614 
observed patients, four cohorts being retrospective and 
three prospective 24-30. 
In regards to hearing, the choice of excluding publications 
not using the AAO-HNS classification of hearing  5 and 
reporting class A and/or class A-B hearing was made, 
as the majority of published studies use the AAO-HNS 
classification system. This enables comparisons and 
overall conclusions to be made. However, studies using 
other classification systems (e.g. the Gardner-Robertson 
system) have indeed been published 27 31. It should be noted 
that an international consensus on the reporting of hearing 
early studies is also a source of potential bias, as CT is less 
accurate than MRI, when estimating tumour size.
Discussion
Very few studies on observation of VS growth and hearing 
have a long-term follow-up (i.e. beyond 5 years). Nearly 
8,000 patients have been observed for tumour growth and 
data exist for more than 2000 patients concerning hearing 
outcome. In addition to the potential aforementioned biases, 
a few more could potentially influence the result of this 
systematic literature review.
The choice of a specific number of patients as an inclusion 
criteria in the selection of papers (see Material and 
Methods) is an obvious factor. A minimum of 30 patients 
had to be observed (only one paper failed to meet this 
criterion) 24. Excluding papers reporting on tumor growth 
without a clear definition of growth, or not reporting a 
mean/median time of follow-up, meant that some papers 
Author Year Study design Patients 
(number)
Mean 
follow-up
(years)
Growth
(%)
Growth
definition
Grade
quality of 
evidence
Grade
strength of 
recommendation
Godefroy 65 2009 Pro cohort 70 3.6 36 ≥ 2 mm Low Weak
Deen 66 1996 Retro cohort 68 3.4 29 > 0 mm Low Weak
Mirz 67 2000 Pro cohort 64 3.6 23 > 1 mm/year Low Weak
Raut 16 2004 Pro cohort 61 6.7 50 > 1 mm/year Low Weak
Hughes 15 2011 Retro cohort 59 5.7 76 > 2 mm Very low Weak
Wiet 68 1995 Retro cohort 53 2.2 40 > 0 mm Very low Weak
Strasnick 69 1994 Retro cohort 50 2.3 68 > 0 mm Very low Weak
Herwadker 70 2005 Pro cohort 50 1.5 42 > 3 x error, 
Bayesian 
Low Weak
Nedzelski 71 2008 Retro cohort 50 3.5 48 ≥ 1 mm Low Weak
Pennings 72 2011 Retro cohort 47 IM 3.6  38 Growth to CPA Low Weak
Régis 73 2010 Pro cohort 47 IM 3.7 74 > 0 mm Very low Weak
Modugno 74 1999 Retro cohort 47 3.0 36 > 0 mm Very low Weak
Reddy 31 2014 Retro cohort 45 3.0 24 > 2 mm Low Weak
Stipkovits 75 2001 Cohort 44 3.5 18 > 0 mm Very low Weak
Tomita 76 2015 Retro cohort 43 4.1 51 > 10% change Very low Weak
O’Reilly 77 2000 Retro cohort 43 2.6 30 > 0 mm Very low Weak
Perry 78 2001 Retro cohort 41 (> 65 y) 3.5 51 > 0 mm Very low Weak
Vokurka 79 2002 Pro cohort 38 1.0 32 > 3 x error, 
Bayesian
Very low Weak
Martin 14 1994 Retro cohort 37 5.5 30 > 2 mm/year Very low Weak
Van de 
Langenberg 80
2011 Retro cohort 36 1.7 42 > 20% change Very low Weak
Glasscock 81 1997 Retro cohort 34 2.4 55 > 2 mm/year Very low Weak
Lee 82 2014 Retro cohort 31 IM 2.6 23 ≥ 2 mm Very low Weak
Sakamoto 83 2001 Retro cohort 31 2.8 45 > 1 mm/year Very low Weak
All studies, n = 64 - - 7783 3.4 36.7 -
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in patients with a VS does not exist and is accordingly 
warranted.
A few larger studies show that normal speech discrimination 
at diagnosis indicates that good hearing will be maintained 
for many years 11 22 23 32 and some studies show a faster decline 
of hearing acuity in patients with growing tumours  17  22  33, 
while others do not.
Although most studies show that growth usually occurs 
within a few years after diagnosis, long-term observational 
studies are needed to provide evidence on long-term growth 
occurrence and the spontaneous course of hearing.
When using the GRADE classification system of study 
quality, “moderate quality” is the highest level achievable for 
observational studies. In this systematic review, it is clear that 
the level of evidence according to this system differs between 
tumour growth (Table  4.1.1.I) and hearing preservation 
Table 4.1.1.II. Selected papers on hearing preservation.
Author
(reference)
Year Study 
design
Patients
(number)
Mean 
follow-up
(years)
Preservation of 
good hearing (%) 
> 70%ds < 30 db 
pta
Preservation 
serviceable hearing 
(%) > 50% ds < 50 db 
pta
Grade
quality of 
evidence
Grade
strength of 
recommendation
Stangerup 11 2010 Pro 
cohort
932 4.7 51 56 Moderate Strong
Stangerup 23 2008 Pro 
cohort
548 3.9 52 55 Moderate Disregarded
Breivik 10 2012 Pro 
cohort
186 3.6 Nr 63 Moderate Strong
Kirchmann 17 2017 Pro 
cohort
156 IAC 9.5 17 34 Moderate Strong
Caye-
Thomasen 22
2007 Pro 
cohort
156 IAC 4.6 47 47 Moderate Disregarded
Tveiten 20 2015 Retro 
cohort
148 8.3 62 67 Moderate Strong
Breivik 84 2013 Pro 
cohort
124 4.6 Nr 24 Moderate Strong
Grayeli 8 2005 Retro 
cohort
105 2.8 52 57 Low Weak
Lin 19 2005 Retro 
cohort
86 6.8 Nr 43 Low Weak
Jethanamest 53 2015 Retro 
cohort
75 2.9 Nr 76 Very low Weak
Godefroy 65 2009 Pro 
cohort
70 3.6 Nr 57 Moderate Strong
Quaranta 64 2007 Retro 
cohort
70 2.8 71 60 Low Weak
Ferri 45 2008 Pro 
cohort
56 3.6 Nr 73 Moderate Strong
Roehm 48 2007 Retro 
cohort 
of elderly
> 65
48 3.0 33 38 Very low Weak
Pennings 72 2011 Retro 
cohort
47 IAC 3.6 65 74 Moderate Strong
Fayad 33 2014 Retro 
cohort
43 4.8 67 63 Very low Weak
Régis 73 2010 Pro 
cohort
40 IAC 3.3 69 68 Low Weak
Lee 82 2014 Retro 
cohort
31 IAC 2.6 45 Nr Very low Weak
All studies, 
n = 18
- - 2217 4.9 50.3% 55.1%
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improvement of audiology tests, increasing access to magnetic 
resonance imaging (MRI) and significant longer and healthier 
lifetime of the population 4. For these reasons, the tumour size 
at diagnosis has been decreasing and treatments such as surgery 
and radiotherapy have improved the chance of hearing and 
facial nerve function preservation 2.
The main management options for acoustic neuromas 
are observation, surgical resection, and radiation therapy. 
Each choice is a balance between the expected morbidity 
of the tumour and of the therapy. In medium-size tumours, 
where growth control is the main goal, surgical resection or 
radiotherapy give good results in terms of disease control and 
functional nerve preservation (V, VII, IX, X, XI, XII cranial 
nerves): surgery is generally recommended for younger and 
healthy patients while radiotherapy for all the other cases 4.
The aim of the present article is to review the most recent 
literature data of radiotherapy results in terms of local control 
and side effects and to discuss the role of radiation treatment 
and the optimal technical approach.
Material and methods
Literature search was performed by using the databases of 
Pubmed and Scopus. The key words “acoustic neuroma”, 
“vestibular schwannoma”, “radiosurgery”, and “fractionated 
stereotactic radiotherapy” were used for searching publications. 
We considered the articles published in the last 10 years. The 
relevance was assessed based on the numerousness of the sample 
size (at least 50 patients), the length of follow-up (median/mean 
5  years), the completeness of analysis of technical data, and 
outcome results in terms of local control and side effects.
Results
In total, 574 articles were found. The initial review was 
based on the title and on the abstract. The articles inadequate 
regarding cohort size and follow-up, or duplicated cohort 
were discarded. Finally, 32 articles fulfilled all inclusion 
criteria. 
Since the first radiation treatment conducted by Leksell in 
1969, several clinical series were published reporting the use 
of radiotherapy for acoustic neuroma. No randomized trial 
was conducted. Few clinical retrospective series were found. 
Although the power of these clinical series did not allow 
to formulate strong evidence, we could find some evidence 
that can help physicians during treatment decision making 
on the following issues: radiotherapy technique, total dose 
and fractionation, tumour control and clinical outcome 
including toxicity, treatment at recurrence, and potential risk 
of malignant transformation. 
The articles analysing large series with adequate follow-up 
are summarized in Tables 4.1.2.I, 4.1.2.II, 4.1.2.III.
The recent largest series of stereotactic radiosurgery 
reported quite detailed data in terms of local control, hearing 
preservation, and side effects. Boari et al. 11 reported a local 
(Table 4.1.1.II). The level of evidence is generally low when 
concerning tumour growth and moderate when concerning 
hearing. The strength of recommendation is weak for a 
number of studies, but fortunately relatively high in most of 
the studies with large cohorts. This generates a fairly strong 
overall recommendation concerning conclusions in regards 
to both tumour growth and hearing outcome, and ultimately 
to the overall validity of the present review.
Conclusions
This systematic literature review of the natural history 
of VS shows that on average, 37% of patients diagnosed 
with a small- or medium-sized unilateral/sporadic VS will 
exhibit tumour growth within 3.4 years of observation. 
55% of patients will preserve serviceable hearing and 50% 
of patients presenting with good hearing at diagnosis will 
preserve this within 4.9 years of observation.
Based on these data, we believe that an active treatment 
of small- and medium-sized VS should await documented 
tumour growth, in order to avoid overtreatment and treatment 
side effects which could be worse than the spontaneous course 
of the disease itself. However, individual considerations or 
symptoms may justify active treatment without documented 
tumour growth, e.g. severe, variable dizziness/vertigo, or an 
aim to preserve hearing.
When considering active treatment to preserve hearing 
in patients with a small- or medium-sized VS it should 
always be recognized that good and/or serviceable hearing 
is preserved spontaneously in at least half of the patients 
within 4.9  years of observation, especially if the speech 
discrimination is normal at diagnosis. If active treatment is 
indeed chosen, the results should be published and compared 
to the present data.
4.1.2. Radiotherapy in acoustic neuroma
M. Krengli, L. Deantonio
Introduction
Neuromas or schwannomas are benign Schwann cell-derived 
tumours. When occurring in the vestibular portion of the eighth 
cranial nerve, they are called acoustic neuromas or vestibular 
schwannomas. This tumour is the most common of the 
cerebellopontine angle (90%) accounting for approximately 6% 
of all intracranial neoplasms. The incidence is approximately 
less than 1 per 100,000 persons/year  1. The natural history 
of acoustic neuroma is a slow growth with an unpredictable 
pattern, or no growth at all, and hearing decline, which takes 
place inexorably over the years in an unforeseeable manner 
and despite tumor growth. Recent studies on observation 
showed that intrameatal tumours may stop growing in more 
than 70% of the cases 2 3. During the last decades, the incidence 
of acoustic neuroma seems to be increasing. This is caused by 
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Table 4.1.2.I. Outcome using stereotactic radiosurgery.
Author Level of 
evidence
N. 
pts
Technique Median 
dose
Mean/
median 
volume
Median/
mean
follow-up 
time
Local 
control
Hearing 
preservation
Toxicity 
VII V Other 
Berkowitz 
2017 5
III 353 GKRS 13 Gy 0.5 cc 63 months 99% 29.7%
self-reported
Nr Nr 12% vertigo
Akpinar 
2016 6
III 88 GKRS 12.5 Gy 0.72 cc 75 months 90%-95% 55%-88% 3.4% Nr Nr
Watanabe 
2016 7
III 183 GKRS 12 Gy 2 cc 114 months 96% 
5 years
49%
5 years
3% 1% Nr
Klijn 
2016 8
III 420 GKRS 11 Gy 1.4 cc 5.1 years 91.3% 
5 years
84.8% 
10 years
42% 
5 years
4% 3.1% Nr
Ellenbogen 
2015 9
III 50 SRS 12.5 Gy 2.4 cc 5.8 years 94% 50% 4% 4% Nr
Mindermann 
2014 10
III 215 GKRS 12.9 Gy 1.85 cc 62.4 months 93% Na Na Na Na
Boari 
2014 11
III 379 GKRS 13 Gy 1.3 cc 75.7 months 97.1% 49% 1.1% 1.8% 7.9% vertigo
4.7% tinnitus
5.3% hydrocephalus
Wangerid 
2014 12
III 128 GKRS Mean 
12.3 Gy 
1.6 cc 104 months 92% Nr 3% 2% 3% hydrocephalus
Hasegawa
2013 13
III 440 GKRS 12.8 Gy 2.8 cc 12.5 years 93% 
5 years 
92% 
10 years
43% 
5 years
34% 
8 years
2.2% 0.5% 0.2-0.7%
Lunsford 
2013 14
III 829 GKRS 13 Gy 2.5 cc 10 years 97% 
10 years
50-77% 1% 3% Nr
Kim 
2013 15
III 60 GKRS Mean 
12.2 Gy 
0.34 cc 62 months 88% 
radiological
100% 
clinical
55% 
5 years
Nr Nr Nr
Pollock 
2013 16
III 293 SRS 13Gy Nr 60.9 months 94%
7 years
Nr Nr Nr Nr
Yomo 
2012 17
III 154 GKRS Mean
12.1 Gy 
1.6 cc 60 months 94.8% Nr 0 11.7 Maximum cochlear 
dose < 4 Gy was 
the sole prognostic 
factor for hearing 
preservation
Roos 
2011 18
III 84 SRS 12 Gy Diameter 
22 mm 
65 months 97.6% 38% Nr Nr Nr
Hsu 
2010 19
III 75 SRS 14 Gy 
median
1.5 cc 97.8 months 92% 
10 years
94.7% 8% Nr 9% complications
Fukuoka 
2009 20
III 152 GKRS 12 Gy 2 cc 5 years 94% 
5 years
92.4% 
8 years
71% 0% 2% 2% dizziness 
5.3% hydrocephalus 
Nr: not reported; Pts: patients; GKRS: Gamma Knife radiosurgery; SRS: stereotactic radiosurgery.
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Table 4.1.2.II. Outcome using fractionated stereotactic radiotherapy, hypofractionated and conventional fractionation.
Author Level
of 
evidence
N. 
pts
Technique Median 
dose
Mean/
median 
volume 
(cc)
Median/
mean
follow-up
Local 
control
Hearing 
preservation
Toxicity 
VII V Other 
Aoyama 
2013 21
III 200 Linac FSRT 50 Gy/2 Gy Diameter 
20 mm
72 months 79% 63.9% 9.5% 11.4% Nr
Wolf 
2013 22
III 93 Linac FSRT 52.5 Gy/25 fr Diameter 
19.6 mm 
5.7 years 93% 
5 years
92% 
10 years
93% 1% 1% 4% 
hydrocephalus 
1% radiation 
brainstem 
necrosis
Litre 
2013 23
III 155 Linac FSRT 50.4 Gy/28 fr 2.45 cc 60 months 99.3% 
3 years
95.2%
> 7 years
54% 2.5% 3.2 2.5% 
hydrocephalus
2.1% tinnitus
Tsai 
2013 24
III 117 CyberKnife 18 Gy/3 fr 4.7 cc 61.1 months 99.1% 81.5% Nr Nr Nr
Vernimmen 
2009 25
III 51 Proton 
beam
26C Gy/3 fr 3.45 cc 71 months 98% 
5 years
42% 9.5% 7% Nr
Pts: patients; Nr: not reported; FSRT: fractionated stereotactic radiotherapy.
Table 4.1.2.III. Selected series of acoustic neuroma comparing stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT).
Author Class 
of 
evidence 
N. 
pts
Technique Median 
dose
Mean/
median 
volume (cc)
Median/
mean
follow-up
Local 
control
Hearing 
preservation
Toxicity
VII V Other 
Combs 
2015 26
III 158
291
SRS
FSRT
13 Gy
57.6 Gy/32 fr
1
3.5
67 months
67 months
94%
10 years
94%
10 years
86%
84%
< 1%
1%
1.8%
14%
3% gait 
uncertainty
Anderson 
2014 27
III 48
37
19
SRS
HSRT
FSRT
12.5 Gy
20 Gy/5 fr
45-50 Gy 
/1.8 Gy
0.66 cc
1.85 cc
83.6 months
43.1 months
53.6 months
97%
5 years
90.5%
5 years
100%
5 years
60%
63.2%
44.4%
2%
0%
0%
4.2%
2.7%
0%
2.1% tinnitus
2.7% tinnitus
Puataweepong 
2013 28
III 39
79
28
SRS
FSRT
12 Gy
25 Gy/5 Gy
45-50 Gy 
/2 Gyr
0.9 cc
3.9 cc
9.5 cc
61 months
61 months
95% 
5 years
100%
5 years
95% 
5 years
75%
5 years
87% 
5 years
63% 
5 years
< 1%
< 1%
0%
0%
< 1% 
hydrocephalus
< 1% 
hydrocephalus
Collen 
2011 29
III 78
41
SRS
FSRT
12.5 Gy
50 Gy/2 Gy
0.83 cc
5.7 cc
62 months 95% 59%
82
16%
3%
3.7%
1%
Nr
Pts: patients; SRS: radiosurgery; FSRT: fractionated stereotactic radiotherapy; HSRT: hypofractionated stereotactic radiotherapy; nr: not reported.
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with mean minimum tumour dose of 21.4 Gy (RBE). After 
a mean follow-up of 60  months, the cohort of 51  patients 
achieved a 5-year local-control rate of 98% with a hearing 
preservation of 42%, a facial nerve preservation of 90.5% 
and a trigeminal nerve preservation of 93%.
Suggested treatment volumes, doses, and dose constraints 
are reported in Tables 4.1.2.IV, 4.1.2.V.
Discussion
During the last decades, the role of radiotherapy in the 
management of acoustic neuromas has been progressively 
established thanks to technologic improvements and the 
availability of long term follow-up data regarding local 
control and adverse effects.
The studies analysed the results of stereotactic 
radiotherapy delivered in a single fraction (i.e. stereotactic 
radiosurgery) or in multiple fractions (i.e. fractionated 
stereotactic radiotherapy), with standard fractionation or 
hypofractionation.
In terms of technical aspects, stereotactic radiosurgery can 
be performed with Gamma Knife (Elekta AB, Stockholm, 
Sweden), with linear accelerators (LINACs) equipped with 
micromultileaf collimators, and with Cyber Knife (Accuray, 
Sunnyvale,CA, USA), a LINAC mounted on a robotic arm. 
LINAC and Cyber Knife can also be easily used for fractionated 
treatments. Most of the studies used Gamma Knife, however, no 
study compared the various technologies in terms of outcome.
control rate of 97.1% with a tumour volume downsizing of 
82.7% after 6.5 years follow-up, in 523 patients treated with 
Gamma Knife stereotactic radiosurgery to a median margin 
dose of 13  Gy. Treatment-related complications consisted 
only in a transient worsening of pre-existing symptoms, and 
the overall rate of serviceable hearing was 49%. Watanabe et 
al. 7 reviewed the results of 183 patients treated with Gamma 
Knife radiotherapy to a median dose of 12 Gy. The actuarial 
5-year progression-free survival rate was 96%. The rate of 
facial nerve palsy was 3%. On the other hand, Hasegawa et 
al. 13, with a progression-free survival rate of 92%, found an 
actuarial 10-year rate for preservation of VII nerve function 
of 97% in the marginal dose group (> 13 Gy) and of 100% in 
the marginal dose group (< 13 Gy).
For what concerns fractionated stereotactic radiotherapy, Tsai 
et al. 14 reviewed the results in 117 patients treated with Cyber 
Knife. A total dose of 18 Gy in 3 fractions was prescribed to 
a median tumour volume of 4.7 cc. Local control rate was 
99.1% with a serviceable hearing preservation rate of 81.5%. 
A French experience  23 reported outcomes in 155 acoustic 
neuromas treated with conventional fractionation. Patients 
received a dose of 50.4 Gy with daily fractions of 1.8 Gy. 
Local tumour control rate was 95.2% after 7-years follow-
up. Facial and trigeminal palsies were observed in 2.5% and 
3.1% of patients, respectively. In regards to particle therapy, 
we found a retrospective study by Vernimmen et al. 25, who 
used protons to a total dose of 26 Gy (RBE) in 3 fractions 
Table 4.1.2.IV. Suggested target volumes and radiation doses for acoustic neuroma.
Target volume Definition Dose
GTV Tumour volume defined as the outer edge 
on post-contrast T1 - w MRI 
CTV CTV = GTV
PTV CTV + no margin in case of GKS
CTV + 0.5-2.0 mm depending on setup system in case of 
SRS
CTV + 1.5-2.0 mm depending on setup system and 
reproducibility of patient positioning in case of FSRT
GKS: 12-13 Gy to the tumour volume in a single session 
prescribed to the 50% isodose (40-100%) 
LINAC-based SRS: 12-13 Gy to the 80-90% isodose 
LINAC-based FSRT: 45-54 Gy, 1.8 Gy/fr to the 95% isodose (or 
hypofractionation)
GTV: gross tumour volume; CTV: clinical target volume; PTV: planning target volume; GKS, Gamma Knife surgery; LINAC: linear accelerator; FSRT: fractionated stereotactic 
radiotherapy; fr: fraction.
Table 4.1.2.V. Normal tissue dose constraints for conventional fractionation and stereotactic radiosurgery 30.
Critical structures Conventional fractionation SRS Event
Spinal cord Dose max < 50 Gy Dose max 13 Gy Myelopathy 
Brainstem Dose max < 55 Gy Dose max 12.5 Gy Permanent cranial neuropathy or necrosis
Cochlea Dose max 55 Gy
Mean dose < 45 Gy
Dose max 12-14 Gy Sensory neural hearing loss
Ventral cochlear nucleus 
Modiolus and the basal turn of the cochlea
≤ 9 Gy
Ideally < 4-5.3 Gy
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median marginal dose of 12-13  Gy and can provide good 
local control, with a progression-free survival rate of 95% 
after a median follow-up of 5-10 years. The average hearing 
preservation rate after treatment is nearly 55%. In most 
studies, facial and trigeminal nerve deterioration rates are 
nearly 3% and 6%, respectively. 
Nowadays, radiotherapy is used as radical treatment or after 
subtotal resection for large lesions (> 3 cm) at excessive risk 
of neurological impairment or in case of disease recurrence 
after surgery 31. Medium size (2-3 cm in the cerebellopontine 
angle) and large tumours (> 3 cm) need an active treatment 
(surgery or radiotherapy) while smaller tumours can be treated 
or just observed. In this regard, we found two retrospective 
studies comparing a “wait and see” approach with an active 
treatment  6  32. In both studies, patients were treated with 
Gamma Knife radiosurgery to a median dose of 12  Gy. 
Breivik et al.  32 reported a serviceable hearing loss in 64% 
patients treated compared to the 76% in the observational 
group. Moreover, a highly significant percentage of patients 
required treatment following initial observation (p < 0.001). 
In contrast, Akpinar et al.  6, comparing patients who 
underwent Gamma Knife early (< 2 years from diagnosis) or 
late (> 2 years after), found higher hearing outcome (88%) 
in patients treated earlier. Up to now, based on literature data, 
the “wait and see” policy is considered the best initial option 
for not growing acoustic neuromas smaller than 1.5 cm, as far 
as quality of life is good. Therefore, stereotactic radiosurgery 
should be considered only in case of large and unresectable/
inoperable lesions or in small but growing lesions.
Stereotactic radiosurgery for acoustic neuroma 
(Figs.  4.1.2.1,  4.1.2.2, 4.1.2.3) is usually prescribed to a 
Fig. 4.1.2.1. Axial T1-weighted post contrast MRI demonstrate a post con-
trast enhancing small acoustic neuroma in the left cerebellopontine angle.
Fig. 4.1.2.3. Radiosurgery treatment plan with volumetric-modulated arc ther-
apy (VMAT). The red colour wash volume is encompassed by the isodose of 95% 
(dose prescription to 13 Gy).
Fig. 4.1.2.2. Coronal T1-weighted post contrast MRI demonstrate a post 
contrast enhancing small acoustic neuroma in the left cerebellopontine angle.
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radiotherapy for retreatment  36. We did not find studies of 
retreatment after a first stereotactic radiosurgery which 
satisfied our inclusion criteria because of the low patient 
number and short length of follow-up. In contrast, we found 
two retrospective studies, where patients were treated with 
stereotactic radiosurgery because of a tumour progression 
after a gross total resection or a partial resection  19 37. The 
larger one treated 90 patients to a median dose of 13 Gy by 
Gamma Knife 37, achieving a tumour control rate of 90%. At 
a mean follow-up of more than 6 years, the complication rate 
was low, and persisting facial nerve deficit and trigeminal 
nerve impairment was 3.3% in both cases.
Although the scarce available data in case of recurrence/
progression after surgery came from retrospective studies, 
we may recommend stereotactic radiosurgery as a potentially 
safe and effective treatment.
A controversial issue is the potential risk of malignant 
transformation in acoustic neuromas after stereotactic 
radiosurgery. We found only one report  13 which described 
1 malignant transformation in a retrospective cohort of 
440 acoustic neuromas (0.3%) after a median follow-up of 
12 years. Annual incidence of malignant transformation was 
0.02%. Based on that, we could conclude that the risk of 
malignant transformation is minimal.
The main limit of the present review is related to the absence 
of clinical randomized trials comparing different radiation 
therapy approaches and series treated with radiation vs. 
surgery. Literature data are only available from retrospective 
observational studies. Moreover, a remarkable number of 
reports were excluded from our analysis because of the 
short follow-up. Long-term observation is actually essential 
in benign tumours to detect not only recurrence but also 
treatment related toxicity that may affect patient’s quality of 
life.
Conclusions
Radiation therapy approaches that have been used in patients 
with acoustic neuromas include stereotactic radiosurgery 
and fractionated stereotactic radiotherapy with photon 
and proton beams as well. The present literature review 
concludes that similar local control can be achieved with 
each of these approaches and that treatment decision could 
be based upon the availability of expertise and technology, 
as well as patient specific factors. Inoperable medium size 
(2-3 cm), large tumours (> 3 cm), and recurrent neuromas 
can be safely treated with radiosurgery and with stereotactic 
radiotherapy, while smaller tumours can undergo observation 
until a growth is detected and an active treatment, which 
can include surgery or radiation, is needed. In any case, the 
treatment choice should be based upon the balance between 
the expected morbidity of the tumour and of the therapy, 
taking into account patient’s preference. 
A fractionated schedule is currently used in case of large 
tumours compressing and displacing the nervous structures 
when surgery is not feasible for local or general patient 
condition or for patient refusal. A total dose of 45-55 Gy in 
20-30 fractions, or an equivalent dose with hypofractionation 
is usually recommended in case of fractionated stereotactic 
radiotherapy. In case of hypofractionation, dose prescription 
can be in the range of 18-25 Gy in 3-5  fractions  24 27 28. In 
this regard, fractionation can be useful compared to single 
fraction in case of close proximity to, or compression of, the 
brainstem and cerebellar hemisphere since it reduces the risk 
of late damage in relation with the low alpha/beta value (i.e. 
sensitivity to large dose per fraction) of the nervous tissue, 
which was estimated of about 3 Gy using the linear quadratic 
model, compared to a quite similar value (2.4 Gy) for acoustic 
neuroma 33. Fractionated stereotactic radiotherapy adopted in 
several literature studies provided a high local control grade, 
with only 4.8% loss of tumour control in long-term follow-
up series 26-28. The risk of neurological deterioration in terms 
of hearing quality and facial deficit was similar to that of 
stereotactic radiosurgery. 
As far as radiation therapy is concerned, no randomized 
controlled studies comparing the safety and efficacy of 
stereotactic radiosurgery and fractionated stereotactic 
radiotherapy have been published. However, studies 
comparing patients with similar tumour characteristics 
showed that results are very similar in terms of local control 
and peripheral nerve toxicity (Table  4.1.2.III). The risk of 
facial and trigeminal nerve deterioration was less for patients 
treated with radiosurgery series compared to patients 
receiving fractionated stereotactic radiotherapy, while the 
chance of preserved hearing showed no difference between 
the two treatment groups  34. In this regard, we found a 
remarkable different study number between the two groups, 
in favour to stereotactic radiosurgery, with also a shorter 
follow-up for fractionated stereotactic radiotherapy series. 
For what concerns radiation dose, literature studies did not 
show relevant differences in tumour control using different 
dose levels and currently doses  ≤  13  Gy for the single 
fraction can be recommended in order to facilitate hearing 
preservation. Moreover, no difference in local control can be 
observed by using a single session (radiosurgery) or multiple 
sessions (fractionated radiotherapy). From the data analysed, 
we can underline that fractionated schedules were used in 
cases of larger tumour volume (> 2.5 cc). 
Proton therapy may be an option for the treatment of acoustic 
neuroma due to the proximity of radiosensitive organs at 
risk. The rapid fall of the dose to zero beyond the Bragg peak 
offers a theoretical advantage in this tumour setting 35. Since 
there is only one study looking at the outcome with proton 
therapy 25, we cannot formulate recommendations about this 
treatment modality.
One more open question is about the role of stereotactic 
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volume of the tumor that might become 26-280% larger than 
the initial size 3.
Pollock et al. noted three types of VS enlargement after 
radiation surgery: type  1 showed tumor regression to 
the initial size or even less. In type  2 the tumor remained 
stable after the initial enlargement and the patient remained 
asymptomatic with no need of any treatment. Type  3 was 
devoted for the tumor that continued to enlarge with 
subsequent risk of compressive symptoms and need for 
further intervention 3.
On magnetic resonance imaging (MRI), a loss of central 
enhancement is found in 93% of the tumor. Multi-septated 
cyst formation is also common after radiation therapy 
secondary to tumor necrosis and protein leak from the 
intratumoral vessels. This reaction remains active till 12-
18 months after radiotherapy when the chronic inflammation 
starts to resolve and be replaced by glial formation to the 
surrounding structures. The excessive scarring of the tumor 
to the adjacent nerves in addition to the direct toxic effect of 
the radiation with the surrounding vasculitis elucidates the 
delayed occurrence of radiation-induced neuropathies and 
even demyelination of the nerves 4. 
In the light of the fact that wait and scan has given us the 
opportunity to study the natural history of VS, which proves 
that a section of VS shows indolent growth or do not grow 
at all 5, it is now important to review the results of RT to find 
out if at least a portion of the success of RT can be attributed 
to the natural biology of the tumor itself. The literature on 
RT shows results in terms of tumor stabilization without 
taking into consideration pretreatment spontaneous arrest of 
growth  6. Very few authors reporting on the success of RT 
have emphasized on the policy of wait and scan to determine 
the natural progression of tumor, and many of their selection 
criteria have been arbitrary. Many reports lack consideration 
of the age or size of tumors, which has a strong correlation 
to tumor growth. Moreover, inclusion of NF II, previously 
treated patients (surgery or RT), referral bias, variations 
in dose and the RT tool (SR or FSR), and short follow-up 
have added to the discrepancies of reporting of the results 
of RT. Most RT authors still report the size of the tumors 
and the hearing results according to old classifications like 
the Koos’ classification  7 and the Gardner-Robertson’s 
classification 8, respectively, instead of the newer and more 
comprehensive guidelines presented in the report of the 
Tokyo Consensus Meeting on Systems for Reporting Results 
in Acoustic Neuroma 9. A recent study by Han et al.  10 has 
observed that the guidelines have made a significant impact 
on standardization of reporting in RS. It can be noted that 
most series on RT have an arbitrary approach to irradiation 
of tumors without a systematic selection criteria or wait-and-
scan protocol before initiation of RT. All sizes of tumors 
have been irradiated. This also includes intrameatal tumors 
that have shown to demonstrate an indolent growth pattern 
4.1.3. Vestibular schwannoma:  
surgery after radiotherapy
G. Piras, A. Russo, A. Caruso, A. Giannuzzi, M. Sanna
Introduction
Vestibular schwannoma (VS) is a tumor that arises from 
Schwann cells of the vestibular nerve. The incidence 
ranges from 10 to 20 per million/year and it accounts for 
75% of cerebellopontine angle tumors, 10% of intracranial 
tumors, and 5% of such tumors occur in patients with 
neurofibromatosis type 2 (NF2) 1.
The cornerstone treatment is complete surgical resection that 
requires an experienced surgical team. With the advances 
in microsurgical techniques and intraoperative monitoring 
tools, excellent outcomes have been achieved in terms of 
preservation of the facial nerve (FN) and, whenever possible, 
serviceable hearing. In 1969, Leksell introduced the use of 
stereotactic radiation therapy for VS treatment 2. Since then, 
the use of radiation therapy (RT) became largely widespread 
because it seems less invasive than surgery. In many centers 
it becomes the modality of treatment for symptomatic elderly 
patients, medically unfit for surgical therapy, patients who 
refuse surgery, tumors occurring in the only hearing ear and 
in some recurrent or residual growing tumors.
The main disadvantage of radiation therapy is the non-
removal of the tumor that retains the risk of growth and thus 
requires long term follow-up.
Role and controversies of radiotherapy  
in vestibular schwannoma
There are two main different modalities of radiation therapy 
in the treatment of vestibular schwannoma:
• The single session protocol or Stereotactic Radiosurgery 
(SR) that consists of delivering to the tumor a single 
high-dose of radiation. The skull should be rigidly 
immobilized to a frame. The radiation beams can be 
delivered by a modified linear accelerator machine or a 
Leksell Gamma Knife machine which is more commonly 
used in the treatment of vestibular schwannoma.
• The fractionated type or Stereotactic Radiotherapy (FSR) 
consists of giving the required radiation dose over several 
sessions. This technique is performed through a linear 
accelerator machine with a relocatable frame (Novalis, 
Radionics) or with a frameless image-guided, robotic 
system (Cyberknife).
Regardless the source of radiation in stereotactic radiotherapy 
(proton, photon, neutron, or ion beams), the tumor center 
receives the maximal radiation dose (isodose) that gradually 
decreases in the periphery and surrounding structures. The 
effect of radiation therapy is not shown until 4-6 weeks after 
treatment when the acute inflammatory reaction starts to 
appear with a progressive focal edema and an increase in the 
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The pathophysiology of hearing loss following radiotherapy 
could be explained by several mechanisms:
• damage to the auditory pathways even from direct effect 
of the radiation or secondary to a decrease in blood flow 
due to vasculitis and hyalinization of vessel walls;
• compression of the cochlear nerve in the internal auditory 
canal secondary to the tumor enlargement;
• acute intracochlear hemorrhage.
Less common complications are ataxia, cerebral edema, 
hemifacial spasm, quadriplegia, hydrocephalus and 
malignant transformation of the VS 35.
The incidence of hydrocephalus secondary to radiotherapy 
ranges from 4% to 14%. It can occur even without 
evidence of increase in the tumor size or compression 
by the tumor. The pathophysiology of communicating 
hydrocephalus following radiotherapy is explained by 
tumor necrosis that results into elevation of CSF protein 
that obstructs the arachnoid granulations with subsequent 
CSF malabsorption 36.
A publication by Jeon et al. 36 showed that nine of 90 patients 
who received radiotherapy as primary treatment of VS 
developed communicating hydrocephalus whereas only one 
of 146 patients (0.68%) who underwent primary surgical 
resection of the tumor developed this complication.
Up to this date, our experience with VS surgery revealed 2 
out of 3,500 patients (0.0006) who developed postoperative 
communicating hydrocephalus after surgical resection of 
their tumor. 
Malignant brain tumor following stereotactic radiotherapy 
of VS has been reported in several studies. It occurred from 
6  months to 19  years after radiation therapy  35. Ron and 
Sadetzki reported that brain tissue exposure to radiation 
doses as low as 1  Gy was sufficient for the development 
of a secondary tumor. Radiation induced malignant brain 
tumor has been reported in solitary schwannoma as well as 
in NF2 35. Warren et al. demonstrated that VS removed from 
NF2 patients previously irradiated had more chromosomal 
anomalies than non-irradiated tumors. Besides this, Baser 
et al. mentioned that NF2 patients who have received 
radiotherapy had a 14-fold increased risk of developing 
malignant brain tumors  37. Despite its low incidence, the 
risk of radiation induced malignant brain tumor and de 
novo benign cerebral tumors should be considered in 
the counseling and the decision making process of VS 
treatment. Since 1993, in order to decrease the incidence 
of radiosurgery complications, the doses of radiation have 
been reduced to 15-25  Gy of isodose and 10-15  Gy of 
marginal dose 38.
Radiation therapy is abused in some centers who recommend 
such treatment for all VS regardless the age of the patient, 
the size of the tumor, the presence of a cystic component and 
without clear evidence of tumor growth 39 40.
It is generally accepted that radiation therapy should not be 
and for which wait and scan is recommended 11-13. It is well 
accepted that wait and scan is an ideal policy in the elderly age 
group with smaller tumors. The age of patients in our wait-
and-scan series and RT series is the same 5, which indicates 
that many of the irradiated patients may have benefitted from 
wait and scan. If it were to be assumed that patients subjected 
to RT had tumors that showed prior growth, then it becomes 
important to define the rate of growth and the size of tumors 
that will prompt an initiation into RT, which is absent in most 
reports. For instance, tumors that show slow growth rates of 
1 to 2 mm/yr should not be a matter of concern in an elderly 
patient, as such patients can be included in a wait and scan 
protocol. Also, SR is indicated in small tumors because of 
the high tumor dose, whereas FSR is indicated for larger 
tumors 14. But the comparisons show that RS has also been 
used for large tumors. The maximum and minimum size of 
tumors that can be irradiated is yet to be defined.
On the other hand, studies have stated that microsurgery is 
better than RT for tumors larger than 2.5 cm 15-19 because of 
increased associated morbidity with RT in such cases 17 20-23. 
Other discrepancies in reporting like including patients with 
previous surgery, NF II, improper classification of tumor 
sizes, and short follow-ups diminish the validity of reports. 
The definition of tumor control is also highly variable 
between series, with some claiming no additional surgical 
intervention to mean tumor control, which is incorrect 24-29. 
As mentioned in our previous study  5, our wait-and-scan 
series shows that a tumor shows no growth in 54%, regression 
in 4% (total of 58%), and progression in 42% of tumors (of 
which 28% showed slow growth). Compared with this, the 
successes of RT ranges from 79% to 99%. If this were to be 
reasoned with our wait-and-scan results, it could be inferred 
that between 21% and 41% of the tumors actually could have 
benefitted from RT.
For the benefit of the patient, both the surgeons and the 
radiotherapists have to be willing to apply the policy of wait 
and scan to suitable patients before subjecting them to any 
definitive treatment. Once this commonality is achieved, 
the efficacy of RT with respect to microsurgery can be then 
compared among the subsets of patients who are not suitable 
for wait and scan or those who have failed wait and scan. This 
must be the direction of future studies that will enable us to 
draw meaningful conclusions. Also, standardized reporting 
criteria as suggested by Battaglia et al. 30 are recommended.
Complications and salvage surgery after radiotherapy
The complication of radiation therapy is underestimated 
and has not been properly addressed in the literature 31. The 
most common complications are hearing loss, trigeminal 
hypoesthesia and facial nerve paralysis with an incidence 
that ranges from 25% to 89%, 19% to 34% and 8% to 32% 
respectively  32-34. These complications can occur up to 28 
months post radiotherapy even without tumor growth  34. 
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function outcomes varied from a report to another depending 
on the completeness of tumor removal, but in all the cases 
the results were much worse than in patients who had not 
received previous radiation therapy. Iwai et al. found that 
33% of their patients had worsening of the facial nerve 
function after at least 11 months of follow-up even though 
in all cases the internal auditory canal was not opened and 
residual tumors were left on the facial nerves 43. Friedman et 
al. recommended subtotal resection of irradiated tumor when 
this is adherent to the facial nerve 41. Despite this protocol, 
these patients had poorer facial nerve function outcomes 
than the non-irradiated group. Regardless of the approach 
and whether the tumor was totally or subtotally removed, no 
single case was encountered with preserved postoperative 
serviceable hearing. We prefer to perform the enlarged 
translabyrinthine, transotic or transcochlear approaches to 
ensure total removal of the tumor because in most of our 
cohort, the tumor size was greater than 1.5 cm or the patients 
had a poor hearing status.
In our series complete tumor removal was achieved in 84.2% 
of the cases. Residual cystic walls of the tumor were left in 
two VS with no sign of growth after a follow-up period of 
3 y and 6 y respectively. Around 73.3% of our patients had 
worsening of FN function postoperatively, and 63.6% of 
those who complained from this deterioration had HB facial 
nerve grade 2-3 31.
These relatively poor facial nerve outcomes are attributed not 
only to the loss of plane between the tumor and the nerve but 
also to the reduction of the neural regeneration secondary to 
radiation therapy. This deficit in neural regeneration and the 
capacity of spontaneous recovery from surgical trauma could 
be attributed to the decrease in blood supply of the nerve 
following radiation therapy 41. According to our experience 
we believe that complete tumor resection is the gold standard 
therapy to prevent a second salvage surgery that will be much 
more difficult with a higher morbidity rate and to avoid the 
risk of malignant tumor transformation.
We recommend subtotal or near total resection only in cases 
of elderly patients or with cystic tumor when the cyst wall 
could be left on vital and neurovascular structures 44.
Conclusions
Radiation therapy should not be considered as an optional 
treatment of vestibular schwannoma without a clear and 
documented evidence of tumor growth. The patients should 
be made aware of its complications and risk of failure, 
especially in young patients and NF2 cases.
Surgical resection of VS after failed radiotherapy is very 
challenging with relatively poor facial nerve outcomes and 
very difficult hearing preservation.
given for tumors greater than 3 cm because of two reasons:
• to avoid compressive symptoms following normal 
expected growth that occurred within the first year;
• to prevent the morbidity related to radiation therapy, 
due to the fact that such large tumors need a higher 
therapeutic dose.
Our experience in VS surgery with a tumor size less than 
3  cm shows excellent outcomes in regards to functional 
preservation of the facial nerve (93.5% grade 1-3) as well 
as preservation of serviceable hearing in cases of small 
tumors (< 1.5 cm) with non-enlarged internal auditory canal 
(36.4%). Complete resection of the tumor was achieved in 
96.2% of these patients with minimal morbidity and no 
recurrent tumor was encountered after at least 3  years of 
follow-up 31.
Excellent results are also reported by other specialized 
referral skull base and neuro-otology centers that showed 
no major benefits of radiotherapy on surgery 41. The rate of 
tumor control with radiotherapy might be overestimated in 
the literature. As written before, in many centers, stereotactic 
radiotherapy is performed before the proof of any tumor 
growth; so, the good result following radiotherapy might 
be attributed to the natural course of the disease and not to 
the efficacy of the radiation 5. In almost all the publications 
that reported good control of the tumor growth following 
radiation therapy, the mean follow-up period ranged from 
2 to 5  years, which is considered as an inadequate period 
in comparison to the follow-up needed to define the success 
of radiation therapy in the treatment of benign brain tumors 
(pituitary tumor, meningioma). Breen et al. reported that 
tumor control rate following radiotherapy for nonfunctional 
pituitary adenoma decreases with time even after 20 years 
of follow-up 42. Therefore, long term follow-up studies (up 
to 2 decades) using the small radiation dose are necessary to 
prove the efficacy of such modality of treatment.
As mentioned previously a tumor enlargement within 1 year 
after radiotherapy is a normal finding and should not be 
considered as an indication to surgery unless the patient has 
compressive symptoms or severe complications secondary to 
tumor growth (brainstem compression, hydrocephalus).
The cranial nerves during this period are very vulnerable to 
be injured during surgical manipulation.
Most authors agreed that removal of VS is more difficult in a 
patient who received radiation therapy when compared to a 
patient who had not 41.
Difficulties in tumor dissection ranged from 43% to 100% 
of the cases. Most common difficulties included a loss of 
the peritumoral arachnoidal plane with thickening of the 
arachnoid, scarring adjacent to the facial nerve, trigeminal 
nerve and brainstem. Other intraoperative difficulties were 
adherence of the tumor to the cerebellum, lower cranial 
nerves, anterior inferior cerebellar artery and excessive 
intraoperative bleeding. The postoperative facial nerve 
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and revision surgery  4 8 11. Some authors advocate a more 
aggressive treatment in order to avoid more dangerous 
complications, such as intracranial infection  4. In fact, 
the occurrence of meningitis is mostly related to CSF 
leakage 14, ranging from 9.85% to 0.14% 3-10 13. Reports of 
aseptic meningitis are not so rare. Avoiding hemorrhage 
during surgery with blood flowing into the arachnoid space 
and reducing the use of heterologous materials (bone wax, 
hemostatic agents, glue) can reduce this risk 4 5 16.
Intracranial hemorrhage
Hemorrhagic complications occur within hours or days after 
surgery, mostly within the first 24 hours 4, representing the 
most serious postoperative complication and the leading 
cause of death in this group of patients 9. The incidence has 
reduced significantly in the last decades, ranging from 0.6% 
to 2.7% in recent series 3-10, and requires surgery in a half of 
the cases 17.
It can present with pontocerebellar angle hematoma, epidural 
hematoma, subdural hematoma, subarachnoid haemorrhage, 
intracerebellar or brainstem hematoma. The major 
responsibles for these complications include: incomplete 
hemostasis during tumour removal, tearing of bridging 
veins, major sinuses or jugular bulb bleeding or bleeding 
from the temporalis muscles  4  8  17. The warning symptom 
is mainly a progressive deterioration of consciousness that 
should be promptly recognized and managed urgently. 
A delayed identification of this condition may result in 
cerebellar oedema, acute hydrocephalus, cerebral herniation 
and brainstem damage, leading to devastating consequences 
quod valetudinem and, as mentioned above, quod vitam. 
Surgical intervention entails wound opening while the 
patient is in the intensive care unit, to decrease intracranial 
pressure before CT scan, hematoma evacuation and external 
ventricular drain placement (EVD)  8  9. In general, during 
the first 24-48  hours after VS surgery, a strict neurologic 
monitoring is strongly recommended and the patient should 
be awakened and extubated as soon as possible  8. Several 
recommendations should be followed in order to reduce the 
risk of postoperative bleeding. A careful haemostasis during 
tumour removal should be performed also to obtain a clear 
vision of surgical field, especially in the farthest area or 
near the brainstem where the haemostasis could be difficult 
to achieve. Some haemostatic agents could be very helpful 
in this setting to achieve valid control of ooze bleeding in 
prohibitive regions  18. SNC parenchyma decompression 
(obtained by the opening of basal cisterns or by tumour 
removal) should not be rapidly performed to avoid bleeding 
from bridging veins and small arteries. At the end of 
surgery the surgical field should be abundantly irrigated 
and a Valsalva manoeuvre should be performed to exclude a 
venous hemorrhage 4 8.
An association between intracerebral hemorrage and large 
4.1.4. Complications in acoustic neuroma surgery
V. Baro, A. Landi, L. Denaro, D. d’Avella
Introduction
The first surgery for vestibular schwannoma (VS) was 
performed by Sir Charles Balance in the second half of 19th 
century 1. At the beginning of this surgery the mortality rate 
was as high as 80-90% and it has remarkably decreased 
especially in the second half of the last century, thanks to the 
introduction of microsurgical techniques and of dedicated 
oto-neurosurgical teams  2. Nowadays the mortality is less 
than 1% 3-9 but the rate of complications is still considerable, 
ranging from 13% to 28.2 % in recent series  6-10, although 
permanent deficits remain in a minority of patients  6. 
Several risk factors have been identified such as tumor size, 
craniectomy instead of craniotomy, park bench position, 
surgical approach, comorbidities and low surgeon case-
load 6 10-12. In this paper, we analyze the complications that 
plague VS surgery not related to facial and cochlear nerves.
Life-threatening complications
Cerebrospinal fluid leakage and meningitis
Cerebrospinal fluid (CSF) leakage is the most common 
complications encountered in VS surgery. Its incidence 
has decreased during the last decades thanks to an 
increased awareness of this issue and to the introduction 
of technical refinements for its prevention. In recent series 
it ranges from 2% to 10.6% 3-11 13 14 and it can present with 
otorrhea, rhinorrhea and wound swelling with or without 
leakage from the incision. According to some authors 
the risk for CSF fistula has been considered higher in the 
retrosigmoid approach 8 9 11 13 although Sughrue et al. found 
that translabyrinthine approach is more likely to cause CSF 
leak  13. Moreover, in some cases, tumour size has been 
associated with a higher incidence  9  15 but there is not a 
general consensus neither for the correlation between CSF 
leakage and surgical approach nor with tumour dimensions. 
The violation of the mastoid and retrolabyrinthine or apical 
cells and difficulties encountered during dura mater closure 
are the main responsible for leakage. Many strategies have 
been developed to reduce this risk, such as the combined 
use of the endoscope to properly check the surgical field, 
the obliteration of all the opened cells with bone wax and 
the obliteration of the cavity with abdominal fat, then 
strengthened with a vascularized muscle flap placed over it. 
The re-placement in situ of the bony flap is associated with 
a lower risk of leakage and the closure of the tegumental 
tissues can be reinforced with temporal fascia and stitches 
instead of staples 4 6 8 10 11. A conservative management can 
be successful, involving head elevation, pression dressing 
with or without punction, supplementary stitches. In case of 
failure, invasive procedures entail lumbar drain placement 
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bony defect can reduce its incidence. The treatment entails 
the use of analgesia (e.g. paracetamol or nonsteroidal anti-
inflammatory drugs, NSAIDs) and in severe cases also 
narcotics. More aggressive approaches include cranioplasty, 
occipital nerve resection or local anaesthetics 20.
Cerebellar dysfunction
Postoperative symptoms that can be ascribed to cerebellar 
dysfunction occur in up to 35% of patients. The majority 
of these recovered over time without need of rehabilitation, 
which is required in a limited number of cases  3  4  6  8. As 
previously mentioned, the persistence of this complication 
is generally due to a vascular insult to cerebellar pathways at 
the cerebellar peduncles 17.
4.1.5. Hearing Preservation Surgery (HPS)  
with retrosigmoid approach 
A. Mazzoni, E. Zanoletti, D. Borsetto, D. Cazzador
HPS has acquired a central role in the management of 
acoustic neuroma, as it offers a coherent line of hearing 
conservation/rehabilitation with respect to, and integrating 
with, the alternative therapies. HPS initiated over 50 years 
ago and had a slow and difficult course with empirical 
development of indications and evaluation of outcome, not 
to mention the operative technique which included both 
otological and neurological surgery and could not be learned 
with laboratory training. The late alternative therapies of 
observation and radiotherapy made more complicated the 
way to a consensual management. The inalienable principle 
of the patient’s choice of therapy excluded the randomization 
necessary to a clinical study and allowed only a progress 
based on third level evidence. 
It is noteworthy that the first cases of HPS were separately 
reported in the neurological and otological fields. The 
pioneers were Elliot and McKissock in 1954 1 who reported 
on two successful cases of tumor removal with suboccipital 
approach. Pertuiset  2, Smith  3, Bremond  4 and Sterkers  5 
followed. In 1984 Jannetta  6 gave a detailed description of 
surgical and neuromonitoring technique and reported on 
the hitherto papers on hearing preservation surgery. In the 
otoneurological field, in 1961 House 7 described the middle 
fossa approach to the internal auditory canal and in the 
following years preserved hearing in few intracanalicular 
cases 8. Glasscock et al. 9 10 contributed to setting the bases of 
HPS with both the middle cranial fossa and the retrosigmoid 
approach. There ensued the diffusion of intraoperative 
monitoring, the classification of hearing, the long debate on 
the exposure of the full canal up to its fundus and the years of 
popularization ending in more realistic expectations. Today, 
the practice of hearing focused management is a goal of all 
the three approaches, HPS, observation and radiotherapy, 
VS has been described In literature 8 10, whereas its relation 
with surgical approach and patients’ positioning is still 
debated 17.
Cerebellar oedema
Cerebellar oedema is predominantly a direct consequence 
of cerebellar manipulation during surgery, especially in 
case of excessive retraction of the cerebellar lobe. This 
complication occurs in less than 1.5% of the cases  4 6-9 and 
it can lead to obstructive hydrocephalus, requiring surgical 
drain placement  19. The treatment includes proper patient 
positioning, hyperventilation, steroids, mannitol and diuretics, 
CSF drainage (EVD) and wound opening  6  19. Limiting 
extensive coagulation during tumour removal is extremely 
important to avoid perforating artery interruption which would 
lead to brainstem ischemia. Coagulation of distal branches 
of the anterior inferior cerebellar arteries is less harmful but 
the persistence of cerebellar dysfunction is usually related to 
vascular injuries to the cerebellar peduncles 17.
Acute hydrocephalus
The occurrence of de-novo hydrocephalus after VS removal 
is  less than  5%, as a result of other complications such 
as cerebellar swelling, haemorrhage, CSF absorption 
impairment (due to blood products or infection) and 
brainstem stroke. Postoperative hydrocephalus usually 
presents with symptoms of intracranial hypertension and its 
treatment entails the resolution of the underlying cause and 
EVD  3-7  9  19. Delayed hydrocephalus, requiring permanent 
shunting is rare, occurring in less than 1.6% of patients 4-6 9.
Lower cranial nerve dysfunction
Lower cranial nerves dysfunction is not a negligible 
drawback, leading to severe complications as aspiration 
pneumonia, which still represents a cause of death in these 
patients. Lower cranial nerve dysfunction affects up to 8.2% 
of patients 3-8 but permanent deficits afflict only less than 1% 
of patients 4 6 8 12.
Non life-threating complications
Postoperative headache
Postoperative headache is a common complication in 
VS surgery, affecting up to a quarter of patients, typically 
decreasing one year after surgery. Even if it is classified as 
a not life-treating complication, it may have an important 
impact on postoperative quality of life 20. This complication 
has been associated with the retrosigmoid approach, 
especially without bone flap replacement  3  11  20. Several 
explanations have been proposed for persistent postoperative 
headache, among these: chemical meningeal irritation from 
the dust generated from the drilling of the internal acustic 
canal, occipital nerve injury, fibrous adhesion between the 
dura mater and the muscles in case of craniectomy and scar 
tissue. Bone flap replacement or cranioplasty to repair the 
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rehabilitation is universally seen as the challenge posed 
by the early diagnosis. None of the three therapies have a 
convincing answer, although there seems to be the mentioned 
more favorable long-term outcome with hearing preservation 
surgery 14 but the lack of level one evidence leaves us with 
the weak level three studies to face the mounting number of 
cases. The necessary “here and now “approach is a sort of 
eclectic guideline taking in the best of every therapy applied 
to the parameters of the individual case, which meant for 
us the multi-optional hearing focused therapy 16. Within this 
frame, the HPS can be recommended for cases of favorable 
size and hearing as mentioned, but conversely it loses its 
preminence in favor of observation with cases off these 
parameters.
4.1.6. Assessing hearing to orient the choice  
of treatment for acoustic neuroma
R. Bovo, F. Sorrentino
Introduction
In patients with a preserved hearing function, we have three 
options for managing acoustic neuroma: 1) observation; 
2) early hearing preservation surgery; or 3) early preservation 
surgery and, in the event of this failing to preserve hearing, 
rehabilitation with a cochlear implant (CI). In terms of 
preserving hearing function, the outcome of any of the above 
treatments is always partial. The results are better when the 
patients’ hearing function is better beforehand and, more 
importantly, if their neural anatomical structures are better 
preserved. This means that the first issue for audiologists is 
how to ensure a thorough assessment of hearing function in 
order to be able to predict the outcome of any therapy. This 
includes considering the degree to which any deterioration 
in hearing function would affect the patient’s quality of life. 
In particular, the clinical indication for hearing preservation 
surgery (HPS), which is the more complex and difficult 
surgical option, has to take into account the realistic 
feasibility of preserving hearing, and the likely impact of 
a preserved hearing function in a given patient. Hearing 
preservation takes priority in the case of surgery involving 
the only hearing ear, or when hearing deterioration in the 
contralateral ear is likely, as in patients with NF2. If possible, 
HPS is strongly indicated in such cases. The choice is less 
clear-cut when the contralateral ear retains a normal hearing 
function or benefits from a hearing aid, and there is no risk 
of hearing declining in the future. In this case, we have to 
balance between a more complex surgery VS the chance to 
maintain a binaural hearing. It should also be noted, that 
the postoperative auditory impairment mainly consists in 
the onset of the head shadow effect when acoustic stimuli 
come from the less well functioning ear. Although not very 
detrimental, this can affect hearing in daily activities, and 
and remains the object of inconcluded discussion due to the 
lack of high evidence studies as well as a universal measure 
of quality of the preserved hearing. 
This aspect is seen also in our experience with HPS, which 
started in1976 with the retrosigmoid approach and adopted 
admission criteria increasingly restrictive  11 as suggested 
by the ongoing experience, from tumor  ≤  3  cm size and 
50  PTA/50 SDS, to reach the final parameters of 10  mm 
and 30  PTA/70 SDS and little altered auditory breinstem 
response (ABR). The surgical technique of retrosigmoid 
approach with retrolabyrinthine meatotomy had a stepwise 
increase of labyrinthine landmarking from the only vestibular 
aqueduct to the semicircular canals, to the transition of dura 
to Fallopius canal 11-13. The outcome in the series of 100 cases 
with parameters of < 10 mm size and 30 PTA/70 SDS had 
a success rate ranging from 54 to 85% depending on the 
modality of evaluation; deafness occurred in 9%. For cases 
exceeding the parameters, the outcome was remarkably 
worse and confirmed that HPS was advisable only for small 
tumors with good hearing. The plain correlation of therapy 
vs outcome of the current papers was investigated in depth 
by searching the quantitative measure of predictivity of 
the preoperative hearing and size with statistical methods 
(unpublished, Zanoletti et al.). It came out that the cut off for 
success was PTA 21 or 27 for the AAO-HNS class A and the 
Tokyo classes A-B, respectively. The cut-off size was 6 mm 
in the cerebello pontine angle, the ABR was with delayed but 
present waves. 
Translating these parameters to the surgeon’s point of view, 
that is the physical condition of the tumor-nerves complex, 
the limited hearing loss means a limited loss of auditory fibers 
and cells, while the size implies a loss caused by the size 
itself as well as by the trauma of dissection. This concept of 
nerve loss is important because a surgical procedure involves 
a loss of auditory cells and fibers and impacts on hearing 
depending on the auditory reserve on which it acts. 
The same predictors of hearing preservation were found 
also in observation and radiotherapy, thus implementing the 
motto “good nerve withstands better the effect of surgery, 
time and radiation”.
There seems to be, however, a difference among therapies as 
to long term outcome. While surgery involves an immediate 
loss in a number of cases and a little loss with passing of 
time, observation and radiotherapy have almost no loss at 
short term and continual sustained loss at mid- and long term 
in such a way that hearing is worse to a significant extent after 
10 years and more 14 15. It is here pertinent to mention that the 
factors for hearing decline are differently present in the three 
therapies. In HPS, factors affecting hearing preservation are 
surgical trauma and time, in observation they are time, tumor 
presence and tumor growth, in radiotherapy they are time, 
tumor presence, tumor growth, and effects of radiation.
The maintenance of hearing with the feasibility of an electric 
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considerably. Damage involving up to 75% of internal hair 
cells (IHCs) does not result in a significant increase in the 
pure tone threshold as long as the outer hair cells (OHCs) are 
intact. On the other hand, total destruction of the OHCs can 
lead to a maximum tonal loss of 50-60 dB, but even limited 
damage can cause a severe loss of frequency selectivity 
and distortion, meaning a significantly worse speech 
intelligibility or hearing impairment with competitive noise. 
Synaptic damage to high-frequency, low-threshold type  1 
neurons is often seen in response to oxidative stress, such 
as noise-induced hearing loss, presbycusis, and exposure to 
ototoxic drugs. It is reasonable to assume that oxidative stress 
can occur in vestibular schwannoma too, due to cochlear 
hypoxia caused by vessel compression, for example. It was 
recently suggested that the factor causing the most damage 
to the cochlear nerve might be the extracellular vesicles 
secreted by vestibular schwannoma 2 3. Tumor necrosis factor 
(TNFα) would act as an ototoxic molecule, while fibroblast 
growth factor 2 (FGF2,) would have a protective role for the 
molecules secreted by vestibular schwannoma. Cochlear 
damage may or may not be associated with a reduction in 
the population of spiral ganglion neurons and/or in their 
connections within the ganglion, and/or with damage to 
the cochlear nerve fibers probably caused by ischemia or 
compression. In addition to structural damage, there may 
also be functional alterations, such as a decline in neural 
conduction velocity or auditory processing. The auditory 
system is characterized by high speed and precision timing. 
A precise temporal encoding is maintained on multiple 
levels within the central nervous system. A loss of speed and 
temporal precision is probably one of the first effects of a 
neuroma exerting pressure on the cochlear nerve fibers. On 
the other hand, aging may also coincide with a decline in 
the speed and accuracy with which we process peripheral 
information at central level, as happens for other sensory 
patients need to be informed about such a possibility. Before 
planning any HPS, it is essential to provide appropriate 
counseling, taking into consideration individual patients’ 
needs and lifestyle, and assessing their acceptance and 
motivation concerning a possible rehabilitation with hearing 
aids or CI in the future.
Finally, in the event of a total or partial failure of HPS, 
audiologists should assess their patient’s residual hearing in 
order to establish whether they would benefit more from a 
hearing aid or CI. The same type of audiological assessment 
is also indicated for patients who undergo early surgery 
without hearing preservation and are fitted with a CI. In our 
opinion, cases in which an initially good hearing function is 
deliberately not preserved should be extremely rare. 
Issue 1: how does initial hearing influence  
the chances of preserving auditory function?
To deal with this first issue, audiologists should use a set 
of audiometric, electrophysiological and imaging tests  1 
to obtain information about the anatomical and functional 
condition of the cochlea, cochlear nerve, and central acoustic 
pathways. This poses a challenge for clinicians because 
numerous histopathological studies have shown that acoustic 
neuroma per se, as well as any surgery or radiotherapy to deal 
with it, can cause various cochlear and neural lesions, which 
are often connected, as shown in Table  4.1.6.I. This often 
makes it really difficult to establish a differential diagnosis 
or identify the site of the damage. Even 3 Tesla MRI and a 
full audiological examination do not always produce reliable 
conclusions.
Acoustic neuromas can cause cochlear damage with loss 
of hair cells, but the correlation between hearing loss and 
cochleograms (corresponding to the correlation between 
pure tone threshold in life and the extent of hair cell loss 
along Corti’s organ at post-mortem examination) varies 
Table 4.1.6.I. Histopathological cochlear and neural damage secondary to neuroma and/or its treatments. Cochlear damage can aggravate the neural 
damage as a result of retrograde degeneration, while the neuroma’s compression of the internal auditory canal, in addition to causing neural damage, can 
aggravate the cochlear damage due to an ischemic effect resulting from compression of blood vessels. Ototoxic molecules seem to be secreted by schwan-
nomas through extracellular vesicles.
Cochlear damage Neural damage
Internal hair cells
Vascular stria
Spiral ligament
Endolymphatic hydrops
Eosinophils and proteins precipitated  
in the perilymphatic spaces
Upregulation of genes that favor neuroma  
and cochlear damage
Æ
Retrograde degeneration
Vascular damage
Extracellular vesicles
with ototoxic molecules
Å
Reduction of ganglionic neurons
and their synapses
Compression  
and 
fiber reduction
Ischemia,
intraneural hemorrhage
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profound or total deafness, then the general considerations 
on single-sided deafness (SSD) could be applied. The 
disadvantages of monaural as opposed to binaural hearing 
have been amply described in the literature, but how best to 
solve the problems involved is still a controversial issue. On 
the one hand, there is agreement on the effects of unilateral 
deafness on infants and children, which include aural 
preference syndrome, a reduction in incidental learning, 
and difficultly listening in school class. On the other hand, 
the consequences of SSD for adults are still widely debated 
and clinical considerations are discordant: there may be the 
head shadow effect, when the primary signal comes from the 
hypoacusic side, and loss of the benefits of binaural hearing 
(binaural masking release, spatial localization, and loudness 
addition). In recent times, the clinical solutions for these 
problems have gone from air conduction CROSS systems 
to bone-anchored hearing implants (BAHI), and the most 
recent, a CI. In this last case, opinions on the cost-benefit 
ratio vary considerably, with much of the debate concerning 
whether recommending a CI in the SSD is clinically justified 
and, if so, whether the costs should be covered by public. 
The discussion stems from the fact that it is difficult to assess 
residual hearing and functional outcomes after CI, especially 
when the contralateral ear is “normal”, as in the case of SSD, 
or markedly asymmetric hearing loss.
Issue 3: how to assess residual hearing  
after unsuccessful HPS for the purposes  
of any rehabilitation with a hearing aid or CI
A first problem concerns the limits of masking during 
audiometric tests, especially when using a free-field signal 
presentation, as in the case of audiometry with a hearing 
aid or CI. We need to bear in mind that verbal signals have 
intensity oscillations of 30 dB, as shown in Fig. 4.1.6.1. So, 
if speech in a free field is sent at 65 dB HL, for example, and 
masking with headphones or inserts on the best ear is sent 
at 65 dB SL, the latter ear will retain a 50% audibility of the 
verbal signal. 
The attenuation of any device reaches a maximum level 
imposed by bone transmission, which is frequency-
specific: for instance, it is about 40 dB for 2,000 Hz 6. HPD 
soundproofing headphones afford an attenuation of about 
30  dB. Patients cannot tolerate a masking noise with an 
intensity in excess of 70 dB SL for more than 1-2 minutes. 
With maximum possible masking, a 50% intelligibility for 
a verbal message is often achieved by a normal-hearing ear. 
For a complete report on the audiological study of SSD, see 
a recent consensus document 7.
The hypothesis of assessing the functional results of a CI 
in SSD with electric vocal audiometry still poses numerous 
difficulties. Patients with a CI benefit from rehabilitation 
with games and exercises in the form of apps for tablets or 
smartphones connected wirelessly to their CI. Such material 
systems, and for the central nervous system as a whole. 
The association between aging and a declining temporal 
processing function was well described by Humes et al. 4 in 
their systematic review. For the same pure tone threshold, 
it is not easy to distinguish between the loss of speed and 
temporal processing capacity due to cochlear nerve fiber 
damage and that due simply to aging.
A slower conduction velocity due to synaptic damage, loss 
of neural fibers or lesser myelination reduces the amount of 
neural patterns, or the information that can be transmitted per 
unit of time. The diversity of the peripheral histopathological 
and functional damage largely explains the different 
outcomes – in terms of speech perception – seen in patients 
with similar tonal audiograms, as well as the sometimes very 
different results obtained with hearing aids or a CI. 
The association between a good hearing before surgery and 
a better hearing preservation afterwards has been observed 
in large series 5. Unfortunately, there is a considerable inter-
individual variability, and the predictive value of these tests 
for individual patients is limited. 
Preoperative hearing assessments traditionally include 
auditory brainstem responses (ABR), pure tone and vocal 
audiometry. A test battery that also involves assessing speech 
intelligibility in quiet and sensitized conditions (such as the 
Matrix test), and a temporal discrimination test might be 
more sensitive and specific. The aim would be to obtain 
statistical confirmation of how this battery of preoperative 
tests correlates with the patients’ follow-up, and the different 
treatments adopted for acoustic neuroma.
Issue 2: how severely does the damage caused  
by the various treatment options affect the patient’s 
daily listening abilities and quality of life?
As mentioned previously, significant differences can be 
seen between tonal threshold and speech intelligibility – in 
conditions of quiet and even more of noise – as a result of 
neuromas and their treatment. There are no conclusive data 
in the literature on the quality of any preserved hearing 
function, especially in relation to the different therapeutic 
options adopted.
Generally, when the threshold asymmetry between the 
two ears exceeds 40  dB, the more impaired ear does not 
contribute any subjectively perceptible benefit. In the case of 
such a hearing loss it is likely that only a hearing aid will be 
able to correct the impairment. 
During pretreatment counseling, patients should be informed 
that even a partial failure of HPS can prompt quite a significant 
deterioration in subjective hearing function, though this can 
generally be overcome with a hearing aid. It is impossible to 
rule out the risk of neural damage, however, which can cause 
qualitative alterations involving distortions and impaired 
temporal functioning, with a consequently worse outcome 
even with a hearing aid. If HPS fails completely, resulting in 
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the cochlear nerve alone, or even the cochlea, is important. 
The most effective electrical stimulation sites for a CI are 
still not known exactly. All the following structures could 
have an important role: residual IHCs; their distal synapses 
and dendrites; the body of ganglion neurons; and/or the 
Ranvier nodes immediately proximal or distal to the soma. 
Unfortunately, we do not know where electrical stimulation 
is most effective, and that is why we believe it is better 
to keep all structures of the peripheral auditory system as 
intact as possible to enable their electrical stimulation. 
Translabyrinthine surgery certainly causes damage to the 
peripheral auditory system as a whole, whereas retrosigmoid 
or middle cranial surgery preserves the cochlear structures 
much better. It should also be noted that we still know little 
about the influence of various types of surgery and RT for 
acoustic neuroma, and subsequent CI rehabilitation, on the 
natural history of the peripheral auditory system. To give an 
example, data in the literature on the timing and frequency 
of cochlear ossification after translabyrinthine surgery are 
extremely variable, with cochlear ossification reportedly 
occurring in 15% to 78% of patients 8-10. Referring to findings 
after CI surgery, more than 30% of patients requiring a modest 
drill-out of the cochlea subsequently experienced worsening 
perceptive outcomes due to progressive ossification. Another 
point in favor of hearing preservation in acoustic neuroma 
surgery (supporting the conviction that it is always better to 
try to preserve hearing rather than plan a CI from the start) 
lies in that CI cannot restore a normal auditory function. It 
is true that children fitted early on with a CI can achieve 
communication skills very similar to those of their normal-
hearing peers, but inter-individual variability is wide and the 
CI still has numerous drawbacks when it comes to hearing in 
noise, or listening to music, as well as a strong technological 
dependence, high costs and other issues. In short, focusing 
on preserving hearing, with the option of a hearing aid if 
necessary, usually achieves better functional results than 
opting for a CI as a first-line approach.
Limits of currently-available hearing classifications 
for HPS
Audiological assessments should measure auditory function 
as reliably as possible in individual patients and homogeneous 
groups, in order to orient treatment strategies, which may 
involve observation alone, radiotherapy, and/or surgery, 
with or without a preserved hearing function. It is only by 
using standardized and comparable tests that we will be 
able to collect significant data to support clinical guidelines 
on appropriate therapies. Five classifications are currently 
used to assess auditory function in patients with acoustic 
neuroma: the Gardner-Robertson 11, the American Academy 
of Otolaryngology-Head and Neck Surgery  12, the Sanna, 
the Tokyo  13 and the Word Recognition Score (WRS)  14. 
Hearing function is classified by pure tone averages (PTA), 
cannot be used for the purposes of vocal audiometry, 
however, because it is impossible to quantify the electrical 
stimulation and correlate it with an acoustic intensity in dB. 
In short, it is not yet possible to apply such a method to judge 
the benefit of a CI in terms of everyday hearing in conditions 
resembling a free field. 
In patients whose HPS failed, the benefit of a hearing aid 
or CI may be significantly lower than expected in relation 
to their residual tonal threshold as a consequence of neural 
damage, as mentioned previously. In particular, patients 
may have significant speech perception difficulties, and a 
more limited prosthetic benefit in noisy and/or reverberant 
acoustic environments. Specific tests can help to reveal these 
difficulties, such as competitive speech audiometry, or time 
discrimination and frequency tests. These methods can help 
clinicians choose the best type of hearing rehabilitation, 
by avoiding a bilateral HA when binaural interference is 
suspected, for example. Such audiometric tests can be useful 
when fitting the hearing aid too: for example, a reduced 
gain can be adopted on frequencies less important to speech 
perception, and any dead zones can be identified. Specific 
strategies can be applied to CI mapping too, such as the 
use of short pulses and low stimulation rates. As mentioned 
previously, some authors only consider it important to focus 
intraoperatively on preserving the integrity of the cochlear 
nerve, regardless of the HPS method adopted, even in early 
surgery for patients with good initial hearing, based on the 
assumption that rehabilitation with a CI can deal with the 
residual total deafness.
We disagree with this approach because restoring hearing 
with a hearing aid in the event of HPS failing usually achieves 
a better functional result than a CI, as a first-line solution. 
Intraoperative cochlear nerve preservation is certainly 
important, but the whole peripheral auditory system forms a 
tightly-knit unit in terms of function and damage response. 
There is consequently some debate as to whether preserving 
Fig. 4.1.6.1. Spectral energy of speech and noise.
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at the maximum comfort level (MCL). Some authors have 
used verbal material at an intensity of 40 dB above the SRT 
(speech reception threshold), i.e. 40 dB above the intensity at 
which patients correctly repeat 50% of the words they hear. 
There is clearly a marked discrepancy between the various 
measurement methods, and this makes it difficult to compare 
published data. There can be significant differences, not only 
in WRS scores, but also in the standard deviation (SD) of 
test-retest differences. It has been calculated that the average 
test-retest difference in WRS drops from -3.63% at 10 dB SL 
to 0.05% at 40  dB  SL. The test-retest SD likewise falls 
gradually from 10.8 at an intensity of 10  dB  SL to 5.6 at 
40 dB.
Proposal for a full battery of audiological tests
A battery of tests - including not only tonal audiometry, 
vocal audiometry and ABR, but also the Matrix test, and a 
temporal discrimination test, could be more useful in clinical 
practice. The Matrix test is a form of vocal audiometry with 
competitive noise that automatically measures the adaptive 
type of s/n needed to obtain 50% of correct answers, which 
represents the speech perception threshold (SRT). Matrix 
tests generally use 20 syntactically correct, but semantically 
unpredictable sentences. The five words in a sentence are 
extracted from a 50-word matrix, so there are 10 alternative 
words for each position in the sentence. The answers are on 
the open list. Up to a patient PTA of about 47 dB HL, the 
SRT is measured with noise; in cases of more severe hearing 
loss, the message is necessarily presented in quiet. In the 
former case, the primary message is presented against a fixed 
noise at 65 dB and an automatic standard adaptive method 
is used 15. 
The advantages of the Matrix test lie in the computerized 
analysis of the answers (which reduces the risk of operator 
error), and the automatic calculation of the slope of the 
curve at the threshold. It is a method used in many countries, 
but the speech material is standardized for each language, 
and perfectly balanced and calibrated, so test results are 
comparable across different languages. The adoption of 
laboratory norms is strongly recommended as this enables 
data to be compared with those obtained elsewhere.
As reported in Table 4.1.6.II, the SRT in quiet is generally the 
same as the PTA. Differences between a patient’s PTA and 
SRT may be secondary to extrinsic and/or intrinsic causes. 
The former include calibration errors between the tonal and 
verbal stimuli, and stimulus presentation or test recording 
errors. The latter may involve patients’ unwillingness to 
cooperate or inability to understand the task, alterations in 
their synchronization and neural speed conduction, auditory 
processing anomalies or impairments in their cognitive, 
memory or attentional functioning, as well as a steeply 
sloping audiogram. In such cases, it would be better to 
calculate the PTA only on the two best frequencies (between 
and speech discrimination scores (SDS),  obtained from 
tonal and vocal audiometry, respectively. For the Gardner-
Robertson classification, the PTA is calculated as the mean 
for the frequencies 500 - 1,000 - 1,000 - 2,000 Hz (by adding 
the threshold value for 1,000  Hz twice). The AAO-HNS 
classification adds a fourth frequency, 3,000 Hz, but in its 
European version this fourth frequency is 4,000 Hz (PTA2), 
and this same frequency is used for the Tokyo classification. 
SDS are quantified in terms of the percentage of correctly 
recognized words and, in the WRS classification, this is the 
only criterion used to distinguish between four different 
classes of increasingly severe hearing function. The term 
“speech discrimination” would be inappropriate in its current 
usage because discriminating involves drawing a distinction 
between pairs of stimuli, whereas vocal audiometry for the 
purposes of classifying a patient’s hearing involves repeating 
open sets of words from a list of numerous different items. 
It is therefore more appropriate to speak of word recognition 
scores (WRS).
Vocal audiometry can be used to assess speech detection 
(SDT), perception (SRT) and intelligibility thresholds, but 
it also enables us to examine the complete intelligibility 
function, which takes the shape of an “S” in Italics on the 
audiometric graph, in normal-hearing individuals at least. 
Properly conducted with an adequate number of stimuli, 
vocal audiometry gives us a precise idea of a patient’s speech 
perception in quiet, and can point to possible distortion 
phenomena. It is not one of the variables considered in 
today’s hearing classifications, however.
When recording WRS, it is not clear what intensity should be 
used to present the verbal message. Normal-hearing subjects 
generally reach a maximum intelligibility for speech already 
at an intensity of between 25 and 40 dB SL (25-40 dB above 
the tonal threshold expressed in PTA). That is why the WRS 
(defined as the maximum percentage of correctly repeated 
words) is often measured at 40 dB SL, presenting the word 
list at a fixed intensity. Some laboratories use an intensity 40 
dB above the speech detection threshold (SDT + 40), instead 
of the PTA, probably obtaining significantly different results. 
In fact, PTA does not coincide with a degree of speech 
detection, as seen in Table 4.1.6.II. 
On the other hand, patients with hearing loss are more likely 
to reach their WRS at the discomfort threshold minus 5 dB 
(uncomfortable listening level [UCL] - 5 dB) or, more rarely, 
Table 4.1.6.II. Correlation between PTA, SRT and SDT in dB HL.
PTA Expected SRT Expected SDT
0 dB HL From -8 to +6 dB HL From -20 dB to -6 dB 
25 17-31 5-9
40 32-46 20-34
67 59-73 47-61
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small  1. Even when utilizing hearing preservation surgery, 
the chances of maintaining a social serviceable hearing in 
the short term range from 0 to 37% in the most experienced 
hands  2  3. Patients with neurofibromatosis type  2 (NF-2) 
or VS in the only or better hearing ear deserve a separate 
consideration, as they are at special risk of developing 
bilateral anacusia, either as a consequence of treatment or 
from the natural course of the disease 4. 
Cochlear implantation (CI) has recently emerged as a 
reasonable therapeutic option for patients with bilateral 
VS or sporadic VS in the only or better hearing ear, when 
anatomical integrity of the cochlear nerve during tumor 
excision is maintained. Since Hoffmann reported the first 
case of ipsilateral CI in a patient with NF2 5, approximately 
85 cases have been reported 6 7. In addition, many case series 
have been published regarding the role of CI in patients with 
a VS in the only hearing ear 8. Results of ipsilateral CI in NF2 
patients and VS in the only hearing ear are promising. Most 
patients benefit at least from sound awareness and aid lip 
reading, with many of them achieving open-set discrimination 
ability. In certain cases outcomes are comparable to those of 
post-lingual implanted non-tumor patients. 
Surgical procedure
VS resection is performed by a modified translabyrinthine 
approach (MTLA) (Fig. 4.1.7.1) associated with posterior 
tympanotomy for CI. Alternatively, MTLA can be 
associated with middle ear obliteration and removal of 
the posterior wall of the external auditory canal (EAC) 
with blind sac closure of the EAC to avoid CSF leakage 
or to simplify the insertion of the array into the round 
500-1000 and 2,000 Hz). In our initial experience, a marked 
discrepancy between PTA and SRT is likely in neuroma 
secondary to dyssynchrony and a reduced conduction 
velocity, and it seems to correlate with a worse prognosis 
after HPS. Inter-individual variability is unfortunately high 
and our findings are not yet significant.
Temporal resolution is generally measured by presenting 
three signals, one lasting longer than the others, and asking the 
subject to identify the more persistent signal. Gap detection 
is another test of time-related discrimination. The stimulus 
used for gap detection is generally a pair of noises separated 
by a very short interval of variable duration. Subjects are 
asked to say whether or not they perceive a gap, and the 
shortest discernible gap corresponds to their gap detection 
threshold. Though our data are not statistically significant, 
we have seen a tendency towards a correlation between 
temporal discrimination test results and the prognosis after 
HPS.
Conclusions
The correlation between a good initial hearing and a better 
preserved hearing after surgery has proved statistically 
significant in large case series, but audiological tests are 
of limited value in predicting the outcome after HPS in 
individual patients. A battery of tests that includes speech 
audiometry with competitive noise and time discrimination 
tests may be more sensitive and specific, and consequently 
more useful in clinical practice. We have already noticed a 
trend towards an association between the results of Matrix 
and temporal discrimination tests and the prognosis for 
patients undergoing HPS. The currently-used classifications 
of hearing preservation all have significant weaknesses. 
The potential benefit of CI in cases of SSD is also still a 
controversial issue, and it is not easy to adopt recently-
published protocols in clinical practice. The functional 
outcome of CI is better when not only the nerve, but the 
whole peripheral auditory system has been preserved.
Early surgery aiming for hearing preservation, and 
subsequent CI in the event of HPS failing, is probably a better 
solution than either taking a wait-and-see approach until 
auditory function deteriorates and then referring patients 
for CI surgery, or opting for translabyrinthine surgery with 
simultaneous CI in patients who still have a good hearing 
function.
4.1.7. Vestibular schwannomas and cochlear implant 
E. Piccirillo, G. Piras, M. Guidi, D. Vlad, M. Sanna
Vestibular schwannoma (VS) patients represent a challenge 
both from surgical and audiological points of view. Whichever 
modality of management is chosen, the chances of preserving 
serviceable hearing in the affected ear in the long term are 
Fig. 4.1.7.1. Tumor removal though a modified translabyrinthine approach 
with middle ear obliteration.
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then performed on the first postoperative follow-up visit 
4 weeks after surgery.
Indications and audiological protocol
Indications for VS resection and simultaneous CI are: 
• intracanalicular tumor with limited extension to the 
cerebello-pontine angle (≤ 0,5 cm);
• intracanalicular tumors with no enlargement of the 
internal auditory canal (IAC) or invasion of the cochlea.
Intraoperatively, after VS removal the CI integrity is 
evaluated through:
• surgeons’ subjective evaluation of the vascular supply 
and anatomical integrity of the cochlear nerve (CN);
• electrophysiological tests for the evaluation of the CN 
integrity: e-ABR, e-CNAP with a dedicated intracochlear 
test electrode inserted into the scala tympani and stapedial 
reflex. All these parameters are matched each other in 
order to decide if to perform CI.
Once the decision has been taken, CI is performed 
through a posterior tympanotomy. 
Outcomes
In 3 previous studies 4 8 9 we analyzed results of simultaneous 
VS removal and CI in different clinical situations.
CI in in patients with sporadic VS in the only or best 
hearing ear and in patients with NF2
Most patients undergoing cochlear implantation in the same 
side of a VS, either after surgical removal or after RT treatment, 
benefit from their device and are users. In a multicentric 
study of 15 patients 4, closed-set discrimination was possible 
in 86% of the patients with a mean discrimination score of 
70 ± 38%, whereas open-set discrimination was achieved by 
64% of patients with a mean postoperative score of 41 ± 33%. 
At the last follow-up, 10 out of 15 patients were CI users. 
Interestingly, no difference was found between the NF2 and 
the sporadic VS groups in terms of audiological outcomes.
Hearing results after implantation in an ear with VS vary 
dramatically as demonstrated in previous studies 10. Several 
prognostic factors have been proposed, including: duration 
of deafness, prolonged time between VS resection and 
implantation, cochlear ossification, and hearing in the 
contralateral ear. 
The presence of contralateral residual hearing has been stated 
as a negative prognostic factor for cochlear implantation 
in patients with VS. Some authors  10 have suggested that 
integration of the signal from the CI with the contralateral 
natural hearing may be a difficult task for some patients. 
Variability in auditory performance depends ultimately 
on the status of the cochlear nerve. The mechanisms 
underlying hearing loss in patients with VS include vascular 
compression of the internal auditory artery, intratumoral 
bleeding, biochemical changes in the inner ear, and direct 
window (Fig. 4.1.7.2). We perform a single-stage technique 
in order to avoid the risk of cochlear ossification following 
VS removal. The surgical incision used is an inverted S 
shape with a superior extension. Intraoperative X-ray with 
Stenvers reconstruction confirms the correct positioning of 
the intracochlear electrodes. Post-operative CT scan can 
confirm the exact position of the array and the absence of 
intracranial complications  (Fig.  4.1.7.3). CI activation is 
Fig. 4.1.7.2. Array insertion though the round window.
Fig. 4.1.7.3. Post-operative CT scan confirms the correct position of the 
array. The surgical cavity is filled with abdominal fat.
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no electrophysiological tests that can be really predictable of 
CN integrity. In case of anatomical and vascular preservation 
of CN integrity, CI should be preferred to ABI even in case of 
doubtful electophysiological data, due to the lower hearing 
performance 11.
4.1.8. The hearing-focused therapy  
in acoustic neuroma: hearing preservation surgery, 
hearing rehabilitation with CI, observation
E. Zanoletti, D. Cazzador, L. Girasoli, C. Pavone, L. Denaro, 
D. d’Avella, A. Martini, A. Mazzoni
Introduction
The best management of small acoustic neuroma in patients 
with well-preserved hearing is still a debated matter. While 
different therapies provide similarly good results in terms of 
control of disease, neurological and facial nerve function, 
hearing loss is not avoidable in the majority of cases. Unilateral 
deafness is associated with loss of speech understanding 
especially in noise, lack of directionality of sound, chronic 
daily fatigue, and a loss of quality of life, and thus outlines the 
problem of prevention and rehabilitation of hearing.
Observation, hearing preservation surgery (HPS), 
traditional surgery and radiotherapy are the available 
options, but their impact on hearing preservation is 
different. The current debate is between observation and 
HPS in small acoustic neuroma with good hearing, as well 
as the role of cochlear implant to rehabilitate hearing in 
case of deafness due to natural course of the disease or its 
therapy.
The hearing-focused approach is a multi-optional strategy 
adopting the treatment with the best chances to preserve 
or rehabilitate hearing, with all the available options. 
Observation, hearing preservation surgery, hearing 
rehabilitation with cochlear implant after translabyrinthine 
surgery or in case of HPS failures, are all to be considered 
and must belong to the cultural and technical background of 
the oto-neurosurgical team. Radiotherapy is not considered a 
method to prevent hearing loss.
Methods and results
Our recent experience of hearing focused approach in small 
acoustic neuroma involved careful evaluation of hearing 
at the diagnosis as well as other tumor parameters. The 
choice of therapy which followed was a balance between the 
different available options and the patient’s will. 
Our ongoing-series  1 included all the currently available 
therapies, i.e. observation (O), radiotherapy (RT), HPS, 
and conventional surgery, which were used according to 
the guidelines in Table  4.1.8.I. HPS replaced O when it 
had a high probability of success, e.g. in patients with the 
mentioned good hearing at diagnosis. 
compression of the cochlear nerve. Surgery may also cause 
mechanical or thermal injury of the cochlear nerve or of the 
labyrinthine artery. It has been suggested that a vascular 
compromise causing hearing loss may lead to successful 
outcomes following CI, whereas significant neuronal 
injury due to tumor growth, RT or surgical trauma may be 
associated with poorer outcomes 10. In recent years different 
electrophysiological tests have been used to determine 
intraoperative candidacy for CI. Nevertheless, positive 
responses do not ensure good CI performance whereas 
patients with negative responses may obtain some benefit 
from the device. Therefore, the decision of implantation is 
usually taken on an anatomical basis.
The presence of a VS in the only or best hearing ear represents 
a clinical challenge.
The main difficulty in these cases is to decide the optimal 
time for therapeutic intervention. Tumor resection may lead to 
bilateral total deafness, whereas a wait and scan policy may lead 
to tumor growth, VIII nerve compression, and deterioration of 
hearing. Cochlear implantation appears as a reasonable option 
for these cases. Deciding whether to implant first the deaf side or 
the tumor side is a difficult task, which must be discussed with 
the patient. In a previous study 8 on ten patients with VS in the 
only hearing ear and cochlear implant on the other side, three 
patients reported a remarkable increase in their CI performance 
after tumor removal, thus what implied loss of hearing in what 
had been their only hearing ear. This could be explained by 
the fact that the auditory cortex gives precedence to the best 
hearing pathway, or that the improvement of the deprived 
auditory pathway via electrical stimulation is hampered by the 
normal hearing. So, once the hearing starts to deteriorate, the 
performance of the CI seems to improve dramatically.
Both strategies can be considered. As a general policy, in 
a deaf ear with no contraindications and no tumor it seems 
more reasonable to implant this one first, before VS removal. 
However, a long duration of deafness and a deterioration of 
hearing on the tumor side hearing may be a valid reason to 
implant the tumor side first. In any case the patient should 
be informed about both possible approaches and discuss the 
pros and cons with the surgeon.
Conclusions
Cochlear implantation in patients with bilateral VS or VS 
in the only or best hearing ear may be an effective support 
for communication, providing open speech perception in 
selected cases. In light of our results and data from previous 
studies, cochlear implantation should be considered as the 
default strategy in VS patients with an intact ipsilateral 
cochlear nerve. Proper preoperative counseling and realistic 
expectations are mandatory. Although it is difficult to 
establish recommendations or protocols, even in patients with 
NF2 and large tumors, the possibility of sparing the cochlear 
nerve should be considered. Unfortunately, to date there are 
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had deteriorated (from class A to C), and the rate of preserved 
class AB hearing was 69%, class A was lost in 10% of cases. 
Discussion
The two groups of O and HPS were homogeneous in terms 
of hearing parameters, but the choice of O or HPS was made 
by the patient. In principle, O afforded a better hearing 
preservation rate than HPS in the short term because of 
the early hearing loss when surgery fails. The progressive 
decline in hearing function under O gradually led to much 
the same rate of hearing loss for both O and HPS over time: 
after two years of follow-up, the rate of preservation of 
the “good” hearing function was 58% in the O group and 
69% in the HPS group. 90% of the hearing preserved cases 
maintained their hearing after two years. The longer follow-
up which is required to evaluate the natural course of hearing 
during observation and the stability of the preserved hearing 
after hearing-preservation surgery will help to understand 
which options is more hearing sparing over time. Similarly, 
hearing rehabilitation with cochlear implant in case of 
tumor-induced or surgical-induced deafness would probably 
expand its indications. 
HPS aims at the preservation of an intact cochlear nerve, 
which in case of failure will be able to receive a cochlear 
implant, whereas translabyrinthine surgery involves 
postsurgical deafness. In both cases this does not prevent 
hearing rehabilitation with cochlear implant, which is a fact 
today and changes the possibilities of therapy of vestibular 
schwannoma. 
Options of therapy
Observation is believed to offer the best chance of preserving 
long-term hearing and combines with the fact that the 
majority of small tumors spontaneously do not grow or 
stop growing. The wait-and-see policy, however, is clearly 
associated with two issues: hearing inexorably declines and, 
when partially preserved, it is of poor quality.
In a representative paper  2, observation for intrameatal 
tumors is associated with a progressive hearing decline over 
the years, with a long-term good hearing preservation rate of 
17% at ten years. In the most favorable condition of patients 
Homogeneous O and HPS groups of “small tumor and 
good hearing” were available for comparison. Hearing was 
measured according to the Tokyo classification 2. Outcomes 
measures to be compared were: the outcome of O, including 
failures leading to active therapy; the results of HPS; the 
time course of hearing function in O vs HPS; the time course 
of hearing function after secondary RT.
At the diagnosis, O was adopted in 71% of cases, HPS in 
22%, excision via a translabyrinthine approach in 7%.
The O approach failed due to tumor growth in 28% of cases, 
over a median period of 25  months (range 9-48  months): 
25% were switched to active treatment (surgery in 20%, 
radiotherapy in 5%), while O continued for 3%. The tumors 
submitted to RT showed no further growth, but the only case 
with good hearing at diagnosis was no longer in class A 
after 27 months. In the group under O with class AB hearing 
(24 cases), a decline in hearing was evident in 42% of cases 
(10 cases) over a mean follow up of two years. The group of 
cases treated with HPS, as a first choice or after a period of 
O, had two different outcomes depending on tumor size and 
hearing function. When favorable factors were present, i.e. 
tumor less than 10 mm in size in the CPA, hearing function 
of at least PTA 30 - SDS 70, with normal or slightly altered 
ABR (Auditory Brain Response), hearing was preserved 
(Tokyo class AB) in 77% of cases, with an overall 85% of 
cases of serviceable hearing (Tokyo class ABC). The failure 
rate was 15%, with poor hearing or deafness, but in the 
subgroup whose hearing function and tumor size were even 
slightly outside the favorable limits, the success rate was 
33%.
The decline in hearing function in the O vs HPS groups was 
as follows:
• the patients with good hearing submitted to O showed a 
hearing deterioration rate of 42% after a median follow-
up of 25  months (range 9 to 48  months), class  A-B 
hearing was thus maintained in 58% of cases;
• among the cases in the HPS group with favorable factors 
(tumor size and hearing function), failures (class  C-F) 
occurred in 23% of cases, while 77% of cases preserved a 
good hearing function in the short term. After a mean two 
years of follow-up (range 9 to 78 months), 1 patient’s hearing 
Table 4.1.8.I. Sporadic small acoustic neuroma: hearing focused management (from Martini et al. 2017 19, mod.).
Acoustic neuroma size  
(mm in the CPA angle)
Decision factors Treatment
< 10 mm Good hearing
(< 30 dB, > 70% SDS, normal or slightly modified ABR)
Hearing preservation surgery or observation*
(HPS failures: rehabilitation with CI as a post-operative option) 
Good hearing
(< 30 dB, > 70% SDS, normal or slightly modified ABR)
+ surgical risk/unwillingness to undergo surgery
Observation*
Poor hearing
(> 30 dB, < 70% SDS)
Observation* or surgery ( + hearing rehabilitation with CI )
*: active treatment (surgery or RT) in the event of tumor growth to > 15 mm, or vertigo, or VII cranial nerve impairment.
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monitoring can help the functional results of a well-handled 
cochlear nerve. If hearing is lost, a cochlear implant is 
indicated. Translabyrinthine tumor resection with hearing 
nerve preservation in combination with cochlear implantation 
can be performed as a single-stage procedure or staged 
surgeries. The risk of early partial cochlear fibrosis after 
translabyrinthine resection of vestibular schwannoma can 
affect more than half of patients 16; in order to allow hearing 
rehabilitation, it is advisable to insert a dummy electrode 
carrier or performing synchronous cochlear implantation.
Although cochlear implantation is possible in both 
bilateral and sporadic schwannoma, most series analyzing 
audiological results include only NF2 patients and do 
not specify the method to test the speech recognition. 
The extensive and recent review by Lloyds  17 on hearing 
outcomes in NF2 showed a speech discrimination score in 
quiet without lip reading equal to 42.2% in 21 cases with CI 
after failed HPS and 38.2% in 16 cases with CI after cochlear 
nerve preserving translabyrinthine surgery. The status of 
the contralateral ear, as well as the methods of testing are 
important when measuring the cochlear implant outcome. 
It seems that in sporadic VS the audiological outcome 
is better when compared to NF2. The CI performances 
between NF2 and sporadic VS groups have been analyzed in 
a recent multi-center study 18: in CI-only condition, 71% of 
patients with sporadic VS achieved open-set discrimination 
(mean SDS  =  55.8%), whereas only 50% of patients with 
NF2 achieved open-set discrimination (mean SDS = 30%).
Personal experience of hearing rehabilitation with CI
In our experience of 14 patients with CI after VS surgery, with 
a minimum follow-up of one year, the percentage of patients 
achieving open-set discrimination was 60% for the sporadic 
group and 22.2 % for the NF2 group. The CI was performed 
in a heterogeneous group of patients: 6 cases was planned 
in translabyrinthine surgery and 8  cases in HPS failures. 
The single-side-deafness patients who were implanted were 
NF2, the other cases of sporadic tumors were patients with 
poor contralateral hearing. No difference was found in terms 
of audiological outcomes between HPS group and cochlear 
nerve-preserving translabyrinthine surgery group. It is 
evident that the methods of outcome measures for cases with 
any contralateral hearing are different, and differently should 
be interpreted when judging CI results.
Several prognostic factors for hearing results after 
implantation in VS have been proposed, but the current 
literature shows conflicting results and lack of evidence. 
Some studies have investigated preoperative hearing, 
duration of deafness, tumor size, surgical approach, timing 
approach (synchronous vs staged), contralateral hearing, 
status of the cochlear nerve 18.
In our philosophy, whenever possible, hearing preservation 
comes first and hearing rehabilitation only if poor hearing 
with intrameatal tumors and a SDS of 100%, hearing was 
reportedly preserved in 73% of cases at 10  years, with a 
SDS > 70%, but there is no mention of the sound level at 
which this speech discrimination was achieved. 
Whether an early diagnosis can avoid the patient any further 
hearing loss with currently-available therapies is the object 
of debate in literature, with such diverging statements: “Early 
risk of deafness is likely to be greatest with microsurgery, 
followed by radiosurgery and observation, but the greatest 
number of serviceable hearing years comes with observation 
compared with proactive treatment” 4 5. HPS has “predictable 
and satisfactory results”  6. “The postoperative preserved 
hearing can be considered durable hearing preservation 
as it is unlikely to change markedly”  7. Small tumors in 
patients with good hearing are “preferably observed” and 
only submitted to radiotherapy in the event of growth 6. The 
spontaneous arrest in the tumor’s growth and the long-term 
hearing preservation enabled by observation alone “makes 
it the benchmark with which every other therapy should be 
compared” 3. The present report moves from this comparison 
recommended by Kirchmann 3.
A Danish study 3 on observation reported that good hearing 
(class A) was preserved at 10 years in 17% of cases (5/29), 
and class A-B hearing in 34% (25/75 cases). The hearing loss 
in these two groups amounted to 83% and 67% respectively. 
The subgroup of 27 cases with SDS 100% at diagnosis 
retained a remarkably better long-term hearing, with the 
reported average PTA of 46 dB and a SDS of 73%, which 
coincides with AAO-HNS class B. 
Radiotherapy appears to be effective in stopping tumor 
growth 8, with a still unknown rate of success in growing vs 
non-growing tumors  9  10. Hearing is preserved in the short 
term, but declines inexorably in the longer term, with only 
a 23% rate of preservation of good hearing at ten years 4 5, 
24 and 12% at 10 and 15  years respectively  11 according 
to recent reports. Hearing preservation surgery (HPS) is 
attributed such different success rates 12 that comparison with 
other therapies is possible if only the subcategory of small 
tumors is considered 13-15.
The option of hearing rehabilitation with cochlear implant 
In recent years the indications to the cochlear implant (CI) 
have extended also in vestibular schwannoma, if the cochlear 
nerve is preserved. Some authors propose positioning the 
CI with the intent of hearing recovery without the surgical 
removal of schwannoma itself, or as rehabilitation after 
radiotherapy. In our experience, we consider the placement 
of CI in vestibular neuroma only in case of failure of HPS or 
in translabyrinthine surgery with cochlear nerve preservation.
Anatomical preservation of the cochlear nerve during the 
microsurgical removal of a small tumor can be more or less 
difficult; the experience in hearing preservation surgery 
as well as the use of electrophysiological intraoperative 
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present, is feasible. When there are no favorable conditions 
at the diagnosis for hearing preservation surgery, observation 
alone is still the best provisional option.
4.1.9. Current molecular knowledge  
on sporadic VIII cranial nerve schwannoma
G. Marioni, N. Favaretto, A. Martini, E. Zanoletti
Introduction
The last 30 years have seen a rising incidence of VIII cranial 
nerve (CN  VIII) schwannomas, involving smaller tumors  1, 
less severe hearing loss at diagnosis, and more patients 
diagnosed at an older age 2. These findings are presumably due 
to more accessible high-quality contrast-enhanced imaging, 
and more widespread screening protocols for asymmetric 
sensorineural hearing loss 2. Recent research set the incidence 
of CN VIII schwannomas at 1.09/100,000 person-years from 
2004 to 2010 based on the US Central Brain Tumor Registry, 
and at 1.1/100,000 in 2004-2011 based on the Surveillance, 
Epidemiology and End Results program 3. As more vestibular 
schwannomas are diagnosed early on, there are more patients 
with good hearing. Our understanding of the natural history 
of these tumors has changed over time, and has modified 
their clinical management. The options of therapy range from 
active treatment, with traditional surgery, hearing preservation 
surgery or radiotherapy, to a wait-and-see approach 4.
Molecular changes occurring before any visible morphological 
changes are responsible for a neoplasm’s biological behavior 
and prognosis. Ideal molecular markers should be strongly 
related to the tumor’s biological/pathological features and 
behavior, and easy to assess with a standardized test. In 
clinical practice, such markers should have a prognostic 
role, predict the efficacy of specific treatments, and serve as 
therapeutic targets. Among the issues in CN VIII schwannoma 
management today, the clinical use of tumor biomarkers is an 
intriguing but still scarcely explored option 5. This brief critical 
review explores the available knowledge on molecular markers 
involved in the biology of sporadic CN  VIII schwannomas 
that show clinical and prognostic potential.
The Merlin gene
Merlin is a tumor suppressor protein encoded by a gene 
on chromosome 22q12.2. Sequence alignment revealed its 
significant homology with a family of proteins including 
moesin, ezrin, radixin, talin, and members of the protein 4.1 
superfamily (or ERM family) 6. Merlin is mainly localized on 
the plasma membrane and interacts with several membrane 
proteins. It exerts its tumor suppressive effects on multiple 
mitogenic signaling pathways by modulating interaction with 
growth factor receptors  7. Merlin turns off the YAP/TAZ-
mediated expression of genes involved in proliferation and anti-
apoptosis 8. In surgical specimens from 36 consecutive sporadic 
is already present at the diagnosis or in cases of failure of 
HPS. In principle, no case of small tumor with good hearing 
is addressed primarily to a translabyrinthine approach and 
synchronous cochlear implant. It is a fact that cochlear 
implantation during or after tumor resection  19, both in 
cochlear nerve-preserving translabyrinthine approach and in 
failures of HPS, is a valid option for hearing rehabilitation. 
This is particularly important in the perspective of NF2 
patients, where “cochlear implantation rather than auditory 
brainstem implantation should be used whenever possible as 
this offers significantly better auditory outcomes” 20.
Conclusions
Early imaging today allows diagnosis of small vestibular 
schwannoma with good hearing. But does early diagnosis 
mean better prognosis for the patient? In principle, a better 
prognosis is achieved when no further losses are to be 
expected after diagnosis. There is a general consensus that 
the currently available therapies offer similarly good results 
concerning neurological losses, facial nerve preservation, and 
cure or control of the disease, but hearing function generally 
suffers a more or less severe deterioration. Hearing loss, or 
deafness, is therefore the residual morbidity confronting the 
therapy or abstention of therapy of an early diagnosis of 
small vestibular schwannoma. 
Within the weaknesses of the clinical studies, including our 
own experience, due to referral and selection biases, the 
comparison between the O and HPS groups shows that:
• At short term, observation offers a better hearing 
function than HPS, because the latter presents cases with 
immediate postoperative hearing loss.
• The course of hearing deterioration is inexorable under 
observation as it reflects the natural history of the disease. 
The outcome of HPS is more durable, in favorable series 
with good results, despite some decline in hearing 
function over time, but pays the price of the immediate 
postoperative failure. The hearing/time diagram for 
observation versus HPS shows a convergence after around 
two years, then the decline in hearing function continues 
at a faster rate under observation. The difference between 
the two options becomes considerable at 5 and 10 years. 
• Patients with SDS of 100% at the diagnosis maintain 
high levels of speech recognition  9, although only their 
mean PTA (0.5 to 4 kHz) can qualify the SDS and should 
always be reported to assess the quality of preserved 
hearing. Those outcome measures which disregard the 
PTA are not representative.
Our experience has reached some provisional indications 1 as 
shown in Table 4.1.8.I, which suggest that active treatment 
with HPS, unlike observation alone, can offer a better chance 
of mid to long-term hearing preservation when favorable 
parameters are present. In case of failures, rehabilitation 
with cochlear implant, or hearing aid when hearing is still 
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heterozygosity, plus 31 unique small NF2 gene variants 
(10 essential splice site, 11 frameshifts, 7 stop gain, 2 missense, 
and 1 in-frame mutation). Several other large chromosomal 
aberrations were discovered too, including 2 tumors with loss 
of a chromosome 21, 3 with loss of an X or Y chromosome, 1 
with copy-neutral loss of heterozygosity in chromosome 15, 
and 1 with loss of 18p and 16q.
Other genes
There are few large studies on global gene dysregulation 
in vestibular schwannoma, but several focusing on selected 
genes 9. Cayé-Thomasen et al. 16 examined gene expression 
in human vestibular nerve versus sporadic vestibular 
schwannoma tissue (16 cases) using microarray technology, 
finding 87 probe sets (representing 78  genes) significantly 
up- or down-regulated in tumor tissue. Eight of the up-
regulated genes are involved in cell cycle regulation, 6 
in cell morphogenesis, 8 in cell development, 11 in cell 
differentiation, 6 in cell death, 13 in cell adhesion, 9 in 
extracellular matrix, and 50 in protein binding (overlapping 
occurring). In 16  sporadic vestibular schwannomas, Sass 
et al.  17 investigated global gene expression concentrating 
on signal transduction pathways and functional molecular 
networks associated with growth. In total 109  genes were 
deregulated in relation to tumor growth rate. Specific genes 
involved in apoptosis, cell growth, and proliferation, e.g. 
neural cell adhesion molecule  1, Erbin, platelet-derived 
growth factor C, and phosphatidylinositide 3-kinase (PI3K), 
were dysregulated in fast-growing tumors. Fourteen pathways 
were associated with tumor growth, including PRPs, paxillin, 
integrin, P21-activated kinase (PAK) signaling, and myeloid 
cell signaling (TREM1). The functional networks generated 
underscored the importance of the PI3K family, among others. 
When Agnihotri et al. 18 studied gene expression in vestibular 
schwannomas, they found PI3K/AKT/mammalian target of 
rapamycin (mTOR) signaling networks overexpressed. They 
tested this pathway for targeted therapy with the compounds 
BEZ235 and PKI-587, and the dual inhibitors of PI3K and 
mTOR both attenuated tumor growth in a preclinical cell 
line model of schwannoma (HEI-293). Pharmacological 
PI3K/AKT/mTOR pathway inhibition with next-generation 
compounds reduced cell viability and increased cell death 
in vitro. 
Although CN VIII schwannomas grow relatively slowly, they 
need angiogenesis to progress beyond a certain size. Among 
multiple angiogenesis-stimulating factors identified, the best 
known is Vascular Endothelial Growth Factor (VEGF): it is 
expressed by vestibular schwannoma cells, and the degree of its 
expression has been correlated with clinical parameters such as 
tumor growth, volume, and microvessel density 19. Anti-VEGF 
bevacizumab has been associated with a shrinkage of most 
growing vestibular schwannomas. Not all patients respond and 
hearing improvement is often transient, however, and there is no 
CN VIII schwannomas, Martini et al.  5 found a significant 
direct correlation between TAZ expression and tumor volume 
calculated with a Multi-Planar Reformation Computer Volume 
application on latest preoperative contrast-enhanced MRI. 
Merlin gene silencing is a molecular feature shared by 
unilateral sporadic vestibular schwannomas and bilateral 
vestibular schwannomas associated with NF2. In sporadic 
cases, somatic bi-allelic merlin gene inactivation seems 
essential to tumor formation 9. Merlin gene mutations consist 
of insertions, deletions, and single-base substitutions resulting 
in frameshifts and nonsense mutations. They mainly prompt 
the synthesis of truncated proteins 9 10. NF2 gene inactivation 
results in total merlin loss, and has been detected in 27% to 
61% cases of sporadic vestibular schwannoma 11.
There is a strong interplay between merlin, p53 (a classic tumor 
suppressor gene), and MDM2: p53-MDM2 dysregulation 
mediates merlin-deficient tumor growth, featuring nuclear 
accumulation of stabilized MDM2, and contributing to nuclear 
export of p53 for degradation. In vitro and in vivo studies revealed 
effects of the MDM2 inhibitor Nutlin-3 on schwannomas: it 
seems to block schwannoma cell proliferation via a cooperative 
recovery of merlin and p53, and a shuttling of both proteins 
from the cytoplasm to the nucleus  12. The p14ARF/MDM2/
p53 pathway is crucial to normal cell cycle progression. There 
is nearly always loss of p14ARF expression at both mRNA 
and protein levels in human merlin-deficient sporadic CN VIII 
schwannoma, and p14ARF/MDM2/p53 pathway disruption is 
fundamental to their onset 13. Merlin reportedly exerts some or 
all of its anti-proliferative effect by maintaining the expression 
of p21 (a negative cell progression regulator), and loss of p21 is 
a prominent feature of merlin-deficient schwannoma 14.
DNA methylation
Sporadic vestibular schwannomas contain no functional 
merlin, though up to 40% of these tumors have an intact 
wild-type merlin gene. Aberrant methylation of the merlin 
gene promoter regions in schwannomas has been explored 
as a potential explanation for the lack of functional merlin. 
Methylation of other genes important to tumor onset, 
angiogenesis and apoptosis has also been investigated 9.
Loss of heterozygosity
Several mechanisms may account for loss of heterozygosity 
(LOH), such as deletion resulting in loss of a chromosome 
segment, mitotic recombination, translocation, and gene 
conversion. LOH is a frequent feature of sporadic vestibular 
schwannoma, and therefore likely to be involved in its onset 
and maintenance  9. On whole-exome sequencing, whole 
transcriptome expression profiling (mRNA-Seq), and mate-
pair analysis on fresh-frozen tumor and matched peripheral 
blood leukocytes from 23 patients with sporadic vestibular 
schwannoma, Carlson et al.  15 found 13  tumors with loss 
of one chromosome  22, 4 with copy-neutral 22q loss of 
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as does the good facial function of HB class 2, when aging or 
other negative factors (such as dysmetabolism) take their toll 
on a “borderline” nerve function. The value of O is supported 
by the preceding considerations. In clinical practice 1 2, O is 
indicated for patients with a normal IX and X cranial nerve 
function, unless they are young, in which case early tumor 
resection is believed to prevent more severe morbidity. Cases 
remaining under O are monitored using imaging and switched 
to active treatment in the event of IX and X nerve paralysis, 
or tumor growth extending to sites at risk, such as the petrous 
apex or cerebellopontine angle (CPA) Another factor in favor 
of O, regardless of any IX and X cranial nerve paralysis, is the 
surgical risk or short life expectancy related to patients’ age or 
comorbidities, even in the case of large tumors.
Surgery relies essentially on the infratemporal approach, type 
A (ITa), and seldom on the infratemporal approach, type B 
approach. It involves a transient facial paresis and closure of 
the external auditory canal, with loss of conductive hearing 
(though this will have already been caused by the tumor). 
The ITa approach affords the highest rate of complete tumor 
excision from the neck to the petro-occipital base, and to the 
c.p.a. The loss of one or more cranial nerves is frequently the 
price to pay for radicality on structures that may be the site of 
microscopic invasion. Closure of the external auditory canal, 
and depression of the auriculo-temporal area are unsightly 
side effects of the approach. It may be necessary to complete 
the ITa approach in successive stages when large tumors 
demand a wide opening between cerebellopontine angle and 
petrous-neck field. The suboccipital approach can be added to 
the petrous field in a second stage.
The role of surgical procedures involving deliberately 
incomplete (partial or subtotal) resections in an effort to 
preserve the nerves is not yet clear. It is difficult to predict the 
outcome in terms of nerve function, and its value awaits the 
test of time, as does the utility of RT on residual tumor.
direct evidence of the effects of anti-VEGF treatment on nerve 
function. Hence the need to clarify how anti-angiogenic therapy 
affects tumor-bearing nerve function 20.
Conclusions
Merlin gene mutations are not found in all tumors, so 
other gene dysregulations, and post-transcriptional 
silencing probably play a part in CN VIII schwannoma 
pathogenesis and growth  9. For a rational choice of early 
surgery or a wait-and-scan policy, we need further studies 
on larger prospective series to seek easily and non-
invasively measurable biological factors influencing tumor 
proliferation  5. Strategies involving global gene expression 
profiling, whole genome sequencing and/or large-scale 
proteomic analyses seem appropriate in an effort to identify 
new molecular candidates for predicting tumor growth  17. 
A better understanding of CN VIII schwannoma molecular 
pathobiology may lead to novel targeted therapies capable 
of inhibiting the tumor’s growth, or even prompting its 
regression  9  21 while minimizing morbidity  6. The growing 
knowledge on the molecular biology will help the choice of 
therapy and has led to the first attempts of targeted medical 
treatment to prevent schwannoma growth.
4.2. Tympano-jugular paraganglioma
4.2.1. Treatment options for sporadic  
tympano-jugular paraganglioma (TJPGL) 
A. Mazzoni, E. Zanoletti, D. Cazzador, A. Martini
TJPGL management may involve observation (O), 
radiotherapy (RT), and surgery (S) to achieve various degrees 
of tumor removal, from complete to deliberately incomplete, 
to partial. The choice between O and active therapy is driven 
by the need to strike the right balance between the morbidities 
associated with the two options. There is a set of converging 
criteria guiding this choice that relate to the function of the IX 
and X cranial nerves, the tumor’s growth rate, and the patient’s 
age (Table 4.2.1.I).
TJPGL is a slow-growing, largely benign tumor. It may spare 
or gradually damage the nerves in the area (usually the IX 
and X cranial nerves), causing pharyngolaryngeal paralysis. 
Compensatory mechanisms limit the disabling effect of 
this damage, whereas they are less effective when acute 
paralysis is caused by surgery on a normally-functioning 
nerve, especially in the elderly. This is why surgery is 
not recommended in older patients with no cranial nerve 
symptoms. The surgical loss of the IX and X cranial nerves is 
disabling at any age, and even the compensatory mechanisms 
that younger patients can acquire may deteriorate with aging, 
Table 4.2.1.I. Criteria of therapy in sporadic jugular foramen paraganglioma.
Cranial 
nerve 
status
Growth Age Therapy
Normal No growth Any age O
Growth < 40 S
40-60 S* or RT
> 60 RT
Paralysis No growth < 60 O or S*
> 60 O
Growth < 60 S
> 60 RT
C3 class S is first option regardless cranial nerves function to prevent growth beyond 
petrous apex. Partial targeted Surgery in cases under O and tumor on facial nerve, or 
compressing the brain stem, or surfacing and bleeding in outer ear canal. *: age and/
or high surgical risk favor O or RT over S; O: observation; S: surgery; RT: radiotherapy.
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From January 1993 to March 2014, 257 patients affected by 
temporal bone paraganglioma referred to the ENT Department 
of Legnano Hospital (Milan). According to Fisch classification, 
142 patients (55.3%) were affected by a Fisch type C or D JFPs 
and were treated with surgery; 28 (10.9%) underwent RT or a 
wait-and-scan policy because of their age (> 65) and/or poor 
general status, or because they refused surgery.
Only few reports are present in literature concerning the 
natural history of JFPs. According to the study of Jansen et al., 
approximately 60% of paragangliomas present an evidence of 
growth during follow-up with a median increase in dimension 
of 0.83mm/year after a mean follow-up of 4.2 years 2. Focusing 
our attention on our cases of JFPs, Fisch type C and D tumors 
were stable in 86.7% of cases after 5 years of follow-up, while 
this rate decreased to 60.0% between 5 and 10 years of follow-
up. Prasad et al. reported similar results  3. It is important to 
underline that there is a trend toward higher rates of tumor 
progression in patients who had a longer follow-up, in fact the 
tumor control rates dramatically slope down to 33.3% after more 
than 10 years of follow-up in the present study, and similar data 
have been reported by Carlson et al. 4. Another important aspect 
is that some tumors have a faster growth rate, that can reach 
2 mm/year. Patients that present JFPs before age 30 (about 15% 
of all cases) usually have faster growing tumors.
Radical surgery is the only treatment that permits to change 
the natural history of JFPs. Both preoperative angiographic 
evaluation and intraoperative bleeding do not show any 
difference when comparing irradiated and not irradiated 
tumors; nevertheless, RT makes the removal of the intracranial 
component of the tumor extremely difficult. In our experience, 
RT reported slightly better long-term rates of tumor control 
when compared with the wait-and-scan group. The downside 
of RT is the presence of new neurological deficits, which appear 
in 20.0% of patients whereas no cases of new CNs deficit 
were reported in the wait and scan group. It therefore seems 
reasonable to state that radiotherapy does not modify the natural 
history of JFPs (Table 4.2.2.I). It is important to underline how 
in literature, particularly for RT treated groups, tumors are 
rarely classified according to the Fisch classification. Usually, 
there appear to be reported based on tumor size, or according 
to the Glasscock-Jackson classification. The latter fact creates 
difficulties when comparing different treatment groups.
For selected cases, a conservative jugulo-petrosectomy could 
RT carries very little or no morbidity in the short term 3 4, but 
the follow-up in studies on its value has been judged too short 
for the type of lesion considered 5. The few long-term reports 3 6 
are of dubious statistical significance due to the small samples 
involved, and modern imaging to assess tumor growth was not 
available in earlier reports 4. Despite these issues, it is generally 
accepted that RT may stabilize tumor for a considerable period 
of time 7, and can have a role in its treatment, especially in the 
elderly and cases of multifocal disease 4 7. That said, only time 
will tell just what part RT has to play in this setting.
Partial targeted surgery  8 involves a limited tumor excision 
in cases previously under O. The resection targets portions 
of tumor in areas at risk, such as the Fallopius canal or the 
brainstem, or bleeding tumors growing in the external auditory 
canal. It can prevent impending damage to facial nerve or brain 
stem, or else repair actual damage to the facial nerve, or deal 
with hemorrhage. It enables a return to O afterwards, striking 
the right balance between the morbidity risk associated with 
active therapy as opposed to O. Very large intradural growths 
can pose a therapeutic quandary relating to the surgical 
dissection needed to deal with extensive neurovascular 
involvement, and the risk of acute brainstem compression 
by edema if the tumor is irradiated. A coherent use of the 
principles of skull base surgery can provide the solution in 
such cases. Extensive bone removal all around the dura to 
which the tumor is rooted enables a preemptive coagulation 
of the main blood supply to the tumor and the removal of an 
ischemic mass 9.
In closing this overview, we wish to point out that the lack of 
randomized trials still prevents us from saying which is the 
most appropriate approach, surgery, RT or O. On the other 
hand, falling back on the popular concept of “surgery tailored 
to individual patients” can be misleading, unless this means 
combining expertise with available modalities, rather than 
resorting to numerosity to mask planning inconsistencies and 
biased case material.
4.2.2. Radical surgery in jugular foramen 
paragangliomas: indications and results
R. Pareschi
Jugular foramen paragangliomas (JFPs) are tumours that 
involve the jugular bulb with different relationships with the 
carotid artery and lower cranial nerves; JFPs are classified as 
type C according to the Fisch classification 1. In ¼ of the cases 
these tumors present an intracranial extension and are thus 
classified as Fisch type D. Open issues still remain concerning 
the treatment of JFPs, these regard their growth rate, the role 
of the radiotherapy, the wait and scan policy, the role and the 
indications of radical or partial surgery, the surgical approach, 
the long term results and the management of the facial nerve, 
of lower cranial nerves and of the internal carotid artery (ICA). 
Table 4.2.2.I. Tumor control rate for radiotherapy and wait-and-scan be-
tween 1992 and 2014.
Tumor control rate 1992-2014
Follow-up Wait and scan Radiotherapy
0-5 years 86% 92%
5-10 years 60% 69%
10-20 years 33% 38%*
*: 20% of new neurological deficit.
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because it permits, with the delicate transposition of the FN, a 
wide exposure, the radical removal of the tumor, a good control 
of bleeding and the management of major vessels (i.e. ICA) 
and nerves. Radical removal of the tumor along with reduction 
of major postoperative complications are our goals. Following 
the rerouting of the FN, postoperative rates of HB grade  I-II 
palsies ranged between 24% and 100% in extant literature, with 
most series ranging from 60% to 90%7. In our experience, at 
1 year of follow-up, HB grade I and II palsies were reported 
in 69% of cases and 25% reported a grade III after FN anterior 
rerouting. Non-rerouting approaches permitted the preservation 
of the facial nerve function in all patients of the present series. A 
recent review of the literature reported HB grade I-II in 95% of 
the non-rerouting approaches at the cost of a significant increase 
of persistence 7. Consequently, even if conservative approaches 
could be performed in selected C1 TJPs, the rerouting of the 
nerve allows an acceptable functional and cosmetic result in 
69% of the cases and should be therefore always performed 
(Table 4.2.2.III).
The most frequently damaged CNs are the IX and X, with 
a pharyngo-laryngeal unilateral paralysis. Sudden deficit 
of preoperative functioning LCNs is the most feared 
complication since it is related with dysphagia, aspiration, 
and dysphonia. The position of the LCNs – covered by the 
medial wall of the jugular bulb  –  and the fact that TJPs 
usually arise from the superolateral aspect of the bulb make 
preservation of LCNs possible in small tumors. Particular 
attention must be given to the inferior petrosal sinuses, which 
run between the lower cranial neves with several anatomical 
variations. Even if the internal jugular vein is ligated and the 
sigmoid sinus closed, the inferior petrosal sinuses continue 
to bleed and need to be packed with haemostatic agents. With 
this manoeuvre, even a simple compression of the nerves 
on the rigid walls of the jugular foramen could bring to a 
postoperative deficit. Consequently, whenever the jugular 
bulb is opened, a risk for LCNs palsy must be considered. 
The preservation of the function of IX and X CNs in C1 
paraganglioma was 74% and 80%, respectively, in our series 
of patients. This rate dramatically slopes down to less than 
20% for C2 paragangliomas. This is in agreement with 
literature reporting the overall incidence of one or more new 
postoperative lower cranial nerve (LCN) deficits between 2.8 
be performed. In our experience, the infratemporal type A 
approach of Fish (ITFA) was chosen as the elective surgical 
procedure in more than 90% of cases. Several approaches have 
been attempted in order to preserve the external and middle ear 
and protect the facial nerve, but the ITFA appears to be the only 
approach that guarantees a safe and complete exposure of the 
jugular foramen and of the intrapetrous carotid artery 3. In our 
experience, this wide exposure allows a complete removal of the 
tumor in more than 90% of cases with a recurrence rate of 4.7% 
after total resection. Similar results are reported in literature 
with radical resection rates ranging between 72 and 100% and 
a recurrence rate form 0 to 28.1% 5. From C1 to C4 tumors the 
chances to achieve a radical resection progressively slope down. 
C1 and C2 tumors are often radically resected (100% for C1 and 
96% for C2) and the long-term tumor control is clearly superior 
to radiotherapy 6. On the other hand, when treating C4 tumors, 
which present cavernous sinus invasion, persistent disease is 
always left at this level due to the high risk of ophtalmoplegia 
(Table  4.4.2.II), despite important advances in perioperative 
management, otoneurosurgical techniques and technologies 
in the last decades. Fisch’s type  D JFPs are tumors with an 
intracranial extension. The intracranial surgical resection in 
non-irradiated patients is usually relatively easy since the 
tumor is easily detachable from the intracranial neurovascular 
structures. This allows a complete resection of 100% of the 
tumor’s extradural component and of 87% of its intradural 
component in our series. After radiotherapy instead, the tumor 
and dura become firmly attached to the brainstem and to the 
cerebellum, making further resection extremely dangerous. 
Considering the high risk of a growing intracranial tumor, the 
high rate of radical resection of the tumor’s intracranial portion 
prior to radiotherapy, and the risk of post-radiation salvage 
surgery, an upfront surgical resection is clearly advisable. 
The facial nerve (FN) is the main obstacle for a correct exposure 
of the jugular formen and of the carotid canal. Its function is at 
risk in every surgical procedure for TJPs. The FN function must 
be evaluated with the House-Brackmann Scale (HB), because 
it is related with the morbidity of the palsy. Management of the 
FN includes simple exposure, a partial or complete mobilization 
or a segmental resection. In our series, 7.7% presented with 
a preoperative FN palsy. Postoperatively a HB grade I-II 
deficit was reported in 73.2% of patients. Consequently there 
was 19.1% of new FN palsy. The anterior rerouting of the 
FN (from the geniculate ganglion to the intraparotid main 
division branches) represents the key point of the infratemporal 
approach type  A. This approach is, in our opinion, the gold 
standard for the management of jugular foramen tumors 
Table 4.2.2.II. Rate of radical resection according to Fisch classification.
Class C1 C2 C3 C4 D1 D2
Rate of 
radical 
resection
100%
(62/62)
96%
(51/53)
75%
(15/20)
0%
(0/7)
100%
(20/20)
90%
(14/16)
Table 4.2.2.III. Postoperative facial nerve function.
House-
Brackmann
Left in 
falloppian canal
Trasposed Cut and 
sutured
Late 
palsy
I
100% 69% 
0 0
II 0 0
III 0 25% 70% 0
IV 0 3% 30% 0
V 0 3% 0 0
VI 0 0 0 0
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been a shift to partial resection with staged radiosurgery, or to 
exclusive radiosurgery, but there is a need for more adequate 
follow-up.
4.2.3. Primary radiotherapy in paraganglioma: 
indications and results
L. Deantonio, M. Krengli
Introduction
Paragangliomas represent highly vascular neuroendocrine 
tumours arising from the extra-adrenal autonomic paraganglia, 
which derive from embryonic neural crest. They differ in their 
anatomic distribution and clinical presentation and can arise 
from either parasympathetic or sympathetic paraganglia. The 
majority of parasympathetic paragangliomas grow in the head 
and neck district. However, head and neck paragangliomas 
represent a rare entity, accounting for approximately 0.6% 
of head and neck tumours and approximately 0.03% of all 
tumours 1. They are in general benign, slow growing and non-
functional. They can frequently involve the carotid body, the 
jugular bulb, the vagal ganglia and the temporal bone. Less 
than one third of paragangliomas have a malignant behaviour. 
This minority usually arise from carotid body and vagal 
nerve. The metastatic spread to regional lymph-nodes or 
less frequently to distant sites are the only indicators of their 
malignant behaviour 2 3. 
Surgical resection or radiotherapy represent the loco-regional 
treatment options in case of head and neck paragangliomas. 
In general, surgery is the first-line therapy of choice for 
carotid body tumours and is selectively preferred in case 
of symptomatic bulky tumours. Moreover, surgery is more 
widely performed for other locations below the head and 
neck district and in secreting paragangliomas. In contrast, 
radiotherapy is the first-line option for jugular and vagal 
paragangliomas and is often employed in case of recurrence 
or persistence after non-radical surgery in relation with the 
anatomic challenges of the head and neck district 4 5. 
A multidisciplinary evaluation is anyway highly recommended 
for paragangliomas, because of the clinical scenario and 
the various treatment options. A single-modality treatment 
should be encouraged in order to achieve long-term symptom 
recovery and high local control rates 5. 
The aim of the present article is to review the most recent 
literature data of radiotherapy in terms of local control and 
side effects and to discuss the role of radiation treatment in 
the management of head and neck paragangliomas.
Materials and methods
Literature search was performed by using the databases 
of Pubmed and Scopus. The key words “head and neck 
paraganglioma”, “paraganglioma”, “primary radiotherapy”, 
“radiotherapy”, “radiosurgery”, and “stereotactic radiation 
and 59% 8. LCN primary dysfunction leads to alterations in 
swallowing, speech, and airway protection. Most patients 
often compensate with speech therapy, and better functional 
results are expected in patients with a preoperative palsy 8. 
Careful preoperative consideration is necessary in elderly 
patients that need to undergo surgery. In this group of patients, 
rehabilitation of swallowing may be impossible when it is a 
result of the combined loss of these nerves 9. With the cut-
off of 65 years old, no patients in our experience reported 
ab-ingestis recurrent pneumonia, permanent tracheostomy or 
gastrostomy (Table 4.2.2.IV). 
Preoperative evaluation of the efficacy of the collateral 
arterial circulation in case of deliberate or accidental ICA 
sacrifice is mandatory. Without any preoperative selection of 
patients the incidence of stroke after permanent occlusion of 
the artery ranges from 17% to 30% 10 and mortality reaches 
10%. Preliminary evaluation of the Circle of Willis without an 
endovascular procedure (Matas test) 11 is performed in all C2-
3-4 cases. A preoperative balloon occlusion test of the ICA is 
not considered necessary. Only in the presence of a good cross 
filling, the patients will be scheduled for a balloon occlusion 
test of the ICA. This is indicated in case of involvement of 
the carotid wall by the tumor and/or if the tumor receives 
multiple vessel vascular supply from the ICA itself that cannot 
be reduced by the embolization. We performed a permanent 
occlusion of the ICA in 14  cases without any residual 
neurological deficit.
The endovascular stenting, in alternative to the PBO, is an 
attractive procedure although the risk of ICA rupture in case of 
wall vessel infiltration is still high, and the vascular flow from 
feeding vessels is not influenced by the stent 12. Consequently, 
when needed, the PBO of the ICA is preferable because, in 
our opinion, it increases the rates of radical resections and 
avoids accidental intraoperative ICA ruptures or postoperative 
pseudoaneurisms.
Conclusions
The management of jugular paragangliomas is challenging, 
highly controversial and evolving. Wait-and-scan management 
represents the default initial strategy for small- to medium-
sized tumors and for all patients unsuitable for surgery. 
Radical surgery represents our choice in patients with small 
tumors (C1). For more advanced lesions (C2, C3, C4, D1, D2) 
we discourage surgery only in patients in precarious general 
conditions and or older then 65. Over the last decade there has 
Table 4.2.2.IV. Postoperative neurological defects.
Class VIII n.c. IX n.c. X n.c.
C1 80% 75% 80%
C2 35% 17% 25%
C3 0 0 0
C4 0 0 0
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patients achieved tumour shrinkage or a stable disease and in 
50% of patients symptom improvement was present. 
In such benign tumours, disease control, generally defined 
as radiographic stability or decrease in size after treatment, 
was achieved in 96-100% of patients after a median follow-
up time of 2-years. Moreover, clinical control, defined as 
improvement or no-change of symptoms, was reported by 
60-100% of cases in the selected studies 7 18. 
The risk of radiotherapy-induced toxicity was generally mild 
and manageable and long-term sequelae have been improved 
by modern radiation planning and treatment techniques. In this 
regard, the selected clinical series reported a low incidence of 
cranial nerves impairment (<  3%)  12. Moreover, Patel et al. 
showed that the risk of progression to non-serviceable hearing 
following radiosurgery was 9% at 1 year and 20% at 5 years 7. 
A small recent study on fractionated stereotactic radiotherapy 
reported neither acute nor late toxicity 8. 
Discussion
Since paragangliomas represent rare benign tumours, all 
results are based on retrospective single cohorts. Although 
the power of the present studies does not allow to formulate 
strong statements, we may find some evidence that can help 
physicians in treatment decision-making on the following 
issues: radiotherapy modality with conventional fractionation 
or single fraction (SRS) or multiple fractions (FSRT), tumour 
therapy” were used for searching literature articles. We 
considered the papers published in the last 10  years. The 
relevance was assessed based on the numerousness of the 
sample size (at least 10  patients), the length of follow-up 
(median/mean of at least of two years), the completeness of 
analysis of technical data, and the outcome in terms of local 
control, survival and side effects.
Results
In total, 304 articles were found. The initial review was based 
on the title and the second one on the abstract. The articles 
that resulted inadequate regarding cohort size and follow-up 
or reported on duplicated cohorts were discarded. Finally, 
14 articles fulfilled all inclusion criteria.
No randomized trials were found, and the reported results 
are based on clinical retrospective series. 
We reviewed the 13-series including 575  patients treated 
with primary radiotherapy, 229 of which with stereotactic 
radiotherapy. In Table 4.2.3.I, we summarized the principal 
data of the selected studies.
For radiation treatment delivery, patients were immobilised 
with customized thermoplastic masks and personalized 
rest neck. Then, a 1 mm slice computed tomography (CT)-
scan was performed and fused with T1- and T2-weighthed 
sequences 8. Target volumes were identified as follows: gross 
tumour volume (GTV) was defined according to the area of 
contrast enhancement on CT and magnetic resonance imaging 
(MRI) (Fig. 4.2.3.1). In case of fractionated treatment, clinical 
target volume (CTV) was defined by adding a 7 mm margin 
to the gross target volume along the main vessels. Planning 
target volume (PTV) was generated by adding a 3  mm 
homogeneous margin to the CTV. In case of radiosurgery, 
CTV corresponded to GTV, and a median margin of 3 mm 
was outlined to generate PTV, based on the machine used for 
delivery and on the accuracy of the immobilization system and 
imaging modality used to verify patient set-up 8 16. 
In case of conventional treatment, a median dose of 45 Gy 
with standard daily fractionation of 1.8 Gy was adopted 12 13 16, 
while in case of stereotactic radiotherapy, a protocol mostly 
with dedicated machines (i.e. Gamma-knife and Cyberknife) 
delivered a median prescription dose of 12-18 Gy in a single 
shot (radiosurgery) or 25 Gy in 3-5 fractions 7 8 15. 
For what concerns conventionally fractionated radiotherapy, 
Gilbo et al. reviewed their 45-year experience on 
156 paragangliomas treated with external beam radiotherapy 
to a median total dose of 45 Gy, achieving tumour control in 
96% of cases at 10 years, with no severe complications  13. 
In terms of stereotactic radiotherapy, Marchetti et al. 
recently reported on 21 patients treated with Cyberknife  9: 
paragangliomas with a median volume of 3.6 cc were treated 
with a single session of 12 Gy, while paragangliomas with 
a median volume of 16  cc received a total dose of 25  Gy 
in 3-5  fractions. At a median follow-up of 35  months, all 
Fig. 4.2.3.1. T1-weighted magnetic resonance imaging showing the typi-
cal salt-and-pepper pattern of the malignant paraganglioma.
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Table 4.2.3.I. Outcome using stereotactic radiosurgery, SRS.
Author Class of 
evidence
N. pts Origin Technique Median 
dose
Mean 
median V
Median/
mean
follow-up 
time
Tumour 
control
Symptom 
control
%
Complications
/toxicity
Cao 
2018 6
III 10
(6 
exclusive 
RT)
Various Proton 
beam
50.4 GyE Nr Median 
24.6 months
100% 70% 50% G1 
fatigue 
30% G1 
headaches
20% G1 
dizziness
10% G1 
dysphagia
Patel 
2018 7
III 85 Jugular glomus GKRS 16 Gy Median 
7 cc
Median 
37 months
Nr 60% 9% 
at 1 year
Tosun 
2018 8
III 12 Various SRS 
CyberKnife
24 Gy/3 fr Median 
35.5 cc
Median 
30 months
100% 100% 
(No clinical 
progression)
0%
Marchetti 
2017 9
III 21 Various SRS 
CyberKnife
12 Gy
25 Gy/3-5 fr
Median 
3.6 cc
Median 
16.1 cc
Median 
46 months
100% 50% 
improved
30% 
unchanged 
15%
Dobberpuhl
2016 10
III 12 Jugular glomus GKRS 15 Gy 8.42 cc Median
27.6 months
100% 80% 1 case 
of facial 
paresis
Schuster 
2016 11
III 14 Jugular glomus SRS
FSRT
15-18 Gy
3-7 Gy/3-15 fr
3.78 cc Median 
28.8 months
92.9% Nr Nr
Smee 
2015 12
III 34 Various SRS
EBRT
14 Gy
45 Gy/25 fr
< 3.5 cm
> 3.5 cm
Median 
3.5 years
100% 97% 3% c.n. 
deficit
Gilbo 
2014 13
III 131 Various RT 45 Gy/25fr Nr Median 
8.7 years
99% at 
5 years
96% at 
10 years
Nr 0% severe 
complications
20% mild 
complications
Galland-
Girodet 
2014 14
III 130 Jugolotympanic, 
carotid body 
tumour
Vagal glomus
RT Mean 
52.2 Gy
Nr Median 
7.6 years
96% at 
5 years
85% at 
10 years
70% 30% 
not severe
Chun 
2014 15
III 31 Jugular glomus FSRT 
CyberKnife
25 Gy/5 fr Nr Median 
24 months
100% 90% G1-2 19%
G3 0%
Dupin 
2014 16
III 66
(46 
exclusive 
RT)
Various EBRT 45 Gy Median
17 cc
Median 
57.4 months
100% at 
5 years
98.7% at 
10 years
Nr Acute: G3 
19.5%
Late: G3 
6.5%
2 cases 
secondary 
tumour
Chen 
2010 17
IIb 15 Jugular glomus GKRS Mean 
14.6 Gy
Mean 
7.4 cc
Median 35 
months
80% 90% 20% 
neurological 
pulsy
Ganz 
2009 18
III 14 Jugular glomus GKRS Mean 
13.6 Gy
Mean 
14.2 cc
Mean 
28 months
100% 100% Transient 
facial palsy (1)
Pts: patients; SRS: radiosurgery; FSRT: Fractionated Stereotactic Radiotherapy; GKRS: Gamma-knife radiosurgery; EBRT: External-Beam Radiotherapy; Nr: not reported.
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radiotherapy, respectively 16. Based on this, we could argue 
that the risk of malignant transformation is limited although 
this finding in the literature is related to the length and 
accuracy of follow-up.
The main limitation of the present review is related to the 
absence of clinical randomized trials comparing different 
radiation therapy approaches. In fact, literature data are only 
available from retrospective studies sometimes with limited 
number of patients and relatively short follow-up.
Conclusions
This literature review on primary radiotherapy for head and 
neck paragangliomas covered the most relevant studies of the 
last 10 years. It showed that radiotherapy which can be used 
with different treatment schedules (including radiosurgery, 
fractionated stereotactic radiotherapy and conventionally 
fractionated radiotherapy) can achieve satisfactory control 
tumour rates even in the long-term with a limited incidence 
of acute and late toxicity. Prospective clinical trials on the 
role of primary radiotherapy are expected to better clarify 
the role of radiotherapy compared to that of surgery and to 
identify the optimal radiation technique in terms of dose and 
fractionation, based on long-term results of local control and 
side effects including the risk of secondary tumours.
4.2.4. Partial surgery in paraganglioma: 
indications and results
R. Bivona, M. Nardone, E. Zanoletti, G. Danesi
Introduction
Although benign and slow-growing lesions, tympano-
jugular paragangliomas have potential severe morbidities 
by aggressive and extended involvement of the skull base. 
The ideal primary treatment of these lesions is surgery with 
the aim of a radical resection, which can be associated with 
postoperative morbidity and sometimes can worsen pre-
existing symptoms  1. Since 1977, surgery of the jugular 
foramen has been standardized by the description of the 
infratemporal approache  2. Though more conservative 
approaches 3 4 have been developed through the years, data 
to validate and standardize the surgical strategy of these 
tumors are still lacking. The main problems of achieving a 
standardized and universally accepted treatment strategy for 
these lesions are their relative rarity, their rich vascularization, 
the scarce knowledge of their natural history along with 
the necessity of dealing with nearby vital structures in the 
skull base which make surgery demanding and potentially 
dangerous. Very high morbidity and mortality were the price 
to pay through the years to achieve a total or grossly total 
resection  5. Neurological sequalae and other complications 
have a significant impact in the patients’ quality of life, 
particularly in the elderly who may have great difficulties in 
volumes, dose prescription, tumour control and clinical 
outcome, role of retreatment and risk of complications.
Based on the available data, a conventional fractionated 
treatment with a schedule at a median dose of 45  Gy is 
considered an optimal approach for primary treatment of 
larger paragangliomas or in case of residual/recurrent tumour 
after surgery 13 16 19. The safety of this approach is suggested 
by Gilbo et al. that did not report any severe complication 
in 156 treated paragangliomas with intensity modulated 
radiation therapy or conventional photon fields. Slightly 
higher late severe complications (6.5%) were reported by 
Dupin et al., but the authors analysed a smaller sample of 
66 patients treated with 60Co-machine 16. 
In the last years, several studies reported tumour control 
outcomes similar or superior to those of conventionally 
fractionated radiotherapy by using stereotactic radiotherapy, 
together with lower toxicity rates  20. For jugular 
paragangliomas, which are more challenging from a surgical 
point of view, stereotactic radiotherapy has been used with 
increasing frequency and satisfactory results  7  8. Literature 
data suggest that the choice between a stereotactic approach 
in 1 or 3-5 fractions may be based on tumour volume, being 
larger tumours (> 3.5 cm) better treated by conventionally 
fractionated radiotherapy.
The brilliant results (which in some series reached 100%) of 
stereotactic radiotherapy for both tumour and clinical control 
may support a radiobiologic concept: we do not know 
radiosensibility and in general express this as α/β ratio in 
the linear-quadratic model, but as these tumours are a slow-
growing benign entity, the α/β ratio might be considered as 
low as those of meningiomas (α/β = 3.76 Gy) or vestibular 
schwannomas (α/β = 2.4 Gy) 21 22 23.
The reported high tumour control rates suggest performing 
stereotactic radiotherapy as a treatment of choice in case of 
bilateral paragangliomas, where a surgical approach for on 
neck sides is at high risk of sequelae. In such cases, surgery 
may be performed for bulky or secreting paragangliomas 
and on the opposite side, a radiotherapy treatment may be 
delivered  14. Alternatively, the neck could bilaterally be 
treated with fractionated stereotactic radiotherapy 9.
Interesting results also came from proton therapy although 
only one study fulfilling the selection criteria was found 
in literature search  6. Cao et al. analysed 10  patients who 
performed the treatment, and all achieved tumour control. 
Only grade 1 late toxicity was reported and in 50% of cases 
in terms of fatigue. The limited literature data on proton 
therapy, despite satisfactory results, do not allow to make 
any strong recommendation in this regard.
An interesting issue is the risk of developing a secondary 
malignant tumour in paraganglioma after radiotherapy. We 
found only one report which described 2 cases of subsequent 
tumours in a retrospective cohort of 46  paragangliomas. 
Both patients developed a meningioma 15 and 18 years after 
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that the promising results of radiosurgical reports have 
sometimes unacceptable short follow-ups  12 and that the 
criteria of success between radiotherapy and surgery differ 
in their nature, since radiotherapy aims to prevent any further 
growth of the tumor, and surgery aims to remove the tumor 
and completely eradicate the disease. Nevertheless, we 
found in literature and in our experience enough arguments 
to support the proposal of a new way of management of 
tympanojugular paraganglioma, leading to an algorithm of 
treatment which has been currently applied on our patients. 
The controversial aspects found in literature and in our 
experience will be discussed further on, along with the new 
protocol of treatment we have adopted and proposed.
Material and methods
Patients
This is a prospective study of all our patients with 
pagangliomas in class C1-C2-C3 treated from 2004 to 2017. 
Epidemiological and clinical data, surgical and histological 
reports, preoperative and postoperative images, complications, 
data on adjuvant therapy and follow-up information were 
reviewed. 76  patients have been included in the present 
analysis. These were 44  females and 26  males with age 
ranging from 19 to 78 years old. The mean age is 45,2 years 
old. Tympanojugular paragangliomas were staged according 
to Fisch and Mattox classification (Table 4.2.4.I). Perioperative 
sequelae were recorded. Follow-up was defined as the period 
of time from surgery to the most recent evaluation. Patients 
with less than 1  year of follow-up were excluded from the 
study. Complications, recurrences, or any other relevant data 
were analyzed during follow-up.  Preoperative radiological 
postoperative rehabilitation  6. For young patients, recovery 
and rehabilitation are easier, but these subjects will need to 
bear with sequalae of surgery all of their life together with 
the perspective of developing a recurrence, because as the 
lifespan is longer, the possibility to develop a recurrence 
is higher. Most glomus tumors grow very slowly and the 
median doubling rate of the tumors is considered to be four 
years. This supports the theory of a watchful-wait policy for 
small non-symptomatic tumors in older patients, but does not 
add much contribute in the management of young patients, 
for whom a treatment is generally required. The potential 
permanent postsurgical disability, along with an increasing 
concern on quality of life, has drawn attention to alternative 
treatments, particularly to radiotherapy. Conventional 
fractionated radiotherapy has been associated with high 
risk of several long-term complications such as: brain stem 
damage, temporal bone necrosis, internal carotid artery 
thrombosis with stenosis together with a still confusing 
rate of secondary malignancies  7. Moreover, the effect of 
radiotherapy on paraganglioma tissue is not well understood 
and glomus cells themselves are generally considered to be 
radioresistant, though a long-term control of tumor growth 
is reported  8. For these reasons, external beam radiation is 
rarely used as a primary treatment of glomus tumors, except 
for inoperable recurrences or for old patients with advanced 
tumors and comorbidities. Over the past years, radiosurgical 
techniques have emerged as promising alternatives to 
traditional surgery, both as a primary treatment or as an 
adjuvant treatment following surgery  9. Radiosurgery has 
currently three main techniques: gamma knife, Linac and 
cyber knife. All of these techniques are refinements of 
conventional radiation therapy and are conceived and tailored 
to the particular characteristics of the tissue and to the site 
of glomus tumors  10. Results are promising and document 
the stability of tumor growth with no new neurological 
deficits in several reports 11. These facts make radiosurgery 
an interesting treatment to be considered in selected cases as 
an alternative or as a complementary instrument to surgery.
Moving from the promising results of radiosurgery and 
the unquestionable unbearable morbidity related to 
extensive surgery, particularly in old patients with a normal 
preoperative neurological status, in recent years we have 
been trying to adapt the treatment to the characteristics of 
the tumor (site, size, potential aggressiveness, growth rate) 
and to the patient (age, state of cranial nerves, symptoms, 
comorbidities, consensus) in order to set when surgery is 
necessary and which kind of surgery to propose. The over 
30-year-long experience of our department on surgical 
treatment of jugular paraganglioma also supported the 
necessity to make an effort to seek for a viable, low morbidity 
and more modern treatment  7. We think that progresses in 
the knowledge of the natural history of the tumor in the 
radiosurgical field cannot be ignored, though we are aware 
Table 4.2.4.I. Classification of jugulotympanic paragangliomas according 
to Fisch and Mattox.
Class Location and extension of paraganglioma
A Paragangliomas that arise along the tympanic plexus 
on promontory
B Paragangliomas with invasion of the hypotympanon;
 cortical bone over the jugular bulb is intact
C
1
Paragangliomas with erosion of the carotid foramen
C
2
Paragangliomas with destruction of the vertical carotid canal
C
3
Paragangliomas with involvement of the horizontal portion 
of the carotid canal; foramen lacerum intact
C
4
Paragangliomas with invasion of the foramen lacerum 
and of the cavernous sinus
De
1/2
Paragangliomas with intracranial but only extradural extension; 
De
1/2
 according to displacement of the dura 
(De
1
  = less than 2 cm; De
2
  = more than 2 cm)
Di
1/2/3
Paragangliomas with intracranial and intradural extension; 
Di
1/2/3
 according to depth of invasion into the posterior cranial fossa 
(Di
1
  = less than 2 cm; Di 
2
 = between 2 and 4 cm;
Di
3
  = more than 4 cm)
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Classification
Classification of jugulotympanic paragangliomas according 
to Fisch and Mattox is shown in Table 4.2.4.I.
Surgical approaches
Tympanojugular paragangliomas have always presented a 
challenge for surgeons as these tumors are vascular, locally 
aggressive, and involve important neurovascular structures, 
as the jugular bulb, the internal carotid artery (ICA), the 
facial and the lower cranial nerves (CNs; IX, X, XI and XII). 
These lesions usually do not imply hearing impairment. The 
selection of the surgical approach (Table 4.2.4.III) was tailored 
according to the location and the extension of the tumor. 
Various patient factors were also taken into account, such as: 
age, general health condition and preoperative cranial nerve 
dysfunction. Surgical strategy can be outlined as:
• infratemporal fossa approach type A (ITF A);
• petroccipital-transigmoid approach (POTS);
• lateral petrosectomy with facial bridge (transotic approach).
evaluation includes high-resolution CT and gadolinium-
enhanced MRI. Additionally, tumor embolization is performed 
2 days before surgery by neuroradiologists.
More specifically, the protocol states that patients aged less 
than 60 years old with paralysis of lower cranial nerves are 
treated with radical removal. If the lower cranial nerves 
status is normal these patients undergo partial removal 
which can be followed or not by radiotherapy. Patients 
aged more than 60 years old are treated with radiotherapy 
or observation (wait and see behavior) unless they develop 
an involvement of lower cranial nerves and/or endocranial 
issues (in Di extension). These conditions may require 
surgery if no comorbidities are described or are life-
threatening (Fig. 4.2.4.1). Surgery has been performed in 67 
out of 76 patients with C class paragangliomas. 6 patients 
have not been treated and are under observation. 22  cases 
showed a D  class extension. Patients’lesion characteristics 
are shown in Table 4.2.4.II.
Table 4.2.4.II. Patients’lesion characteristics.
Class N. of cases
C
1
15/76
C
2
53/76
C
3
6/76
Fig. 4.2.4.1. Algorithm of treatment of tympano-jugular paraganglioma.
Table 4.2.4.III. Surgical approaches.
Surgical approach Patients
ITF A 9
POTS 17
Transotic 44
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has been performed in 67 out of 76  patients. A deliberate 
incomplete removal was performed in 53 cases. In 14 patients 
a radical removal was obtained. 3  patients undergone 
exclusive radiotherapy. Preoperative cranial nerve status was 
related with tumor extension and is shown in Table 4.2.4.IV.
Post-operative morbidity rates are satisfying. Main 
complication was hearing loss which is present in 89% of 
cases, a new deficit of lower cranial nerves was described in 
2% of patients. No cases of meningitis is reported. Moreover, 
there was 1 case of temporary ischaemia and 1  death. In 
13 patients (19%) a facial nerve deficit was described. 6 cases 
underwent facial nerve grafting, of these cases: 3 showed a 
III grade HBS, 2 showed a IV grade HBS and 1 case did not 
recover nerve function despite grafting. 
Preliminary results show a stability of residual tumor for 
87.5% of patients who underwent radiotherapy after partial 
surgery and for 91.9% of patients who are enrolled in the 
wait and see group after partial surgery. Most of the patients 
who underwent partial removal have a residual which is 
monitored with post-operative serial imaging with MRI 
with gadolinium at six months after surgery and after a year. 
Subsequent follow-up provides a MRI with gadolinium once 
a year.
The primary approach used in most cases was a lateral 
petrosectomy with facial bridge.
The objective of the infratemporal fossa type A approach 
approach is exposure of the infralabyrinthine and apical 
compartments of the temporal bone, of the mandibular fossa 
and posterior infratemporal fossa by subtotal petrosectomy and 
anterior transposition of the facial nerve. It is a cranio-temporo-
cervical approach requiring a combination of otoneurosurgical 
and head and neck surgery techniques. The type A approach 
is used for removal of tumors involving the jugular foramen, 
primarily class C and D glomus temporale tumors. The pars 
vascularis and pars nervosa can be exposed, together with the 
vertical tract and part of the horizontal tract of the internal carotid 
artery. The incision is extended into the neck to expose the 
vessels and the cranial nerves in the neck 13. The POTS approach 
has been developed for removing tumors situated in the jugular 
foramen together with their local extension into the adjacent 
parts of the skull base, the cerebellopontine angle (CPA) and 
the parapharyngeal space (PPS). The POTS approach involves a 
posterolateral exposure and an anteromedially directed surgical 
axis which allows the surgeon to leave the external and middle 
ear complex, together with the facial nerve, entirely undisturbed. 
Single-stage removal of intra- and extradural lesions extending 
from the CPA to the PPS can be achieved with minimal risk of 
cerebrospinal fluid (CSF) leak. In essence, the POTS approach 
is the combination of a retrolabyrinthine petrosectomy and 
a retrosigmoid craniotomy. The external ear canal, tympanic 
cavity, and facial nerve are left in situ 14. 
The transotic approach to the CPA was first introduced in 
response to the limitations of the translabyrinthine technique. 
The objective of this approach is to obtain a direct lateral 
exposure and the widest possible access to the CPA through the 
medial wall of the temporal bone, from the superior petrosal 
sinus to the jugular bulb, and from the internal carotid artery 
to the sigmoid sinus. The tympanic and mastoid portions of 
the fallopian canal are left in situ. As a natural extension of 
subtotal petrosectomy, the transotic approach was initially 
designed for acoustic neuromas and has then expanded to 
include other pathologies like temporal paragangliomas 13. 
The treatment of intradural extension of these pathologies 
is tailored according to depth of invasion into the posterior 
cranial fossa. 
Statistical analysis
A p value less than 0.05 was considered as significant. 
Mann-Whitney U test was applied to evaluate if radiotherapy 
is more valuable rather than a wait and see behavior on 
residuals after partial surgery. No difference was found 
(p = 0.9229) (Fig. 4.2.4.2). 
Results
Patients underwent surgical resection via different 
approaches. Tumor resection can be partial or total. Surgery 
Fig. 4.2.4.2. Comparison between the two groups of patients with residual 
tumor after partial surgery.
Table 4.2.4.IV. Pre-operative cranial nerve status related with tumor ex-
tension.
C1 C2 C3
None 4 10
CN’s IX-X-XI-XII 7 4
CN VII 2 5 2
Hearing loss, tinnitus, vertigo 6 19 6
Hydrocefalus 1
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the necessity of an extensive skull base surgery in some cases. 
In literature, the most successful experiences  1  15 report an 
unexpected 10% rate of recurrences in total (or gross total) 
removal. Other reports  16 have a rate of recurrences around 
70%. Two aspects must be considered when reporting surgical 
outcomes of tympano-jugular paraganglioma: the mean length 
of follow-up and its modality. This defines the minimum 
length of an acceptable follow-up and the instrumental 
way of assessment of the residual/recurrent disease. When 
angiography is performed at two years of follow-up (shorter 
follow-up should not be accepted as a mean to assess the 
outcome of surgery) a minimal recurrence becomes evident, 
and it reported. The same recurrence might take more time to 
become evident at an MRI. The latter fact is relevant because 
it reveals how total removal is often a gross total removal, with 
unexpected and underestimated residual disease, although this 
does not necessarily affect the therapeutic attitude towards the 
recurrence. In this setting, the enthusiasm for outcome success 
despite its morbidity should be faced with more criticism. 
No significant results were found in this preliminary report. The 
most obvious limitation in this research was the small sample 
size. Further studies are needed to verify our hypothesis and, 
as previously stated, a prospective cohort study is ongoing to 
assess whether radiotherapy is more valuable when compared 
to a wait and see behavior on tumor residuals after partial 
surgery and to confirm the validity of our protocol.
Case 1
A case of C2 (Figs. 4.2.4.3A, B). 
Case 2 
A case of C2 D2 (Figs. 4.2.4.4A, B, C).
Discussion
Treatment of jugular paragangliomas remains controversial. 
Surgery has been considered the gold standard since it 
offers a radical removal of the tumor despite its morbidity. 
Nevertheless, functional consequences of postoperative 
complications and long-term sequelae are so wide to doubt 
Fig. 4.2.4.3. A) A case of C2; B) Post-op. after partial surgery. Fig. 4.2.4.4. A) A case of C2 D2e; B) Stable at 4 years of follow-up; 
C) Stable at 7 years of follow-up.
A
B
A
B
C
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to another important factor: patient’s age. There is a 
general agreement that elderly patients should not undergo 
extensive surgery 17 18 20 21 because of the difficulties of post-
surgical rehabilitation and the presence of comorbidities 
which adds problems to the recovery. The problem is to 
define which is the cut off age to separate “young” patients 
from “old” patients, along with all elderly patients who 
are biologically younger and may be good candidates for 
surgery and viceversa. Young patients usually have no 
medical factors contraindicating aggressive surgery and 
cope more easily with postoperative neurological deficit 
recovery. In case of recurrence, radiation can be offered 
with success rather than salvage surgery, which is generally 
more complicated in a treated field. Moreover, in the setting 
of a shorter lifespan and a lower possibility of developing 
recurrences, radiotherapy (radiosurgery) could play its role 
as first line treatment for elderly patients. By stating this, 
we do not mean that recent radiosurgical techniques are 
superior to surgery in treating jugular paragangliomas. We 
have already mentioned the two basic biases of radiosurgical 
reports: the shortness of follow-up and the criterion of 
success, which is different between the two kinds of 
treatment. Radiosurgical literature, in some cases, does not 
make distinction between carotid body and jugular glomus 
tumors, giving cumulative rates of success. Similarly, 
no distinction is made between the treatment of primary 
tumors and post-surgical recurrences. Our aim was to seek 
for a strategy for management of jugular paraganglioma 
which might have offered the safest treatment from both 
oncological and functional points of view, trying to use 
all the treatment modalities that are available nowadays. 
Radical surgery, radiosurgery, observation, and planned 
subtotal surgery are all viable options which can be applied 
according to the characteristics of the tumor and of the 
patient. It is within this setting that we have developed our 
algorithm, which we have been using for 13 years, with a 
rate of local control of 91.9%.
The protocol was applied to our case material and it is 
described in details in Figure  4.2.4.1. The value of this 
protocol will be discussed after adequate follow-up of at 
least 10 years for each patient. At the moment our experience 
is valuable as a preliminary report, and this “preliminary” 
aspect should be applied also to all those reports, both 
surgical and radiosurgical, which aim to draw conclusions 
with a range of follow-up which sometimes is even less than 
1 year.
The natural history of the disease, the impact of post-surgical 
morbidity on the patient’s quality of life, along with a rate 
of total removal (which is often more a gross total removal 
rather than a total removal as long as the time of follow-
up increases), should lead to a serious reflection about 
the need to find a common strategy which could be more 
respectful for nerve function along with good oncological 
The rate of residual/recurrent disease assessed by yearly 
MRIs, varies from 30% with a range of follow-up of 2,5-
13 years to 10%1 with a range of follow-up of 3-144 months. 
50% of recurrences 16 was not treated and remained stable at 
the follow-up. A good rate of stable residuals was observed in 
our experience. The relative stability of the residual disease 
represents a contribute to the concept of planned subtotal 
resection to preserve function, though some authors  15 
state that “the temporary benefit to the patient of avoiding 
a facial nerve weakness, or lower cranial nerves palsy, 
should be balanced against the possibility that, because of 
the infiltrating nature of paraganglioma, tumoral remnants 
may spread along the dural surfaces and the spongy bone, 
reaching areas where they become unresectable”. Actually, 
most authors agree that residual/recurrent disease may be 
treated with success by radiosurgery when the size is not 
more than 3 cm  12 13 17-19. Partial removal +  radiosurgery is 
thus advocated in bigger residual lesions  17  19. A watchful 
wait and scan policy  16  19 is also adopted in case of small 
residual with no growth.
All the different attitudes towards the residual and, more 
importantly, towards a previously treated primary tumor, 
cannot avoid to consider the problem of the functional 
status of the cranial nerves. When cranial nerve deficit 
is present before the treatment, the therapeutic balance 
is undoubtedly in favor of a radical-extensive surgery, 
when radicality can be achieved without exposing vital 
structures to an excessive risk. When cranial nerves are 
normal (which does not necessarily mean that they are not 
involved by the tumor), other options should be discussed, 
as post-surgical acquired cranial nerve palsies are scarcely 
tolerated, especially in elderly patients. In some cases, 
the natural history of an untreated tumor will lead to the 
same functional imbalance, but those issuse are much 
more tolerated because they occur progressively and not 
as an acute post-surgical iatrogenic event  19. Preoperative 
neurological deficits make the surgical decision easier, 
and adopting a conservative approach in asymptomatic 
patients seems to be reasonable. Not all authors agree 
that the preoperative function of the lower cranial nerves 
should impact on the therapeutic choice 1. A rate of 55% of 
surgically-acquired lower cranial nerve disfunction (with 
preoperative normal cranial nerves) does not seem to justify 
the need of discussing and proposing new therapeutic 
strategies in order to reduce morbidity. A lack of data about 
pre-treatment status of the lower cranial nerves is observed 
both in surgical and radiosurgical series.
While the presence of a preoperative paralysis simplifies the 
therapeutic choice, whilst the normal status of lower cranial 
nerves demands more close attention, therefore a wait 
and scan policy has been proposed, along with exclusive 
radiotherapy or planned partial resection followed by 
radiosurgery 7. All described options must be also correlated 
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tumor; 2) to assess the efficacy of the collateral circulation 
in maintaining a correct perfusion of the areas that would be 
affected by the manipulation or sacrifice of the artery. The 
investigations used for this purpose include high-resolution 
CT and angio-CT scans, MRI with gadolinium enhance-
ment, magnetic resonance angiography (MRA), and digital 
subtraction angiography. Narrowing and irregularities of the 
arterial lumen are strongly suggestive of infiltration of the 
ICA wall. To determine the efficacy of collateral circulation, 
four-vessel angiography with manual cross-compression 
test, xenon-enhanced computed tomography cerebral blood 
flow, single-photon emission computed tomography, and ca-
rotid stump pressure management are used.
The indications for preoperative endovascular intervention 
of the ICA are:
1. encasement of the distal cervical and petrosal vertical 
segments of the ICA between 270 and 360°, as shown by 
CT and MRI in the axial plane;
2. evidence of stenosis and irregularities of the arterial 
lumen of the distal cervical and petrosal segments of the 
ICA as determined by angiography;
3. all class  C3 and C4 TJPs, vagal and carotid body 
paragangliomas;
4. extensive blood supply from ICA branches as seen on 
angiography;
5. previous surgery with ICA manipulation and/or previous 
radiotherapy.
In these situations, the options include: preoperative perma-
nent balloon occlusion (PBO), external-internal carotid ar-
tery bypass followed by PBO or reinforcement with intra-ar-
terial stents. In this chapter, we will briefly discuss PBO and 
stenting of the ICA.
Preoperative endovascular management of the ICA
Permanent balloon occlusion
A balloon occlusion test (BOT) is performed if there is good 
cross-filling from at least one of the two communicating sys-
tems. A PBO can be performed if the patient tolerated the 
BOT and angiographic data demonstrated good cross-flow. 
The BOT-PBO procedure is performed under local anesthe-
sia with mild sedation and systemic heparinization. A bilat-
eral femoral approach is employed in which an 8F guiding 
catheter is inserted into one femoral artery and positioned 
in the ICA that will be occluded. The contralateral femoral 
artery puncture is used for angiographic evaluation. To per-
manently occlude the ICA, a 16 gold-valve balloon mounted 
on a chronic indwelling Foley catheter (Minyvasis, Genne-
villiers, France) is used. The first balloon is usually placed 
into the cavernous segment of the ICA just proximal to the 
origin of the ophthalmic artery and two more balloons are 
located at the carotid foramen and in the neck just distal to 
the bifurcation. After balloon inflation, occlusion of the ICA 
results. Radiotherapists and surgeons should no longer 
debate about the best treatment for jugular paragangliomas: 
their knowledge must be shared to set the best treatment 
strategy for each patient, which could be either be surgical, 
radiotherapic or an integration of both.
Conclusions
The value of this protocol will be discussed after an adequate 
follow-up of at least 10 years for each patient. At the moment, 
preliminary post-operative clinical data are quite satisfying 
with acceptable post-operative complications and stability 
of tumor residual. A prospective  cohort study is ongoing 
to assess whether radiotherapy is more valuable rather than 
wait and see behavior on residuals after partial surgery and 
to confirm the validity of our protocol. 
4.2.5. Management of internal carotid artery  
in skull base paraganglioma surgery
M. Sanna, E. Piccirillo, G. Piras, L. Lauda, A. Caruso
The surgical management of skull base paragangliomas is 
particularly challenging as a result of their complex anatom-
ical location, the local major neurovascular structures, and 
the proximity of intracranial structures. The internal carotid 
artery (ICA) is often involved by tympanojugular paragan-
gliomas (TJPs) in its upper cervical and petrous portions 1 2. 
Similarly, carotid body paragangliomas and vagal paragan-
gliomas are also intimately related to the ICA.
We have developed the application of preoperative stenting 
of the ICA in the management of TJPs since 2003 to avoid 
preoperative closure or bypass procedures and to protect and 
preserve integrity of the ICA during surger 3 4. Preoperative 
stent insertion also permits an aggressive ICA dissection with 
significant reduction of surgical risks 3-11. In class C3 and C4 
tumors, major encasement of the ICA is usually found at the 
inferomedial wall of the horizontal petrous segment.
Curative treatment necessitates aggressive removal of the 
bone in the region of the carotid canal and dissection of the 
arterial wall in class C3 and C4 tumors. We have noted that 
most recurrences were localized to the area around and medial 
to the petrous ICA 6. Preoperative endovascular intervention 
in the form of intra-arterial stents in the cervical and petrous 
(vertical and horizontal) segments of the ICA allows total tu-
mor clearance in these areas without compromising the artery. 
In our experience of over 30 cases, stenting of the ICA has 
transformed the therapeutic management in cases of advanced 
TJPs, dramatically reducing the number of inoperable TJPs.
Preoperative assessment of the ICA
The goals of preoperative assessment are to: 1) determine 
the degree and extent of involvement of the artery by the 
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The timing of reinforcement with stents also plays an import-
ant role; an interval of at least 4-6 weeks is advocated between 
stenting and surgery. This allows the formation of a stabilized 
neointimal lining on the luminal surface of the stent. In the pres-
ence of significant blood supply from the ICA, a bare stent is 
ineffective in reducing the vascular supply to the tumor. In such 
situations, the use of PBO, preoperative embolization with par-
ticles during temporary balloon occlusion of the ICA, and inser-
tion of covered stents are possible alternative solutions. Present 
literature suggests that covered stents have several theoretical 
disadvantages, increased thrombogenicity, rigidity, and greater 
difficulty in positioning at arterial angles, when compared to 
bare stents.
One month after the stent insertion, the neointimal layer is de-
veloped and subsequent subadventitial dissection can be safely 
performed (Fig. 4.2.5.1).
Intraoperative management of the ICA
Intraoperatively, the ICA may require the following types 
of intervention, depending on degree of involvement: 1) 
decompression with or without partial mobilization of the 
artery; 2) subperiosteal dissection; 3) subadventitial dissec-
tion; 4) subadventitial dissection with stent coverage; 5) ar-
terial resection (after preoperative PBO).
Simple decompression
This technique is employed when the tumor is around the ICA 
but not adherent to the artery (i.e., Fisch class C1 TJPs). Decom-
pression of the ICA is performed after identifying it medial to 
the Eustachian tube by drilling out the tympanic bone. A large 
diamond burr is used parallel to the course of the artery. Drilling 
is advanced both laterally and medially to the artery. By remov-
ing the bone anterior to the ICA, the artery can be displaced 
laterally or medially, by manipulating it with the tip of the suc-
tion tube while drilling is being performed. If additional drilling 
around the ICA is required, a vessel loop is wrapped around the 
artery to enable a wider range and better control.
is confirmed angiographically by injection of contrast into 
the guiding catheter, followed by confirmatory angiography 
to establish that adequate crossflow is achieved, with special 
attention to the symmetry of the arterial, capillary, and ve-
nous phases on either side. The patient’s physical and mental 
status is then monitored for 20 min. The first balloon is then 
detached. If balloon occlusion is not tolerated, the balloon 
is deflated immediately. In most cases this is evident very 
quickly, in the first few minutes after carotid occlusion. If 
asymmetry (> 1 s) in the capillary and venous phases of the 
angiogram is identified, angiography is repeated a few min-
utes later. If this asymmetry does not correct, the balloon is 
deflated and alternatives must be considered. After PBO, the 
patient is monitored for 24 h in an intensive care unit. Sur-
gery is scheduled only after 3-4 weeks.
Intra-arterial stenting
The introduction of preoperative reinforcement of the ICA with 
stents is a significant advancement in the surgical management 
of patients who are at risk of damage to this vessel. Stent inser-
tion reinforces the artery and allows a more aggressive carotid 
dissection while reducing the possibility of intraoperative injury 
to the ICA. To reduce the risk of thromboembolic complica-
tions, antiplatelet therapy is introduced 5 days before the stent 
insertion using a combination of clopidogrel (75 mg/day) and 
aspirin (100 mg/day). This therapeutic regimen is administrated 
for 1-3 months after stenting and then reduced to single-drug 
treatment with aspirin only. Antiplatelet agents are stopped and 
low molecular weight heparin (LMWH) commenced 5  days 
before surgery. Antiplatelet agents are introduced 2 days after 
surgery and LMWH is stopped 3 days after surgery. The patient 
then is placed on lifelong antiplatelet therapy. Reinforcement 
with stents is performed under general anesthesia as a separate 
procedure following diagnostic angiography. Three different 
types of self-expanding nitinol stents are used: Xpert Stent 
System (Abbott Laboratories Vascular Enterprises, Dublin, Ire-
land), Neuroform 3 (Boston Scientific, Fremont, CA), and LEO 
(Balt Extrusion, Montmorency, France). We consider the Xpert 
stent the most suitable for reinforcement of both the cervical 
and intratemporal portions of the ICA because of its diameter (4 
or 5 mm) and length (20, 30, or 40 mm). To reduce the possibil-
ity of injuring the ICA at the stent-tumor border, at least 10 mm 
of tumor-free vessel wall must be reinforced with the stent, both 
proximally and distally.
To achieve this, it is necessary to insert up to two or even three 
stents. Each stent is carefully selected and tailored to the indi-
vidual patient. It is difficult to negotiate the stent between the 
vertical and horizontal portions of the carotid canal and in ar-
teries that are coiled or kinked in the neck, and great care must 
be taken while this is being performed. In such situations, softer 
and more flexible stents must be chosen, to reduce the risk of 
dissection of the ICA. If a stent placement is technically impos-
sible, a PBO is the next option.
Fig. 4.2.5.1. Stenting of the ICA, as shown by the angiogram (left picture).
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Intraoperative internal carotid artery injury
Prevention of injury to the ICA must be achieved at all costs. 
However, in rare occasions, a vascular injury may be encoun-
tered. In such cases, the presence of proximal and distal con-
trol allows temporary occlusion, while a primary repair is car-
ried out. A primary principle in such situations is to achieve an 
adequate visualization.
Temporary compression or occlusion is quickly achieved by 
using previously placed control tapes. A variety of atraumatic 
vascular clips can also be used. Back-bleeding is a reassuring 
sign indicating some degree of collateral flow and allowing 
repair to be carried out in a timely fashion. Once the controls 
are achieved proximally and distally, small lacerations to the 
arterial wall or avulsion of the caroticotympanic branches can 
often be controlled with judicious use of bipolar cautery. Fine 
tips are used to approximate the edges in the longitudinal di-
rection of the laceration. A low energy pulse is applied, and the 
forceps are advanced. The process is repeated until the lacera-
tion is sealed. The occlusion is partially and then fully released 
to ensure closure. A layer of Surgicel® is placed over the repair 
and reinforced with fibrin glue. For small to medium defects, 
direct suture repair is recommended. Double armed vascular 
sutures are used while temporary occlusion is applied. Care to 
evert the edges is important as to avoid significant stenosis, as 
previously stated. Patch grafting and bypass using saphenous 
vein are options in extreme situations. In case of a stented ICA, 
the greatest risk is potential injury at the transition point of the 
stented and non-stented artery. It is imperative to use minimal 
traction at this point. Facilities for rapid transfer of the patient to 
the neuroradiology unit once temporary control is gained are es-
sential, with the options of emergency balloon occlusion or cov-
ered stent placement. Apart from repair of the artery, important 
resuscitation principles must also be adhered to. Judicious vol-
ume replacement, estimation of blood loss, and consideration of 
component therapy are made. Following repair, normotension 
and adequate circulating volume must be maintained to ensure 
adequate repair and neuroprotection. Any injury to the internal 
carotid artery or subadventitial dissection must be followed up 
radiographically due to the risk of pseudo-aneurysm formation. 
Vasospasm of the ICA can also occur while manipulating the 
ICA. The etiology can be multifactorial but includes mechanical 
trauma, thermal changes, desiccation, and prolonged exposure 
to blood. Therefore, irrigation with warmed saline and a gentle 
technique are essential to minimize this risk. It has been report-
ed that younger patients are more prone to this complication 
due to increased vascular tonicity and reactivity. If the surgeon 
notices any segmental reduction in the ICA, manipulation must 
stop, and papaverine is placed onto the artery. The surgeon must 
wait till normotension or mild hypertension is achieved.
Conclusions
ICA involvement is no longer considered a limiting factor in 
TJP surgery, but requires an accurate preoperative neuroimag-
Subperiosteal dissection
This technique is indicated when the tumor involves the perios-
teum of the carotid canal without reaching the adventitia. In this 
technique, a plane of dissection is developed between the ad-
ventitia of the ICA and the periosteum of the carotid canal. This 
is relatively easier and safer in the vertical petrous segment, as 
the ICA is thicker and more accessible when compared to the 
horizontal segment. The dissection of the tumor is started at the 
cervical level, from an uninvolved extratemporal segment of the 
ICA, where a good plane of dissection is easily identified. The 
bone of the carotid canal around the ICA from its entrance into 
the temporal bone is drilled out along with the tumor infiltrating 
the bone and periosteum. Gentle displacement of the ICA, from 
its entrance in the skull base to at least the genu of its horizontal 
segment, is required if the tumor has extended anterior to the 
artery. There could be areas where the tumor may extend into 
the adventitia of the artery, and subadventitial dissection may 
be required.
Subadventitial dissection
This technique is applied to tumors that infiltrate the adventitia 
without reaching the muscular layer (media) of the ICA. Subad-
ventitial dissection consists of separating the adventitia from the 
muscular layer. The wall of the ICA at the level of the vertical 
segment is 1.5-2.0 mm thick with the adventitia being approx-
imately 1 mm thick. The adventitia is absent in the horizontal 
portion. Therefore, subadventitial dissection can only be execut-
ed in the vertical portion.
The intraoperative risk of a vascular injury is especially high in 
irradiated or previously operated cases. Small lacerations to the 
arterial wall, or any avulsion of the carotic-tympanic branches, 
can often be controlled with judicious use of bipolar cautery. 
For small to medium defects, direct suture repair is recommend-
ed. Double-armed vascular sutures are used while temporary 
occlusion is applied. Taking care to evert the edges of the artery 
while suturing is important to avoid stenosis. The postoperative 
risks of subadventitial dissection include weakening of the ves-
sel leading to subsequent blowout or to dilatation and delayed 
aneurysm formation.
Dissection and resection following permanent  
balloon occlusion
Following balloon occlusion of the artery, dissection is started 
in its cervical tract directed upwards. It is ligated immediately 
proximally to the proximal balloon using a large vascular clip, 
followed by en bloc resection of the artery with the surround-
ing tumor. Care must be taken to identify the distal segment of 
the occluded artery and transection must be performed here to 
avoid excessive traction on the cavernous sinus segment during 
final tumor removal. In rare cases with failed tumor emboliza-
tion due to tumor high flow blood supply, permanent balloon 
occlusion can be performed even in cases with stent insertion.
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Treatment
The optimal therapy should offer the best chance of survival 
and involves radical surgery plus adjuvant radiotherapy. The 
more extensively the tumor is removed, the better the prognosis. 
Completeness of resection is considered the most important 
prognostic factor  11, but there is the problem of preserving 
function which feasibility depends on the subsites affected by 
the tumor and the intrinsic morbidity of the surgical approach. 
The cranial nerves may be damaged both by the disease and by 
the surgical approach: cranial nerve VI, when the disease is in 
the petrous apex or crossed by the surgical corridor; the lower 
cranial nerves from IX to XII, when the tumor extends infero-
laterally in the jugular foramen, lower clivus and condyle, or 
when surgery requires extensive drilling in the medial aspect 
of the jugular foramen. The nerves in the cavernous sinus may 
be affected by the disease, but rarely by the surgical procedure 
because chordoma in the cavernous sinus is unlikely to be 
referred for surgery. When a pure lateral approach is chosen, 
generally combined with the anterior surgical route, it may 
run across cranial nerves  VII and VIII and whether they are 
sacrificed or preserved depends on the extent of the tumor and 
the boundaries of an oncologically safe resection. The nerve VII 
may be transposed if a wider exposure is required in the jugular 
foramen or along the intrapetrous vertical carotid artery.
Surgery involves anterior approaches to the median-central skull 
base (which nowadays are mainly performed endoscopically), 
combined with lateral approaches to remove the lateral, infero-
lateral or supero-lateral extensions of the tumor. The goal 
of surgery should be the removal of all macroscopic tumor, 
since it is generally agreed that this is the most important 
factor influencing survival. Adjuvant radiation is the rule after 
surgery, even in cases where no macroscopic residual tumor is 
evident 5 11 12 14 15.
There has been debate in the recent literature concerning the 
need for extensive surgery and the related degree of morbidity, 
which differs for each approach. The clivus region is reached by 
anterior surgical corridors, using a microscopic or endoscopic 
transnasal approach 15-23. The endoscopic transnasal route was 
recently developed with a view to reducing the morbidity vis-
à-vis the more extensive transfacial or combined transcranial 
approaches. It often led to less complete resections, however, 
when exclusively endoscopic transnasal procedures were used. 
Whether this negatively affected prognosis is still being debated. 
Combined approaches to the clivus involve transcranial routes 
and lateral approaches, all of them may be performed to reach 
the different areas of the upper-, mid-, lower clivus and the 
surrounding sites. The extradural corridors may be used to 
resect also intradural localizations. 
After the completion of anterior approaches, the more frequent 
lateral extensions of the tumour are in the petroclival area, the 
rhinopharynx up to the petrous apex, the jugular foramen, the 
foramen magnum, with or without the transdural component in 
the cerebello pontine angle, the prepontine cystern.
ing evaluation of the extent of ICA invasion by the tumor and 
appropriate perioperative management. Decompression of the 
ICA and subperiosteal dissection are relatively simple surgical 
procedures that can be used in cases where the adventitia of the 
ICA is free of involvement. Preoperative endovascular interven-
tion in the form of intra-arterial stents in the cervical and petrous 
segments of the ICA has transformed the therapeutic manage-
ment in cases of advanced TJPs. Stenting of the ICA avoids 
the need for potentially troublesome maneuvers like PBO, 
bypass procedures, and arterial repair or reconstruction. PBO 
is currently limited to those patients in which stent placement 
is technically impossible or in patients with tumors that derive 
significant blood supply from the ICA. No major perioperative 
complications, related either to preoperative stenting or intraop-
erative surgical management of the ICA, have been reported to 
date in our series of patients.
4.3. Other lesions
4.3.1 Chordoma and chondrosarcoma
E. Zanoletti, R. Colangeli, S. Munari, A. Mazzoni
Chordoma 
Introduction
Chordomas are malignant lesions with a locally aggressive 
behavior that grow in the central skull base with a median 
localization. Patients’ mean age at presentation is 60  years, 
though some cases have been reported in younger people and 
even in the pediatric population 1-3.
These lesions arise from the remnants of undifferentiated 
notochord tissue  4. Skull base chordomas account for only 
0.1% to 0.2% of all intracranial tumors 5. The growth pattern 
differs, depending on the tissue where the tumor is located: 
it is expansive with macroscopic growth in soft tissues and 
the intradural compartment, or infiltrative and destructive in 
bone. Although chordomas are considered histologically low-
grade malignancies 6, they carry a poor prognosis and tend to 
recur, even after extensive surgery and post-operative adjuvant 
radiation therapy. They are locally destructive with a variable 
pattern of invasion and a considerable metastatic potential: 
disease spreading to the lung (58-60%), liver (20-22%), bone 
(18%), soft tissue and lymph nodes has been reported in up 
to 65% of patients, especially among those with advanced 
disease  7-9. The reported overall survival rate is of 50-60% at 
5 years and 30-40% at 10 years 10-13, with a mean 50% rate of 
disease progression. Chordomas are diagnosed on contrast-
enhanced MRI and bone CT, with an intermediate-low signal on 
T1- and a high signal on T2-weighted images, and a moderate to 
high contrast enhancement. Bone CT is useful for ascertaining 
bone erosion due to the lytic nature of the lesion 14 15.
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follow-up (at six months at best), which is hardly informative 
for a slow-growing malignant disease. As well as being the 
most influential prognostic factor, assessing completeness of 
resection is important because there are differences between the 
concepts of residual disease, recurrence and progression. This is 
an issue that negatively influences the reliability of reports from 
an oncological perspective and, when an exclusive anterior 
endoscopic approach is suggested as the main treatment, it is 
evident how misleading the conclusions might be.
Conclusions
In our experience, combining anterior and lateral approaches 
enables an extensive, macroscopically complete resection 
with ample bone drilling in the clivus, but probably cannot 
manage microscopically invisible bone infiltration in the 
clivus and adjacent bone. Removal to this extent is mandatory 
to achieve good disease control in view of the adjuvant 
radiation, which is recommended to eradicate microscopic 
disease, in macroscopically free surgical fields. The intrinsic 
morbidity of a given approach should be neither disregarded 
nor exaggerated, since our knowledge of the range of 
approaches to the skull base allows us to strike the right 
balance between their various pros and cons. Each procedure 
should be considered from an oncological perspective. 
Aggressive treatment aiming for little or no residual disease 
should be achieved at the first resection. Planning to leave 
residual tumor in areas that are critical when using the 
anterior approach is acceptable, when the removal can be 
completed with a combined or staged transcranial/lateral 
procedure. Staging the approaches may also allow for a more 
efficient and safer removal of the intradural component, to 
prevent CSF leak. The intradural tumor is not an inoperable 
site in principle, but neither is it susceptible to radiation 
because of the risks to the nervous tissues and resection 
should be preferred.
Chondrosarcoma
Introduction
Chondrosarcomas are rare cartilaginous tumors. Only 1% 
of chondrosarcomas occur in the skull base  28, typically 
arising from skull base synchondroses, such as the petroclival 
(66%), petro-occipital, spheno-occipital, and sphenopetrosal 
synchondroses  29-31. Chondrosarcomas tend to develop at 
the end of the fourth decade of life, with a slight female 
predominance. Most of these tumors are sporadic, though 
they have been associated with diseases of endochondroma 
formation including Ollier disease and Maffucci syndrome 32. 
Chondrosarcoma manifests as a destructive, mineralized 
mass that invades bone and extends into soft tissues. Lesions 
typically show an infiltrative pattern, replacing normal marrow 
elements and spreading through the Haversian canals  29  33. 
Histologically, they can be of the conventional, mesenchymal, 
clear-cell, or dedifferentiated type. Almost all skull base 
Staging or combining the approaches involves:
• the infratemporal C for the rhinopharynx, para-clival and 
para-sphenoid area;
• the infratemporal B (or C + B) for the petroclival area;
• the infratemporal A to the jugular foramen and the Petro-
occipital trans-sigmoid approach (POTS) to resect a limited 
tumour in the jugular foramen, or as an extradural corridor 
to remove intradural lesions in the lower aspect of the 
cerebello pontine angle 24-27;
• the far-lateral approach to the foramen magnum.
A sub-temporal approach with temporal craniotomy may be 
combined with the mentioned approaches to resect tumour 
extensions in the middle cranial fossa. A comprehensive surgery 
may thus involve one or more surgeries after the anterior 
approach, combined or staged, to accomplish a bony resection 
as much complete as possible.
Open issues
Some aspects that influence prognosis need to be borne in 
mind when planning surgery for chordoma, moving from our 
knowledge of the disease’s aggressiveness and the need for 
its radical removal. Whatever the chosen surgical approach, 
it should allow the resection of tumor in the soft tissues and 
extensive drilling in the bone, as bony margins are difficult to 
assess for infiltration. Staged surgery is a viable option when 
using combined approaches, such as extensive extradural 
surgery followed by the removal of intradural tumor, with a 
view to preventing the risk of CSF leak.
Reports on the outcome of surgery for chordoma are not easy 
to compare because data are heterogeneous, and numerous 
aspects thus remain unclear. Outcome data should distinguish 
between primary and recurrent cases and specify the number 
of surgical procedures performed for each patient, the surgical 
approaches used, the percentage of intradural invasion, the 
adjuvant radiotherapy administered, the rate of recurrence or 
residual disease, the overall and disease-free survival rates at 5 
and 10 years calculated according to the Kaplan-Meier method 
the length of follow-up. 
The most appropriate extent of surgical resection is also a matter 
of debate: different ways are used to define it, meaning different 
degrees of residual disease. It has to be distinguished from 
disease recurrence and progression. The most often used, but 
somewhat imprecise, classifications of the extent of resection 
refer to: gross total resections (no visible, or small questionable 
tumor remnants); subtotal resections (more than 90% of the 
tumor removed); and partial resections (less than 90% of the 
tumor removed and biopsies). 
Although there is agreement on the need to report the above-
mentioned details, the literature often lacks such relevant 
outcome data. Overall and disease-free survival rates are scarcely 
reported and, when available, they should be correlated with 
the length of follow-up and the completeness of resection. The 
majority of authors reported only on their patients’ short-term 
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morbidity of surgery thus becomes particularly important. 
When the localization and extent of the disease allow for 
a conservative approach, this is to be preferred for low-
grade disease, whereas high-grade tumors warrant extensive 
removal of bone surrounding the tumor, a necessity that 
generally makes attempting conservative surgery unfeasible.
Treatment
Since the site of involvement is the mid-lower clivus laterally 
extending to the jugular foramen, the petro-occipito-trans-
sigmoid (POTS) surgical approach is judged to be more 
conservative than other lateral approaches to these areas (the 
infratemporal approaches A and B) 42. The POTS approach 43-45 
leaves the facial nerve in place and preserves the middle ear, 
while affording direct access to the jugular foramen and adjacent 
areas, also providing a surgical corridor to the petro-clival 
junction, the neck, and the intradural extension of the tumor into 
the posterior fossa. The tumor’s degree of differentiation (G1, 
G2, G3) strongly influences the management strategies and 
prognosis: this enhances the need for extensive removal plus 
adjuvant radiation therapy, whereas low-grade tumors may be 
cured with radical surgery alone. Endoscopic tumor resection 
may be a valid alternative, but it affords a more limited access, 
and may be oncologically questionable if the approach cannot 
assure a safe, complete resection of the tumor when otherwise 
feasible with other approaches.
Open issues
There is no general consensus on the role of radiotherapy in 
chondrosarcoma of the skull base, though it is increasingly 
used for palliative purposes, or as an adjuvant therapy 
in the case of residual disease  46-48. It has generally been 
considered pointless for low-grade chondrosarcoma, but 
strongly recommended  49 for high-grade tumors. Instead 
of conventional radiotherapy, proton beam therapy has 
reportedly been used with promising results in this setting 50. 
That said, an inadequate follow-up and the pooling of results 
for chordoma and chondrosarcoma (without distinguishing 
between low-, medium-, and high-grade chondrosarcoma, 
or between total, gross total, and partial resections) make 
these results unreliable for the purposes of judging the 
efficacy of proton beam therapy, especially for low-grade 
chondrosarcoma. 
Since partial removal is now accepted as a way to strike a 
balance between the goals of achieving a cure and limiting 
the morbidity of treatment, the significance of partial, 
subtotal, and gross total removal is still being debated. It is 
not clear where surgery should stop, and how small a residual 
should be for it to be considered curable with postoperative 
radiotherapy. Low-grade tumors are locally aggressive, 
but slow-growing and rather radioresistant, making the 
combination of partial surgery plus radiotherapy highly 
questionable 29 51. 
Endoscopic approaches to chondrosarcoma of the petrous 
chondrosarcomas are of the conventional type, while the 
mesenchymal type is only occasionally reported (<10%) 34.
Chordoma and chondrosarcoma were historically grouped 
together because they share similar clinical, radiological and 
pathological features, and they were managed surgically in 
the same way 35-39, but this can be misleading. Both lesions 
are rare, accounting for less than 1% of intracranial lesions, 
and both pose a challenge for their effective treatment due to 
their proximity to the cranial nerves, the brainstem and the 
skull base vessels, but these are probably the only aspects 
they have in common.
Despite being localized in the same area (the mid-central skull 
base), in small lesions it is clear that chordoma originates 
from the midline, and chondrosarcoma from a paramedian 
or more lateral site. They also differ in histopathology and 
prognosis, and their surgical treatment should differ too.
The diagnosis of chondrosarcoma is radiological. Biopsy 
would be useful to differentiate between more and less 
malignant lesions, but it is scarcely feasible when the lesion 
is located in the central or paramedian skull base. Moreover, 
when there are clearly different clusters of differentiation 
in the same lesion, the findings on any biopsy risk being 
inconclusive. Chondrosarcoma shares some radiological 
features with chordoma: they are both lytic mass that 
destroy bone, with similar T1W and T2W characteristics 
on MRI (intermediate-to-low T1-weighted signal intensity, 
classically high T2-weighted signal intensity, heterogeneous 
enhancement after gadolinium), but chordoma is a midline 
clival lesion while chondrosarcoma arises mainly along the 
lateral margin of the clivus in the petro-occipital fissure, 
not in the midline clivus. In addition, chondrosarcoma may 
show characteristic chondroid calcification within the tumor 
matrix in about 50% of cases 40.
Yeom et al. retrospectively analyzed conventional and 
diffusion-weighted MRI findings in 19  patients with 
histologically-confirmed chordomas and chondrosarcomas: 
the conventional imaging features were similar for the 
two tumors, but poorly-differentiated chordomas revealed 
a significantly lower T2-weighted signal intensity. 
Diffusion-weighted imaging seems a very promising 
method for distinguishing between these tumors because 
chondrosarcomas were found associated with a higher 
ADC (apparent diffusion coefficient) than classic or poorly-
differentiated chordomas 41.
Pathology shows different degrees of aggressiveness, 
pointing to different treatment options: a surgical resection 
appropriate for a low-grade chondrosarcoma cannot be 
applied as is to a high-grade lesion.
Low-grade chondrosarcoma is known to be scarcely 
radiosensitive and, especially in younger patients, any 
treatment that falls short of curing the disease would 
mean having to manage residual disease in years to come. 
Balancing the goal of complete resection against the 
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temporal bone and for years it was often misinterpreted as 
paraganglioma, metastatic renal cell carcinoma, choroid 
plexus papilloma, ceruminous gland adenocarcinoma, or 
aggressive papillary tumor. The first case of ELST was 
described in 1984 by Hassard et al. during sac decompression 
surgery for hydrops  1; in 1989, Heffner reviewed 20 cases 
and established that papillary tumor of the temporal 
bone originated from the endolymphatic sac epithelium, 
referring to it as a “low-grade adenocarcinoma” 2. The term 
“endolymphatic sac tumor” was first used by Li et al. in 1993 
and afterwards recognized by World Health Organization 
tumor classification 3.
ELSTs may be sporadic or associated with von Hippel–
Lindau (VHL) disease, a genetic disorder inherited as an 
autosomal dominant trait with a variable expression and 
caused by inactivation of the VHL tumor suppressor gene on 
the short arm of chromosome 3. Patients with VHL disease 
could present ELST from 3% to 24% of cases and they are 
also more likely to have bilateral ELST  4. VHL disease 
predisposes patients to multiple tumors and cysts in many 
organs that most frequently appear during young adulthood, 
such as hemangioblastomas in the central nervous system, 
clear cell renal carcinoma, pheochromocytoma, ELST, 
retinal angioma and pancreatic cystadenoma 5.
Common symptoms caused by ELST are sensorineural 
hearing loss, tinnitus, vertigo, dizziness, aural fullness, 
balance disturbances, ear pain, and facial nerve palsy. 
Hearing loss is the most frequent symptom and may be 
sudden or progressive, tending to develop at an early 
stage and is almost always irreversible. According to some 
studies, the development of a progressive hearing loss 
seems to correlate to a characteristic audiological pattern: 
in fact it has been suggested that a low-frequencies hearing 
loss is associated with small ELST while larger tumor are 
associated with profound sensorineural hearing loss that 
affect all frequencies  6. The audiovestibular morbidity in 
ELST is caused by various pathophysiological mechanisms: 
direct invasion of the otic capsule and inner ear apparatus, 
intralabyrinthine hemorrhage, and endolymphatic hydrops 5.
However, ELST can also occur with normal hearing 
and remains relatively asymptomatic until significant 
surrounding tissue destruction has occurred. Late-onset 
symptoms are relating to tumor growth and invasion, 
toward cerebellopontine angle, medial cranial fossa, jugular 
foramen, fallopian canal, petrous apex or cavernous and 
sphenoid sinuses; the severity of the related functional 
impairment depends on the sites and subsites affected by the 
tumor’s extension. Regional or distant metastases are very 
uncommon but a few metastatic cases in the spinal canal 
have been reported 7.
Neuroimaging is the gold standard in ELST diagnosis, 
including contrast-enhanced high-resolution magnetic 
resonance imaging (MRI) of the inner ear and computed 
apex have also been proposed, but some concern has been 
voiced over the safety and efficacy of this procedure. The 
boundaries of resection cannot always run along free 
margins, and, in principle, a gross total removal is already 
considered a success in this setting 52. 
The reported 10-year survival rates for chondrosarcoma are 
83%, 64%, and 29% for grades 1, 2 and 3, respectively (i.e. 
low-, medium-, and high-grade tumors, or well-, moderately-, 
and undifferentiated CS). A 10-year follow-up is considered 
essential to assess real disease control and obtain reliable 
survival rates because a 5-year follow-up may not always 
accurately reflect whether or not a patient is tumor-free 51. 
Conclusions 
Since low-grade chondrosarcoma grows slowly but 
continuously, an attempt to cure the disease, or at least 
control its progression, is mandatory. Surgical removal 
offers the best chance of cure, though radical surgery is often 
technically demanding, and associated with morbidities. It 
is important to strike the right balance between the goals of 
treatment and a patient’s quality of life, but the complexity 
of surgery involving the central skull base should not tip the 
balance in favor of alternative treatments of still dubious 
efficacy. 
The proposed new partial resections and adjuvant treatments 
must still face the test of time, since the meaningful follow-
up of low-grade tumors takes longer than in the case of high-
grade malignancies. When radical removal is feasible via an 
approach that carries a limited morbidity, the aim should be 
to cure the disease. Staged surgery is another viable option to 
cure extra- and intradural tumors.
Adjuvant therapies involving various forms of radiation are 
mandatory for high-grade tumors, hopefully not only as a 
complement to oncologically unsafe resections. In patients 
with a favorable prognosis, the disease can be cured with 
radical surgery alone, saving radiation therapy for the 
management of any late recurrences.
4.3.2. Endolymphatic sac tumours
G. Tealdo, L. Girasoli, D. Borsetto, E. Zanoletti
Endolymphatic sac tumor (ELST) is a rare malignancy 
occurring in the inner ear, on the posteromedial wall of the 
temporal bone originating from endolymphatic epithelium 
within intraosseous portion of duct or sac. ELST is a slow-
growing low-grade malignancy with local aggressiveness 
(invasive growth pattern with infiltration of the petrous bone, 
destruction of the labyrinth and dura involvement) but low 
risk of distant metastases.
ELST is a highly vascularized tumor and is histopathologically 
characterized by papillary and glandular architecture; it was 
historically classified as primary adenomatous tumor of the 
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endolymphatic sac is crucial. Surgical treatment of extensive 
ELST requires the use of different lateral skull base 
approaches chosen according to tumor localization, tumor 
size, and invasion pathways 4:
• translabyrinthine approach, for extension through 
labyrinth and/or intradurally in the posterior fossa;
• lateral or subtotal petrosectomy, for involvement of the 
middle ear;
• trans-sigmoid petro-occipital approach (POTS), for 
extension to the jugular foramen but preservation of the 
middle ear 9;
• type A infratemporal approach, for involvement of the 
jugular foramen along the intrapetrous vertical carotid 
artery;
• transmastoid-transpetrous approach combined with 
a subtemporal/middle cranial fossa approach, for 
involvement of petrous apex or middle cranial fossa.
Before attempting a complete removal of an extensive ELST, 
surgeon should consider the intrinsic morbidity of each 
planned approach, the existing preoperative morbidity, the 
probability of complete tumor resection, the expected short-
term and long-term prognosis and the life expectancy of the 
patient 4.
Rehabilitation with cochlear implant may be proposed 
in all the cases where it has been surgically preserved the 
otic capsule and the cochleovestibular nerve, although the 
surgical trauma associated with tumor’s removal may prevent 
the proper functioning of cochlea. When ELST is bilateral 
(about in 30% of VHL patients) the cochlear implantation is 
the best solution that can be offered to the patient 4.
The role of radiotherapy (stereotactic or fractionated) is still 
unclear and has been restricted by the limited available data. 
Radiotherapy should be considered in tumor recurrence, 
unresectable tumor, residual disease after subtotal resection, 
or in poor surgical candidates; in these cases, salvage 
radiotherapy might have a positive impact in terms of tumor 
control/tumor progression-free survival 10.
Late recurrences are not so rare, therefore long follow-up is 
necessary to assess efficacy of treatment.
4.3.3. Posterior fossa meningiomas:  
the neuro-otologist perspective
G. Danesi, R. Bivona, V.C. Iglesias, D. Lepera, R. Pareschi
Introduction
Posterior fossa meningiomas (PFM) are a surgical 
challenge with high morbidity and potential mortality 
due to the surrounding vital structures, the encasement of 
nerves and vessels, the common large size at diagnosis, 
and their potentially invasive behavior. The natural 
history of these lesions suggests progressive growth with 
gradual neurological deterioration until death  1  2. Even if 
tomography (CT) of the temporal bone with thin-slice-bone 
algorithm. Specific radiological findings in MRI include 
hyperintense focal signals on T1-weighted unenhanced 
scan (due to hypervascularity), a markedly heterogeneous 
enhancement after gadolinium, and a heterogeneous signal 
on T2-weighted sequences. CT scan often demonstrates 
a focal erosion of the retrocochlear posteromedial border 
of the petrous temporal bone, with intratumoral spiculated 
calcifications 4. Arteriography can provide further information 
on the involvement of intracranial vessels and may be useful 
in extensive tumors in order to plan a safe surgical procedure.
Despite the fact that the slow growth of this tumor makes it 
difficult to diagnose early on, in recent years there has been 
an increase in number of reported ELST cases, that could be 
attributed to improvements in imaging methods and screening 
of VHL patients. The international recommendations on 
screening for ELST in VHL patients vary widely, although 
there is a common agreement on the importance of periodical 
neuroimaging (contrast-enhanced MRI and/or bone CT 
scan). The role of tonal audiometry to screen VHL patients 
for early diagnosis of ELST is still controversial; according to 
Lonser et al. 8, audiometric examination is useful to integrate 
radiological data and to show the concomitant presence (or 
progression) of hearing loss.
Early and complete tumor resection is widely regarded as the 
treatment of choice in all cases of ELST. Total resection with 
adequate bone removal around the area of macroscopically 
evident tumor often leads to long disease-free intervals, while 
subtotal surgery involves persistence of the disease with a 
high risk of progression. Early treatment is crucial to prevent 
tumor recurrence in critical sites, where surgery would 
involve higher morbidity. VHL patients, who often suffer 
from blindness and impaired balance due to concomitant 
retinal and cerebellar hemangioblastomas, should be 
cured before other neurological impairment establishes as 
consequence of the ELST or of its late surgical removal. 
The “wait and see” strategy may be a temporary solution in 
VHL patients to enable the treatment of other concomitant 
tumors 4 but carries the risk of delayed major surgery with 
increased morbidity.
Small ELST, when early diagnosis is followed by early 
surgery, is often related to hearing loss, without further 
surgical morbidity. This principle can be considered valid 
both with and without preoperative serviceable hearing, since 
it is difficult to ensure the removal of a small tumor within 
the endolymphatic sac and vestibular aqueduct without 
hearing loss or impairment. There are reports in the literature 
of small tumors being removed in which hearing was spared. 
For small ELSTs either a transmastoid-retrolabyrinthine 
approach or a retrosigmoid approach can be proposed, with 
preservation of inner ear structures and VII-VIII cranial 
nerves 6.
Drilling of the petrous bone at the entrance of the 
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patient factors, such as age, general health, preoperative 
cranial nerve dysfunction, and preoperative hearing. 
Common finding is that the retrosigmoid approach is perhaps 
one of the most commonly used surgical approaches for 
removing skull base meningiomas  3. Considerations must 
be given to tumor invasion of the cavernous sinus and IAC, 
to their tentorial attachments, and their anterior expansion 
towards the jugular foramen. Retrosigmoid approach in 
such cases leads to residual tumor that is usually managed 
with radiosurgery. Since radiosurgery does not guarantee 
the prevention of the recurrence of tumors, complete 
surgical resection is still the main strategy. Transpetrous 
approaches requires a dedicated long-lasting training and a 
deep knowledge of the complex anatomy of the PB but have 
important advantages when compared to the retrosigmoid 
(RS) approaches:
1. The wide surgical field, a shorter working distance 
between the craniectomy and the tumor, and a better 
orientation toward the lateral and ventral brain stem, 
limiting the brain retraction.
2. The early resection of the osteo-dural insertion of the 
meningioma, with coagulation of the tumor’s feeding 
vessels.
3. The early identification and control of the facial nerve 
before any dissection or removal of the tumor, and an 
increased protection of the anatomical and functional 
integrity of the facial nerve (except for the TCA).
For retromeatal meningiomas the surgical approaches were: 
RS, translabyrinthine (TLab), petroccipital-transigmoid 
(POTS) and retrolabyrinthine-subtemporal (RLabST).
• The RS approach was indicated in all cases with a normal 
or socially useful preoperative hearing (Class A or B of 
Tokyo Classification)  4. The size and the intrameatal 
extension of the tumor did not influence the choice of 
this approach. A standard lateral RS approach with the 
patient in park-bench position was used in this group. The 
RS approach is a versatile type of craniotomy extending 
from the sigmoid and the transverse sinus to the occipital 
squama. Opening of the dura and retraction of cerebellum 
gives a wide access to the CPA after an early drainage 
of the cerebellomedullary cistern. Retrolabyrinthine 
meatotomy allows exposure of the IAC for the removal of 
total resection remains the gold standard for patients, the 
complete removal within the restrictions of acceptable 
morbidity is not always achievable.
Classification
Between 1996 and 2017 we treated 90 PFM in our two 
tertiary skull-base centers (Legnano and Bergamo - Italy). 
They were classified as retromeatal, perimeatal and 
premeatal, according to the relationship between the main 
dural attachment and the IAC. 
Retromeatal meningiomas (posterior petrous bone (PB) 
meningiomas) originate from the dura of the posterior PB, 
between the posterior wall of the IAC and the groove of 
the sigmoid sinus. They occupy the posterior part of the 
cerebellar-pontine angle (PCA), usually dislocating antero-
superiorly the acoustic-facial bundle. We diagnosed 21 cases 
of retromeatal meningiomas; 18  patients presented an 
inframeatal extension encroaching the jugular foramen. In 
2 cases the tumor extended extracranially into the neck and 
in 18 cases the dural attachment involved the tentorium with 
a transtentorial extension.
Perimeatal meningiomas arise from the dura in the contest 
of IAC and the dislocation of the nerves is unpredictable. We 
reported 19 perimeatal meningiomas.
Premeatal meningiomas (anterior PB meningiomas) arise 
from the dura around the porus trigeminalis (petrous apex 
(PA) meningiomas) or from the dura of the petroclival (PC) 
junction or directly from the clivus (PC meningiomas). They 
occupy the anterior part of the CPA and dislocate postero-
inferiorly the acoustic-facial bundle, immediately behind the 
dura of the posterior PB. Premeatal meningiomas are more 
difficult to remove because the cranial nerves are located 
between the surgeon and the tumor. We reported 50  cases 
of retromeatal meningiomas. Fifteen meningiomas of this 
group presented a tentorial or a transtentorial extension, with 
the invasion of the Meckel cave in 11 cases. In 9 cases, the 
invasion of the cavernous sinus, upper clivus and middle 
cranial fossa was evident. 
Symptoms
Trigeminal symptoms (disaestesia and neuralgia) and 
abducent nerve palsy were more frequent in the premeatal 
group. Hearing and vestibular symptoms predominantly 
occurred in association with retromeatal and perimeatal 
tumors. Others symptoms like headache, cerebellar signs 
had similar distribution between premeatal and retromeatal 
groups. 
Surgical approaches
The selection of surgical approaches (Table  4.3.3.I) were 
tailored according to the location and the extension of the 
tumor, growth direction, form and size, the main symptoms 
related to the invaded vital structures and on the basis of 
Table 4.3.3.I. Selection of surgical approach according to the location and 
the extension of the tumor.
Retromeatal Premeatal Perimeatal
RS 9 TLabTAp 20 TLab 19
TLab 7 TC 18
POTS 3 TLab+FAR 
LATERAL
1
RLabST 2 Combined 
petrosal 
11
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performed were mainly the translabyrinthine/transapical 
approach (TLabTAp) and the transcochlear approach (TC), 
only one case initially treated with a TLab surgery then 
requested a far lateral approach, in 11  cases combined 
petrosal approaches were performed. 
• The TLabTAp is an anterior extension of the TLAb in 
which the internal auditory canal is exposed 360° around 
its circumference. The cornerstone of this approach is 
the postero-inferior transposition of the acoustic-facial 
bundle in continuity with the intracisternal tract that, for 
premeatal meningiomas, is usually located in the interface 
between the posterior PB dura and tumor. This maneuver 
respects the functional integrity of the facial nerve (if it 
is not infiltrated by the tumor) allowing for the complete 
drilling out of the bone and the exposure of the dura 
around the porus trigeminalis (PA). The postero-inferior 
dislocation of the acoustic-facial bundle opens a corridor 
to the anterior CPA through which the removal of large PA 
and PC meningiomas is possible. The limit of this access 
is the midline extension of the tumor. An extention beyond 
this line should be treated by a TC approach. 
• The TC represents the widest available access to 
the posterior fossa. It allows for the exposure of the 
omolateral CPA, prepontine area and contralateral CPA. 
This approach is indicated for giant PA, PC or clival 
meningiomas extending beyond the mid-line, between 
the clivus and the pons. Compared with the TLabTAp, TC 
approach presents some additional surgical steps: 1) the 
removal of outer ear canal and tympanic cavity with 
closure of the external ear canal; 2)  total petrosectomy 
extended to the middle and lower clivus located medially 
to the cochlea and the vertical tract of the petrous 
internal carotid artery (ICA); and 3) the postero-inferior 
transposition of the intratemporal facial nerve along with 
its intrameatal tract. This maneuver does not allow the 
functional integrity of the facial nerve. After surgery, a 
grade III facial palsy (according to the House Brackmann 
Classification) 7 is the best result that can be obtained and 
this is the most important draw-back of this approach. 
• Combined petrosal approaches actually describe numerous 
surgical approaches to the petroclival area well suited for 
these tumors. The transtentorial step was necessary in 
ten of them where the dura of the middle fossa above the 
superior aspect of the petrosal bone and the tentorium over 
the trigeminal nerve are resected. Indications to the trans-
tentorial approach are: lesion extending from the PF to the 
midbrain, lesions extending from the middle fossa to the 
PF and lesions arising from the tentorium.
Tumor resection 
It is clear that a complete resection is important, as the extent 
of resection influences the rate of recurrence, which in turn 
influences the prognosis. However, deliberate residuals must 
the intrameatal extension of the tumor with a high rate of 
hearing preservation. 
• The TLab approach is indicated in all cases with a 
significant deterioration of the hearing (Class  C, D or 
E of Tokio classification)  4 or in elderly patients with 
huge symptomatic tumors. The access of this approach 
is the mastoid and the target is the IAC and CPA. After 
a wide conservative mastoidectomy is performed, the 
occipital pre- and retrosigmoid dura along with the dura 
of the temporal lobe are exposed thus allowing for the 
retraction of sigmoid sinus with a significant widening 
of the surgical field. The posterior wall of the external 
auditory canal, the tympanic cavity, the cochlea and the 
facial nerve are left in place. The posterior labyrinth 
is completely drilled out together with the bone that is 
lateral, superior and inferior to the IAC. The canalicular 
dura is completely uncovered until the fundus and the 
facial nerve entering in the fallopian canal is evident. 
Once the approach is performed, the jugular bulb is the 
inferior limit and the temporal dura with the superior 
petrous sinus are the superior limits. The presigmoid dura 
is transected and the CPA is widely exposed.
• The POTS approach has been developed for removing 
tumors located in the jugular foramen together with 
their local extension into the adjacent parts of the skull 
base, the CPA, and the parapharyngeal space (PPS). 
POTS approach involves a posterolateral exposure and 
an anteromedially directed surgical axis which allows the 
surgeon to leave the external and middle ear complex, 
together with the facial nerve, entirely undisturbed. 
Single-stage removal of intra- and extradural lesions 
extending from the CPA to the PPS can be achieved 
with minimal risk of cerebrospinal fluid (CSF) leak. 
In essence, the POTS approach is the combination of 
a retrolabyrinthine petrosectomy and retrosigmoid 
craniotomy. The external ear canal, tympanic cavity, and 
facial nerve are left in situ 5.
• The RLabST is one of the most limited of the 
transpetrosal approaches of the posterior fossa. After 
a wide conservative mastoidectomy is performed the 
sigmoid sinus is skeletonized inferiorly through the 
infralabyrinthine air cells to the jugular bulb. Complete 
skeletonization of the facial nerve is unnecessary. All 
three semicircular canals are therefore skeletonized but 
preserved. Removal of the bone plates on the middle 
and posterior fossa dura mater and the sigmoid sinus 
completes the extradural part of the retrolabyrinthine 
approach. This approach provides exposure of the CPA 
but does not give the surgeon adequate visualization of 
the anterior brainstem or petroclival region 6. 
For perimeatal meningiomas, the TLab surgical approach 
was performed.
For premeatal meningiomas, the surgical approaches 
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Grade 1-2 was achieved in 69% of our patients. Choosing a 
different approach for the 3 categories led us to achieve a low 
rate of morbidity, particularly in retromeatal and perimeatal 
groups. 90% of patients in these groups lacked complications. 
Retromeatal tumors represented the more accessible tumors 
in our series. A postoperative HB Grade 1-2 was achieved in 
all cases except in one TLab approach (Table 4.3.3.IV). 
Premeatal tumors are the most critical due to their anatomical 
correlations, with facial nerve function affected in half of 
the patients. However, despite of the high surgical risks in 
treating these tumors, we eventually achieved a 24% lack of 
complications. 
Hearing function interestingly is not as deeply considered 
as facial nerve function in the literature. Transcochlear and 
translabyrinthine approaches require a sacrifice of hearing but 
often the decision to proceed with these approaches is made 
because of large tumor extension involving the IAC, petrous 
ridge, clivus, or cavernous sinus, or because of brainstem 
compression or basilar artery involvement. Moreover, as 
previously shown, these approaches let us achieve a very high 
rate of GTR accounting about 73% for TC and TLab approach 
themselves. In retromeatal meningiomas, a postoperative 
Class  A-B (Tokyo classification) was obtained in 12 out of 
14 patients (85.7%). In premeatal and perimeatal meningiomas 
hearing preservation was attempted only in 11  patients 
with small or middle size premeatal meningiomas, with the 
largest diameter of maximum 2.5 cm. This goal was achieved 
managing the tumor by a combined petrosal approach. 
Additionally, we reported 9/90 (10%) cases of IV, V and 
VI c.n. palsy, and 4/90 (4.4%) cases of lower cranial nerves 
palsy (Table 4.3.3.V). In 1 case we reported an ab-ingestis 
pneumonia and no cases of perioperative death, cerebrospinal 
fluid leakage or meningitis occurred.
Conclusions
Total resection is the only way to cure patients affected by 
PFM. GTR is the aim of surgery as the extent of resection 
influences the rate of recurrence, which in turn influences 
the prognosis. We aimed to show how different surgical 
approaches might help to reach GTR and low morbidity, 
be taken into account, and pieces of tumor are deliberately 
left in situ when pia mater, jugular foramen, cavernous sinus 
and Gasser ganglion are infiltrated. The extent of tumor 
resection was defined by the intraoperative findings using 
the Simpson Classification  8. The Simpson Grade  1 and 2 
corresponded to a gross total resection (GTR). Simpson 
Grade 3, 4 or 5 are related to a non-total resection (near total 
or partial resection). 
GTR was achieved in 69/90 patients, 77%. In retromeatal 
meningiomas, a total resection was obtained in 20/21 cases 
(95%). In perimeatal meningiomas GTR was obtained in all 
cases. In premeatal meningiomas, GTR was 76%, reflecting 
their difficult surgical treatment. A Grade  3 (near total 
resection) was evident in 4/90 patients (4%), and Grade 4-5 
(partial resection) in 9/90  patients (10%) (Table  4.3.3.II; 
Fig. 4.3.3.1). The main tumor residual was represented by the 
transtentorial extension (20%) and the involvement of jugular 
foramen (8.8%), the gasser ganglion and the cavernous sinus 
(1% respectively). Moreover, the consistency, bleeding and 
adherence of the tumor to the brain stem and to vessels 
prevented their total removal, permitting only brain-stem 
decompression.
The GTR according to the surgical approach is reported in 
Table 4.3.3.III. 
Morbidity 
Many surgery-related morbidities worry both patients and 
surgeons. Thanks to the different surgical approaches, a HB 
Table 4.3.3.II. Extent of tumor resection.
Description Retromeatal Premeatal Perimeatal
Simpson 
Grade 1-2
GTR 
(p < 0.001)
20/21 
(95.2%)
38/50 
(76%)
19/19 
(100%)
Simpson 
Grade 3
NTR 0/21 
(0%)
4/50 
(8%)
0/19 
(0%)
Simpson
Grade 4-5
PTR 1/21 
(4.7%)
8/50 
(16%)
0/19 
(0%)
Fig. 4.3.3.1. Rate of GTR, NTR, partial resection. 
Table 4.3.3.III. GTR according to the surgical approach 6.
GTR according to the approach
TLabTAp 18/20 (90%)
TC 13/18 (72.2%)
RS 9/9 (100%)
POTS 1/3 (33.3%)
TLab+FL 0/1 (0%)
TLab 19/26 (73%)
RLabST 2/2 (100%)
Combined petrosal 7/11 (63.6%)
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On the contrary, in the case of meningiomas which develop 
and grow more laterally, control and removal of the lesion is 
usually far more simple.
Sphenoid wing meningiomas
These tumors are traditionally divided into meningiomas of 
the medial, middle and lateral third of the lesser sphenoid 
wing. Medial third meningiomas, usually known as anterior 
clinoid meningiomas, can extend to the cavernous sinus and 
the orbit. Meningiomas of the middle and lateral thirds of 
the lesser sphenoid wing are the simplest to remove. These 
tumours grow mainly in the middle cranial fossa displacing 
the frontal and temporal lobes and involve the middle 
cerebral artery and its branches to a greater or lesser extent, 
depending on their size.
Pterional craniotomy is the most suitable approach. More 
complex approaches, such as fronto-orbital and, all the more 
so, fronto-orbital-zygomatic craniotomy, are not indicated as 
the tumor itself creates enough room to allow a good control 
of the lesion and of the neurovascular structures with no need 
to extend the craniotomy, if not to the sphenoid wing. This 
makes it possible to ‘transform’ a basal tumour into a convex 
meningioma, which is far easier to remove.
Their removal has a very low morbidity and mortality rate 1.
Although the resection of medial sphenoid wing 
meningiomas is more problematic, wider craniotomies are 
not really indicated. For these lesions, it is debated whether 
there is an advantage in unroofing the optic canal before 
tumour resection, in order to allow a safer manipulation of 
the optic nerve and to control any extension of the lesion 
into the canal itself. Visual alterations are, in fact, the main 
symptom of medial sphenoid wing meningiomas.
If the cavernous sinus is involved, current practice prefers to 
avoid removing this part of the lesion in favour of subsequent 
treatment with radiosurgery 2-4.
Given the involvement of the optic nerve as well as of the 
major branches and, above all, of the smaller branches of 
the internal carotid artery, the outcome of the resection 
of these meningiomas is associated with a higher rate of 
complications and incomplete removal 3-6.
Petrous bone meningiomas
Petrous bone meningiomas arise from the posterior surface 
of the petrous bone i.e. from its infratentorial aspect. Very 
unfrequently do these meningiomas extend to the middle 
fossa, on the supratentorial surface of the petrous bone, but, 
when they do, the lesion often grows simultaneously on both 
sides of the petrous bone (Fig. 4.3.4.1). 
Surgical resection of a tumour growth on the middle cranial 
fossa is not so difficult, given the absence of important 
vessels and cranial nerves. Nevertheless, it requires the 
elevation of the temporal lobe and manipulation of the basal 
temporal veins, including the vein of Labbé. The inferior 
especially on facial nerve function. In this study, we reviewed 
a large sample size of 90 patients with PFM. Though it is 
generally considered challenging to resect tumors at this 
location, different approaches bring satisfactory results with 
an excellent extension of resection, preservation of cranial 
nerves, and low complication rates in our two centers.
4.3.4. Lateral skull base meningiomas:  
the neurosurgeon’s perspective
F. Calbucci, I. Borghesi, A. Fioravanti, S. Bartolini, R. Draghi
Lateral skull base meningiomas involve middle and posterior 
cranial fossae. They develop mainly from the lesser sphenoid 
wing and from the petrous bone. Most medial forms of both 
these locations typically involve arteries and cranial nerves, and 
may even involve the cavernous sinus, making tumor removal 
particularly challenging and, in some cases, incomplete.
Table 4.3.3.V. Postoperative morbidity.
Retromeatal Premeatal Perimeatal
None 17/21 (80.9%) 12/50 (24%) 17/19 (89.4%)
CN’s IX-X-XI-XII 3/21 (14.2%) 1/50 (2%) 0/19 (0%)
CN’s IV-V-VI 0/21 (0%) 9/50 (18%) 0/19 (0%)
CN VII 1/21 (4.7%) 25/50 (50%) 2/19 (10.5%)
Trigeminal signs 0/21 (0%) 2/50 (4%) 0/19 (0%)
Cerebellar signs 0/21 (0%) 1/50 (2%) 0/19 (0%)
Table 4.3.3.IV. Postoperative facial nerve function.
HB in retromeatal TLab POTS RLabST RS
I-II HB 6/7 (85.7%)
(p < 0.001)
3/3 
(100%)
2/2 
(100%)
9/9
(100%)
III HB 1/7
(14.2%)
0/2 
(0%)
0/2
(0%)
0/9
(0%)
IV-V-VI HB 0/7 (0%) 0/2 
(0%)
0/2 
(0%)
0/9 
(0%)
HB in perimeatal TLab
I-II HB 17/19 (89.4%) 
(p < 0.001)
III HB 2/19 (10.5%)
IV-V-VI HB 0/19 (0%)
HB in Premeatal TLabTAp TC TLab
+ FL
Combined 
petrosal
I-II HB 16/20 (80%)
(p < 0.001)
0/18 
(0%)
0/1 
(0%)
9/11 
(81.8%)
III HB 2/20 
(10%)
15/18 
(83.3%)
0/1
(0%)
0/11
(0%)
IV-V-VI HB 2/20
(10%)
3/18 
(16.6%)
1/1 
(100%)
2/11 
(18.1%)
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(V, VII and VIII) or inferiorly (lower cranial nerves) and 
protected by a generally well-preserved arachnoid layer. 
In the majority of cases, cleavage from the cerebellum is 
simple. The main vessels are not significantly involved. 
The dural attachment can be removed.
• B – Meningiomas arising from the dura mater around 
the IAM. These tumours are surgically more challenging 
due to their extremely close proximity to cranial 
nerves and vessels. These lesions, in turn, are divided 
into meningiomas growing between the IAM and the 
tentorium (b1 subgroup) and those developing between 
the IAM and lacerum foramen (b2 subgroup).
 – b1 – Given the dural attachment and growth direction 
of the lesions, these meningiomas displace the VII 
and VIII nerves inferiorly, adhering to or encasing 
them. Similarly, the IV and V nerves are usually 
pushed forwards and upwards, to varying degrees.
The Superior Cerebellar Artery (SCA) and the Ante-
rior Inferior Cerebellar Artery (AICA) are frequently 
involved. Adhesions to the tentorium are not usually 
firm, while the removal of the dural attachment is not 
easy to achieve. Surgical outcomes are often associat-
ed with cranial nerve deficits. Vascular damage to ar-
teries as well as veins (in particular the petrous vein) 
may have severe consequences.
 – b2 – Removal of these meningiomas, growing 
between the IAM and lacerum foramen, is far more 
challenging as they involve the lower cranial nerves. 
The VII and the VIII cranial nerves are usually pushed 
upwards, but the lower cranial nerves can be encased 
by the tumor and their bundles variously separated 
and adherent to the lesion. The Posterior Inferior 
Cerebellar Artery (PICA) is often involved. Surgical 
removal in these cases is frequently partial or subtotal 
and associated with more severe neurological deficits.
• C – These are a group of small meningiomas which 
develop medially to the IAM. They are not called 
border of the posterior temporal craniotomy must be as 
near as possible to the middle fossa floor to minimize brain 
manipulation, as in subtemporal approaches to the internal 
acoustic meatus (although this is an extradural route) or to 
the clivus (Kawase’s approach).
Petrous bone meningiomas are generally considered to be 
the tumours arising from the posterior aspect of the petrous 
bone, once known as Cerebellopontine Angle Meningiomas. 
Currently, the latter term is no longer acceptable since these 
lesions are by no means a homogeneous group of tumours. 
Surgical difficulties and outcomes greatly depend on the 
site of origin of the meningioma. For this reason, several 
classifications have been proposed in the literature, taking 
this heterogeneity into account 7-9.
Our group has adopted a useful classification, taken in part 
from the literature but mostly from first-hand experience 
of more than 120  patients operated on, which divides 
meningiomas into four groups (Fig. 4.3.4.2).
• A – Meningiomas developing from the petrous bone, 
posterior to the Internal Acoustic Meatus (IAM). These 
lesions are often large, but technically do not present 
many surgical difficulties as the tumour is not in close 
relation to the cranial nerves, which are pushed forwards 
Fig. 4.3.4.1. Meningioma arising on both sides of the petrous bone (mid-
dle and posterior fossae). 
Fig. 4.3.4.2. The dural origin of the different groups of petrous bone 
meningiomas: A group, green; b1 subgroup, light blue; b2 subgroup, blue; 
C group, orange; D group, area included in the red line.
*: IAM; r: lacerum foramen.
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and frontotemporal approaches with tentorium incision and, 
more recently, endoscopic transnasal approaches 12 13.
To date, there is no general consensus as to the best approach 
or as to whether there is a single approach which can 
be suitable in all cases. After years of debate and an ever 
wider range of treated cases, it is now generally agreed that 
the simplest and technically least difficult approach with 
the lowest risk of approach-related complications is to be 
preferred, ensuring at the same time the easiest and safest 
tumour removal. 
It is also important to mention adjuvant treatment such as 
radiosurgery, which has proven to be effective in many cases 
in the event of remnants or tumour recurrence 14 15.
In conclusion, we may suggest this algorithm for the 
treatment of petroclival meningiomas 16.
In meningiomas limited to the posterior cranial fossa which 
extend laterally to the petrous bone, the retrosigmoid 
approach is the best choice, ensuring total tumour control. 
The approach is simple, quick and carries a low risk. 
Furthermore, any small supratentorial components can be 
removed by incising the free edge of the tentorium and/or 
drilling the upper border of the petrous apex 17 18.
If the meningioma extends significantly to the middle fossa, 
the presigmoid transpetrous approach (which preserves 
the labyrinth and divides the superior petrous sinus and 
tentorium) is useful to gain access to and control the lesion 
in both its supra and infratentorial components. However, 
it must be pointed out that the elevation of the posterior 
temporal lobe and manipulation of its basal veins, especially 
on the left side, entails some risks.
In meningiomas with main extension to the median clivus – for 
which the extended endoscopic transsphenoidal approach 
is currently an option of great interest  –  the transpetrous 
approach can be performed, with possible removal of the 
labyrinth to achieve a better and wider control of the deep-
seated lesion, especially if hearing is already damaged. The 
transcoclear approach, which has a very high risk of facial 
nerve damage 19 20 and very few advantages compared to the 
previously described approaches, is not indicated.
In sphenopetroclival meningiomas (with the involvement 
of the sphenoid wing, middle fossa, cavernous sinus, 
tentorium, clivus and petrous bone) a two-step removal of 
the supratentorial portion (with a pterional approach) and 
of the infratentorial portion (with a retrosigmoid approach), 
combined with radiosurgery treatment of cavernous 
sinus remnant can be considered a safe and undemanding 
therapeutic option. Nevertheless, several authors still 
recommend a one-step combined supra and infratentorial 
approach 21 22.
Finally, we should never forget that, after the approach 
comes the most important part of surgery: removal of the 
tumour, which often encases vessels and nerves, displaces 
the brainstem, requiring strenuous and long hours of work.
“petroclival meningiomas” as tumours medial to the 
IAM are generally defined, because, given their small 
size, they are confined to the apex of the petrous bone. 
For this reason, they are also known as “petrous apex 
meningiomas”.
These can cause severe trigeminal neuralgia which is dif-
ficult to treat and which often disappears after tumour 
resection. These meningiomas are not difficult to remove, 
if it weren’t for their deep position and proximity to the 
IV and V nerves.
• D – These tumours are defined as “broad-based 
meningiomas”. Their attachment spreads over most of 
the posterior surface of the petrous bone, hence, they are 
the most difficult to remove. They are generally large in 
size and surgical removal carries the same difficulties and 
risks as all the previous groups. Partial removal and poor 
control of dural attachment are not infrequent.
Pre-operative MRI can establish different meningioma 
types and assess the likelihood of success, together with the 
potential risks of surgery. However, the extent of resection and 
surgical outcome also depend on a very important variable, 
which cannot be assessed before surgery: the consistency of 
the meningioma, which can worsen the outcome of surgery 
if the tumour is fibrous. 
Retrosigmoid craniotomy is the best procedure in all 
described groups. Transpetrous approaches have no real 
advantage and are rarely used in these cases 7 10.
Petroclival meningiomas
Petroclival skull base meningiomas are the most difficult to 
treat and carry the highest surgical risks. By definition, these 
lesions develop from the clivus and grow towards the petrous 
bone, medially to the IAM and upwards, to the upper third 
of the clivus. They often involve the cavernous sinus and 
middle fossa (Sphenopetroclival meningiomas).
These tumours can be very large, although onset symptoms 
are frequently mild (e.g. slight instability, hearing loss, facial 
hypo-dysesthesia).
Most posterior fossa cranial nerves, the cerebellar arteries, 
the basilar artery and its perforating branches, are often 
involved.
Given the deep-seated nature of these lesions, beyond the 
cranial nerves of the cerebellopontine angle, surgeons 
are forced to operate in very narrow spaces between the 
nerves. Thus, as already mentioned, the resection of these 
meningiomas is challenging and involves a significant risk of 
damage to the cranial nerves and brainstem vessels 11.
In order to reduce these risks and increase the extent of 
resection, several approaches have been studied and adopted 
in order to obtain the best surgical exposure and good control 
of the tumor and of the neurovascular structures. These 
procedures include transpetrous, subtemporal, one-step or 
multi-step supra and infratentorial, combined, retrosigmoid 
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UK’s Multidisciplinary Guidelines on lateral skull base 
cancer management 3.
Treatment
Surgery on primary tumor
Radical surgery is the mainstay of TBSCC treatment, and 
negative surgical margins a fundamental prognostic factor. 
Clinical research has focused on two main surgical options: 
en bloc resection along anatomical planes of dissection 
through normal tissue, or piecemeal removal of the tumor 
until normal tissue is found. En bloc temporal bone resection 
may be lateral, subtotal or total and, unlike the piecemeal 
approach, it provides a full specimen for histology, enabling 
correlations between clinical and pathological features, and 
outcomes 9. Curative surgery for TBSCC is contraindicated 
in cases of cavernous sinus involvement, massive intracranial 
invasion, unresectable neck disease, distant metastases, 
and poor general health. Dura mater infiltration does not 
contraindicate surgery (which can be done without further 
morbidity), but it carries a dismal prognosis 10.
Neck surgery 
The external ear canal and middle ear are drained by the parotid 
and periparotid, pre- and postauricular, submandibular, upper 
deep cervical and retropharyngeal lymph nodes. Clinically 
positive necks must always be treated in patients with TBSCC, 
but whether and how to treat clinically negative necks is still 
debated. Lymph node involvement in TBSCC is relatively 
uncommon (10-23%), with levels I and II the most often 
affected 5. Elective neck dissection (preferably a selective neck 
dissection [I-III]) is recommended in all patients with locally-
advanced TBSCC and clinically negative nodes 1.
Parotid gland surgery
TBSCC may extend directly into the parotid gland, or involve the 
gland’s first-line draining nodes. Parotid involvement reportedly 
occurs in 10-62% of cases 11. Some surgeons routinely include 
a superficial parotidectomy in en bloc resections for TBSCC, 
even in patients with no clinical or radiological signs of salivary 
gland involvement or close margins 3 5.
Other treatments
Radiotherapy (RT) alone is rarely curative, but most authors 
advocate total doses of 65-75 Gy for inoperable patients 12. 
Common side effects of RT include bone and/or soft tissue 
necrosis. RT seems a reasonable palliative option for 
unresectable disease extending beyond the dura mater. 
Adjuvant postoperative RT is indicated for advanced (T3-T4) 
TBSCC, intracranial invasion, or aggressive pathological 
features such as perineural/vascular invasion, close (< 5 mm) 
or positive surgical margins, lymph node metastases, or 
extracapsular spread  13. Though not all agree, numerous 
authors advocate postoperative RT for T2 TBSCC too, given 
its aggressiveness 5.
4.3.5. Primary squamous cell carcinoma  
of the temporal bone
G. Marioni, A. Lovato, A. Mazzoni, E. Zanoletti
Introduction
Squamous cell carcinoma (SCC) originating from the 
external auditory canal and extending into the temporal bone 
is an aggressive malignancy accounting for under 0.2% of all 
head and neck tumors 1.
This critical analysis concerns temporal bone SCC (TBSCC), 
its rational preoperative assessment and staging, the efficacy 
of different treatments by tumor stage, the main currently-
used and promising prognostic factors.
Diagnosis
TBSCC is usually diagnosed late because early signs and 
symptoms are not specific. Most patients initially complain 
of symptoms that are frequently attributed to inflammatory 
ear diseases. Facial nerve palsy at presentation is considered 
a sign of advanced disease  1. Early diagnosis is crucial to 
prompt treatment.
Micro-otoscopy with extensive, multiple biopsies is essential 
to the diagnosis and histological characterization of TBSCC. 
The primary tumor is assessed by combining temporal bone 
high-resolution computed tomography (CT) with contrast-
enhanced magnetic resonance imaging (MRI). High-
resolution CT is mandatory for its sensitivity in detecting 
early bone erosion (often the first sign of the disease spreading 
locally). Contrast-enhanced MRI shows the tumor’s extent 
and better differentiates it from non-neoplastic soft tissue; 
it can reveal petrous apex or temporomandibular joint 
involvement, dura mater invasion or intracranial spread  2 3. 
Cervical metastases are confirmed in about 18% of cases, 
often involving the intra-parotid lymph nodes as well as 
neck levels I and II 4 5. CT and MRI are generally reasonably 
reliable for detecting nodal metastases, and for planning 
curative neck dissection  6. Distant metastases of TBSCC 
are rather unusual and believed to occur late, with deposits 
in lung, bone, liver, and brain  4. They should be ruled out 
with total-body positron emission tomography (PET) before 
planning any treatment 7.
Staging
No internationally-accepted staging system is available for 
TBSCC. Classifications have been proposed, but none have 
been endorsed by the International Union Against Cancer 
or the American Joint Committee on Cancer. Moody et 
al.  8 suggested updating the Pittsburgh system to focus on 
clinical facial nerve involvement, based on the assumption 
that nerve palsy indicates the middle ear’s medial wall or 
mastoid invasion. This is the most often used system for 
staging TBSCC for now, as recently recommended by the 
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investigated 20. CD105 expression (in tumor vessel endothelial 
cells) and MASPIN cytoplasmic expression (in carcinoma 
cells) were found directly and inversely related, respectively, 
with TBSCC recurrence rates  21  22, and epidermal growth 
factor receptor (EGFR) expression was found significantly 
associated with a poor survival  23. A case of advanced 
TBSCC treated with the EGFR inhibitor cetuximab and RT, 
achieving a complete response and a disease-free two-year 
follow-up has recently been reported 24.
Conclusions
Managing TBSCC is a challenge, even at expert centers 
adopting precise guidelines on its diagnosis, staging, treatment 
and follow-up. TBSCC should be managed by multidisciplinary 
teams of oto-neurosurgeons, head and neck surgeons, plastic 
surgeons, oncologists, radiotherapists, dedicated radiologists, 
and pathologists (at least), particularly in advanced cases. 
Prospective, randomized, multi-institutional (and preferably 
international) studies are needed to compare TBSCC treatment 
outcomes and develop appropriate guidelines.
4.3.6. Petrous bone cholesteatoma
D. Zanetti, G. Conte, L. Magnoni, F. Di Berardino
Introduction
Petrous bone cholesteatoma (PBC), also defined as “invasive” 
or “medially extensive” cholesteatoma, is a lesion located 
medial to the otic capsule. It accounts for 10% of the lesions 
involving the petrous pyramid  1 2. Compared to middle ear 
cholesteatoma it is rare, representing less than 4% of all 
temporal bone cholesteatomas; its incidence has remained 
stable during the last 4 decades 2. 
PBC can be congenital, arising from ectodermal embryonic 
remnants within the otic capsule, acquired (post-otitic), or 
iatrogenic, after failure of previous middle ear surgery  3. 
Histologically the 3 etiological variants are indistinguishable: 
they all present as a collection of desquamated epithelium, 
keratin, and cellular debris, sharing similar histologic 
features with odontogenic keratocysts and epidermal cysts.
After remaining silent for years, they manifest with either 
otorrhea, vertigo, otalgia or their combination, followed by 
facial nerve weakness and tinnitus  2  4; in Danesi’s  5 series 
no patient complained of vertigo pre-operatively, possibly 
due to long-standing vestibular areflexia related with the 
advanced extension of the disease at the time of surgery, 
often associated with multiple fistulas. In Álvarez’s 6 series 
of 25 patients, ¾ presented with facial paresis. Intracranial 
suppurative complications, such as recurrent aseptic 
meningitis  7 are frequently encountered in PBC, especially 
in populations living in lower socio-economic conditions.
A classification of the site and extension of PBCs was 
initially proposed by Fisch, who separated supra- and infra-
The value of chemotherapy is still not clear, but it seems to have 
a role in advanced (especially T4) disease, residual disease, and 
metastases 2 14. Nakagawa et al. 15 reported using preoperative 
chemo-radiotherapy (CRT) for TBSCC, and others have since 
done so too 16. Various anticancer drugs (including cisplatin, 
carboplatin, fluorouracil, and docetaxel) were used in very 
small case series of TBSCC, but recent findings suggest that 
TPF (docetaxel, cisplatin, and 5-fluorouracil) is safe and 
effective as the first option in this setting 17 18.
Prognosis 
TBSCC patients’prognosis and overall survival vary 
considerably, depending on disease stage at diagnosis, 
treatments, and oncological radicality of surgery. The primary 
tumor’s extent (T stage) is a very important prognostic factor, 
even more than N stage. Medial or posterior spread to the otic 
capsule, mastoid, infra-labyrinthine area, para-pharyngeal 
spaces, and dura mater carries a worse prognosis. A literature 
review (spanning 1976-2008) by Higgins and Antonio (19) 
pointed to facial nerve involvement as a negative prognostic 
factor. Most studies found no correlation between prognosis 
and pathological grade 1, whereas positive surgical margins 
at histology 5, and distant metastases carry a poor prognosis 1. 
Recurrent TBSCC treatment and prognosis 
Disease-related mortality rates are high for TBSCC 
recurring after treatment. A literature review spanning 1995-
2013 found a disease-specific survival of 18% to 65% for 
stages III-IV. Salvage surgery with curative intent might be 
feasible for early recurrences if radicality is still achievable 1. 
A preliminary investigation supported other palliative 
treatments (chemotherapy, RT, or specialist care) in cases of 
loco-regionally advanced recurrent TBSCC 7.
Follow-up
There is a paucity of precise guidelines on the follow-up of 
surgically-treated TBSCC patients. Zanoletti et al.  7 recently 
recommended at least: clinical examination and contrast-
enhanced head and neck MRI every 2 months in the 1st year, 
every 4 months in the 2nd, and every 6 months in the 3rd to 5th years. 
In a cohort of patients with recurrent TBSCC, the same authors 
found that distant metastases were diagnosed 6 to 15 months 
after primary treatment. In 2001, Sasaki 4 recommended annual 
chest CT to detect distant metastases in patients with TBSCC. 
Nowadays, total-body PET could be used to detect loco-regional 
TBSCC recurrences and distant metastases.
Diagnostic and therapeutic prospects
Molecular changes in malignancies occur before any 
morphological changes are visible, and are responsible for 
prognosis, and response to primary therapy. Biomarkers that 
might reflect the biological features of TBSCC are now being 
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being preferred for its higher spatial resolution and lower 
radiation dose  9 10. Typically, PBC appears as an expansive 
soft-tissue mass in the apical portion of the petrous bone, with 
large areas of bone reabsorption (Fig. 4.3.6.2). CT yields high 
negative predictive value in diagnosing cholesteatoma, ruling 
out the presence of cholesteatoma when the tympanic cavity 
is well pneumatized. Conversely, CT has a low specificity 
because it cannot easily differentiate cholesteatoma from 
other soft-tissue masses 11. Typical CT findings associated to 
a soft-tissue mass within the petrous apex that suggest a PBC 
(even if the tympanic membrane is normal at otomicroscopy) 
are the erosion of the tegmen tympani, the posterior and 
inferior wall of the petrous pyramid, the carotic canal and, 
sometimes, the upper clivus. In literature, bony erosion 
has been reported from 50 to 97% of CT scans of patients 
with histologically-proven cholesteatoma, thus resulting as 
a reliable (but not perfect) imaging marker  11. The density 
values of cholesteatoma are not significantly different from 
those of the other petrous bone lesions. Thus, CT is unable to 
differentiate cholesteatoma from inflammatory or scar tissue. 
Its value is the high spatial resolution that allows defining 
the localization and extension of the PBC and the signs 
of erosion of relevant bony structures such as the tegmen, 
the Fallopian canal, the labyrinth and cochlea, the internal 
carotid artery (ICA), the jugular bulb (JB) and the sigmoid 
sinus.
Magnetic Resonance Imaging (MRI) usually provides 
complementary information compared to CT. It is superior in 
differentiating cholesteatoma from mimicking lesions but it is 
inferior in defining its localization and extension because of the 
lower spatial resolution. For these reasons, MRI is indicated 
after CT, when the latter and the clinical examination are not 
conclusive in the diagnosis or when a recurrence is suspected 
after surgery. MRI protocol for PBC includes multiplanar 
conventional T1-weighted and T2-weighted sequences, 
and diffusion-weighted (DW) sequences (Fig.  4.3.6.3) 
labyrinthine lesions. In 1993 Sanna et al categorized petrous 
bone cholesteatomas into 5 Classes: Class I, supralabyrinthine; 
Class II, infralabyrinthine; Class III, infralabyrinthine-apical; 
Class IV, massive; and Class V, apical (Fig. 4.3.6.1). Later on, 
the same Authors 4 added another stage for disease extending 
beyond the borders of the temporal bone.
Despite its slow-growing habit, the osteolythic capacity of 
PBC leads to exposure and adhesion to relevant anatomical 
structures such as the facial nerve, carotid artery and 
dura mater. In Danesi et al.  5 series of 81  patients, a 
labyrinthine erosion/fistula was evident at surgery in 83% 
(infralabyrinthine/apical) to 100% (apical and massive) 
cholesteatomas. A cochlear erosion appeared again in all 
cases of massive PBC, while it was less frequent in other 
stages of the disease; erosion and infiltration of the internal 
auditory canal (IAC) was present in 100% of massive and ¾ 
of the infralabyrinthine/apical cholesteatomas. Conversely, 
an intracranial erosion and CSF leak occurred rarely. 
Surgery is the only accepted treatment. Given the complex 
anatomy of the petrous bone, surgical removal of these 
lesions can be very challenging. A single best approach has 
not yet been identified.
Frequent post-operative complications or sequelae include 
cerebrospinal fluid (CSF) leaks, facial nerve palsies and 
anacusis 8; recurrence is highly likely 6. 
Advances in imaging
Multisection computed-tomography (MSCT) is the traditional 
technique of choice when cholesteatoma is clinically 
suspected, providing a spatial resolution of 0.4 x 0.4 mm in 
plane and 0.5 mm in slice thickness. In the last years the use 
of flat-panel CT (FPCT) has taken place in clinical practice, 
Fig. 4.3.6.1. Schematic drawing of Sanna’s classification of PBC (see text 
for detailed description).
Fig. 4.3.6.2. A 38 years-old male with recent vertigo and recurrent otor-
rhea. Flat-panel CT scans (a: axial; b: coronal) showed a soft-tissue mass 
occupying the left petrous apex (arrow), determining a large erosion of the 
anterior, superior and posterior surface of the petrous pyramid, suggesting 
the presence of an invasive cholesteatoma.
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layers 13. On early post-contrast T1-weighted sequences, slow-
enhancing inflammatory/scar tissue can be misdiagnosed as 
cholesteatoma, causing false positive results. The acquisition 
of late (45  min) post-contrast T1-weighted sequences can 
differentiate non-enhancing and avascular cholesteatoma 
from slow enhancing inflammatory/scar tissue 14. Table 4.3.6.I 
summarizes the MRI characteristics of cholesteatoma and 
its mimicking lesions. It should be acknowledged that post-
contrast sequences are not usually needed because pre-contrast 
sequences are sufficient for the diagnosis.
Approaches and surgical issues
The medial portion of the petrous bone and the petrous 
apex are difficult-to-access regions, owing to the anatomical 
boundaries represented by the ICA, JB, middle (MCF) and 
posterior cranial fossa (PCF) dura. Furthermore, all lateral 
skull base surgical trajectories come across the facial nerve, 
labyrinth and cochlea; despite wide bone removal and 
careful mobilization of the facial nerve and of the JB, some 
deep areas such as the medial surface of the ICA will remain 
a blind spot 15.
Traditional lateral skull base approaches, either transmastoid/
transtemporal or through middle cranial fossa craniotomy, 
are usually performed under magnification by an operative 
microscope. They include the transcochlear, the modified 
transcochlear and the transotic approach 15. 
The first two approaches imply the mobilization of the 
facial nerve from the Fallopian canal (“re-routing”); in all 
3  techniques, the destruction of the labyrinth and of the 
cochlea are inevitable surgical steps, followed by Eustachian 
tube plugging and blind-sac closure of the external auditory 
canal (EAC). The surgical cavity is then filled with adipose 
tissue harvested from the peri-umbilical region.
Most surgeons address PBC on the basis of their personal 
experience and surgical skills  16; in tertiary referral Skull 
Base/Neuro-Otology centers these lesion are more often 
managed by a systematic approach  1  4  17; nevertheless, an 
approach tailored on the location and extension of the disease 
observed with current imaging modalities and accounting for 
the pre-operative functional status is reasonable.
A non-conventional transmastoid subarcuate approach was 
developed by Van Dinther et al.  18 in order to remove a 
small PBC through the center of the superior semicircular 
arch, preserving its integrity and sparing hearing function. 
Cholesteatomas show a high signal intensity on DW sequence 
attributed to an impeded diffusion of water molecules and a T2 
shine-through effect 12. In the literature, the DW sequence was 
associated with an excellent specificity and positive predictive 
values (up to 100%) in patients with or without history of 
previous surgery 12. Cholesterol granuloma and inflammatory/
scar tissue do not show high signal on DW sequence. On 
pre-contrast T1-weighted sequences a PBC has a low signal 
intensity, easily differentiable from cholesterol granuloma 
which has a high signal. On T2-weighted sequences it appears 
with an intermediate signal, while inflammatory or scar tissue 
are characterized by a high signal intensity. After contrast-agent 
administration cholesteatoma does not show enhancement 
because it is a non-vascularised tissue; however, sometimes a 
thin peripheral rim of enhancement can be seen on T1-weighted 
images after intravenous administration of gadolinium because 
of the presence of epithelial (matrix) and granular (perimatrix) 
Fig. 4.3.6.3. MRI in the axial plane showed a soft-tissue mass in the left 
petrous apex (arrows) with low signal on T1-weighted sequence A), high 
signal on T2-weighted sequence B), high signal on DWI C) with correspond-
ing low ADC (Apparent Diffusion Coefficient) D). MRI findings unequivocally 
confirm the suspicion of PBC.
Table 4.3.6.I. Signals of cholesteatoma and mimicking lesions on MR sequences.
  T1-weighted T2-weighted Diffusion-weighted Late post-contrast 
T1-weighted*
Cholesteatoma Low Intermediate High Low
Inflammatory/scar tissue Low High Low High
Cholesterol granuloma High High Low High
*: 45 minutes after intravenous contra-agent administration.
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stenting is usually not necessary, since no cases of severe 
hemorrhage are reported in the PBC literature 1 2 17.
For PBC extending beyond the ICA, its gentle mobiliza-
tion may widen the surgical view of the medial surface 
under the microscope, but, again, it should only be per-
formed cautiously.
3. Dura mater
In PBC, the matrix is usually tightly adherent to the meninges 
and a loose perimatrix is missing. Bipolar coagulation of 
dural portions helps removing it or avoiding relapses 1 3 4. In 
our personal experience, the local application of solutions of 
mucolytic agents followed by brushing with neurosurgical 
cottonoids has been proven helpful. In case of inadvertent 
dural breakdown with CSF leakage, immediate sealing 
with a dural patch is required, with careful avoidance of 
intracranial penetration of keratinized epithelium.
Outcomes
The main aim of surgery of PBC is the radical removal of the 
disease with absence of recurrence. The latter should have 
a priority over an unpredictable preservation of hearing or 
even over the risk of facial palsy, although this aspect is still 
a subject of debate.
In agreement with other Authors 16 an individualized surgical 
treatment of PBC should strive to achieve the least recurrence 
rate as well as the facial functional outcome, at the price of 
sacrificing hearing. 
Obviously enough, this peculiar approach is limited to small 
and very selected supralabyrinthine cholesteatomas.
Kojima et al.  19 removed a supra- and infracochlear PBC 
through an extended middle cranial fossa approach with 
the assistance of endoscopy. Although acceptable in terms 
of functional sparing, in our opinion this approach should 
be reserved to cases with locations and extension hardly 
accessible through the more conventional routes, owing to 
possible higher morbidity.
As an alternative to the invasive lateral skull base procedures, 
a totally endoscopic trans-sphenoidal approach has been 
proposed by few Authors with the purpose of avoiding 
a craniotomy, promoting faster recovery and reducing 
postoperative morbidity 20 21. Unfortunately, the experiences 
remain very limited and the outcomes uncertain.
Whatever the selected approach, a few basic surgical pitfalls 
have been derived from cumulative experiences, especially 
by leading Skull Base centers:
1. Facial nerve
The main hurdle to the surgical access to the petrous apex 
is the Fallopian canal. 
The facial nerve can be exposed, thinned and already 
damaged at the time of surgery in a relevant percentage 
of PBC. It a reported series 5 it was found interrupted in 
35% of cases. This occurred in ¾ of the apical lesions, 
half of the massive cases and 1/3 of the supra- and in-
fralabyrinthine cholesteatomas. Half of these patients 
suffered a post-operative House-Brackmann grade V or 
VI facial palsy.
When the facial canal is intact, it represents an obstacle 
to complete visualization of deep and medial areas. The 
traditional solution to gain better access is represented by 
facial nerve “rerouting”, usually in a posterior position 
by first skeletonizing and uncovering the bony shell of 
the canal, then sectioning the greater superficial petrosal 
nerve and translocating the nerve to the posterior edge of 
the petrosectomy cavity. Even delicate manipulations of 
the nerve lead to an inevitable transient palsy.
The transotic approach, which preserves the integrity 
of the bony Fallopian canal, combined with the use of 
endoscopes anterior and posterior to the canal to work 
“beyond the blind corner” (Fig.  4.3.6.4) is an effective 
mean to avoid post-operative paresis. Care must be taken 
to prevent heating of the facial canal with the drill and 
with the endoscope.
2. ICA
Invasive cholesteatoma may erode the cortical bone of 
the carotic canal, exposing the adventitial layer of the 
intrapetrous carotid artery, without infiltrating it. Careful 
dissection of the adherent matrix from the carotid wall is 
essential to avoid relapses. The thickness of the adventitia 
is usually sufficient to prevent accidental tearing of 
the wall, which can result fatal to the patient; carotid 
Fig. 4.3.6.4. Schematic drawing of transotic approach to right the petrous 
apex with representation of the use of an endoscope to access blind spots 
(MCF: middle cranial fossa dura; PCF: posterior cranial fossa dura; IAC: inter-
nal auditory canal; JB: Jugular bulb; VII: Fallopian canal; ICA: internal carotid 
artery; SS: sigmoid sinus).
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grafting, with great auricular or sural nerve 24, based on the 
length and location of the injured nerve segment, can be 
performed simultaneously. In case of long-standing palsies, 
a hypoglossal-facial nerve transfer is preferred  16. In all 
procedures, a recovery not exceeding House-Brackmann 
grade III can be expected 1 4 5 24, with the exception of primary 
direct anastomosis.
Cholesteatoma recurrence
Recurrences can develop from remnants of the cholesteatoma 
matrix adherent to the facial nerve, dura mater or ICA 4 and 
can also lead to postoperative complications.
The recurrence rate for the classical trans-mastoid routes 
ranges between 5 and 28% in literature  1  3  4  6  17; long-term 
observation is needed because relapses have been observed 
even 8 years after surgery.
“Exclusion” of the petrosectomy cavity by blind sac closure 
of the external auditory canal and plugging of the Eustachian 
tube orifice, combined with filling of the cavity with adipose 
tissue grafts and additional muscolo-periosteal flaps is the 
universally accepted surgical solution to minimize the risks 
of CSF leaks and infection, which also warrants adequate 
protection of the neurovascular structures. The drawback is 
the absence of control of the cavity in the event of a possible 
recurrence of the disease, which must then rely upon 
imaging. To partially overcome this issue fibrin glue can be 
used instead of fat and muscle to fill the operative field, in 
order to pneumatize the cavity and improve postoperative 
imaging.
Alternatively, an “open” surgical technique can be selected 
in order to allow periodical inspection of the petrosectomy 
cavity; although the latter rtechnique can expose the patient 
to a higher chance of post-operative complications and 
it is not clear if the recurrence rate is lowered  6. In open 
techniques, the reinforcement of the dura with full thickness 
cartilage palisades with attached perichondrium in an 
underlay fashion, covered by a posteriorly based periosteal 
flap, can be recommended 2.
Endoscopy vs microscopy
One recent advance in lateral skull base surgery has been 
the introduction of endoscopes. Although the microscope 
offers a wide field of view, with different degrees of 
magnification and an excellent illumination, deep recesses 
within the temporal bone may remain out of sight. In recent 
years, endoscopic surgical techniques applied to the ear have 
gained respect and widespread use, increasing knowledge 
and refining their outcomes 26 27. 
 A variety of endoscopes that differ in size (4 mm vs 2.7 mm), 
length (8-15-20 mm) and angle of view (0°, 30°, or 70°) can 
assist surgery for PBC, allowing access to areas such as the 
medial or anterior wall of the ICA, the infralabyrinthine 
compartment, the anterior part of the internal auditory canal 
and even the sphenoid sinus 15.
Hearing and equilibrium
Post-operative vestibular impairment is rather unusual, 
which is not surprising, considering the very low incidence 
of pre-operative vestibular symptoms.
The chance of preserving the residual hearing is very low, 
although a few reports claim it is feasible  22, by means of 
modifications of the surgical techniques, such as partial 
(selective) ablation of the semicircular canals in the so-called 
modified translabyrinthine approach 23.
At the time of surgery, cholesteatoma has often already 
invaded the inner ear structures  24 and hearing is largely 
compromised or anacusis is already present.
Nevertheless, in those rare cases with preserved hearing 
and normal inner ear anatomy, a labyrinthectomy and a 
cochleostomy might be sidestepped and a more conservative 
approach considered. Conversely, no question about 
sacrificing the hearing remnants should rise in case of 
massive or inaccessible cholesteatoma 16 23.
In the rare instances in which the PBC arises in the only 
hearing ear, the surgeon may elect either one of the following 
two solutions: 1) performing an “open” (canal wall down) 
technique in which the disease is simply exteriorized and 
its evolution can be easily followed-up without endangering 
the inner ear 6; 2) the contralateral ear is rehabilitated with a 
cochlear implant (if feasible) and the PBC is addressed soon 
after 25.
In the era of cochlear implants, the opportunity of 
rehabilitating hearing has to be integrated in the pre-
operative planning. Proven the contralateral hearing is at least 
partially compromised, a cochlear implant would certainly 
be beneficial to the patient who will lose hearing after PBC 
removal 25. Quite obviously, the cochlea should be intact and 
free from disease in order to insert the array, and the implant 
would be buried under the final cavity obliteration. Then, the 
question of the timing of the implantation rises: simultaneous 
implantation would provide the greatest speech perception 
results and would spare the patient a second operation; 
however, it would also hamper the chance to follow-up the 
potential recurrence by means of MR imaging. On the other 
side, a delayed implantation might not be feasible because 
of potential ossification of the cochlear lumen after surgical 
trauma.
Facial nerve
Even if the nerve is intact, the surgical manipulations needed 
to reach the most difficult areas can endanger it. Facial 
nerve function is more likely to be preserved in patients 
with preoperative facial palsy mild or moderate; an early 
diagnosis by current imaging methods is essential. 
When preoperative facial palsy is present, a decompression 
of the Fallopian canal from the first genu to the silo-mastoid 
foramen is required. In the event of nerve interruption, 
its repair through either primary neurorrhaphy or nerve 
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effectively deal with such lesions. In the last decade, rapid 
advances have been made in lateral and endoscopic skull 
base surgery in terms of accurate mapping of the anatomy 
of the PA and the surrounding areas and formulation of 
appropriate surgical approaches. Facial nerve monitoring 
and interventional neuroradiology have greatly improved 
the safety of surgical procedures.
Management of the diseases of the PA is also complicated 
because of the delayed and variable presentation of 
symptoms. Due to the variability of symptoms, it is difficult 
to diagnose them based on clinical findings alone and hence 
they remain undetected for many months or years before a 
diagnosis is made. With the advent of modern skull base 
surgery, advances in neuroimaging, and neuroanesthesia, it 
is today possible to precisely locate and extirpate almost all 
types of tumors 1.
Anatomy of the petrous apex
The PA is a part of the central skull base and is defined as 
the portion of the petrous temporal bone anteromedial to the 
bony labyrinth and lateral to the petro-occipital fissure  1-3. 
The anteromedial margin of the PA forms the posterior limit 
of the middle cranial fossa (MCF). The PA is divided into 
two compartments: a larger anterior triangular (principally 
consisting of bone marrow or air cells) one and a smaller 
posterior quadrangular one (derived from the dense bone 
of the otic capsule) (Fig. 5.1.1). At the junction of the PA 
with the sphenoid and occipital bone, the PA is separated 
from the clivus by an ovoid horizontal gap, the foramen 
The sets of instruments specifically designed for 
endoscopic middle ear surgery can be too short for 
reaching the petrous apex, but modified sinus surgery 
(longer) tools or neurosurgical instruments can effectively 
replace them.
The main drawback of endoscopy is that one-hand surgical 
procedures somehow limit an adequate drilling of the 
temporal bone  15. The advantage of bimanual dissection 
under the microscope can be compensated by a second 
operator holding the endoscope, and, if needed, also a second 
suction tube (such as in endoscopic surgery of the anterior 
skull base).
Nowadays, endoscopes are commonly employed to assist 
conventional petrous bone microscopic procedures. as they 
allow inspection of hidden areas and guarantee a more 
reliable radical removal of the cholesteatoma. 
Some Authors claim that an exclusively endoscopic 
approach can achieve complete eradication of the 
cholesteatoma in a less invasive fashion, reducing the risk 
of residuals, and lowering the risk of lesions of the dura, of 
the major vessels and of the facial nerve 15 28.
These approaches seem very promising in terms of 
functional preservation, but up to now, the experiences are 
limited and long-term results are lacking, especially for 
what concerns the recurrence rate.
5. The view of the expert:  
a free choice topic
5.1. Petrous apex and surrounding areas 
lesions: clinical and surgical management
M. Sanna, A. Taibah, A. Russo, E. Piccirillo, G. Piras
Introduction
The petrous apex (PA) is a pyramid shaped part of the 
temporal bone that is surrounded by the brain, complex 
neurovascular structures, and the organ of hearing. 
Multiple pathologic processes may affect the PA which 
range from infections like petrous apicitis to complex 
tumors like chondrosarcomas. Diseases affecting the PA 
not only tend to have serious morbidities as they affect 
important structures in the surrounding area, but they 
are also surgically difficult to approach due to the deep 
location in the skull base. The presence of the internal 
carotid artery (ICA) and the facial nerve which lie close to 
the PA render surgery even more challenging. The treating 
surgeon must have a thorough understanding of the 
anatomy, clinical pathology and skull base approaches to 
Fig. 5.1.1. The petrous apex is divided into an anterior triangular and a 
posterior quadrangular (Q) compartment. 
GsG: Gasserian Ganglion; V2: Maxillary branch of Trigeminal Nerve; V3: 
Mandibular branch of Trigeminal Nerve; MMA: Middle Meningeal Artery; GSPN: 
Greater Superficial Petrosal nerve; ICA: Internal Carotid Artery; IPS: Inferior 
Petrosal Sinus; SPS: Superior Petrosal Sinus; PFD: Posterior Fossa Dura; SSC: 
Superior Semicircular Canal; Co: Cochlea; IAC: Internal Auditory Canal. GG: 
Geniculate ganglion.
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Pathologies affecting the petrous apex
A variety of diseases affect the PA and these can arise 
from the bone, meninges, pneumatized air cells, middle 
ear, cranial nerves, endolymphatic sac, or from the para-
ganglionic chemoreceptors of the jugular bulb at the skull 
base. Razek et al. 4 proposed a classification of the lesions of 
the PA based on the type of lesions. In the following sections, 
we will discuss some of the most important lesions and the 
most relevant surgical approaches. 
Petrous apex cholesterol granuloma (PACG)
A PACG is a lesion that primarily develops as a result of a 
foreign body-giant cell response to cholesterol deposits. This 
lesion becomes a cavity with a fibrous lining and is filled 
by a golden to brownish yellow fluid that contains lipids 
and cholesterol crystals. It is surrounded by foreign body-
giant cells, reactive fibrous tissue, vascular proliferation, and 
chronic inflammation. Cholesterol granulomas are the most 
common lesions arising in the PA. Classically, they occur in 
patients with a pneumatized PA and a long-standing history 
of otitis media. Pneumatization of the PA has been reported 
in about 9-30% of temporal bones and this partially explains 
the rarity of the disease. There are two theories to explain 
the origin of PACG: the older obstruction-vacuum theory 
and the newer theory proposed by Jackler et al of marrow 
exposure 5. The exposed marrow theory has been supported 
by evidence from recent studies 6. Clinical features of PACG 
may overlap with some of the other inner ear pathologies, 
therefore radiological diagnosis is often crucial in supporting 
the diagnosis. Many times the diagnosis is incidental. In our 
series  7 the following symptoms were noted: hearing loss 
(60%), vertigo and tinnitus (27%), diplopia (40%), headache 
(27%), facial paresthesia (13%), trigeminal neuralgia (7%), 
and hemifacial spasm (7%). Other signs like seizures and 
signs of brainstem compression may appear in larger lesions. 
Magnetic resonance imaging (MRI) is a reliable tool for the 
diagnosis of this lesion. Although most other PA lesions have 
low or intermediate signal intensity on T1-weighted images, 
PACG is usually hyperintense on both T1-and T2-weighted 
images. Computed tomography (CT) scan will show an 
isodense lesion, with evidence of bone erosion. 
Management of PACG can be conservative or surgical. Small 
lesions that are asymptomatic or those that are discovered 
incidentally can be managed by a wait-and-scan policy. In 
our series of 30 patients, 13 were managed with the latter 
policy and in this group only one lesion showed growth of 
the lesion during the follow-up. Larger lesions or those that 
induce symptoms must be operated. 
The main goal of surgery is drainage and ventilation of the 
cavity after removal of the lesion. There are several surgical 
approaches that have been proposed in literature including 
the MCF approach, suboccipital approach, infralabyrinthine 
(IL) approach, infracochlear (IC) approach, transotic 
lacerum, which contains a bridge of dense fibrous tissue 
and cartilage. Above the foramen lacerum, the petrous ICA 
exits the medial opening of the carotid canal to continue as 
the cavernous portion. On the superomedial surface of the 
PA there is an important landmark, a shallow depression on 
which lies the trigeminal ganglion within the Meckel’s cave. 
Trigeminal symptoms are often associated with lesions in 
this area because to the latter relationship between the nerve 
and the PA. Dorello’s canal carries the sixth cranial nerve 
from the dural margin along the petroclival junction to the 
posterior cavernous sinus (Fig. 5.1.2). Lesions of the PA or 
petroclival junction are notorious for invading or compressing 
Dorello’s canal therefore leading to sixth cranial nerve palsy 
and diplopia. The inferior extracranial surface of the PA is 
intimately related to the nasopharynx. The posteromedial 
margin of the PA meets the clivus, which is formed by the 
basiocciput and the sphenoid. Invasive neoplasms of the 
nasopharynx, thus, can traverse the sinus of Morgagni and 
readily gain access to anatomical structures of the bony skull 
base, including the PA. In approximately one-third of cases, 
the PA has aerated cells which are in communication with the 
middle ear by anatomical tracts (peritubal, posteromedial, 
and subarcuate) extending superiorly and inferiorly 3. 
The ICA is the most prominent structure in the PA. The 
petrous ICA enters the temporal bone into the carotid canal 
and extends till the foramen lacerum. It has three sections: a 
vertical portion, the genu, and the horizontal portion. At its 
entrance, the vertical ICA lies anterior to the cochlea. The 
anteromedial part of the roof of the horizontal ICA is formed 
by a thin plate of the bone that separates the artery from the 
trigeminal ganglion.
Fig. 5.1.2. The course of the right petrous internal carotid artery (ICA) and 
the anterior foramen lacerum (AFL) can be identified in this dissected speci-
men. Other visible structures are the abducens nerve (VI) in the Dorello’s ca-
nal (DC) and the anterior inferior cerebellar artery (AICA).
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secondary cholesteatoma and the slow-growing nature of 
this lesion leads to a delayed diagnosis. Apart from this, 
congenital PBC presenting with sudden onset facial palsy 
is often misdiagnosed as a Bell’s palsy due to a normal 
otoscopy. Sanna et al. 8 9 proposed a classification for PBC 
that is widely used. Of the categories in the classification, 
the infralabyrinthine-apical, massive, and apical PBC affect 
the PA. The PBCs can be either congenital or acquired. The 
term congenital cholesteatoma is used to describe lesions 
that are believed to arise from epithelial cell remnants within 
the temporal bone. The acquired type is the result of a medial 
invasion of cholesteatoma from the tympanomastoid region. 
Supralabyrinthine PBCs were the most common type with 
92 (45.8%) cases, followed by massive PBCs in 72 (35.8%) 
cases. Apical PBCs were rare with just four (2%) of cases in 
the series. Two of the main differentiating factors between 
congenital and acquired PBC are the following: while 
in acquired PBC, the cavity is connected to the external 
auditory canal and is therefore at risk for secondary bacterial 
invasion, in the congenital form the lesion is essentially 
sterile. Second, the mastoid will be more sclerosed in the 
acquired form due to long-standing infection in comparison 
to congenital PBC where pneumatization is normal. The 
most common clinical presentation of PBC is hearing loss 
and facial palsy and is common in both congenital and 
acquired cholesteatomas. In one of the largest series of PBC 
published (n  =  246)  10, we found an incidence of 64% of 
hearing loss and 53% of facial palsy. The commonest sites 
for the involvement of the facial nerve in our series were 
the tympanic portion (94%), geniculate ganglion (84%), 
and the labyrinthine portion (69%). The facial nerve was 
involved in multiple segments in most of the patients. On 
CT scan, PBCs appear as a nonenhancing, expansive lesions 
with bony destruction. On MRI they show an intermediate to 
low-signal intensity on T1-weighted images and high-signal 
intensity on T2-weighted images. There is no enhancement 
after contrast administration. Diffusion-weighted imaging 
is useful in diagnosing cholesteatomas, as the lesions often 
show a restricted diffusion, a feature that can be particularly 
beneficial in detection of recurrent cholesteatomas after 
surgical resection.
The main factors to be taken into consideration while treating 
PBCs are complete eradication of the disease, preservation 
of facial nerve function, prevention of cerebrospinal 
fluid leak (and thus meningitis), cavity obliteration, and 
hearing preservation whenever feasible. The choice of the 
surgical approach has evolved from a radical petromastoid 
exenteration with marsupialization of the cavity, to closed 
and obliterative techniques following complete eradication. 
The decision regarding the surgical approach depends on 
several factors, of which the most significant are the extent 
of the disease and preoperative facial nerve function 10. The 
approach is chosen depending on the type of PBC and its 
(TO) approach, infratemporal fossa approach (ITFA) 
type  B, and the transnasal-transsphenoidal approaches. 
The factors influencing the choice of surgical approach 
are: preoperative hearing function, location and extent of 
the lesion, relationship with neurovascular structures, and 
patients’anatomical variations (e.g. high jugular bulb). 
We do not favor MCF approaches because of the limited 
control on the ICA, the difficulty in placing a drain through 
this approach (especially when aeration of the cavity 
becomes important in subtotal removals), and because 
of the risk of developing meningitis by contamination of 
the subarachnoid spaces by the fluid content of the cyst. 
In case of preoperative serviceable hearing, IL and IC 
approaches are appropriate choices. The IL approach is 
the best option in serviceable hearing because it does not 
involve manipulation of the tympanic membrane (TM) 
and ossicular chain as the drainage tube is positioned 
in the mastoid cavity. The risk of injury to the ICA is 
minimal and revision surgery, when necessary, can be 
easily accomplished with a postauricular incision without 
having to manipulate the TM and the ossicular chain. 
Complications include sensorineural hearing loss and facial 
nerve injury. The IC approach provides adequate access to 
the PA, but has certain drawbacks. It requires maneuvers on 
the TM, enlargement of external auditory canal followed by 
reconstruction of the tympanic plate with bone patè. There 
is also a risk of ICA injury during exposure. The catheter 
is positioned close to the TM and revision surgery requires 
the elevation of the TM. The main downside in both the IL 
and IC approaches is evident in cases in which the jugular 
bulb is high. To avoid injury to the jugular bulb, particularly 
when it is dominant, we prefer to approach the lesions 
using an ITFA type  B. This approach presents excellent 
exposure, complete control of the intrapetrous ICA, and the 
possibility of complete cyst removal from the clivus and 
sphenoid sinus. The disadvantages of ITFA type  B are a 
blind sac closure of the external auditory canal which leads 
to a loss of conductive hearing and the retraction of the 
mandibular condyle with sacrifice of the mandibular (V3) 
branch of the trigeminal nerve, which leads to difficulties in 
mastication. The translabyrinthine (TL) and TO approaches 
are used for patients without serviceable hearing and huge 
lesions. These approaches allow a wide and direct exposure 
of the PA. We recommend combining the ITFA type  B 
with the TL or TO approach for those lesions extending 
anteriorly to the ICA and eroding the clivus to achieve 
complete removal of the cyst wall. If the PACG extends into 
the sphenoid sinus or abuts its posterior wall, a transnasal 
endoscopic approach is indicated. 
Petrous bone cholesteatoma (PBC)
The PBC is an epidermoid cyst of the petrous portion of the 
temporal bone. The PBC of the PA is less frequent than a 
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class C3 and C4 tumors are generally considered as large 
tumors and these tumors have the potential to involve the 
PA 12. As TJPs grow out of the jugular foramen, they tend 
to follow two paths; the first one extends either into the 
carotid canal, the PA, and the clivus and the second one 
into the intradural space through the medial wall of the 
jugular bulb, thus involving the lower cranial nerves in 
the process. As a rule, ITFA type A with a transcondylar-
transtubercular extension can be used for C2-C4 tumors. 
If the tumor involves the clivus or foramen magnum, 
additional procedures such as a modified transcochlear 
approach or the extreme lateral transcondylar approaches 
are necessary. If TJPs involve the cavernous sinus, a 
residual disease should be intentionally left at this level 
to avoid compromising cranial nerves  III, IV, and VI. 
For tumors extending to the foramen magnum and lower 
clivus, a modified transcochlear approach type D or the 
extreme lateral approach may be used. Tympanojugular 
paragangliomas frequently involve the ICA due to 
their close anatomical proximity. When indicated, the 
tumor must be dissected from the arterial wall. This can 
be accomplished by subperiosteal and subadventitial 
dissection. When the tumor encapsulates the artery causing 
stenosis, manipulation without proper endovascular 
intervention may be complicated by severe bleeding, 
incomplete removal, or cerebral vascular accident. An ICA 
balloon occlusion is performed in the case where the ICA 
is infiltrated by the tumor and the collateral blood flow 
is sufficient. In cases with insufficient collateral blood 
flow, we have developed the technique of intra-arterial 
stenting of the ICA 12 13. This technique reinforces the ICA 
so that the surgeon can easily establish a cleavage plane 
on the external surface of the stent and more aggressively 
remove the tumor without the risk of ICA tearing. This 
new technique can allow reappraisal of selected cases 
previously suited only for subtotal resection. 
Chordoma and chondrosarcoma
Chordomas are a rare and unusual group of malignant 
tumors that are believed to arise from the persistent rests 
of the embryonal notochord. These are believed to be more 
frequent in the male gender. The pathogenesis of chordomas 
remains unclear. Chondrosarcomas of the skull base are 
rare slow growing locally aggressive malignant tumors 
that constitute 0.15% of all intracranial neoplasms. It has 
been hypothesized that cranial base chondrosarcomas may 
originate from multipotential mesenchymal cells or from 
embryonal cartilage remnants of skull synchondroses. The 
most common tumor sites of origin of both these entities 
nearly overlap and have been reported to be the petroclival, 
petro-occipital, spheno-occipital, and the sphenopetrosal 
synchondroses. Both chordomas and chondrosarcomas cause 
symptoms primarily related to cranial nerve involvement as: 
extent, which should be determined according to CT scan 
and MRI findings. 
Meningioma involving the petrous apex
Meningiomas involving the PA and the adjacent clivus are 
some of the most difficult lesions to manage in this area. 
The petroclival and posterior petrous face meningiomas 
involve the PA. Petroclival meningiomas arise from the 
clivus or petroclival junction medially to the trigeminal 
nerve. They may extend along the petrous pyramid, middle 
fossa, or into the cavernous sinus. Large tumors displace or 
encase the basilar artery or its branches. As with most other 
lesions of the PA, in our series, hearing loss (76.5%), tinnitus 
(44.4%), instability (51.8%), and vertigo (22.2%) were 
the most common presenting complaints. Other features 
include facial paresis, ataxic gait, trigeminal neuralgia, facial 
anesthesia, and headaches. On CT, meningiomas appear 
to be hyperattenuating to brain, iso-to hypointense on T1-
weighted images, and iso-to hyperintense on T2-weighted 
images. They also demonstrate postcontrast enhancement. 
Meningiomas may cause hyperostosis of the PA, a finding 
that is most evident on CT. Angiography of both vertebral 
and ICA is performed to determine the major arterial 
branches and the blood supply to the tumor. The adoption of 
a particular approach for petroclival meningiomas depends 
on the location of the tumor. Tumors of the upper and middle 
clival area tend to involve the PA. Upper clival tumors can be 
approached by the frontotemporal orbitozygomatic approach 
or the middle fossa transpetrous approach as described by 
House et al. in 1986  11. Tumors of the middle clivus can 
be adequately approached by modified transcochlear, 
retrolabyrinthine, suboccipital, or TL approaches, of which 
the modified transcochlear approach type  A is the safest. 
The modified transcochlear approach offers a wide and 
safe exposure, needs no cerebellar or brainstem retraction, 
permits removal of the invaded dura or bone, and can be 
extended to afford excellent control of anterior, superior, or 
inferior tumor extensions. Disadvantages of this approach are 
the sacrifice of hearing function and facial nerve impairment. 
Hearing preservation surgeries, however, provide restricted 
access to the tumor and also involve retraction of the 
cerebellum. Posterior petrous face meningiomas can be 
divided into lesions lying anterior, posterior, or centered 
on the internal auditory canal. Lesions lying anterior to 
the internal auditory canal tend to involve the PA and they 
can be approached in the following ways: small lesions are 
managed by a middle fossa transpetrous approach and larger 
lesions not reaching the midline can be managed with a 
retrolabyrinthine subtemporal transapical approach with or 
without transtentorial extension.
Paraganglioma involving the PA
Tympanojugular paragangliomas (TJPs) are benign tumors 
involving the middle ear cleft and the skull base. Fisch 
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Therapeutic options for patients with facial nerve 
neuromas include surgical intervention, observation, and 
radiotherapy  14. Nowadays, surgical resection with facial 
nerve repair is usually the standard management for 
patients with poor facial function [House-Brackmann (HB) 
grade III or worse]. In patients presenting with normal or 
near-normal facial nerve function, initial observation with 
periodic examination and imaging is usually recommended. 
However, in rare occasions, surgeons can face a situation 
in which the decision-making process is particularly 
challenging. In these complex cases treatment should be 
individualized. We recommend early surgical intervention 
regardless of the preoperative facial and hearing functions 
in the following cases: intratemporal facial nerve 
neuromas extending with a large tumor component into 
the parotid, multiple-segment tumors extending in both the 
cerebellopontine angle and the MCF, fast-growing tumors, 
and large tumors with temporal lobe compression. The 
surgical approaches of tumors involving the PA include 
MCF-transpetrous approach, combined MCF-transmastoid 
approach, transcochlear approach, or the TL approach. In 
most of the cases, it becomes necessary to reconstruct the 
cut sections of the nerve after tumor removal. We prefer 
to use the sural nerve as a cable nerve graft to replace the 
lost segment of the nerve. A maximum recovery of the 
postoperative facial nerve function to HB grade III can be 
expected after nerve grafting 14 15. 
Trigeminal schwannoma
These are rare tumors of the Schwann cells. This is one 
of the important lesions involving the Meckel’s cave area. 
Naturally, clinical presentation corresponds to a trigeminal 
nerve dysfunction: neuralgia, neurasthenia, or numbness. 
If the lesion is large, then mass effect symptoms may be 
present. Depending on their location they can be classified 
as:
• Type I. Predominantly middle fossa tumors; the approach 
in these cases is the frontotemporal orbitozygomatic.
• Type II. Predominantly posterior fossa tumors with 
limited middle fossa involvement; modified transcochlear 
approach type  C, retrolabyrinthine subtemporal 
transtentorial approach (for hearing preservation), or the 
middle fossa transpetrous approach are utilized for these 
lesions. 
• Type III. Significant middle and posterior fossa 
components; combined frontotemporal orbitozygomatic 
and transpetrous approaches are recommended. 
• Type IV. Extradural tumors involving the infratemporal 
fossa and surrounding structures; the approach used is an 
infratemporal transzygomatic approach (ITFA type D). 
Osteoclastoma (Giant Cell Tumor, GCT)
Giant Cell Tumors are a group of rare benign neoplasms that 
are most commonly found in the epiphysis of long bones. 
dysfunction of extraocular movement with diplopia, hearing 
loss, dizziness and tinnitus, sensory disturbances of the face, 
and dysphagia. Pain and headache may be present due to 
erosion of bone or pressure due to the tumor. The CT most 
commonly reveals bone destruction and a soft tissue mass 
with tumoral calcification, which is encountered in 56% 
of tumors. On T1-weighted MRI, chondrosarcomas have a 
low-to-intermediate signal intensity and are isointense or 
hypointense compared to the gray matter. On proton density 
and T2-weighted images, they have a high-signal intensity 
and are hyperintense compared the gray matter. Contrast 
enhancement is typically heterogeneous. A radiologic 
distinction between chondrosarcoma and chordoma is 
usually not possible. 
Surgery is considered the standard of care in the treatment 
of skull base chordomas and chondrosarcomas. Proton 
beam radiotherapy or radiosurgery is often used as adjuvant 
therapy. The surgical intervention needs to be aggressive in 
these lesions. Small lesions with good preoperative hearing 
can be managed by the middle fossa transpetrous approach 
with extensive removal of the bone of the PA. Larger lesions 
with involvement of the vertical or the inferolateral aspects 
of the horizontal ICA necessitate a wider approach such as 
the ITFA type  B or its combination with a TO approach. 
If preoperative hearing is good, then a retrolabyrinthine 
subtemporal transtentorial approach can be used. Extensive 
transdural cases will necessitate the addition of a modified 
transcochlear approach. 
Facial nerve neuroma
Facial nerve neuromas are uncommon benign neoplasms 
of Schwann cells. They represent only the 0.8% of all 
intrapetrous lesions. Although these tumors involve all 
portions of the facial nerve, the geniculate ganglion is 
the commonest site and hence these lesions are also most 
likely to involve the PA. Symptoms in facial nerve neuroma 
have an insidious onset that also depends on the location 
and extent of the lesion. Progressive or sudden facial 
palsy is a common symptom. In our series of 103  facial 
nerve tumors, only 76% of our patients presented with 
the classic gradual facial palsy  14. Other presentations 
included sudden or recurrent hemifacial palsy. Facial nerve 
function was normal in 9.5% of the cases. Facial nerve 
neuroma is found to be the cause in approximately 5% of 
patients presenting with Bell’s palsy. Due to the proximity 
of the tumor to the cochlea, a sensorineural or conductive 
hearing loss can occur, depending on whether the tumor 
originates proximal or distal to the geniculate ganglion. CT 
scan shows enlargement of the facial canal, bone erosion, 
or an enhancing soft tissue mass while MRI shows hypo-
or isointense tissue on T1-weighted imaging, hyper or 
isointense tissue on T2-weighted imaging with marked 
contrast enhancement 15. 
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5.2. The evolving evidence based algorithm 
in vestibular schwannoma management
D.A. Moffat, D.G. Hardy, S.L.K. Lloyd, S. Jefferies, R. Macfarlane
Introduction
Our fascination with the vestibular schwannoma continues 
unabated over many centuries. Persig  1 reported on an 
excavated skeleton of a 5 yr old boy from as long ago as 2,300 
years BC which clearly demonstrated tumour widening of 
the left internal auditory canal (IAC) and widening of the 
hypoglossal canal which almost certainly meant that the 
child had neurofibromatosis type 2 (NF2).
Diagnosis
Sandifort in 1777  2 was the first to report a vestibular 
schwannoma at autopsy and Sir Charles Bell was the first 
to diagnose one in 1830 3. It was not until 1895 that Thomas 
Annandale  4 undertook the first successful operation in 
Edinburgh on May 3rd of that year. Previously there was 
no treatment for vestibular schwannoma and patients 
succumbed eventually from raised intracranial pressure 
and brainstem compression. There was no imaging and 
the diagnosis could only be made when the neurological 
signs of a large mass at this site were present. Although 
vestibular schwannoma was the most likely diagnosis other 
pathologies existed in this anatomical region but could not 
be differentially diagnosed. 
In the 1960s an audiometric test battery was used to 
differentiate cochlear and retrocochlear deafness and Jerger 
reported on hearing tests in otological diagnosis in 1962 5. 
Speech audiometry in vestibular schwannoma cases  6 
often revealed distortion for phonetically balanced speech 
sounds presumably due to asynchronous neuronal firing 
due to tumour compression and a disproportionately poor 
speech discrimination score (SDS) compared with the pure 
tone audiometric threshold (PTA) threshold. Tone decay 
was a retrocochlear feature as was stapedial reflex decay. 
Fowler’s alternate loudness balance test assessed the degree 
of recruitment 7. Bekesy audiometry 8 proved disappointing 
in differentiation between sensory and neural deafness but 
the SISI or small increment sensitivity index was better, 
recruiting deafness allowing the small increments to be heard 
but not in retrocochlear deafness  5. In the 1960s and early 
1970s this full test battery was used but the results of a study 
of this in 500 cases of acoustic neuroma by Johnson 1977 9 
revealed that the number of positive results for retrocochlear 
deafness was disappointingly low. Stapedial reflex decay 
proved to be the most effective in differentiation but by itself 
audiometry was not as clinically useful as we had wished. 
Our hopes turned to auditory evoked potentials (AEP).
Electrodiagnostic tests, both transtympanic electroco-
chleography (ECochG) and auditory brainstem responses 
Of the total 1-2% of these lesions present in the head and 
neck with the skull base being a commonly reported site 
(temporal, sphenoid, and ethmoid bones). In the skull base 
the temporal bone is a common site of occurrence of GCTs. 
Although benign, these tumors have a locally destructive 
character that can be potentially dangerous in the presence 
of intricate nervous and vascular structures of the temporal 
bone and skull base. Hearing loss, tinnitus, and subcutaneous 
masses are the most commonly reported symptoms in GCTs 
of the skull base. The TM is often intact as the tumor is 
anteromedial to it. The radiological picture of a GCT is an 
osteolytic lesion. Both CT and MRI are essential for tumor 
staging and management. Although CT is superior to MRI 
in outlining tumor extent and bony destruction of the skull 
base, MRI is currently the best imaging modality for GCT 
because of its superior contrast resolution and multiplanar 
imaging capabilities that allow accurate tumor delineation. 
The GCT shows low intensity on T1 and heterogeneous high 
intensity on T2-weighted images. Gadolinium enhancement 
reveals areas of hypervascularity and enhancement with a 
very heterogeneous signal pattern. 
The surgical approach depends on the position and extent 
of the tumor. Since most GCTs are found involving the 
temporal bone and the infratemporal fossa, the ITFA types B 
and D provide an ideal approach and exposure to these 
tumors with a blind-sac closure of the EAC. For tumors 
involving the MCF with or without dural invasion, a MCF 
craniotomy must be performed. For additional exposure any 
skull base procedures may be added. Posterior extensions 
into the posterior cranial fossa (PCF), although rare, can be 
aggressive and extremely challenging to treat.
Conclusions
The PA is a complex area surrounded by vital neurovascular 
structures and the brain. Pathologies lying in this area are 
a diagnostic and surgical challenge. A variety of diseases, 
especially neoplasms, affect the PA and the skull base. 
Surgery is the treatment of choice for all neoplastic lesions. 
In the past, surgical excision of lesions of this area were 
hampered with serious complications and morbidities. 
However, in the era of modern skull base surgery, this 
is no longer the case due to the evolution of excellent 
surgical approaches aided by advances in neuroradiology, 
neuroanesthesia, and microsurgery. Modern imaging studies 
have also greatly increased the ability to diagnose lesions, 
especially in spite of an often vague symptomatology 
associated with these lesions. Tumors involving the 
temporal ICA are no longer deemed inaccessible or 
inoperable due to the development of appropriate surgical 
approaches and the technique of stenting. In quaternary 
referral skull base centers across the world, PA as well as 
other skull base pathologies are routinely performed with 
minimal morbidities or complications. 
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neuroma in 1894  14 but it is now thought to have been a 
meningioma and that Thomas Annandale was the first in 
1895 4.
Harvey Cushing, the father of American neurosurgery was a 
true pioneer. In 1917 Cushing published his work on acoustic 
neuroma based on 30 cases  15. He used a subcapsular 
resection and he sewed the edges of the tumour remnant 
together. The mortality from other series around that time 
was 70% and Cushing was able to reduce the mortality to 
15% which was outstanding. Walter Dandy was previously 
Cushing’s trainee and pre-eminent at that time and he had 
a great battle with Cushing over the treatment of acoustic 
neuromas. Dandy 16 was the first to show that they could be 
removed in their totality rather than by intracapsular removal 
as proposed by Cushing.
William House the modern fore-father of otoneurological 
surgery, in his landmark paper of 1963 17 described the use 
of the middle fossa approach for a variety of conditions. He 
also revitalised interest in the translabyrinthine approach to 
acoustic neuromas first described and proposed by Panse in 
1904 18. 
With this the modern era was born with the three main 
surgical approaches, translabyrinthine, retrosigmoid and 
middle fossa. Any size of vestibular schwannoma can 
be excised via a translabyrinthine approach but hearing 
preservation procedures are either by the retrosigmoid or 
middle fossa approach.
The evolution of watch, wait and rescan management
Observation is non-invasive but we need to know what 
happens over time to these patients. They still have their 
tumour and their symptoms. This management option was 
proposed by Thomsen and Tos  19 and emerged in 1988 
(ABR) were exciting advances enabling us with the former 
to study the electrical responses in the outer hair cells and 
first order cochlear neurones and in the latter the brainstem 
auditory pathway. Electrocochleography was not very help-
ful and rarely was the marked widening of the action poten-
tial (Kiang potential)  10 seen and it was difficult to obtain 
a response probably due to asynchronous neuronal firing 
caused by the tumour stretching the nerve. That is not to 
say that Kiang’s experiment in blowing up a balloon in the 
IAC of an anaesthetised cat to mimic tumour compression 
of the cochlear nerve and producing this wide potential was 
not extremely elegant. 
ABR proved to be a good test and delay in the fifth wave 
(J5) and the J3-5 interval produced, according to a recent 
Danish study, a sensitivity of 80% and and a specificity of 
77%. “Stacked” ABR (Don and Brackmann 1997 11 allowed 
small tumours to be diagnosed. The problem was that in 53% 
of cases no recording could be made because of a dead ear 
or no consistent response. This led to the employment of the 
“rule of three’ where 2 out of three positives of widening of 
the IAC on Xray, absence or hypofunction of the labyrinth 
on caloric testing, and abnormal ABR would lead to a high 
suspicion of VS triggering CT with air meatography if 
necessary. 
The evolution of definitive diagnostic imaging was 
remarkable. A number of views of the IAC on plain Xrays 
were developed in order to demonstrate widening of the 
canal and in particular Stenver’s view which was described in 
1917. Although Dandy described pneumoencephalography 
in 1919 12 it was not until much later that it was refined to 
image the posterior fossa. The importance of the position of 
anterior inferior cerebellar artery (AICA) led to the use of 
vertebral angiography in 1956. The advent of hypocycloidal 
tomography in 1959 gave a clearer view of the IACs and 
made it more likely that tumour widening could be detected. 
Myodil cisternography could diagnose larger tumours. The 
advent of CT following its discovery by Hounsfield in1973 13 
allowed imaging of extrameatal tumours but as bone has a 
positive signal intrameatal tumours could not be seen. This 
led on to air meatography in 1975 and a small intracanalicular 
vestibular schwannoma could present as a non-filling IAC 
mass of soft tissue density.
MRI is now our “gold standard” diagnostic tool either by T2 
weighted MRI or by T1 weighted image enhancement with 
Gadolinium DTPA (Fig. 5.2.1). The increasing resolution of 
MRI has enabled tumours as small as 3 mm to be detected.
Management
The evolution of surgical management 
The evolution of the surgical management of vestibular 
schwannoma is remarkable. Sir Charles Ballance was said 
to be the first surgeon to successfully remove an acoustic 
Fig. 5.2.1. Axial T1 Weighted image enhanced with Gadolinium DTPA re-
vealing a 3mm vestibular schwannoma at the fundus of the left IAC (white 
arrow).
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Results
These are the outcomes of the three modalities for managing 
vestibular schwannoma in our Departments at Cambridge 
University Hospital.
Outcome of unilateral sporadic vestibular schwannoma 
surgery
There were 1,056  surgical cases operated on over a 30  year 
period.
All patients had a histologically proven unilateral sporadic 
vestibular schwannoma.
In this series 923 (87%)  of the tumours were excised via a 
translabyrinthine approach and 132 (13%) were retrosigmoid 
operations.
One patient had a combined translabyrinthine /retrosigmoid 
approach in 1982.
Patient demographics
There were 523 male patients and 533 females in the series. 
The age range was 13-86 years with a median of 53.8 years 
and standard deviation of 12.6 years. The majority of patients 
presented in their 6th and 7th decades.
Tumour size (n = 1,044)
Tumour size was the maximum medio-lateral measurement in 
centimetres in the axial plane through the IAC and can be seen 
in the histogram in Figure 5.2.2.
Only 19% (195) had tumours less than 1.5  cm. The largest 
group was 1.5 to 2.4 cm, 36% (375) of tumours and there were 
23% (245) with tumours 2.5-3.4 cm, 15% (154) between 3.5 
and 4.4 cm and 7% with tumours greater than 4.5 cm. Thus 45% 
of tumours were greater than 2.5 cm.
Tumour excision (n = 1,032)
10% (99) of tumours were significantly adherent to the 
brainstem reflecting the significant proportion of large tumours 
in this series. 95% (985) had a total excision, 4% (41) had a near 
largely following the Danish studies on tumour growth from 
their National database. 
The evolution of stereotactic radiotherapy
Stereotactic radiosurgery (SRS) was first developed in 1949 
by the Swedish neurosurgeon Lars Leksell 20 and given as a 
single high dose fraction of radiation. The compact gamma 
knife was developed in 1968 and by then stereotactic proton 
beams had replaced the x-rays and the heavy particle beam 
presented as an excellent replacement for the surgical knife 
and hence the terms gamma knife and radiosurgery were 
coined. Radiotherapy can also be given by multiple fractions 
by LINAC (the linear accelerator) and called fractionated 
stereotactic radiotherapy (FRST). The dose is usually 
50 Gray in 30 fractions over 6 weeks. 
Methods
The design was an original cohort study using prospectively 
collected clinical and surgical data of patients with sporadic 
unilateral vestibular shwannomas. The detailed clinical 
records of the surgical patients and those in the watch, wait 
and rescan groups were obtained from a 230 point database 
initially established on Filemaker Pro 5 software in 1985 
and latterly on Filemaker Pro 13  *. In the watch, wait and 
rescan group linear measurements were used to assess 
tumour size and two or more magnetic resonance scans were 
included. The slice providing the most representative part of 
the tumour was identified in the axial and coronal planes. 
Maximal tumour size was measured in three axes, medio-
lateral, antero-posterior and cranio-caudal. For tumours 
with extracanalicular extension, maximal medio-lateral 
measurements were made along the long axis of the internal 
auditory canal and included the intracanalicular portion of 
the tumour. Antero-posterior measurements were made in 
an axis parallel to the posterior face of the temporal bone. 
Axial images were used for these measurements. Cranio-
caudal size was assessed using coronal images. The point 
of growth and pattern of growth progression were assessed. 
Based on the literature investigating inter-observer error, 
tumour growth was defined as greater than 2 mm increase 
in the maximal tumour diameter in a direction parallel to 
the internal auditory canal on subsequent scans 21. Data was 
analysed using appropriate statistical techniques. The data 
from the stereotactic radiotherapy group was retrieved from 
the Department of Oncology.
The evolving algorithm for treatment is dependent now on 
detailed studies of outcome producing an evidence base for 
each management option.
* Filemaker, Inc. is a subsidiary of Apple Inc. Fig. 5.2.2. Histogram of tumour size in the surgical series (n = 1,044).
RS: retrosigmoid approach; MF: middle fossa approach; TL: 
translabyrinthine approach.
E. Zanoletti et al.
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Hemifacial spasm (n = 879)
The incidence of significant hemifacial spasm at 3 months 
postoperatively was 4.6% in this series but as you would 
expect with continuing nerve regeneration this increases to 
11% at 12 months and then does not significantly increase 
thereafter enabling us to advise our patients accordingly.
Cerebrospinal fluid (CSF) leak (n = 1,056)
The CSF leak rate over this whole series was 6.5% with a 
control rate of 3.1% with lumbar drainage and 3.4% requiring 
re-exploration. An analysis of the re-exploration rate over time 
revealed that 9 cases or 25% of all leaks were re-explored in the 
first 100 cases. This improved over time as the surgical closure 
technique evolved and is now at 1% for the last 200 cases. 
Meningitis (n = 881)
The overall meningitis rate was 1.3% (14 cases).
Headache at 12 months postoperative (n = 781)
Generalised headache was slightly less after the retrosigmoid 
approach at 5% as compared with 9% for the translabyrinthine 
approach but localised headache was four times more 
frequent in the retrosigmoid approach at 8% compared with 
2% in the translabyrinthine cases. Occipital neuralgia was 
five times more frequent after the retrosigmoid approach at 
15% compared with 3% in the translabyrinthine approach.
Quality of life (QoL)
Surgical outcome with regards to hearing, tinnitus and 
dizziness are important parameters of quality of life for the 
patient in VS. We have studied the postoperative change in 
the hearing 23, tinnitus 24 and vestibular handicap inventories 25. 
This has altered the way we counsel patients pre-operatively 
and led to, for example, instituting pre-operative vestibular 
rehabilitation exercises.
Other complications (n = 1,047)
The other complications are what might be expected in major 
intracranial surgery and are listed in Table 5.2.I.
Residual and recurrent tumour
• Retrosigmoid (n  =  132). Recurrent or residual tumour 
total excision leaving capsular remnants usually on a cranial 
nerve in order to preserve neurological function. Only 1% (6) 
had a subtotal excision with 95% or more of the tumour being 
excised. No patients had a partial excision.
Mortality (n = 1,056)
There was a zero operative mortality and a 0.76% 
perioperative mortality. There were 8 deaths 7 of which were 
in the first 250 cases in the first decade of the surgery. There 
has only been one death in the last 20 years of surgery.
Facial nerve state at surgery (n = 1,002)
In 40% (402) of patients the nerves were intact and normal at 
surgery. In 58% (577) the facial nerve was significantly thinned 
by tumour compression and 2% (23) were lost at surgery.
Facial nerve outcome (n = 1,056) 22
The data analysis of the facial nerve results for the whole 
series over 30  years since 1982 reveals that for small 
tumours, less than 1.5 cm, 81% have normal function or a 
House Brackmann I or II result and 96% have a HBI to III or 
satisfactory outcome. 
For tumours of 1.5 to 2.4 cm, 71% have a normal face and 
95% have a satisfactory result. Tumours of 2.5 to 3.4  cm, 
53% are normal and 85% satisfactory. 
Tumours of 3.5 to 4.4 cm, 43% are normal and 75% 
satisfactory. For giant tumours larger than 4.5 cm, 39% are 
normal and 71% satisfactory. 
Figure 5.2.3 shows the current facial nerve outcome of the 
last 200  operations. The facial nerve outcomes are even 
better than the series as a whole reflecting the effect of long 
term surgical experience.
Fig. 5.2.3. Facial nerve outcome of the last 200 surgical cases. The facial 
nerve outcome for tumours less than 1.5 cm in maximal diameter was 94% 
with a normal face or House Brackmann I or II result and 100% had a HBI to 
III or satisfactory outcome. For tumours of 1.5 to 2.4 cm, 80% had a normal 
face and 99% a satisfactory result and in tumours of 2.5 to 3.4 cm, 67% 
were normal and 94% satisfactory. In tumours of 3.5 to 4.4 cm, 54% were 
normal and 83% satisfactory and tumours larger than 4.5 cm it was 33% 
normal and 54% satisfactory.
Table 5.2.I. Other complications of vestibular schwannoma surgery 
(n = 1,047).
Deep venous thrombosis (DVT) 1.2% (12)
Pulmonary embolism 0.9% (9)
Respiratory infection 1.7% (18) 
Scalp wound infection 1.2% (12)
Thigh wound
 – infection 1.5% (16)
 – haematoma 4% (42) 
Myocardial infarction 0.6% (6)
Temporary dysphagia 2% (20)
Trigeminal numbness at 3 months 2.5% (26)
VI nerve palsy at 24 months 1% (11)
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was present in 3.8% (5 patients) of retrosigmoid approach 
cases. This is very unlikely to grow if it is only a small 
volume of tumour and we have not had to re-operate on 
any of these patients. Linear enhancement in the IAC was 
present in 5.3% and it can be difficult to know whether 
this is postoperative surgical change or residual tumour. 
These patients require interval scanning for a few years to 
establish the situation.
• Translabyrinthine (n = 510). Recurrent or residual tumour 
was only seen in 0.6% (3 patients) of the translabyrinthine 
cases where total excision was attempted. Enhancement 
not thought to be tumour occurred in 3.5% (18 patients) 
and of these 18 patients:
• linear enhancement of the IAC or dura was seen in 12;
• enhancement around the fat plug in 3;
• hyperintensity at the fundus in 2; 
• a small nodule of doubtful significance in one patient.
Outcome of watch, wait and rescan management
There were 381 patients with sporadic unilateral vestibular 
on the database with at least two MRI scan results. 
Patient demographics
There were 175 males (46%) and 206 females (54%). The 
mean age at diagnosis was 60.9  years (SD  12.1). The age 
range was 26 to 98 years. There were 187 right sided tumours 
(49%) and 194 left sided tumours (51%). The mean interval 
between first and last scans was 4.2 years (SD 3.2; range: 0.5 
to 17 years).
Growth characteristics of vestibular schwannoma 21
A summary of the analysis of this data can be seen in 
Table 5.2.II.
Hearing change in watch, wait and rescan management 26
A summary of the analysis of this data can be seen in 
Table 5.2.III.
Since 1988 there has been an increasing number of patients 
opting for observation of their tumours by watch, wait and 
rescan management compared with microsurgical excision 
(Fig. 5.2.4).
Outcome of fractionated stereotactic radiotherapy treatment 
(FSRT)
Tumour growth control rate (n = 70)
The results of fractionated stereotactic radiotherapy for 
vestibular schwannoma treated with a dose of 50  Gray in 
30 fractions over 6 weeks revealed a tumour control rate of 
97%. All tumours were growing pre-treatment as it was not 
our policy to irradiate non-growing tumours.
Preservation of serviceable hearing (n = 70)
57% preservation of serviceable hearing defined as AAO-
HNS class A or B or Gardner-Robinson class 1 or 2. 
Malignant change (n = 70)
There was no induction of malignant change in this series (0%).
Complications of FRST (n = 70)
The complications of FSRT can be seen in Table 5.2.IV.
Discussion
Sackett et al stated in 1995 27 that “evidence based medicine 
(EBM) is the conscientious, explicit and judicious use of 
current best evidence in making decisions about the care of 
individual patients”. He also said that “because the randomised 
Table 5.2.II. Vestibular schwannoma growth data (n = 381).
67% overall did not grow 
59% no growth - 8% involute
33% of tumours grew in this series.
The patterns of growth are totally variable over time
Growth is usually slow with an annual rate of 2.3 mm
10% grow rapidly (> 5mm/annum)
10% of tumours showed growth even after 5 years
Growth characteristics are unpredictable
There are no factors that predict growth in our series
Table 5.2.III. VS under observation - Change in hearing over time (n = 381).
Hearing outcomes significantly worse in tumour ear
Hearing deteriorates faster in growing tumours
Hearing deteriorates faster than by presbyacusis alone even in non-
growing tumours
Class A hearing in intracanalicular tumours may be preserved
Hearing preservation rates in watch and wait patients should be 
compared with hearing preservation surgery and radiotherapy
Loss of candidacy for hearing preservation surgery by 50/50 rule 
30% after 3 years - 50% after 5 years
VS: vestibular schwannoma.
Fig. 5.2.4. Histogram illustrating illustrating the increasing number of pa-
tients undergoing observation of their unilateral sporadic vestibular schwan-
nomas compared with those undergoing microsurgical removal.
E. Zanoletti et al.
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Patients will also want to know the outcome of SRS in 
comparison with FSRT so that they can make an informed 
decision on which form of radiotherapy they would prefer 
to have.
A systematic review or meta-analysis of papers reporting 
outcome of SRS and FSRT was attempted by Persson et al. 32 
but unfortunately no randomised controlled trial was identified 
and therefore a meta-analysis was not possible and a case 
series comparison only could be reported and even then there 
were 19 papers on long-term tumour control for SRS but only 
2 papers reporting outcome from FRST. There was a tumour 
growth control rate 95% for SRS and 95.2% with FSRT. The 
mean deterioration ratio for serviceable hearing was 49% in 
SRS and 45% for FSRT. 
Facial nerve deterioration occurred in 3.6% for SRS and 
11.2% for FSRT. Trigeminal nerve deterioration occurred in 
6.0% for SRS and 8.4% for FSRT.
Watch, wait and rescan management is obviously an attractive 
non-invasive option for patients but they still have their tumour 
and their symptoms and outcome is important and they need 
to know what will happen over time. The data shows that their 
hearing will deteriorate faster than by presbyacusis alone even 
if their tumour does not grow and a proportion, 30% after 
3  years and 50% after 5  years, will lose their candidacy for 
hearing preservation surgery. This is an important consideration 
especially if the hearing is not normal in the contralateral ear. 
Vestibular disturbance can be markedly deleterious to quality 
of life in a small proportion of cases and it may be necessary 
to consider gentamicin ablation of the labyrinth or become an 
indication for surgery. There is also some discussion as to when 
MRI scanning can be stopped in non-growing tumours. Our 
data suggests that up to 10% can start growing after 5 years and 
there is, therefore, an indication to continue scanning every 3 or 
5 years in the longer term. Our protocol in this group is to scan 
at 6 months after diagnosis and then every year for 3 years, then 
every 2 years for 6 years and then every 3 years thereafter.
The outcome of surgical excision of these tumours continues 
to improve with advances in neuro-anaesthesia, neurosurgical 
intensive care and the use of ultrasonic cavitrons, lasers and 
endoscopy as well as cranial nerve monitoring.
It is, however, major intracranial surgery and patients must 
be given a detailed account of all aspects of surgical outcome 
in order to make an informed choice of management. Neuro-
otologists are rightly concerned about total loss of hearing 
with the translabyrinthine approach and retention of socially 
useful hearing with the retrosigmoid approach has been 
disappointingly low but recent reports on the hearing outcome 
of the middle fossa approach have been more encouraging. 
However, there should be an awareness that in unilateral VS 
the patients main concern is dizziness more than hearing 
especially if the contralateral ear has normal hearing. 
A detailed study of the outcome of each of the three current 
modalities of treatment enables the practice of evidence 
trial is so much more likely to inform us and so much less 
likely to mislead us it has become the “Gold standard” for 
judging whether a treatment does more harm than good”.
It has become clear that the resultant creation of the current 
levels of evidence for treatment and the randomised trial 
as the “gold standard” is more applicable to medicine than 
surgery where it is difficult to achieve more than level  3 
evidence. Recently a new schema for evidence based surgery 
has been proposed 28 called the “expertise-based randomized 
trials” extolling the virtues of comparing two different 
surgical procedures for the same pathology.
The evolving algorithm for the management of vestibular 
schwannoma is dependent now on detailed studies of 
outcome producing an evidence base for each management 
option enabling the patient to give true informed consent to 
treatment based on this.
The overall risk/benefit analysis of any treatment is multifactorial 
and detailed surgical outcome data informs this but critically the 
patient needs to know their likely quality of life postoperatively 
related to morbidity if they are going to opt for this treatment. 
Our Cambridge study using the European Organisation for 
Research into the Treatment of Cancer (EORTC) 29 concluded 
that patients with tumours less than 1.5cm had a significantly 
better outcome than larger tumours. A second study using a 
modified SF36 questionnaire concluded that reduced quality 
of life (QOL) after surgical treatment coupled with minimal 
preoperative symptoms and a 67% chance of no growth in 
smaller tumours supported a conservative approach to patient 
management in small tumours 30. 
Gamma knife QoL has been reported as better than surgery 
in papers using the Penn Qual for Acoustic neuroma and also 
the Myrseth Group 31 from Norway. 
Thus a critical comparison of the outcome of surgery with 
stereotactic radiotherapy is vital if consent to treatment is 
to be fully informed. We do not believe in treating non- 
growing tumours with SRS but some centres will irradiate 
non-growing tumours and therefore since 67% of small 
to medium sized VS are not growing in any case the high 
percentage of tumour control reported from these centres 
with SRS will be spurious if two thirds of the tumours 
are not growing. Also, the patients need to be informed 
of the risk of SRS treatment with regard to malignant 
transformation. The exact risk in VS is not known but we 
quote a malignancy rate of 1% per decade from the pituitary 
adenoma study. 
Table 5.2.IV. Complications of fractionated stereotactic radiotherapy for 
VS (n = 70).
3% hydrocephalus VP shunt (ventriculo-peritoneal shunt)
3% trigeminal neuralgia 
3% facial palsy (recovered) 
VS: vestibular schwannoma.
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Conclusions
The publication of outcome and audit data from a detailed 
analysis of clinical databases within a multidisciplinary skull 
base unit in Cambridge has enabled the establishment of an 
evidence base for the three current modalities of treatment 
in the management of unilateral sporadic vestibular 
schwannoma. It has optimised patient care and validated 
informed consent to treatment and has allowed an evidence 
based algorithm in tumour management to evolve.
5.3. Management of NF2:  
from vestibular schwannoma microsurgery 
to hearing restoration
M. Kalamarides, H. Jia, H. Wu, O. Sterkers, D. Bernardeschi
Introduction
Neurofibromatosis type  2 (NF2) is a genetic disorder 
which occurres with a birth incidence of approximately 1 
in 25000 with a dominant pattern of inheritance. Bilateral 
vestibular schwannomas (VS) appear in 90-95% of NF2 
patients, as well as other benign nervous system tumors  1. 
Various managements, including “Wait and Scan” (periodic 
radiological and audiological evaluations), surgical 
treatment (decompression of internal auditory meatus; 
partial, sub-total, or total VS removal), radiation-based 
therapy (single-fraction stereotactic radiosurgery, SRS, 
and fractionated stereotactic radiotherapy, FRST), and 
chemotherapy (Bevacizumab) have been proposed for 
these patients whose disease burden is quite heterogeneous. 
Because most patients suffer bilateral sensorineural hearing 
loss (SNHL), the restoration of a serviceable hearing by 
acoustic amplification (hearing aid, HA), or rehabilitation 
by electrical stimulation applied to the remaining auditory 
structures in the cochlea (cochlear implant, CI) or directly 
to the cochlear nucleus (auditory brainstem implant, ABI) 
are also an essential goal of the treatment. In order to make a 
better decision for each individual with overall consideration 
of symptoms, tumor size and life threat, surgical risks, and 
natural history of tumor growth, a multidisciplinary medical 
team has been set up in NF2 reference centers including 
otologists, neurosurgeons, audiologists, speech therapists, 
neuro-radiologists, geneticists and psychologists 2.
VS management and hearing preservation 
Wait and scan
VS in NF2 are usually slow growing tumors although 
individual observation provided a wide growth range (0.4-
10 mm/year). In our series, 25% of 92 VS in 46 patients 
showed a fast growth rate (>  3  mm/year). This subgroup 
was mostly represented by young individuals 3. This result 
based tumour management and the creation of an algorithm 
for most patients with a vestibular schwannoma (Fig. 5.2.5).
In small tumours less than 15  mm extrameatal diameter 
the options are watch, wait and rescan or surgery by the 
retrosigmoid hearing preservation approach if the maximum 
speech discrimination score is better than 50% and there is no 
tumour in the fundus of the IAC. The middle fossa approach 
if the tumour is intracanalicular and laterally arising and 
by the translabyrinthine approach if the maximum speech 
discrimination is less than 50%. We only offer stereotactic 
radiotherapy for growing tumours. Growing tumours are 
offered SRS (fractionated LINAC or gamma knife) or surgical 
excision. Growing tumours after stereotactic radiotherapy 
are offered surgery. Tumours larger than 15 mm extrameatal 
are recommended to have surgery or offered SRS if no larger 
than 30 mm. In patients with tumours larger than 30 mm and 
in whom there is a very high risk then watch, wait and rescan 
management is adopted with the possibility of the insertion 
of a ventriculo-peritoneal shunt.
In the future this algorithm may change with the possibity of 
treating unilateral VS with the anti-vascular endothelial growth 
factor drug Bevacizumab from which the early results of a 
national study have been encouraging in neurofibromatosis 
type 2 (NF2) patients in the United Kingdom. 
The creation of a videoconferenced multidisciplinary team 
clinic both for unilateral sporadic VS and separately for 
tumours in NF2 has optimised patient care and management 
and facilitated the development of clinical databases and 
the measurement of outcome and audit. There is now a UK 
National Database for both which enables the establishment 
of an evidence base for the developing algorithm for the 
management of acoustic tumours. 
Fig. 5.2.5. The current management algorithm for patients with a unilat-
eral sporadic vestibular schwannoma.
E. Zanoletti et al.
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the risk of facial nerve paralysis in small and mid-sized 
VS remaines low, at a rate of less than 10% at 1year post-
surgery 9.
With modern intraoperative cochlear nerve monitoring, 
hearing preservation became more frequent than before. This 
is now achieved in 60-70% of patients via MFA and in 30-
40% of patients via RS 10. No predictive factors for hearing 
preservation were identified in sporadic VS although hearing 
appeared to be better preserved in cases in which PTA is 
not – or only moderately –  altered with a normal ABR, if 
the tumor does not invade the cochlear fossa for MFA, or if 
the IAM fundus is free of tumor for RS. However, a higher 
rate of VS recurrence has been reported after tumor removal 
through MFA than through RS 10. 
Decompression of the internal auditory meatus 
As hearing preservation by microsurgical resection 
showed various rates of success and cannot be precisely 
anticipated, a surgical technique which involves less 
trauma to the auditory nerve and its surroundings has 
been developed. It involves a decompression of the IAM 
through a MFA. An image-guided navigation system has 
been adapted to this technique to accurately and safely 
open the roof of IAM  11. With this technique, hearing 
preservation was achieved in approximately 90% of NF2 
patients, which is mandatory in case only one hearing 
ear is present. Further, cochlear implantation could still 
be possible if these patients lose their hearing later on, 
as the auditory nerve and the inner ear vascularization 
have not been previously damaged during the surgical 
manipulations of IAM decompression. 
Chemotherapy
Nearly all VS express vascular endothelial growth 
factors (VEGF, MGF-A). Bevacizumab, a humanized 
immunoglobulin G monoclonal antibody which binds 
to VEGF with high specificity, was applied in trials for 
NF2  patients. Short-term usage showed good efficacy 
for controlling tumor growth as well as preserving useful 
hearing, although its side effects appeared with a long 
term use  12. Additionally, it seems that treatment effect 
was transient and that the benefits could be reversed 
when discontinuing discontinuing the drug. A prospective 
protocol study aimed at minimizing side effects by 
administering low bevacizumab dosages on a small sample 
of patients  14 demonstrated a hearing response in at least 
1/3 of patients for 3  months  12. This hearing response 
was correlated to biomarkers indicating a reduced tumor-
associated oedema and an improved oxygenation that 
impacted on tumor volume. Patients treated with other 
drugs are too few to conclude about drug efficacy although 
some patients preserved hearing by long-term treatment 
with Everolimus 13.
suggested that the first magnetic resonance imaging (MRI) 
should be performed 6  months after diagnosis and then 
annually. Meanwhile, spontaneous shrinkage or no growth 
of VS could also be observed in a part of cases (14% in 
our series). It should be emphasized that after removing 
one-sided large VS, contralateral VS may appear to grow 
more rapidly, because presumably of the repositioning 
of the displaced brainstem toward the operated side, as 
the non-operated sided tumor less is compressed to the 
cerebellopontine angle (CPA) 4.
Vestibular schwannoma growth was not correlated to 
hearing loss in small samples of NF2 patients 3. For what 
concerns tumor growth rates, this was observed in 31%, 
64%, and 79% of cases at 1, 2, and 3 years from diagnosis, 
respectively. Hearing deterioration was observed in 5%, 
13%, and 16% of cases at 1, 2, and 3 years from diagnosis, 
respectively 5. Useful hearing was still present in 65 to 74% 
of NF2 patients after more than 6 years from diagnosis 3. 
As a consequence, the “wait and scan” policy can be 
recommended as a “natural hearing preservation” strategy, 
especially in middle age or older patients with small or mid-
sized tumors, because the VS growth might be, if present, 
rather slow, and hearing function may be maintained at a 
useful level for a long period of time in the majority of these 
NF2 patients.
Radiation therapy
Radiation therapy is an alternative treatment for NF2 
which includes two main techniques (SRS and FRST) 
whose radiation schedules and doses are different. Up 
to now, their outcomes still remain controversial. Some 
institutions reported that small and mid-sized tumors are 
well controlled with a 5-year local control rate of about 
75~87%, although still growing VS may be considered 
as under control  6. Furthermore, in most reported series, 
the natural growth rate of VS was not descripted before 
treatment and was not analyzed in the results. Lloyd 
et al., in a meta-analysis of 9 papers, concluded that 
generally 41.1% patients maintained serviceable hearing 
on long-term follow up with a mean tumor control rate 
of 81.4% 7. It should be recalled that a risk of malignant 
transformation of NF2 both VS and meningiomas exists 
with radiation therapy 8.
Vestibular schwannoma microsurgical resection 
Microsurgical resection of small or mid-sized VS with an 
attempt to preserve hearing could be achieved either by 
middle cranial fossa approach (MFA) or retro-sigmoid 
approach (RS), depending on the size of VS and invasion 
of the fundus of the internal auditory meatus (IAM). Recent 
improvements in endoscope-based skull base surgery 
allowed for tumor removal from the fundus under direct 
vision and relieved the major drawbacks of RS. With the 
development of intraoperative facial nerve monitoring, 
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scan demonstrated that auditory cortex is well activated 
though ABI 19, suggesting that coding strategies which were 
developed for CI but not for ABI might not be properly 
adapted to mapping of the cochlear nucleus. 
However, ABI could be recommended in young NF2 patients 
whose VS are growing rapidly and are often large at 
diagnosis, because no other therapeutic option is available. 
Probably because of the high brain plasticity in younger 
population, ABI performances appear to be better than in 
other populations. 
Conclusions
The combination of different management options should 
be now considered to improve both hearing preservation 
and tumor volume control. Decompression of IAM and 
chemotherapy, mainly Bevacizumab, are today the best 
options to preserve useful hearing in NF2 patients especially 
as NF2 related VS are generally growing tumors. To restore 
hearing, older patients with no or slow growth of small and 
mid-sized VS are candidate for CI without tumor resection, 
while young patients with large and growing VS are 
candidates for ABI with tumor resection. Because of small 
size samples and large individual differences, no prospective 
and randomized data could be completed in NF2  patients. 
Further studies might be focused on these topics to draw 
conclusions with higher confidence.
5.4. When preservation of auditory function 
is a must: technique and outcome  
in a series of neurofibromatosis type II
C. Matthies, M. Breun, W. Shehata-Dieler, R. Hagen 
Introduction
Bilateral auditory perception of our surroundings, of noises 
at different intensities, of harmony and modulation of voices 
and music, of sounds arriving at different angles, are essential 
data to our notion, as individuals, of being present within the 
world we live in. Slight unilateral changes, due, for instance, 
to presence of water in an external ear canal under the shower 
or music tone modulation as very early signs, and increasing 
or sudden hypo-acusis as intermediate signs of a developing 
acoustic tumor are irritating experiences for everyone. 
Though the majority of neoplasms of the vestibulo-cochlear 
nerve or in its proximity are generally histologically benign, 
they do compress, stretch and finally destroy the functions 
of this complex nerve. Any tissue growth near these pre-
damaged nerves is frequently followed by further hearing 
decline or loss.
By comparing the symptoms of these diseases and the 
likelihood of further hearing function deterioration, it is 
Hearing rehabilitation in NF2
Hearing aid
Hearing aids deliver an amplified sound passing through 
the damaged cochlea and auditory nervous pathways to the 
brain. In NF2 patients with moderate to severe hearing loss, 
conventional hearing aid could be proposed as a transient but 
low risk and atraumatic management. Most of the patients 
prefer not to adopt this solution because sounds usually 
appear distorted and sound intelligibility in noisy conditions 
is poor. 
Cochlear implant (CI)
Because a functional integrity of the auditory nerve cannot 
be guaranteed during surgery, cochlear implantation in 
NF2-related VS was not considered until recently. The 
main reasons might be an insufficient benefit and a mild 
performance obtained with ABI, together with a lack of ABI 
availability in some medical centers or countries. In these 
situations, best effort was taken to preserve the cochlear 
nerve. Intraoperative auditory monitoring is useful in this 
situation to aid intraoperative decision-making for either 
CI or ABI. The absence of intraoperative responses imply 
a post-operative non-functional auditory nerve, although 
a good response cannot guarantee hearing preservation. 
Because of poor and uncertain rates of hearing preservation 
through the retro-sigmoid approach, some authors suggested 
to remove the tumor through a trans-labyrinthine approach 
despite preoperative hearing level. This is because the latter 
approach allows early identification of the cochlear nerve 
and visualization of it all along the IAM and CPA. During 
the same surgical procedure, it is possible to implant a CI 
electrode array into the scala tympani of the cochlea 14-16. In 
order to ensure the maximum integrity of the auditory nerve, 
cochlear implantation without tumor removal was proposed 
and especially applied in older patients with sporadic VS, 
whose tumors were stable or slowly growing.
Indeed, CI in NF2 patients show better performances than 
ABI, although audiological features, tumor features and 
age of the two populations were different  14-18. With recent 
technological developments, either CI or ABI do not preclude 
postoperative radiological evaluations with MRI at 1.5 T or 
3.0 T for purposefully-built devices. Furthermore, a previous 
SRS does not contraindicate the placement of CI or ABI.
Auditory brainstem implant (ABI)
In most cases, ABI was implanted on the only hearing 
side, although in some cases it was implanted on the first 
side with the device switched off until contralateral total 
hearing loss was present (Sleeper ABI) 16. The ABI showed 
the expected auditory benefit with lip-reading aid in most 
cases. Intelligibility with ABI remains uncertain and few 
NF2 patients presented good open set performance without 
lip-reading  14  17  18. Indeed, positron emission tomography 
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and retroflection were the routine imaging techniques used. 
In case of unusual findings, additional diagnostics such as 
electrophysiology or spine MRI are performed. All patients 
were investigated with a neck provocation test which 
included tilting and rotating the patient’s head on both sides 
and keeping it in position for at least 30 seconds to investigate 
for eventual sensory or motor disturbances related to nervous 
compression. 
Neuro-monitoring
Before patient positioning, neurophysiological monitoring 
is set up. This routinely consists of: bilateral auditory 
brainstem responses, bilateral EMG and MEP of the facial 
nerve (Orbicularis oris) and unilaterally for Orbicularis 
oculi. Additionally, in severe compression of the brainstem 
or cranio-cervical junction or cervical stenosis/ disc disease, 
M-SEP are performed to control positioning of the patient 
and later on dissection close to the brainstem.
Multi-modality monitoring of auditory function is individually 
indicated and may involve additional non-invasive electro-
cochleography and/or direct brainstem (D-ABR) and/ or nerve 
recording (D-NAP).
Surgery
Microsurgery is performed via a retro-sigmoid trans-meatal 
approach in the semi-sitting position with the head rotated 
toward the tumor side or in a supine position with the head 
rotated contra-laterally. Patients above 65  years of age 
or patients with advanced cerebrospinal fluid spaces are 
usually selected for the supine position. Further, an indirect 
Valsalva maneuver is performed during examination by 
trans-oesophageal Doppler sonography to identify a patent 
foramen ovale, a further indication for the supine position.
Pre-surgical fluid loading with 1,000  ml Ringer solution 
infusion is scheduled for all patients operated in the semi-
sitting position. Prophylactic medications include single shot 
cefuroxime or cefazolin (repeated at 6 hours during surgery) 
and methylprednisolone which is initially administered at 
16 mg in a single shot, then 8 mg twice a day for three days 
and finally gradually reduced.
Surgical approach is performed via a slightly curved skin 
incision, followed by blunt separation of soft tissues, paying 
attention not to cut short head muscles. Finally, a 5  cm 
osteoplastic craniotomy within the angle of the transverse and 
sigmoid sinuses is performed. In-apparently opened veins 
are identified and sealed under jugular venous compression.
Dura opening is C-shaped, laterally convex. After releasing 
CSF, the cerebellum is covered by moist cotton and held 
medially. Sharp dissection of the arachnoid leads to 
identification of cranial nerves and vessels (Figs. 5.4.1A, B). 
Special measures with regard to audition: at the medial 
junction of the VIII cranial nerve with the brainstem, a 
nearfield electrode is placed and its position may be secured 
by placing some moist gelfoam and cotton around it.
difficult for the doctor to suggest the most appropriate 
patient-tailored strategy: should the patient undergo a wait 
and scan observation strategy in order to enjoy hearing 
function as long as the nature of the disease allows it and 
accept its “natural” decline and final loss? Or should the 
underlying disease be treated with partial tumor reduction 
by radiation or by surgical tumor enucleation with the aim 
of nerve decompression? Or, furthermore, is complete 
tumor resection with the goal of nerve decompression and 
eradication from the disease the best treatment option?
The problem may furtherly be more complex at times 
as statistically, 5 to 7% of patients with a vestibular 
schwannoma, present with bilateral lesions and an underlying 
genetic disease: neurofibromatosis type 2 (NF2). The danger 
of bilateral deafness is a lifelong problem in this condition, 
also because auditory function is endangered much earlier in 
life, usually below 30 years (and often below 20 years of life) 
when comparing these patients with subjects with sporadic 
vestibular shwannomas. 
Any recommendation depends on the patient’s individual 
anatomy and his personal attitude towards the problem.
Some patients rate their interest in keeping some of their 
natural hearing as the most important goal. Therefore, both 
general and individual guidelines are necessary on what 
policy is best to follow, especially if preservation of auditory 
function is a must for the patient and thus more appreciated 
than any other goal.
In this study, we intended to collect all the technical methods 
and tools that enable hearing preservation, from the indication 
of the type of therapy to technical aspects in performance.
Materials and methods
Patients
A prospectively and continuously collected series of 
patients with vestibular schwannomas in NF2  –  operated 
by the first author or jointly with the senior author  –  was 
analyzed for tumor extension by Hannover Tumor Extension 
Classification, auditory function before and after surgery 
by Hannover Auditory Classification as well as for the 
types of applied technical tools. Special focus was on those 
measures that enable or ensure auditory preservation, and 
these are outlined in detail and are illustrated by typical case 
presentations.
Diagnostics and preparation of surgery
Patients with a serviceable hearing function are generally 
interested in a hearing preservation surgery. These 
patients were preoperatively investigated by pure tone 
audiometry, speech discrimination testing and evoked 
response audiometry. In addition, facial nerve function was 
documented by standardized photo and video-graphics and 
by electrophysiological tests of blink reflexes. Bone window 
CT, enhanced MRI, and x-rays of the cervical spine at ante-
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principle: to minimize pressure and elongation of the 
involved cranial nerves. The main steps involve the internal 
auditory canal (IAC) (Fig.  5.4.1D), the tumor within the 
cerebellopontine angle (CPA) (Figs.  5.4.1A-C), the tumor 
Further, under the course of the VIII cranial nerve, gelfoam 
soaked with diluted vasodilative medication is placed to 
accompany the nerve and its vasa nervorum.
The sequence of microsurgical steps follows the following 
Fig. 5.4.1. Case 1: A) After retrosigmoid exposure of this T3b tumor; 
B)  electrophysiological mapping and tumor enucleation are performed; 
C) during CUSA enucleation, continuous irrigation is applied; D) the IAC is 
opened and the lateral portion of the tumor is mobilized and loosened; E) at 
exposure of the VIII nerve, a direct nearfield electrode is placed; and F) it is 
kept in place with some moist cottons during further dissection at the tumor 
nerve plane; G) until final complete intra-extra-meatal resection with ana-
tomical and functional preservation of acoustic and facial nerves is reached.
B F
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and the acoustic nerve will be visible. The tumor remnant is 
then lifted and the arachnoid covering and accompanying the 
acoustic nerve is moved away allowing a complete elevation 
of the tumor upwards (Fig. 5.4.1F). Some moist gel-foam is 
placed in between the structures to keep a clear separation. 
Then the tumor is lifted in an upward-lateral direction away 
from the brainstem and the arachnoid cover is moved away 
from the tumor. Here, the junction of the acoustic nerve 
with the brainstem first, and, subsequently, the origin of the 
facial nerve are met. By holding the tumor remnants more 
lateral, the superior medial cleavage plane between tumor 
and fascicles can be separated. Here, all fascicles should be 
conserved primarily at the medial site, as in a postero-anterior 
direction the superior vestibular nerve, the intermedius nerve 
and most anterior the facial nerve fascicles will be found, 
respectively. When the cleavage plane with the tumor is 
evident, dissection at the upper border towards the internal 
auditory canal is feasible. At this point, the direction of 
dissection will need to change from medial to lateral. In view 
of the strong arachnoid adhesion at the level of the porus, the 
tumor has to be lifted upwards again and to be moved and 
rolled softly upwards away from the facial fascicles, until 
final sharp dissection from the arachnoid/connective tissue 
and complete anatomical preservation of the healthy nerve 
fascicles (Fig. 5.4.1G) is accomplished.
Before closure, extensive inspection for displaced tumor 
remnants and for insidious bleeding sites is mandatory, under 
elevated venous pressure. The cranial nerves are covered 
with a light layer of moist gel-foam. Sealing of the meatal 
mastoid air cells may be performed by synthetic wax or by 
autologous pieces of fat or muscle.
Counteracting any deterioration of ABR, D-ABR and D-NAP 
Systematic measures are undertaken and, if necessary, 
repeated throughout the tumor removal up to the final 
closure measures. The following steps are always carried 
out, with very few exceptions (see below) at reporting of 
amplitude reduction, latency increase or disappearance of 
ABR components:
• Stop of action, release of structures.
• Irrigation with body temperature Ringer solution.
• Exchange with the neuro-anesthesiologist on current body 
temperature and systemic perfusion pressure; request to 
use plasma expanders/ lift arterial blood pressure by 10 to 
30 mmHg, depending on general constitution.
• Observation for signs of recovery. 
If recovery comes up quickly (5 to 15 seconds), continuation 
of surgery is possible.
If recovery comes up slowly/partially (15 to 60  seconds), 
additional irrigation with vasoactive solutions may be tried.
If recovery comes up, but takes 2 to 4 minutes and remains 
partial, a permanent quality drop in hearing function is 
likely. Therefore, a decision on whether to stop the procedure 
or to continue under strict guidelines has to be taken. 
relation with the brainstem and vessels, the tumor relation 
with the nerves inside and outside the IAC (Figs. 5.4.1D-F).
Handling of the IAC tumor part (Fig. 5.4.1D): the dura over 
the posterior aspect of the meatus is incised and resected in 
a C-shape and conserved between moist cotton layers for 
future manipulation. The medial entrance to the IAC, the 
upper and lower borders are visible and may be palpated by 
a slim hook. The posterior wall of the meatus is removed 
layer-wise by sharp diamond burrs with repeated intervals 
of at least 15  seconds to control hearing. If the region is 
strongly pneumatized, for prevention of substantial fluid 
entering the air cells and preventing air conduction during 
microsurgery, sealing of the cells with synthetic wax is an 
option. While resecting the posterior wall, the semicircular 
canals, the vestibulum and the jugular bulb are respected and 
preserved; neuro-navigation or calculation by bone window 
CT scans and measuring with slim hooks a defined length 
will support this endeavor. In general, the preservation of 
3.5 mm of the lateral wall of the IAC will ensure vestibular 
system preservation. Meticulous drilling around vestibular 
structures 1 is also possible with complete survey of the IAC 
and preservation of function.
The intra-meatal dorsal dura layer is split and resected by 
using micro-scissors. Partial intra-meatal enucleation may be 
performed by using the micro-CUSA. By sliding underneath 
and along the upper vestibular nerve with a hook this part 
of the tumor is loosened. Anteriorly the facial nerve can be 
now identified by mechanic or electric activation. Sliding 
between the inferior vestibular nerve and the tumor then 
allows to mobilize the lateral part of the tumor as well; this 
will mostly pop out and show a completely even and round 
surface. If the lateral part is still adherent, it is left in situ 
and the more medial parts of the tumor are removed using 
delicate movements in a medial to lateral direction. Then the 
intra-meatal healthy parts of the acoustic and facial nerves 
are exposed, at least in their medial and middle thirds. The 
most lateral third may be lifted out now or later, depending 
on hearing functional status.
Tumor resection within the CPA (Figs.  5.4.1A-C) is 
preceded by electric mapping for motor nerve fascicles. The 
arachnoid, together with the adjacent vessels is now moved 
upwards or downwards from the posterior tumor surface and 
the enucleation is performed with micro-scissors, platelet 
shaped knives and CUSA. Instead extensive use of bipolar 
cautery of small vessels, the surgical field is kept clean by 
continuous irrigation (Fig.  5.4.1C) with tempered Ringer 
solution, which prevents closure of essential vasa nervorum 
as well as heat development.
Dissection of tumor remnants from nerve fascicles may 
be accomplished after sufficient volume reduction and 
identification and cutting of either both vestibular nerves or 
of the one from which the tumor origins. With a fine hook, 
the border between the tumorous inferior vestibular nerve 
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Pre-surgical function showed some preserved hearing in 
14 cases with small to medium tumors and in 26 cases with 
large tumors (Table 5.4.II).
Post-surgical auditory function was documented in 7 of the 
14 small to medium tumors (50%) and in 9 of the 26 large 
tumors (35%) (Table 5.4.II).
All patients expressed that the retained auditory function was 
useful to them. In some of the patients with very large tumors, 
before surgery an agreement for an auditory brainstem 
implant was found and implanted successfully in 26 cases; 
one patient received a well-functioning Cochlear implant; 
3 patients had been implanted with ABI before and retained 
the function during tumor recurrence surgery (Fig. 5.4.3).
With regards to postpone further surgery and to maintain a 
currently useful residual hearing or facial function, 4 patients 
are currently under trial treatment with Bevacizumab.
Case presentation #1 
After an early onset of NF2, this female opted for microsurgery 
with an attempt of hearing preservation. Complete resection 
under multimodality monitoring was successfully carried 
out. Critical phases were greatly supported by nearfield 
recording. She has been free of any recurrence for 2 years 
and has become a mother of a healthy boy (Fig. 5.4.1).
Case presentation #2
At the age of 19, this female suffered from ataxia and bilateral 
repeated hearing losses with partial recovery. This continued 
despite partial tumor shrinkage under Bevacizumab trial. A 
decision for surgery of the small left sided tumor with realistic 
If recovery does not come up, but deterioration continues, 
specific actions may be attempted: tumor remnants are 
lifted upwards and held in this position for several seconds 
to minutes; any downward or posterior stretch is avoided. 
Additional flooding of the surgical field with warm Ringer 
solution may be helpful. If recovery comes up, soaked gel-
foam pieces are put along the nerve course and microsurgery 
may be continued.
If signs of recovery come up quickly, quick continuation of 
microsurgery is possible. 
Deterioration with short breaks and recovery may be repeated 
many times.
Despite repeated breaks and repeated recoveries, the acoustic 
system may become more vulnerable and at a sudden point, 
recovery may be scarce or lacking.
If signs of recovery come up only slowly and remain 
incomplete, further resection may be tried with utmost care, 
but at the slightest further deterioration, a direct stop is 
indicated and possibly a complete stop of any further action 
has to be considered.
Based on a pre-surgical clear-cut compromise agreed on with 
the patient, hearing preservation or completeness of resection 
is set first or second on the list of goals and intraoperative 
management is accordingly decided.
In general, in a viable acoustic nerve with reliable auditory 
monitoring, complete resection may be feasible.
In more advanced neurophysiological compromises, the 
range of tolerated actions is smaller. Especially when 
final dissection of tumor remnants (“capsule”) from the 
nerves is accomplished, critical ABR changes may prevent 
completeness of resection. At this point, a “gross total 
resection” may be achieved with minimal seeds of tumor at 
some sites along the nerve course.
In late stages of the disease, decompressive surgery with 
opening of the IAC and partial intra-meatal and CPA 
resection may be possible. Still, this result, mainly due to 
the reduction of pressure, may allow some stable hearing 
preservation for many years.
A further option for a critical situation such as unilateral 
deafness and repeated hearing drops on the tumor side, may 
solely be bony decompression and opening of the meatal 
dura.
Results
There were 76 VS operations performed in 57  patients as 
outlined above.
Tumor extensions were: small T1 and T2 (intra- extra-meatal 
tumors) in 5 cases, medium sized tumor T3a (partial filling 
of the cistern) in 14 patients and large tumors in 57 cases: 11 
with T3b (broad brainstem contact and filled cistern), 16 with 
T4a (moderate brainstem compression, 16 with T4b (severe 
brainstem compression) and 14 with T5 (tumor growth over 
the midline). (Table 5.4.I, Fig. 5.4.2).
Table 5.4.I. Tumor extension by Hannover classification in NF2 series.
Extension 
class
T1 T2 T3a T3b T4a T4b T5
N 1 4 14 11 16 16 14
Fig. 5.4.2. Tumor extension by Hannover classification in NF2 series.
Small to medium tumor classes T1, T2 and T3a were present in 25%, while 
75% of tumors at the time of surgery showed brainstem involvement (T3b) or 
compression (T4a, T4b), or severe dislocation with growth over the midline (T5).
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3 years. New balance and hearing problems made him decide 
for tumor resection and ABI placement (Fig. 5.4.5).
Discussion
Concerning auditory function, patients with NF2 are in 
a three-fold disadvantageous situation compared to non-
NF-patients: in NF2 the danger of deafness is bilateral, it 
develops much earlier in life, and the chances of preservation 
of auditory function after treatment are reduced when 
compared to non-NF schwannomas  2-5. NF2 schwannomas 
often take a multifocal origin, at various fascicles and at 
various sites along a fascicle; the cleavage plane is less clear 
and more adhesive. In view of the early onset of symptoms, 
often below age 20, mostly below age 30, the risk of hearing 
loss endangers school education as well as professional 
training and long-term perspectives.
Especially patients with only one hearing ear – after sudden 
hearing loss or treatment  –  are reluctant to undergo any 
further treatment, and tend to postpone it as long as their 
symptoms are not seriously life threatening.
Subsequently, the treatment options are discussed in view of 
the literature.
Alternatives to microsurgery
“Natural course”
The wait and scan option has been suggested mainly for non-
NF patients with unilateral VS, based on the observation that 
some VS do not or only slowly grow over months or years 
and that nerve function may remain stable for a long period. 
Furthermore, it is agreed that radiation treatment should 
only be applied after proven tumor growth, and therefore, an 
identification of the individuals’ growth speed is important.
In a literature review, Sughrue et al. could identify that tumor 
growth rate (below or above 2.5  mm/ year) predicted the 
likelihood of hearing function decline 6.
Despite slow or moderate growth in some patients, it is 
also known that functions of the vestibulo-cochlear nerve 
suffer a continuous decline over time. After 7 to 14 years of 
perspective to preserve hearing had to be postponed in view of 
repeated clinical collapses attributed to the severe brainstem 
compression coming from the right sided tumor. After resection 
of the right VS, brainstem mapping and implantation of an ABI 
were carried out in a single-stage procedure. She recovered well 
and makes continuous progress with open speech understanding 
and listens to music. In order to stabilize her left natural hearing 
(60 dB loss, 65% SDS), she is under Bevacizumab trial again 
and acoustic symptoms have subsided (Fig. 5.4.4).
Case presentation #3
This 43-year-old male had been deaf for a long time on the 
left side because of a VS for which he underwent surgery 
20  years ago. He was reluctant to undergo surgery of 
his growing right VS with functional hearing. Due to its 
enlargement and cyst formation, he experienced ataxia and 
hearing drops. During surgery, a decompression of the IAC, 
cyst resection and partial tumor resection were performed. 
His gait and his hearing improved and were stable over 
Table 5.4.II.
II.a. Small and medium-sized vestibular schwannomas in NF2.
  Auditory function by Hannover classification system  
  H1 H2 H3 H4 H5 H6  
Pre-op. 6 4 2 2 1 4  
Post-op. 2 0 3 2 0 12 7 of 14
50%
II.b. Large vestibular schwannomas in NF2.
  Auditory function by Hannover classification system  
  H1 H2 H3 H4 H5 H6  
Pre-op. 9 7 8 2 1 30  
Post-op. 4 3 1 1 0 48 9 of 26
35%
Fig. 5.4.3. Preserved natural and rehabilitated bionic hearing function in 
52/57 patients.
In 57 patients unilateral or bilateral VS surgery with hearing preservation and 
with bionic implantation of an ABI or CI created auditory function in 52 patients 
(91%): with 26 patients with some natural hearing ear (9 unilateral, 10 bilateral 
natural and 7 unilateral natural and unilateral bionic) and 26 patients with 
functional bionic implant.
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observation, most patients are deaf 7, while in faster growing 
tumors, deafness occurs after 7 years in a best case scenario. 
Interestingly, in some patients without a proven tumor 
growth, after a decade of observation, hearing also gets lost 7. 
These data rely on analysis of non-NF-schwannomas. In NF-
schwannomas the situation is more critical, and sudden or 
early hearing loss occurs more often.
Another problem in this option of observation is the 
dissociation between tumor size and symptoms. While in 
some small tumors, symptoms may be advanced with loss 
of vestibular and acoustic functions, patients with large – at 
times even brainstem compressive  –  tumors (case  #2, 
Fig.  5.4.4) that still have a serviceable hearing exist. In 
functional hearing decline in small tumors, a harder tumor 
consistency and/or a more infiltrative/adhesive growth is 
assumed.
There is some truth in the statement by Lloyd and colleagues 
2017, that “conservative management offers the best chance 
of hearing preservation in stable tumors” 8; however, stable 
conditions are not typical in young and middle-aged NF 
patients.
In general, pure observation in NF will lead to acoustic 
decline in all young patients (< 30 years), while only patients 
with late manifestations have a realistic chance of natural 
hearing conservation.
Radiosurgery
For some patients, the concept of radio-surgical treatment is 
especially attractive in order to prevent multiple operations 
or to get a break from a series of surgeries. 
The results are generally positive for unilateral sporadic VS, 
and functional outcome is mostly better than microsurgery: 
A comparative study on microsurgery versus radiosurgery 
Fig. 5.4.4. Case #2: A) despite Bevacizumab trial with temporary response, worsening of the clinical status necessitates surgery of the large R VS and ABI 
implantation in view of repeated hearing drops in the L; B), C) under further bevacizumab trial the L VS has been stable over the last 2 years.
Fig. 5.4.5. Case #3: A) this cystic VS with severe brainstem compression is treated by partial decompression and IAC opening in 2006, with improvement 
of gait and hearing; B), C) despite growth of solid tumor, thanks to open IAC, hearing remains useful until 2008; D) in 2009, due to further progress of the 
disease, deterioration of gait and auditory function led to surgery and ABI implantation; E) at control in 2011, the brainstem is well decompressed and clinical 
function has remained stable until now.
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by antibody immune therapy has brought some hope for NF2 
patients. Treatment with Bevacizumab is effective in 60 to 
70% of patients and in many of them it stops deterioration of 
hearing function 20. In conclusion, it is helpful for the goal of 
hearing preservation “in the short term” 8.
Blakely investigated the radiological and hearing response 
to one-year intermittent bevacizumab treatment and found 
43% radiological response and 36% clinical response with 
sustained hearing 21. Analysis of subjective patient reporting 
confirmed preserved and even improved auditory function, 
mainly in speech discrimination, under Bevacizumab  22. 
However, after 1 to 3  years, the effect on tumor volume 
and function usually subsides, and another solution must be 
considered. About one third to 50% of patients do not show 
any effect.
Auditory rehabilitation
Auditory rehabilitation by cochlear implant or auditory 
brainstem implant is an option, when hearing preservation 
is not achieved or is functionally insufficient. Again, the 
results are less good than in non-tumor patients needing an 
acoustic implant  10. In few selected cases and series, good 
results could be reported with CI in NF2  23 with speech 
discrimination up to 63% in 10 of 12  patients. Lloyd et 
al. found better benefit from CI, if the related tumor was 
neither treated by surgery nor by radiosurgery  8. Better CI 
outcome was also documented by Peng and colleagues 24, but 
they noted a secondary decline of auditory function in 4 of 
10 patients.
Speech discrimination scores are generally reported low for 
ABI, as mostly there is no open speech understanding by 
ABI, but a word recognition of 33% 25, and an understanding 
supported by lip reading in CUNY of 38% to 94% 24.
An attempt for improving ABI performance by combined 
penetrating and surface ABI gave better results for surface 
electrodes  26, and the penetrating model was abandoned. 
Recent studies could show definite improvement and 
increasing cases with open set speech perception 27 28.
Conclusions
In summary, for NF2 patients one of the most important 
goals is to conserve at least unilateral natural functional 
hearing for as long as possible. Chances for this endeavor 
are more realistic in early microsurgical decompression: by 
removal of the posterior wall of the IAC and by reduction 
of tumor volume the acoustic nerve is decompressed and its 
microcirculation is recovered. Intra-operative fluid irrigation 
with vasodilating medication and nearfield monitoring 
increase the chances of good functional outcome. If complete 
resection is feasible, it is attempted. In some patients, auditory 
function remains useful for over 10 years or longer. In case 
of deterioration, decompressive surgery may be performed 
again. This option speaks rather not for an early decision for 
radiosurgery. Radiosurgery is recommended to be reserved 
(RS) by Myrseth et al. 2009 showed no hearing preservation 
by surgery, but 68% by RS at 2 years 9.
Reported rates of hearing preservation show a wide range 
that goes from 41% 10 11 to 25% 12 compared to 52% obtained 
by microsurgery.
Even in an experienced center, tumor control was good, 
reported at 84% in NF2, but HP was maintained only in 3 of 
12 patients at an average long term of 7.6 years 12.
According to personal experience, the decline in hearing 
quality after RS is more significant when compared with the 
tumor’s natural course.
Combination of partial resection and radiosurgery
As an alternative to microsurgery or radiosurgery alone, the 
combination of both has been advocated by some centers 13 14: 
thereby, one avoids any dissection at the tumor-nerve-border 
to minimize the potential damage, but only performs some 
enucleation, and aims at reducing the risk of further growth 
by subsequent radiosurgery. The latter is performed under 
more difficult conditions, as the tumor borders are less even.
The special risk of application of ionizing treatment to 
patients with a lesion in a tumor suppressor gene has to be 
taken into consideration. The inherent risk is significantly 
elevated up to the age of 40. Accordingly, the average VS 
patient with a unilateral sporadic tumor and the typical age of 
diagnosis at mid 40ties to 50ies is in a much less vulnerable 
phase of life than the NF-2-patient in need of treatment.
Microsurgery
The concept of auditory function preservation and the proof 
of its feasibility have taken a long way in unilateral sporadic 
tumors  2 4 15 and the question whom to operate or not needs 
complex considerations  16. As pointed out above, the 
preservation of hearing in NF is more challenging and less 
successful than in non-NF tumors 3 5. Although a recent survey 
states that surgical resection “invariably leads to complete 
loss of ipsilateral hearing”  10, some centers could prove the 
opposite 3 5 17. The reported rates of HP were 41.6% 17, while 
Zhao achieved 58% of hearing of any quality 18. Samii et al. 
obtained 35% average preservation rate, but in well preserved 
pre-operative hearing function a conservation rate up to 65% 
was possible 3 5. Despite the high proportion of large tumors 
(75%) in our series presented here, average preservation rate 
was 40%, with 50% in small to medium and 35% in large 
tumors. Besides limited tumor extension and useful functional 
preoperative hearing also the quality of pre-surgical ABR is 
important; as it has been stated long ago: “The chances of 
good outcomes are best when surgery is performed early and 
when there is a good preoperative hearing function” 5.
Still, the burden of suffering from a brain tumor plays an 
essential role even in unilateral sporadic VS patients  19, a 
factor which is multiplied in NF2. 
Antibody-immuno-therapy
Over the last 10 years, the option to influence tumor growth 
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• The craniotomy must reach the posterior border of the 
sigmoid sinus anteriorly, but it is not necessary to entirely 
skeletonize it. All opened mastoid air cells should 
be obliterated using Horsley bone wax to avoid CSF 
leakage through these cells to the middle ear cavities. 
The opening of the dura is certain when transmitted CSF 
pulsations are clearly seen. This is a sign of spontaneous 
cerebellar retraction thanks to the deep anesthesia and 
hyperventilation performed to reach pCO2 of 25. The 
opening of the dura is a U-shaped incision to form an 
anteriorly based dural flap. This flap is suspended 
anteriorly using a stitch or fibrin glue. A fine cottonoid 
or synthetic dura substitute is introduced to protect the 
cerebellum. Following the posterior surface of the petrous 
bone in an anteroinferior direction to reach the lower 
cranial nerve area, the posterior cistern. is opened. The 
cerebrospinal fluid escapes and the cerebellum falls away 
without any pressure on it; The retrosigmoid approach 
provides a direct and "protected surgical corridor" to 
access the CPA (Fig. 5.5.2).
• After dissecting the arachnoid wrapping the cranial 
nerves by using the operative microscope, an endoscopic 
look of the CPA is made with a 4 mm, 30 degrees angled 
rigid endoscope.
The CPA is endoscopically divided into two zones and 
separated by the acoustic-facial bundle.The superior 
zone corresponds to the trigeminal nerve which is 
visualized from the Meckel’s cave to the pons. The most 
common compressing vessel of the trigeminal nerve 
is he Superior Cerebellar Artery (SCA). The inferior 
zone corresponds to the lower cranial nerve zone that is 
inspected in case of hemi-facial spasm. A high vertebral 
artery and the Posterior-Inferior Cerebellar Artery 
(PICA) are the most common offending vessels at the 
for later stages and later periods of age, primarily because 
of the risk of inducing further tumors in a genetic lesion 
of tumor control, and secondly because secondary hearing 
decline after RS is more pronounced when compared to the 
natural course of the disease.
If pre-surgical ABR and audiometry speak against any 
realistic chance of preservation, functional rehabilitation 
should be tested and discussed with the patient beforehand 
and ABI or CI should be implanted without long latency.
5.5. Endoscope-assisted microsurgery  
of trigeminal, facial and auditory nerves
J. Magnan
Cranial nerves in the Cerebellopontine Angle (CPA) share 
a common pathology: the neuro-vascular compression 
syndrome induced by an offending contact of vascular 
structures to the related cranial nerves which have been 
definitively proved by surgical decompression of the cross-
compression and the resolution of the patient’s symptoms 1. 
Dandy  2, Gardner  3 and Jannetta  4 were the pioneers to 
promote such concept and to develop microvascular 
decompression surgery (MVD) of cranial nerves in the 
cerebellopontine angle (CPA). After a period of little 
acceptance, the neurovascular decompression procedure has 
been popularized by several technological improvements: 
MRI preoperative assessment in T2 sequences, minimally 
invasive techniques 5, endoscope-assisted microsurgery 6 7.
Technique
Endoscope-assisted minimally invasive retrosigmoid 
approach 8 9.
• The patient is placed in the dorsal decubitus position, with 
the head non-fixed, flexed and turned to the contralateral 
side.
• The landmarks are the posterior border of the mastoid and 
the Frankfurt line that corresponds to the posterior extension 
of the line joining the outer canther of the eye to the superior 
border of the external auditory canal. The skin incision is 
curvilinear, 6 to 8 cm long, passing over the posterior part 
of the craniotomy area, about two finger breadth behind 
the pinna. The cutaneous flap is anteriorly based whereas 
the underlying musculoperiosteal flap is dissected in a 
posteriorly based fashion (Fig. 5.5.1). The mastoid emissary 
vein is identified and coagulated and blocked with bone 
wax. Burring for the craniotomy is centered on this vein 
using a cutting burr head. Bone dust is collected to make 
"bone pâté" that will be used during closure. A circular bone 
flap may be removed in one piece to be put back in place 
at the end of the procedure. The retromastoid retrosigmoid 
craniotomy is usually 15 to 20 mm.
Fig. 5.5.1. Left minimally invasive retrosigmoid approach; the craniotomy 
is centered on the mastoid emissary vein.
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5-0  silk sutures. Due to the small size of the dural 
flap opening a watertight closure is not always easy to 
achieve. For bridging the defect, a synthetic absorbable 
dural substitute is useful to use. The gaps between 
sutures are filled by pieces of subcutaneous fat and a 
fibrin glue layer, the dura is then covered by another 
piece of dural substitute, Surgicel and fibrin glue. The 
craniotomy is then filled with a mixture of "bone pâté" 
and fibrin glue, and the bone is put back in place. The 
musculo-aponeurotic flap is sutured in place; finally, the 
subcutaneous and skin layers sutured. Duration of the 
intervention is usually between 11/2 to 21/2 hours.
Indications and results 
Trigeminal nerve 10 11
The offending artery is: the SCA alone in 46%, associated 
in 30%; a venous structure alone in 11% or associated to 
artery in 18%, other arteries alone (AICA, dolicho-vertebral 
artery, basilar artery) in 4%. Multiple combinations in 34% 
(Figs. 5.5.3A, B, C). 
The SCA is detached from the nerve and pons by dissecting the 
pial-arachnoidal wrapping that maintains the artery adherent 
to the nerve with microscissors or sharp microinstrument 
(Fig. 5.5.4A, B, C). The SCA with its two branches is further 
kept apart from the trigeminal nerve in a horizontal position 
toward the tentorium by fibrin glue and Teflon.
A venous structure is involved alone in 11%, or associated to an 
artery in 18%, other arteries alone (AICA, dolicho-vertebral 
artery, basilar artery) in 4%, but multiple combinations are 
present in 34%. The vein, usually is an aberrant trigeminal 
vein, is rarely mobilized but mainly coagulated with bipolar 
coagulation after verifying that this vein doesn’t represent 
the predominant venous drainage.
Results
In literature, the success of the procedure varies from 73% 
to 97%. Since 1994 we have performed MVD on 301 
patients suffering of trigeminal neuralgia resistant to medical 
treatment. The oldest patient was 87 years old. The complete 
resolution of the pain is immediate in 86 % and required 
revision surgery to increase the overall successful result at 
91%. The recurrence after immediate postoperative relief 
is mentioned in all MVD series. The recurrence occurred 
in 14% in our patients, between 3 months to 2 years after 
initial surgery. Its main cause is the fibrous tissue around 
the trigeminal nerve inducing a new neurovascular conflict 
or embedding the Teflon in the nerve. Post-operative 
complications were limited to CSF leak in 2%. No facial 
paralysis or hearing loss were present in our series.
Facial nerve 12-14
The most common offending vessel in hemifacial spasm 
is PICA alone in 37% (Fig.  5.5.5) or rising from a 
Root Exit Zone (REZ) of the facial nerve. The auditory 
nerve is the most exposed nerve in the middle of the 
CPA. The Anterior-Inferior Cerebellar Artery (AICA) 
is commonly in contact with the acousticofacial nerve 
bundle. So its role as an offending vessel is less obvious 
and its decompression more delicate. The surgeon must 
be aware of potential thermal injury to the auditory 
nerve by the heat of the endoscope tip. Consequently, 
close and prolonged contact between cranial nerves and 
endoscope tip should be avoided. Whatever the site of 
the neurovascular compression, MVD aims to change 
the offending vessel axis in order to keep it away from 
the offended cranial nerve. This surgical procedure is 
done under the operating microscope. The offending 
vessel is carefully mobilized using a microelevator or a 
microhook. Further meticulous and careful dissections 
allow the artery to change its axis of direction. By 
inserting one or more small Teflon pads (2 to 3  mm) 
between the artery and the nerve and adjusting it or 
them with a microinstrument, the decompression is 
completed. Teflon is an inert material well tolerated in 
the CPA. The operation ends with another endoscopic 
look to assess the correct positioning of the Teflon pad 
and to check for the absence of contact between the 
decompressed nerve and all adjacent vascular structures 
that could maintain the hyperactivity of the nerve.
• Before closure, the operative field should be 
bloodless and is filled with physiological saline at 
body temperature to extrude air, which could cause 
postoperative headaches. The dura is sutured using 
Fig. 5.5.2. Left minimally retrosigmoid approach; the “protected” surgical 
corridor to access the cerebellopontine angle.
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spasm is achieved in 94% but 11% required an additional 
revision surgery. The complete resolution of spasm is 
immediate within one week of surgery in 75% off patients 
and delayed up to several weeks or months in 25% of 
patients, with 2 successful results after a long period of 
12 and 18 months. The explanation for this delay is not 
clear and evokes the hypothesis of a residual hyperactivity 
of the facial nucleus. The result of MVD is stable over 
time, only 2 patients developed a distant recurrence, 5 and 
11 years later.
The complications are low, essentially CSL leak in 3%. The 
incidence of hearing impairment to a level of deafness has 
decreased over the years from 5% to 1%. Only 1 postoperative 
facial paralysis occurred in a revision surgery of a patient 
operated previously somewhere else. 
Auditory nerve 15 16
The relationship between the vascular compression and 
the symptoms is a “thorny issue” because of the lack of 
specificity of clinical signs and the frequency of AICA loop 
in contact with the acousticofacial nerve bundle.
dolichovertebral artery just below the REZ of the facial nerve 
and distorting it in 32% (Figs. 5.5.6A, B).
The endoscope-assisted procedure allows correct 
visualization of multiple offending vessels: a PICA with 
an obvious offending vertebral artery (11%) obstructing 
the view, a second loop of PICA at the medullo-pontine 
scissure, or an AICA along the brainstem underlying the 
other vessels (9%). The bifurcation of a dominant PICA 
or AICA occurs in contact with the root of the facial 
nerve and the vascular angle formed by this division 
embedding the nerve (8%). The AICA can be responsible 
for a facial compression in 13%, either on the cisternal 
course of the nerve or at the porus. If AICA is not the 
most common offending vessel, its pulsatile contact to a 
“hyperfunctioning” facial nerve can maintain hyperactivity 
on it and therefore lead to an abnormal muscle response.
Results
The success of the procedures varies from 83 to 97% 
in the literature. Since 1990, 705 patients suffering of 
hemifacial spasm were operated on. The complete relief of 
Fig. 5.5.3. Endoscopy of the left CPA. A) V (trigeminal nerve), SCA (superior cerebellar artery),VIII (auditory nerve), AICA (anterior-inferior cerebellar artery), 
VII (facial nerve), VA (vertebral artery), PICA (posterior-inferior cerebellar artery); B) offending vessels (AICA and VA) at the Root Exit Zone of the facial nerve 
(VII); C) decompression of the facial nerve (VII) with Teflon pad (T).
Fig. 5.5.4. Right trigeminal neuralgia. A) operating microscope view, V (trigeminal), VIII (auditory); B) endoscope view of the decompression of the SCA (su-
perior cerebellar artery) from the trigeminal nerve (V); C) Teflon pads(T) insulating trigeminal nerve (V) from SCA and AICA.
A B C
A B C
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induced cochleovestibular neuropathy is still a controversial 
diagnosis with an uncertain vascular decompression. In the 
literature, the success rate varies from 33 to 77% with a large 
range of interpretation.
Since 1993 we performed 64 MVD of the auditory nerve in 
62 cases mainly for unilateral incapacitating tinnitus alone or 
associated with vestibular symptoms in 40% and 2 cases of 
disabling vertigo without tinnitus.
At 2  year follow-up, tinnitus symptom was absent in 21%, 
decreased significantly for the patient in 31%, similar in 44% 
and worsening in 4%. The best results were obtained in cases 
of subarcuate artery “hugging” the auditory nerve (7 cases), 
no positive result was achieved in cases of intracanalicular 
AICA loop. Interestingly, the hearing thresholds were slightly 
improved and ABR I-III  <  0.2  ms relative to non-operated 
1. MRI must be done with thin slices 0.4 mm to show the 
distortion of the nerve.
2. Complementary tests must confirm the involvement of 
the cochlear nerve in tinnitus with ABR abnormality 
(I-III inter peak prolonged latency of more 0.2 ms or I-III 
inter peak absolute interval superior to 2.3 ms) or of the 
vestibular nerve with a hyporreflexia that is relatively 
insensitive but at least points the affected side.
AICA, alone in 40% (Fig. 5.5.7A) or associated with PICA 
in 10%, is the more delicate vessel to manipulate because of 
the complexity of its course. This lies between the seventh 
and eight cranial nerves in 50% of patients, which prevents 
a fully efficient and complete vascular decompression. 
An intracanalicular loop requires drilling of the internal 
auditory canal (Fig. 5.5.7B). The labyrinthine artery rising 
from the most lateral loop limits the displacement of the 
vessel. Consequently peri-operative cochlear monitoring 
is mandatory. By placing the recording electrode in the 
foramen of Luschka, ABR (auditory brainstem response), 
CCAP (cochlear compound action potential) and 
DNAP (dorsal nucleus action potential) can be recorded 
(Fig. 5.5.8).
The other offending vessels can be the PICA in 28%, a 
subsarcuate artery “hugging” the auditory nerve in 20% 
(Fig. 5.5.8) and vein in 5%.
Results
The surgical results are not comparable to those obtained 
for trigeminal or facial nerves. Vascular compression-
Fig. 5.5.5. Left hemifacial spasm with embedded PICA loop at the REZ of 
facial nerve.
Fig. 5.5.6. Left hemifacial spasm. A) decompression of the REZ of the fa-
cial nerve (VII) from an offenfing PICA loop rising from VA (vertebral artery); 
B) Teflon (T) between the facial nerve and the offending vascular loop.
A
B
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Surgery of auditory nerve is more challenging and the results 
are not comparable with those for trigeminal neuralgia and 
hemifacial spasm. Once the selection of the patients with 
vascular compression-induced tinnitus or vertigo will be 
clarified, the MVD of the auditory nerve should get a full 
acceptance.
Acknowledgements to Professor Carlo Zini and Pr. Mars 
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5.6. Modern shifts in the clinical 
epidemiology of sporadic vestibular 
schwannoma and its implications
J.P. Marinelli, B.R. Grossardt, M.L. Carlson
Introduction
Since Eduard Sandifort’s initial postmortem description of 
a “certain hard body” arising from the 8th Cranial Nerve in 
1777, the management of sporadic vestibular schwannoma 
(VS) has been characterized by several distinctive eras  1. 
From finger tumor enucleation in the late 1800s and 
Cushing’s bilateral suboccipital craniectomy in the early 
1900s to radiosurgery and observation with serial imaging 
in recent decades, the management of VS has gradually 
shifted towards increasingly conservative management 
over the last century  2. Indeed, recent estimates suggest 
that a significant number of patients now undergo an initial 
period of observation alone, and the role of microsurgery 
continues to be reserved for fewer patients 3. 
Motivated by the significant sequelae of surgical 
intervention at the time, the origins of conservative 
management bear their inception to the mid-to late-1900s. 
side returned normal in patients with successful results. 
Postoperative hearing was unchanged in 37%; a 5 to 10 dB 
hearing loss was present in 15% and there was 1 case of 
hearing loss. In the follow up, one sudden and one progressive 
hearing loss occurred. The vestibular disorders disappeared 
without recurrence in 56%, and MVD was ineffective in 44%.
Conclusions
Surgery of trigeminal and facial nerves based on 
neurovascular decompression is the only curative treatment 
of patient suffering of trigeminal neuralgia and hemifacial 
spasm. Combining the use of both microscope and endoscope 
increases the efficiency of the procedure and decreases 
drastically the potential morbidity of the surgical procedure. 
Fig. 5.5.7. Left incapacitating tinnitus. A) intracanalicular AICA loop VII 
(facial) VIIII (auditory); B) drilling of the internal auditory canal to expose the 
cross-compression
Fig. 5.5.8. Subarcuate artery (As) “hugging the auditory nerve” (VIII).A
B
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The controversy: how common is vestibular schwannoma, 
really? 
Partly secondary to imprecise usage of these epidemiological 
definitions, the literature on the epidemiology of sporadic 
VS can appear inconsistent. For instance, the oft given 
response to the clinical question of, “How common is VS?” 
is, “1 in 100,000.” This response reflects population-based 
studies’ estimates of disease incidence, which historically 
have reported incidence rates within this range  3  9-12. Yet, 
MRI studies performed in the early 2000s show that the 
prevalence of incidental VS exceeds these incidence rates 
by at least an order of magnitude 13-15. Stated another way, 
the prevalence of a subset of the affected VS population 
(i.e., those with incidental and theoretically asymptomatic 
tumors) far exceeded the incidence of all new patients. Of 
course, as alluded to in the preceding paragraph surrounding 
definitional distinctions within clinical epidemiologic 
research, it is expected that the prevalence of VS would 
exceed the incidence rate; however, the magnitude at 
which MRI studies’ prevalence exceeds the incidence 
rate raises the possibility that population-based studies 
underestimate the commonness of VS. Compounding this, 
temporal bone studies performed at autopsy suggested that 
the prevalence of incidental tumors may approximate 1 per 
1,000 persons 16 17.
Incidence of sporadic vestibular schwannoma 
Historical incidence rates
In the 1960s and 1970s, population-based studies from 
the Faroe Islands and Denmark estimated the incidence 
rate of VS to be less than 1 newly diagnosed case per 
100,000 person-years; specifically, 0.54 new cases per 
100,000 person-years in Denmark from 1957 to 1976. In 
the United States, historical population-based research 
has been limited by the absence of a centralized health 
system and accompanying population-based databases. 
Perhaps the only available epidemiological resource 
dating back to this period within the United States is the 
Rochester Epidemiology Project (REP), a unique medical 
records-linkage system that connects patient encounters 
from every resident of Olmsted County, Minnesota 
across providers within the geographic region (including 
Olmsted Medical Center, Mayo Clinic, and other private 
and smaller providers)  18. Interestingly, using the REP 
exhaustive infrastructure, the incidence of VS from 1966 
to 1975 approximated more modern estimates of disease 
incidence at a rate of 1.5 new cases per 100,000 person-
years 7.
Incidence using Denmark’s national database
Some of the most robust existing clinical epidemiologic 
research was performed using Denmark’s unique national VS 
database. Beginning in 1976, all patients diagnosed with VS 
Yet, modern trends indicate that patients are increasingly 
being managed conservatively in the 21st century. In part, 
these observations are explained by a fundamental shift in 
the patient demographic of sporadic VS. Thought to stem 
from heightened use of magnetic resonance imaging (MRI), 
recent population-based studies suggest that VS is far more 
common than initially considered, with disease incidence 
paralleling traditionally more “common” diseases such 
as Parkinson’s disease and Hodgkin’s lymphoma  4-8. In 
the current work, we review this evolution in the patient 
demographic of sporadic VS and its implications for future 
disease management and public health.
Background and controversies 
Understanding clinical epidemiologic research 
Before discussing the relevant controversies and emerging 
data regarding the epidemiology of VS, it is essential to 
first understand two key distinct definitions within the 
confines of clinical epidemiologic research (Fig.  5.6.1). 
First, the incidence of a disease is defined by the rate of 
new, previously undiagnosed cases in a given population 
over a specified time interval. With the burden of verifying 
patients’ first-ever lifetime diagnosis over a defined 
period in time, the reporting of disease incidence is 
almost exclusively confined to population-based studies. 
Next, disease prevalence represents the cross-sectional 
proportion (or frequency) of a given population who 
are living with a disease, often reported on a specific 
date. In a chronic disease, where people live many years 
without being “cured,” incident cases accumulate over 
time resulting in prevalence frequencies that significantly 
exceed incidence rates with a trend towards the highest 
disease prevalence in older age groups. In summary, the 
incidence rate of a disease provides information about the 
rate at which people are developing the disease of interest, 
and disease prevalence describes how many people are 
affected by the disease within a population at a specific 
point in time.
Fig. 5.6.1. Contrasting disease incidence to disease prevalence within the 
confines of epidemiologic research. 
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County is driven by health care, with nearly 40% of the 
population working is this industry, a feature nearly 4-times 
the national average in the United States. Moreover, this 
characteristic likely significantly influences overall health 
literacy and patients’ ease-of-access to medical care and thus 
MRI  7. Substantiating this rationale surrounding patients’ 
ease-of-access to MRI, nearly 1 in 3 individuals 70 years and 
older living in Olmsted County in 2017 have undergone head 
imaging with MRI 8.
Prevalence of sporadic vestibular schwannoma 
Historical prevalence from temporal bone studies 
The first estimates of disease prevalence stem from temporal 
bone studies performed at autopsy that investigated 
incidentally diagnosed VS  16  24  25. Prevalence estimates 
of VS from temporal bone studies have varied widely, 
ranging from 2.4% to 0%  24  26. Nonetheless, the ability 
of temporal bone studies to detect even the smallest of 
tumors render offers a distinctive look at the prevalence of 
incidental tumors. However, the implications of temporal 
bone findings on the clinical epidemiology and population 
health aspects of VS are inherently limited by study design. 
Beyond the current limitations of MRI that preclude 
clinical diagnosis of sub-millimeter tumors, autopsy data is 
unavoidably biased towards sicker, elderly individuals with 
multiple comorbidities. Moreover, the selection of temporal 
bones comprising these studies has been questioned  26-28. 
Notwithstanding these limitations, temporal bone studies 
provide unparalleled insight into the natural history of VS, 
demonstrating that over time, many people develop small 
VSs that often go undetected clinically. 
Prevalence of incidental tumors in MRI studies 
In the early 2000s, several studies reviewed thousands of 
historical MRI scans and reported that the clinical prevalence 
of incidentally diagnosed VS ranged between 20 and 70 
persons per 100,000 persons (0.02% to 0.07%) 13 14. Albeit 
biased towards older patients who required head imaging 
for various indications, these studies demonstrate that a 
surprisingly large number of people have asymptomatic 
VS, and these studies foreshadow a fundamental shift in the 
patient demographic of VS. In particular, many people are 
now being incidentally diagnosed with asymptomatic VS, 
when only 10 to 20 years prior to the advent and widespread 
use of MRI, such patients would have died without ever 
being diagnosed with VS. 
Recent developments in disease prevalence 
Using the REP, the prevalence of sporadic VS was examined in 
the population of nearly 160,000 persons residing in Olmsted 
County, Minnesota, on January 1, 2017 8. Concomitant with 
the elevated incidence rates of VS observed in the same 
population over the past 30 years 7, the current prevalence of 
in Denmark are referred to Copenhagen University Hospital 
for management 11. Since database inception, patients have 
been prospectively registered in this national database, 
enabling national population-based estimates of incidence 
rates over time 19. Using this database, it was determined that 
the incidence of VS increased from 0.78 per 100,000 person-
years from 1978-1983 to 1.74 during 1996-2001, peaking 
at 2.28 in 2004. Four years later, Stangerup and colleagues 
demonstrated that the national incidence began declining to a 
rate of 1.94 per 100,000 person-years in 2008 12 20.
Incidence estimates in the United States 
As previously stated, population-based research in the United 
States has been limited by the lack of longstanding national 
database registries. Nevertheless, after the Benign Brain 
Tumor Cancer Registries Amendment Act of 2004 (Public 
Law 107-260), the registration of VS has been nationally 
mandated. Since that time, studies have shown that the 
incidence of VS in the United States is approximately 1.1 
per 100,000 person-years in 2011 3 10.
Recent developments in disease incidence 
Perhaps the first recent study to show VS may affect 
significantly more people than the aforementioned 
population-based studies’ suggest was a conference 
paper that examined the incidence of VS in Beverly Hills, 
California  6. In this study, Schwartz and Fisher identified 
11 cases of VS from 1999-2004 resulting in an incidence rate 
of 5.4 per 100,000 person-years. Corroborated by the MRI 
studies on incidentally diagnosed tumors published around 
the same time, the unique patient demographic of Beverly 
Hills likely contributed to the distinctly elevated detection 
rate of VS in this population. 
Recently, using a national database in Taiwan over the 
period of 2001 to 2012, the highest annual incidence rate 
was observed to reach 3.72 per 100,000 person-years. 
Interestingly, the incidence climbed to 4.86 per 100,000 
person-years amongst those persons aged 60-69 years  21. 
Similarly, Maarten, et al. examined the national incidence 
of VS in the Netherlands and showed that incidence of VS in 
the Leiden region was 3.32 per 100,000 person-years from 
2009-2012 22. 
Including data through 2016, the incidence of sporadic VS 
in Olmsted County, Minnesota was estimated using the REP. 
Amidst a population of approximately 160,000 persons, the 
incidence rate of VS was shown to be 4.2 per 100,000 person-
years from 2006-2016 with an increase over the last five years 
to 4.5  7  23. Most notably, the incidence rate increased with 
older age, with an incidence rate of 11.1 per 100,000 person-
years in those aged 60-69  years and 18.3 in individuals 
aged 70 years and older. Similar to the demographic of the 
population of Beverly Hills in the study by Schwartz and 
Fisher, the Olmsted County population possesses several 
unique characteristics. Namely, the economy of Olmsted 
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showed that nearly a third of tumors were confined to the 
internal auditory canal at time of diagnosis  12. Strikingly, 
over the last decade in Olmsted County, nearly 75% of 
tumors were intracanalicular at diagnosis. Moreover, the 
median intracanalicular size has steadily decreased over 
the last 3 decades from 8 mm to 4 mm in the most recent 
decade 7.
Etiology of an increasingly common tumor
The most commonly employed rationale behind the rising 
incidence of VS stems from a combination of increased use 
of MRI and increasingly widespread implementation of 
screening protocols for asymmetrical sensorineural hearing 
loss. That is to say, the increase in disease incidence has 
been primarily driven by improved detection rather than a 
true increase in disease development. Supporting this theory, 
past population-based studies have shown that an inflection 
point in the incidence rate of VS exists around the time of the 
advent of MRI and widespread use of contrast enhanced thin 
slice MRI. For instance, in Denmark, the incidence of VS 
increased from roughly 0.8 per 100,000 person-years in the 
pre-MRI era to 1.74 from 1996-2001. In Olmsted County, 
the incidence rate increased from 1.4 per 100,000 person-
years in the pre-CT era to 2.1 from 1986-1995 and 3.2 from 
1996-2005 in the era of MRI. 
Implications of a changing patient demographic 
The observed shifts in the patient demographic of sporadic VS 
bear several important implications. First, the rising disease 
sporadic VS amongst all ages was 42.0 per 100,000 persons 
(0.042%) and increased to 109.1 in those aged 60-69 (0.11%) 
and 212.4 (0.21%) in those 70 years and older. Moreover, the 
prevalence of asymptomatic, incidentally diagnosed tumors 
was 10.3 per 100,000 (0.010%) among adults age 20 and 
older and was highest amongst those age 70 years and older 
at 31.2 (0.031%). Substantiating these prevalence estimates, 
when including only those persons who had undergone head 
imaging with MRI, the prevalence of incidental tumors 
closely paralleled past MRI studies 8. 
The changing patient demographic
An aging patient population
The recent findings surrounding disease incidence rates and 
prevalence frequencies suggest that the modern demographic 
of patients diagnosed with sporadic VS is changing. As 
mentioned previously, the highest incidence rate is found in 
elderly persons, approximating 20 per 100,000 person-years 
for those 70 years and older from the most recent population-
based estimates  7. Naturally following disease incidence 
rates, the prevalence amongst this elderly population is 
over 1 in 500 persons  8. Correspondingly, the median age 
at diagnosis steadily increased over the past several decades 
from approximately 50 years to 60 years 7 12. The analogous 
increase in life-expectancy over this time period alone cannot 
account for the increase in average age at diagnosis.
Evolving symptomatology and incidentally diagnosed tumors
Stemming from improved detection methods and disease 
understanding, patients are now being diagnosed with 
fewer attributable symptoms and at significantly shorter 
times after symptom onset compared to decades prior. Once 
commonly presenting with multiple cranial neuropathies 
and hydrocephalus  2, patients with only audiovestibular 
symptoms or no symptoms characterize the modern era 
(Fig. 5.6.2A, B) 7.
The increasingly common incidental tumor typifies the 
current shifts in VS epidemiology. With the growing use 
of MRI in routine diagnostic workup, small incidental 
tumors are frequently found (Fig.  5.6.2C, D). To this end, 
nearly 25% of all tumors diagnosed over the most recent 
decade in Olmsted County were found incidentally after 
patients underwent neuroimaging for seemingly unrelated 
indications 7. In this way, the incidence rate of incidentally 
diagnosed tumors alone in this population was approximately 
1 per 100,000 person-years over the most recent decade. 
Changing tumor size and location 
Inextricably connected to the rising incidence of incidentally 
diagnosed tumors, patients are now most often diagnosed 
with small intracanalicular tumors. Fifty years ago, all 
tumors were diagnosed only after significant extension into 
the cerebellopontine angle 7. By 2001, Danish national data 
Fig. 5.6.2. A, B) 68-year-old man with minimal asymmetrical sensorineural 
hearing loss and a 4 mm right-sided intracanalicular vestibular schwannoma 
that has not grown over the course of 18 months of observation. C, D) 58-year-
old woman with an incidentally diagnosed 2 mm right-sided distal intracanali-
cular lesion most consistent with a tiny vestibular schwannoma.
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person-years with disease prevalence of 1 in 2,000 overall 
and reaching 1 in 500 in adults aged 70 years and older. These 
incidence rates parallel disorders such as Parkinson ’s disease 
and Hodgkin’s lymphoma, and the prevalence frequencies of 
VS surpass the threshold of a “rare disease” by several countries’ 
definitions. Lastly, the aging patient demographic foreshadows 
that the emerging era of VS management will be one largely 
composed of “chronic disease management” opposed to one 
characterized by definitive surgical treatment. 
5.7. Preventing surgical morbidity  
in jugular paraganglioma
The two ends of aggressiveness,  
the partial targeted approach and the extended 
skull base petro-occipital approach
A. Mazzoni
The tympano-jugular paraganglioma (TJPGL) seems to present 
evolving concepts concerning both nature and treatment of the 
tumor. It is not universally defined a benign tumor, as some 
authors state that it is malignant  1 with a genetic dependent 
aggressiveness. Clinical experience, on the other hand, points 
out its capricious behavior and thus seems to belittle how its 
still obscure nature influence the principles of therapy. 
Treatment morbidities, mainly surgical but not only, impact on 
the choice of treatment. For instance, the function of the IX, 
X cranial nerves decides the choice between observational and 
active therapy. While it is undisputed that the infratemporal 
approach type A allows radical removal and recovery of the 
tumor albeit with morbidities, a continuum of alternative 
procedures aims at avoiding or lowering such morbidities. 
There are two procedures lying at the two ends of surgical 
aggressiveness that have been lately proposed and may deserve 
to be discussed, the partial targeted surgery (PTS) on tumor 
submitted to observation  1, and the extended petro-occipital 
approach (POa)  2 to large intradural growth often deemed to 
incomplete resection or even considered inoperable. 
The PTS is mainly a principle of therapy and adopts 
conventional approaches  2. It involves resection of a limited 
portion of a growing tumor causing an actual or potential 
damage and thus permitting to continue an otherwise correct 
observation. In other words, since it is applied to a case under 
observation, it extends the principle of the balance between 
natural and surgical morbidity in favor of observation by 
removing the tumor portion that can change the balance. The 
PTS is directed to three conditions as follow. The bleeding 
growth in the external auditory canal, tumor in contact with, or 
invading, the Fallopius canal and tumor compressing the brain 
stem. The procedure on the external auditory canal involves 
removing the tumor and suturing the canal skin. The procedure 
on the facial nerve involves a mastoidectomy or a lateral 
prevalence fundamentally alters the way in which we think 
about VS as a whole. For instance, recent incidence rates for 
VS exceed those of historically much more publicized diseases 
such as Hodgkin’s lymphoma and closely parallel the rates of 
Parkinson’s disease, the second most common neurodegenerative 
disorder worldwide 4 5. What is more, most countries define a 
“rare disease” based on a disease prevalence that falls between 1 
in 1,500 to 1 in 2,500 persons. For instance, the European Union 
defines rare diseases as those with a life-threatening or chronic 
debilitating condition with a prevalence of 50 per 100,000 
persons (or, 1 in 2,000)  29. Similarly, the Rare Disease Act of 
2002 (Public Law 107-280) defines a rare disease in the United 
States to be one with a prevalence less than 1 per 1,500 persons. 
To be considered a rare disease in Taiwan, disease prevalence 
must not be more than 1 per 10,000 persons. Narrower than 
all the aforementioned countries, China defines a rare disease 
as one with a prevalence less than 1 in 500,000 persons  30. 
Therefore, by recent prevalence estimates, VS would no longer 
be officially considered a “rare disease” in several areas of the 
world. Moreover, among those over age 60, the prevalence of 
sporadic VS exceeds rare disease thresholds by over an order of 
magnitude in both Europe and the United States. 
Beyond reclassifying sporadic VS as a more common disease 
than originally considered, the shifting patient demographic 
towards an aging population harbors larger healthcare 
implications. With the highest disease incidence amongst older 
individuals who often carry other medical comorbidities, initial 
management with observation by serial imaging will likely 
continue to be increasingly employed. First, there is growing 
concern surrounding the potential deleterious long-term health 
implications of repeated use of intravenous contrast for MRI 
following gadolinium deposition  31. Moreover, compounded 
by the likelihood that the incidence of VS will only increase 
in the coming years with increasing use of MRI, the cost of 
serial imaging will continue to rise. These two concerns may 
further drive the practice of obtaining non-contrast thinly sliced 
heavily-weighted T2 imaging for disease surveillance, thereby 
reducing gadolinium exposure and cost of imaging.
Finally, the aging, often incidentally diagnosed patient 
demographic characterizes an ongoing transition in the 
management of sporadic VS at-large. The increased ability to 
detect even small VSs amongst an elderly population suggests 
that the emerging era of VS management will be one largely 
comprised of “chronic disease management” compared to one 
of microsurgery and radiosurgery of decades past. 
Conclusions 
Historically considered a rare tumor that presented with multiple 
cranial neuropathies, hydrocephalus, and the “Syndrome of the 
Cerebellopontile Angle” in the Cushing era  2, sporadic VS in 
the modern era is characterized by symptomatology limited to 
audiovestibular symptoms alone or no symptoms (i.e., incidental 
cases). Disease incidence rates now approach 5 per 100,000 
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in order to make it clear and understood also by not so ex-
perienced readers. Some others adopted a synthetic overview, 
underlining principles and key-points where they concentrated 
their experience and referenced articles.
It was in the 1960s that it gradually started to become clear 
that skull base surgery involves making room around a 
targeted lesion lying within the skull base or at adjacent sites, 
creating a space within both the bone and the intra- and extra-
cranial tissues. Imaging was the tool used for diagnostics and 
for planning the treatment, and the microscope the instrument 
for performing it. The same fundamentals still apply today, but 
it is becoming clear that microsurgery has reached its limit. 
The microscope and our micromanual skills are unable to 
further improve our precision. A breakthrough is needed in 
the mechanical tissue handling methods. 
Leaving aside this issue for the moment, there are other points 
attracting our attention, such as: teaching and training in 
the area of skull base surgery; the opportunities for authors 
and centers to share details of their techniques; the lack of 
basic research to fill the gap, for instance, between better 
diagnostics (thanks to more advanced technologies) and the 
therapies available; and the dual nature of today’s skull base 
surgeons. This last issue is of particular interest to us. The 
multidisciplinary nature of skull base surgery necessitates 
a joint effort by two or more specialists, otologists and 
neurosurgeon, or the combination in the same surgeon of 
techniques drawn from different specialties - in other words, 
procedures performed either by more than one surgeon or 
by one surgeon with more than one type of expertise. Is the 
procedure planned and performed in the same way in both 
cases? Probably not, but progress has come from both sources, 
so it is our conviction that both should be maintained.
What about the next generation of skull base surgeons, who 
will take responsibility for the survival and advancement 
of skull base surgery? Though it might seem obvious, we 
should always bear in mind that learning the mind-driven 
craftsmanship needed for one of the most difficult types of 
surgery demands a lasting commitment to gaining experience 
(both “en solitaire” and through teaching-mentoring), a 
clear will to share our experiences, and the awareness and 
acceptance of the burden of such a complex surgical field. 
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petrosectomy, and removal of the local tumor with the option 
of grafting. The large intradural tumor compressing the brain 
stem is resected with an transigmoid petro-occipital approach, 
that is a suboccipital craniotomy combined with a transigmoid 
petrosectomy. The removal of the intradural tumor eliminates 
the brain compression and avoids a larger and riskier procedure 
including the dissection from the carotid artery. Indication to 
PTS is the same as observation of which it is a surgical appendix 
allowing the continuance of the same. 
The PO 3 approach is the second stage removal of the intradural 
TJPGL of which the extradural part was previously removed 
with the infratemporal A approach. It is a combination of a full 
fledge suboccipital approach with the extradural field of the IT 
A approach. This approach is dedicated to the > 4 cm. large 
intradural PGL and aims at extending the operability and safety 
of resection of large tumors that can be, and in the past were 
felt to be, hardly operable. The highlights of the approach are 
as follows:
• the surgical field of the previous IT A approach is reopened by 
removing the obliterating fat up to the internal carotid artery; 
• petrous bone,posterior half of occipital condyle and low 
clivus are drilled off to circumpherentially expose the dura 
all around the root of the intradural tumor; 
• the dura is coagulated around the tumor root thus obtaining 
closure of the main blood supply and shrinking of the mass; 
• suboccipital craniotomy adjoining the extradural field of the 
IT A approach. 
The room gained combining the two approaches and the pre-
hemptive closure of blood supply are the fundamental steps 
for safe resection. The tumor mass can be displaced anteri-
orly into the field of skull base removal thus exposing the 
interface tumor-brain stem, and dissected. 
Our experience suggested that changing the goal of surgery 
as in PTS as well as enlarging the access as in the PO ap-
proach can lessen the morbidity. Trial by other centers will 
say whether these approaches can be part of the multioption-
al therapies for TJPGL.
6. Conclusions
A. Mazzoni
The goal of this report was to take a sort of snapshot of the 
present state of affairs in the domain of skull base surgery, 
which has become a focus of interest in otology and 
neurosurgery, and made some surprising progress. The many 
contributors deserve our appreciation for the quality of their 
work, and for succeeding in condensing their topic in the 
limited space allowed by the setting of this report.
In order to comply with the size constraint and preserve in-
formative power,  each topic was treated following two ways. 
Some of the  authors choose a wide exposure of their topic, 
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